{"PMC3403912": [["IntroductionCoronaviruses are single-stranded RNA viruses that generally cause respiratory or intestinal infections such as severe acute respiratory syndrome (SARS) in humans and transmissible gastroenteritis (TGE) in pigs.", [["respiratory", "ANATOMY", 79, 90], ["intestinal", "ANATOMY", 94, 104], ["respiratory or intestinal infections", "DISEASE", 79, 115], ["acute respiratory syndrome", "DISEASE", 131, 157], ["SARS", "DISEASE", 159, 163], ["transmissible gastroenteritis", "DISEASE", 179, 208], ["TGE", "DISEASE", 210, 213], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["intestinal", "ORGAN", 94, 104], ["humans", "ORGANISM", 168, 174], ["pigs", "ORGANISM", 218, 222], ["humans", "SPECIES", 168, 174], ["pigs", "SPECIES", 218, 222], ["humans", "SPECIES", 168, 174], ["pigs", "SPECIES", 218, 222], ["IntroductionCoronaviruses", "PROBLEM", 0, 25], ["single-stranded RNA viruses", "PROBLEM", 30, 57], ["respiratory or intestinal infections", "PROBLEM", 79, 115], ["severe acute respiratory syndrome", "PROBLEM", 124, 157], ["SARS", "PROBLEM", 159, 163], ["transmissible gastroenteritis", "PROBLEM", 179, 208], ["intestinal", "ANATOMY", 94, 104], ["infections", "OBSERVATION", 105, 115], ["severe", "OBSERVATION_MODIFIER", 124, 130], ["acute", "OBSERVATION_MODIFIER", 131, 136], ["respiratory syndrome", "OBSERVATION", 137, 157], ["transmissible", "OBSERVATION_MODIFIER", 179, 192], ["gastroenteritis", "OBSERVATION", 193, 208]]], ["Feline coronaviruses (FCoV) have been classified into two biotypes, comprising the ubiquitous feline enteric coronavirus (FECV) and infectious peritonitis virus (FIPV).", [["Feline coronaviruses", "DISEASE", 0, 20], ["feline enteric coronavirus", "DISEASE", 94, 120], ["infectious peritonitis", "DISEASE", 132, 154], ["Feline coronaviruses", "ORGANISM", 0, 20], ["FCoV", "CANCER", 22, 26], ["feline enteric coronavirus", "ORGANISM", 94, 120], ["FECV", "ORGANISM", 122, 126], ["infectious peritonitis virus", "ORGANISM", 132, 160], ["Feline", "SPECIES", 0, 6], ["feline enteric coronavirus", "SPECIES", 94, 120], ["infectious peritonitis virus", "SPECIES", 132, 160], ["Feline coronaviruses", "SPECIES", 0, 20], ["FCoV", "SPECIES", 22, 26], ["feline enteric coronavirus", "SPECIES", 94, 120], ["FECV", "SPECIES", 122, 126], ["infectious peritonitis virus", "SPECIES", 132, 160], ["FIPV", "SPECIES", 162, 166], ["Feline coronaviruses (FCoV", "PROBLEM", 0, 26], ["the ubiquitous feline enteric coronavirus (FECV)", "PROBLEM", 79, 127], ["infectious peritonitis virus", "PROBLEM", 132, 160], ["enteric coronavirus", "ANATOMY", 101, 120], ["infectious", "OBSERVATION_MODIFIER", 132, 142], ["peritonitis", "OBSERVATION", 143, 154]]], ["The widely accepted theory in vitro is that FIPV arises by mutation of parental FECV in the gastrointestinal tract of infected cats, then systemically spreads and causes FIP that is fatal in cats [1,2].", [["gastrointestinal tract", "ANATOMY", 92, 114], ["FIP", "DISEASE", 170, 173], ["FIPV", "GENE_OR_GENE_PRODUCT", 44, 48], ["FECV", "GENE_OR_GENE_PRODUCT", 80, 84], ["gastrointestinal tract", "ORGAN", 92, 114], ["cats", "ORGANISM", 127, 131], ["cats", "ORGANISM", 191, 195], ["FIPV", "PROTEIN", 44, 48], ["cats", "SPECIES", 127, 131], ["FIPV", "PROBLEM", 44, 48], ["infected cats", "PROBLEM", 118, 131], ["FIP", "PROBLEM", 170, 173], ["FIPV", "OBSERVATION", 44, 48], ["gastrointestinal tract", "ANATOMY", 92, 114], ["infected", "OBSERVATION", 118, 126], ["FIP", "OBSERVATION", 170, 173]]], ["Although the mutation sites are not fully understood, some accessory genes are candidates for the site of the critical mutations responsible for FIP [3,4].", [["FIP", "DISEASE", 145, 148], ["accessory genes", "DNA", 59, 74], ["the mutation sites", "PROBLEM", 9, 27], ["the critical mutations", "PROBLEM", 106, 128], ["FIP", "PROBLEM", 145, 148]]], ["Approximately 80 % of all purebred cats are infected with feline coronavirus and among these, 5-12 % develop the classical symptoms of effusive/wet FIP, the non-effusive/dry form of FIP, or a combination of the two [5].IntroductionMany strategies have been developed to cure FIP.", [["feline coronavirus", "DISEASE", 58, 76], ["FIP", "DISEASE", 148, 151], ["FIP", "DISEASE", 182, 185], ["FIP", "DISEASE", 275, 278], ["cats", "ORGANISM", 35, 39], ["feline coronavirus", "ORGANISM", 58, 76], ["cats", "SPECIES", 35, 39], ["feline coronavirus", "SPECIES", 58, 76], ["feline coronavirus", "SPECIES", 58, 76], ["all purebred cats", "PROBLEM", 22, 39], ["feline coronavirus", "PROBLEM", 58, 76], ["the classical symptoms", "PROBLEM", 109, 131], ["effusive", "PROBLEM", 135, 143], ["wet FIP", "PROBLEM", 144, 151], ["the non-effusive/dry form of FIP", "PROBLEM", 153, 185], ["feline coronavirus", "OBSERVATION", 58, 76], ["wet FIP", "OBSERVATION", 144, 151], ["FIP", "OBSERVATION", 182, 185]]], ["Interferon \u03c9 inhibits FIPV in vitro but is ineffective in vivo [6].", [["FIPV", "CHEMICAL", 22, 26], ["Interferon \u03c9", "GENE_OR_GENE_PRODUCT", 0, 12], ["FIPV", "SIMPLE_CHEMICAL", 22, 26], ["Interferon \u03c9", "PROTEIN", 0, 12], ["FIPV", "PROTEIN", 22, 26], ["Interferon", "TREATMENT", 0, 10], ["FIPV in vitro", "TREATMENT", 22, 35]]], ["Various other immunosuppressants, such as glucocorticoids and cyclophosphamide, have been studied, but although these drugs prolong life, the outcome of FIPV infection remains fatal [7].", [["glucocorticoids", "CHEMICAL", 42, 57], ["cyclophosphamide", "CHEMICAL", 62, 78], ["FIPV", "CHEMICAL", 153, 157], ["infection", "DISEASE", 158, 167], ["cyclophosphamide", "CHEMICAL", 62, 78], ["glucocorticoids", "SIMPLE_CHEMICAL", 42, 57], ["cyclophosphamide", "SIMPLE_CHEMICAL", 62, 78], ["FIPV", "SPECIES", 153, 157], ["Various other immunosuppressants", "TREATMENT", 0, 32], ["glucocorticoids", "TREATMENT", 42, 57], ["cyclophosphamide", "TREATMENT", 62, 78], ["these drugs prolong life", "TREATMENT", 112, 136], ["FIPV infection", "PROBLEM", 153, 167], ["immunosuppressants", "OBSERVATION", 14, 32], ["FIPV infection", "OBSERVATION", 153, 167]]], ["Thus, an effective vaccine and therapeutic medicine against FIPV are still needed.IntroductionInvestigators have reported that the immunosuppressant cyclosporin A (CsA) can suppress the genomic replication and transcription of several viruses [8-11].", [["FIPV", "CHEMICAL", 60, 64], ["cyclosporin A", "CHEMICAL", 149, 162], ["CsA", "CHEMICAL", 164, 167], ["cyclosporin A", "CHEMICAL", 149, 162], ["CsA", "CHEMICAL", 164, 167], ["FIPV", "SIMPLE_CHEMICAL", 60, 64], ["cyclosporin A", "SIMPLE_CHEMICAL", 149, 162], ["CsA", "SIMPLE_CHEMICAL", 164, 167], ["FIPV", "SPECIES", 60, 64], ["an effective vaccine", "TREATMENT", 6, 26], ["therapeutic medicine", "TREATMENT", 31, 51], ["FIPV", "PROBLEM", 60, 64], ["the immunosuppressant cyclosporin A (CsA)", "TREATMENT", 127, 168], ["the genomic replication", "PROBLEM", 182, 205], ["several viruses", "PROBLEM", 227, 242]]], ["Cyclophilins (CyP) are cellular factors with high affinity for CsA [12] and comprise a family of cellular peptidyl-prolyl cis-trans isomerases (PPIases) that catalyze the cis-trans interconversion of the amino-terminal of peptide bonds to proline residues, thus facilitating changes in protein conformation as a chaperone protein [13].", [["cellular", "ANATOMY", 23, 31], ["cellular", "ANATOMY", 97, 105], ["Cyclophilins", "CHEMICAL", 0, 12], ["CyP", "CHEMICAL", 14, 17], ["CsA", "CHEMICAL", 63, 66], ["amino-terminal", "CHEMICAL", 204, 218], ["proline", "CHEMICAL", 239, 246], ["Cyclophilins", "CHEMICAL", 0, 12], ["CsA", "CHEMICAL", 63, 66], ["peptidyl", "CHEMICAL", 106, 114], ["prolyl", "CHEMICAL", 115, 121], ["amino", "CHEMICAL", 204, 209], ["proline", "CHEMICAL", 239, 246], ["Cyclophilins", "GENE_OR_GENE_PRODUCT", 0, 12], ["CyP", "SIMPLE_CHEMICAL", 14, 17], ["cellular", "CELL", 23, 31], ["CsA", "SIMPLE_CHEMICAL", 63, 66], ["cellular", "CELL", 97, 105], ["PPIases", "GENE_OR_GENE_PRODUCT", 144, 151], ["amino", "AMINO_ACID", 204, 209], ["proline", "AMINO_ACID", 239, 246], ["Cyclophilins", "PROTEIN", 0, 12], ["CyP", "PROTEIN", 14, 17], ["cellular factors", "PROTEIN", 23, 39], ["cellular peptidyl-prolyl cis-trans isomerases", "PROTEIN", 97, 142], ["PPIases", "PROTEIN", 144, 151], ["chaperone protein", "PROTEIN", 312, 329], ["Cyclophilins (CyP)", "TREATMENT", 0, 18], ["cellular factors", "PROBLEM", 23, 39], ["CsA", "TEST", 63, 66], ["cellular peptidyl-prolyl cis-trans isomerases (PPIases", "TREATMENT", 97, 151], ["the amino-terminal of peptide bonds", "TREATMENT", 200, 235], ["proline residues", "PROBLEM", 239, 255], ["facilitating changes in protein conformation", "PROBLEM", 262, 306]]], ["Cyclosporin A blocks both the enzymatic activities of CyP that lead to the calcineurin (CN)-NF-AT and P-glycoprotein pathways.", [["Cyclosporin A", "CHEMICAL", 0, 13], ["Cyclosporin A", "CHEMICAL", 0, 13], ["Cyclosporin A", "SIMPLE_CHEMICAL", 0, 13], ["CyP", "SIMPLE_CHEMICAL", 54, 57], ["calcineurin", "GENE_OR_GENE_PRODUCT", 75, 86], ["NF-AT", "GENE_OR_GENE_PRODUCT", 92, 97], ["CyP", "PROTEIN", 54, 57], ["calcineurin", "PROTEIN", 75, 86], ["CN", "PROTEIN", 88, 90], ["glycoprotein", "PROTEIN", 104, 116], ["Cyclosporin A blocks", "TREATMENT", 0, 20], ["the calcineurin (CN", "TEST", 71, 90], ["NF", "TEST", 92, 94]]], ["The capsid protein of human immunodeficiency virus type 1 (HIV-1) possesses a cyclophilin A (CyPA) binding site for incorporation into the virion [14,15].", [["human immunodeficiency virus", "DISEASE", 22, 50], ["human immunodeficiency virus type 1", "ORGANISM", 22, 57], ["HIV-1", "ORGANISM", 59, 64], ["cyclophilin A", "GENE_OR_GENE_PRODUCT", 78, 91], ["CyPA", "GENE_OR_GENE_PRODUCT", 93, 97], ["capsid protein", "PROTEIN", 4, 18], ["cyclophilin A (CyPA) binding site", "DNA", 78, 111], ["human immunodeficiency virus type 1", "SPECIES", 22, 57], ["HIV-1", "SPECIES", 59, 64], ["human immunodeficiency virus type 1", "SPECIES", 22, 57], ["HIV-1", "SPECIES", 59, 64], ["The capsid protein", "TEST", 0, 18], ["human immunodeficiency virus type", "PROBLEM", 22, 55], ["a cyclophilin A (CyPA) binding site", "TREATMENT", 76, 111], ["capsid protein", "OBSERVATION", 4, 18]]], ["A CsA-induced reduction in CyPA inhibits transport of the reverse-transcribed viral genome to the nucleus [16].", [["nucleus", "ANATOMY", 98, 105], ["CsA", "CHEMICAL", 2, 5], ["CyPA", "CHEMICAL", 27, 31], ["CsA", "CHEMICAL", 2, 5], ["CyPA", "CHEMICAL", 27, 31], ["CsA", "SIMPLE_CHEMICAL", 2, 5], ["CyPA", "SIMPLE_CHEMICAL", 27, 31], ["nucleus", "CELLULAR_COMPONENT", 98, 105], ["CyPA", "PROTEIN", 27, 31], ["reverse-transcribed viral genome", "DNA", 58, 90], ["A CsA-induced reduction in CyPA", "TREATMENT", 0, 31], ["reduction", "OBSERVATION_MODIFIER", 14, 23], ["CyPA", "OBSERVATION", 27, 31], ["viral genome", "OBSERVATION", 78, 90], ["nucleus", "ANATOMY", 98, 105]]], ["Cyclophilin B (CyPB) is another target of CsA that promotes hepatitis C virus (HCV) replication by regulating the RNA-binding ability of the HCV NS5B protein.", [["Cyclophilin B", "CHEMICAL", 0, 13], ["CyPB", "CHEMICAL", 15, 19], ["CsA", "CHEMICAL", 42, 45], ["hepatitis C", "DISEASE", 60, 71], ["CsA", "CHEMICAL", 42, 45], ["Cyclophilin B", "GENE_OR_GENE_PRODUCT", 0, 13], ["CyPB", "GENE_OR_GENE_PRODUCT", 15, 19], ["CsA", "SIMPLE_CHEMICAL", 42, 45], ["hepatitis C virus", "ORGANISM", 60, 77], ["HCV", "ORGANISM", 79, 82], ["HCV", "ORGANISM", 141, 144], ["Cyclophilin B", "PROTEIN", 0, 13], ["CyPB", "PROTEIN", 15, 19], ["HCV NS5B protein", "PROTEIN", 141, 157], ["hepatitis C virus", "SPECIES", 60, 77], ["hepatitis C virus", "SPECIES", 60, 77], ["HCV", "SPECIES", 79, 82], ["HCV", "SPECIES", 141, 144], ["Cyclophilin B (CyPB)", "TREATMENT", 0, 20], ["CsA", "PROBLEM", 42, 45], ["hepatitis C virus", "PROBLEM", 60, 77], ["HCV) replication", "TREATMENT", 79, 95], ["the HCV NS5B protein", "TREATMENT", 137, 157], ["hepatitis", "OBSERVATION", 60, 69]]], ["In addition, CyPA facilitates mouse cytomegalovirus (MCMV) replication and CyPB is required for the infectious entry of human papillomavirus type 16.IntroductionHere, we show that CsA inhibits intracellular replication of the FIPV genome and viral protein expression in vitro independently of the NF-AT pathway.Cell culture and virus ::: Materials and methodsFelis catus whole fetus-4 (fcwf-4; American Type Culture Collection, VA, USA) cells were maintained in Dulbecco\u2019s modified Eagle\u2019s medium (D-MEM, Sigma-Aldrich, Tokyo, Japan) supplemented with 10 % fetal bovine serum (JRH, Nissui, Tokyo, Japan).", [["intracellular", "ANATOMY", 193, 206], ["Cell", "ANATOMY", 311, 315], ["VA, USA) cells", "ANATOMY", 428, 442], ["fetal bovine serum", "ANATOMY", 557, 575], ["CyPA", "CHEMICAL", 13, 17], ["human papillomavirus type", "DISEASE", 120, 145], ["CsA", "CHEMICAL", 180, 183], ["CsA", "CHEMICAL", 180, 183], ["CyPA", "GENE_OR_GENE_PRODUCT", 13, 17], ["mouse cytomegalovirus", "ORGANISM", 30, 51], ["MCMV", "ORGANISM", 53, 57], ["CyPB", "GENE_OR_GENE_PRODUCT", 75, 79], ["human papillomavirus type 16", "ORGANISM", 120, 148], ["CsA", "SIMPLE_CHEMICAL", 180, 183], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 193, 206], ["FIPV", "GENE_OR_GENE_PRODUCT", 226, 230], ["NF-AT", "GENE_OR_GENE_PRODUCT", 297, 302], ["Cell", "CELL", 311, 315], ["Felis", "ORGANISM", 359, 364], ["fcwf-4", "CELL", 386, 392], ["VA, USA) cells", "CELL", 428, 442], ["bovine", "ORGANISM", 563, 569], ["serum", "ORGANISM_SUBSTANCE", 570, 575], ["CyPA", "PROTEIN", 13, 17], ["CyPB", "PROTEIN", 75, 79], ["FIPV genome", "DNA", 226, 237], ["NF", "PROTEIN", 297, 299], ["mouse", "SPECIES", 30, 35], ["human", "SPECIES", 120, 125], ["bovine", "SPECIES", 563, 569], ["mouse cytomegalovirus", "SPECIES", 30, 51], ["MCMV", "SPECIES", 53, 57], ["human papillomavirus type 16", "SPECIES", 120, 148], ["FIPV", "SPECIES", 226, 230], ["Felis catus", "SPECIES", 359, 370], ["bovine", "SPECIES", 563, 569], ["CyPA facilitates mouse cytomegalovirus (MCMV) replication", "TREATMENT", 13, 70], ["CyPB", "TREATMENT", 75, 79], ["CsA", "TREATMENT", 180, 183], ["the FIPV genome", "TREATMENT", 222, 237], ["viral protein expression", "PROBLEM", 242, 266], ["Cell culture", "TEST", 311, 323], ["fetus", "TEST", 377, 382], ["FIPV genome", "OBSERVATION", 226, 237], ["viral protein expression", "OBSERVATION", 242, 266]]], ["We propagated FIPV (79\u20101146 strain; a gift from Dr Tsutomu Hodatsu, Kitasato University, Japan) in fcwf-4 cells and then purified them by linear sucrose gradient ultracentrifugation.Cells treated with cyclosporin A, cyclosporin H, and FK506 ::: Materials and methodsWe inoculated fcwf-4 cells with FIPV 79\u20131146 at a multiplicity of infection (MOI) of 1 plaque-forming unit (pfu) per cell to study their effects on FIPV infection.", [["fcwf-4 cells", "ANATOMY", 99, 111], ["Cells", "ANATOMY", 182, 187], ["fcwf-4 cells", "ANATOMY", 280, 292], ["plaque", "ANATOMY", 353, 359], ["cell", "ANATOMY", 383, 387], ["FIPV", "CHEMICAL", 14, 18], ["sucrose", "CHEMICAL", 145, 152], ["cyclosporin A", "CHEMICAL", 201, 214], ["cyclosporin H", "CHEMICAL", 216, 229], ["FK506", "CHEMICAL", 235, 240], ["FIPV 79\u20131146", "CHEMICAL", 298, 310], ["multiplicity of infection", "DISEASE", 316, 341], ["infection", "DISEASE", 419, 428], ["sucrose", "CHEMICAL", 145, 152], ["cyclosporin A", "CHEMICAL", 201, 214], ["cyclosporin H", "CHEMICAL", 216, 229], ["FK506", "CHEMICAL", 235, 240], ["fcwf-4 cells", "CELL", 99, 111], ["Cells", "CELL", 182, 187], ["cyclosporin A", "SIMPLE_CHEMICAL", 201, 214], ["cyclosporin H", "SIMPLE_CHEMICAL", 216, 229], ["FK506", "SIMPLE_CHEMICAL", 235, 240], ["fcwf-4 cells", "CELL", 280, 292], ["FIPV 79\u20131146", "CELL", 298, 310], ["cell", "CELL", 383, 387], ["FIPV", "SIMPLE_CHEMICAL", 414, 418], ["fcwf-4 cells", "CELL_LINE", 99, 111], ["fcwf-4 cells", "CELL_LINE", 280, 292], ["FIPV", "SPECIES", 414, 418], ["linear sucrose gradient ultracentrifugation", "TREATMENT", 138, 181], ["cyclosporin", "TREATMENT", 201, 212], ["cyclosporin H", "TREATMENT", 216, 229], ["Materials", "TEST", 245, 254], ["methodsWe inoculated fcwf", "TEST", 259, 284], ["FIPV", "TEST", 298, 302], ["infection", "PROBLEM", 332, 341], ["1 plaque", "PROBLEM", 351, 359], ["FIPV infection", "PROBLEM", 414, 428], ["FIPV", "OBSERVATION_MODIFIER", 14, 18], ["infection", "OBSERVATION", 332, 341], ["FIPV", "OBSERVATION_MODIFIER", 414, 418], ["infection", "OBSERVATION", 419, 428]]], ["After adsorption for 1 h at 37\u00b0C, the medium containing the virus was removed, and the cells were rinsed three times with phosphate-buffered saline [PBS (\u2212)] and incubated with or without various concentrations of CsA (Sigma-Aldrich), cyclosporin H (CsH; Cosmobio, Tokyo, Japan) and FK506 (Sigma-Aldrich) for 20 h.", [["cells", "ANATOMY", 87, 92], ["phosphate", "CHEMICAL", 122, 131], ["CsA", "CHEMICAL", 214, 217], ["cyclosporin H", "CHEMICAL", 235, 248], ["CsH", "CHEMICAL", 250, 253], ["FK506", "CHEMICAL", 283, 288], ["Sigma-Aldrich", "CHEMICAL", 290, 303], ["phosphate", "CHEMICAL", 122, 131], ["CsA", "CHEMICAL", 214, 217], ["cyclosporin H", "CHEMICAL", 235, 248], ["CsH", "CHEMICAL", 250, 253], ["Cosmobio", "CHEMICAL", 255, 263], ["FK506", "CHEMICAL", 283, 288], ["cells", "CELL", 87, 92], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 122, 147], ["CsA", "SIMPLE_CHEMICAL", 214, 217], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 219, 232], ["cyclosporin H", "SIMPLE_CHEMICAL", 235, 248], ["CsH", "SIMPLE_CHEMICAL", 250, 253], ["FK506", "SIMPLE_CHEMICAL", 283, 288], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 290, 303], ["the medium containing the virus", "TREATMENT", 34, 65], ["the cells", "TREATMENT", 83, 92], ["phosphate-buffered saline [PBS", "TREATMENT", 122, 152], ["CsA (Sigma-Aldrich)", "TREATMENT", 214, 233], ["cyclosporin H", "TREATMENT", 235, 248], ["FK506 (Sigma-Aldrich)", "TREATMENT", 283, 304]]], ["The cells were then processed for photography.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["photography", "TEST", 34, 45]]], ["The cells were adsorbed with FIPV, rinsed three times with PBS (\u2212), overlaid with DMEM containing 5 % fetal bovine serum and 2 % Agarose S (Nippon Gene, Toyama, Japan).", [["cells", "ANATOMY", 4, 9], ["fetal bovine serum", "ANATOMY", 102, 120], ["FIPV", "CHEMICAL", 29, 33], ["FIPV", "CHEMICAL", 29, 33], ["cells", "CELL", 4, 9], ["FIPV", "SIMPLE_CHEMICAL", 29, 33], ["bovine", "ORGANISM", 108, 114], ["serum", "ORGANISM_SUBSTANCE", 115, 120], ["bovine", "SPECIES", 108, 114], ["bovine", "SPECIES", 108, 114], ["FIPV", "TREATMENT", 29, 33], ["DMEM", "TREATMENT", 82, 86], ["5 % fetal bovine serum", "TREATMENT", 98, 120], ["2 % Agarose S", "TREATMENT", 125, 138]]], ["After a 20-h incubation, the cells were stained with Giemsa solution and the plaques were counted.Plasmid constructs ::: Materials and methodsWe isolated the nucleocapsid (N) gene of FIPV from the plasmid pBRDI1 (provided by Dr Peter J. M. Rottier, Institute of Biomembranes, Utrecht University, The Netherlands) containing the FIPV 79\u20131146 genome, using the polymerase chain reaction (PCR) with the primers 5\u2019-ACAAGGACGACGACGACAAGGCCACACAGGGACAACGCG-3\u2019 and 5\u2019-CCGGAATTCTTAGTTCGTAACCTCATCAA-3\u2019 for the first amplification.", [["cells", "ANATOMY", 29, 34], ["plaques", "ANATOMY", 77, 84], ["plasmid", "ANATOMY", 197, 204], ["Giemsa", "CHEMICAL", 53, 59], ["cells", "CELL", 29, 34], ["Giemsa", "SIMPLE_CHEMICAL", 53, 59], ["plaques", "PATHOLOGICAL_FORMATION", 77, 84], ["FIPV", "GENE_OR_GENE_PRODUCT", 183, 187], ["Plasmid constructs", "DNA", 98, 116], ["nucleocapsid (N) gene", "DNA", 158, 179], ["FIPV", "DNA", 183, 187], ["plasmid pBRDI1", "DNA", 197, 211], ["FIPV 79\u20131146 genome", "DNA", 328, 347], ["FIPV 79\u20131146", "SPECIES", 328, 340], ["a 20-h incubation", "TREATMENT", 6, 23], ["the cells", "TREATMENT", 25, 34], ["Giemsa solution", "TREATMENT", 53, 68], ["the plaques", "PROBLEM", 73, 84], ["the nucleocapsid (N) gene of FIPV", "TREATMENT", 154, 187], ["the FIPV", "TEST", 324, 332], ["the polymerase chain reaction", "PROBLEM", 355, 384], ["PCR", "TEST", 386, 389], ["the primers", "TEST", 396, 407], ["ACAAGGACGACGACGACAAGGCCACACAGGGACAACGCG", "TEST", 411, 450], ["CCGGAATTCTTAGTTCGTAACCTCATCAA", "TEST", 461, 490], ["plaques", "OBSERVATION", 77, 84]]], ["The products of the first amplification were purified by electrophoresis and gel extraction, and then a second PCR proceeded with the purified products and primers containing a FLAG-tagged sequence: (5\u2019-GCCACCATGGACTACAAGGACGACGACGACAAG-3\u2019 and 5\u2019-CCGGAATTCTTAGTTCGTAACCTCATCAA-3\u2019).", [["FLAG", "GENE_OR_GENE_PRODUCT", 177, 181], ["FLAG", "PROTEIN", 177, 181], ["gel extraction", "TREATMENT", 77, 91], ["a second PCR", "TEST", 102, 114], ["the purified products", "TREATMENT", 130, 151], ["a FLAG-tagged sequence", "TEST", 175, 197], ["GCCACCATGGACTACAAGGACGACGACGACAAG", "TEST", 203, 236]]], ["The second PCR products were cut with Nco I and Eco RI and subcloned into the sites between Nco I and Eco RI of the pTri-EX 1.1 vector (Novagen, Takara Bio, Kyoto, Japan) to express FLAG-tagged N protein.Real-time, quantitative reverse transcription-PCR (qRT-PCR) ::: Materials and methodsThe fcwf-4 cells were infected at an MOI of 1 pfu per cell and then incubated with or without CsA, CsH or FK506.", [["fcwf-4 cells", "ANATOMY", 293, 305], ["cell", "ANATOMY", 343, 347], ["CsA", "CHEMICAL", 383, 386], ["CsH", "CHEMICAL", 388, 391], ["FK506", "CHEMICAL", 395, 400], ["CsA", "CHEMICAL", 383, 386], ["CsH", "CHEMICAL", 388, 391], ["FK506", "CHEMICAL", 395, 400], ["Nco I", "GENE_OR_GENE_PRODUCT", 38, 43], ["Eco RI", "GENE_OR_GENE_PRODUCT", 48, 54], ["Nco I", "GENE_OR_GENE_PRODUCT", 92, 97], ["Eco RI", "GENE_OR_GENE_PRODUCT", 102, 108], ["FLAG", "GENE_OR_GENE_PRODUCT", 182, 186], ["fcwf-4 cells", "CELL", 293, 305], ["cell", "CELL", 343, 347], ["CsA", "SIMPLE_CHEMICAL", 383, 386], ["CsH", "SIMPLE_CHEMICAL", 388, 391], ["FK506", "SIMPLE_CHEMICAL", 395, 400], ["Nco I", "DNA", 38, 43], ["Eco RI", "DNA", 48, 54], ["Nco I", "DNA", 92, 97], ["Eco RI", "DNA", 102, 108], ["pTri-EX 1.1 vector", "DNA", 116, 134], ["FLAG", "PROTEIN", 182, 186], ["N protein", "PROTEIN", 194, 203], ["fcwf-4 cells", "CELL_LINE", 293, 305], ["The second PCR products", "TREATMENT", 0, 23], ["Nco I and Eco RI", "TREATMENT", 38, 54], ["Novagen", "TREATMENT", 136, 143], ["Takara Bio", "TREATMENT", 145, 155], ["FLAG", "TEST", 182, 186], ["The fcwf-4 cells", "PROBLEM", 289, 305], ["FK506", "TREATMENT", 395, 400], ["4 cells", "OBSERVATION_MODIFIER", 298, 305]]], ["The medium was removed at 22 h post-infection, and RNAiso-plus (Takara Bio) was added to the cells for RNA preparation according to the manufacturer\u2019s protocol.", [["cells", "ANATOMY", 93, 98], ["infection", "DISEASE", 36, 45], ["Takara Bio", "ORGANISM", 64, 74], ["cells", "CELL", 93, 98], ["infection", "PROBLEM", 36, 45], ["RNAiso-plus (Takara Bio)", "TREATMENT", 51, 75], ["RNA preparation", "TREATMENT", 103, 118], ["medium", "OBSERVATION_MODIFIER", 4, 10], ["infection", "OBSERVATION", 36, 45]]], ["Total RNA (800 ng) was reverse-transcribed using the PrimeScript RT-PCR kit (Perfect Real Time; Takara Bio).", [["Total RNA", "TEST", 0, 9], ["the PrimeScript RT", "TREATMENT", 49, 67]]], ["Viral cDNA were quantified by real-time PCR using the forward and reverse primers to the FIPV-N gene (5\u2019-TGGCCACACAGGGACAAC-3\u2019) and (5\u2019-AGAACGACCACGTCTTTTGGAA-3\u2019), and the TaqMan probe (FAM-GTTGCA GCACAGCCAGCATAAACAA-BHQ-1).", [["Viral", "ORGANISM", 0, 5], ["FIPV-N", "GENE_OR_GENE_PRODUCT", 89, 95], ["Viral cDNA", "DNA", 0, 10], ["forward and reverse primers", "DNA", 54, 81], ["FIPV", "DNA", 89, 93], ["N gene", "DNA", 94, 100], ["TaqMan probe", "DNA", 172, 184], ["BHQ", "DNA", 217, 220], ["Viral cDNA", "TEST", 0, 10], ["reverse primers", "TREATMENT", 66, 81], ["TGGCCACACAGGGACAAC", "TEST", 105, 123], ["AGAACGACCACGTCTTTTGGAA", "TEST", 136, 158], ["the TaqMan probe", "TEST", 168, 184], ["FAM", "TEST", 186, 189]]], ["Reaction mixtures were prepared according to the manufacturer\u2019s protocol using Premix EXTaq (Takara Bio), and sequences were amplified using a 7500 Sequence Detection System (Applied Biosystems, Tokyo, Japan) under the following cycling conditions: initial denaturation at 95\u00b0C for 10 s and 40 cycles at 95\u00b0C for 5 s and 60\u00b0C for 36 s each.", [["Premix EXTaq", "DNA", 79, 91], ["Takara Bio", "DNA", 93, 103], ["Premix EXTaq (Takara Bio", "TREATMENT", 79, 103], ["initial denaturation", "PROBLEM", 249, 269]]], ["Complementary DNA to the FIPV-N gene was cloned into the pTri-EX 1.1 vector, which was serially diluted to provide standards for FIPV gene quantification.", [["DNA", "CELLULAR_COMPONENT", 14, 17], ["FIPV-N", "GENE_OR_GENE_PRODUCT", 25, 31], ["FIPV", "GENE_OR_GENE_PRODUCT", 129, 133], ["FIPV", "DNA", 25, 29], ["N gene", "DNA", 30, 36], ["pTri-EX 1.1 vector", "DNA", 57, 75], ["FIPV gene", "DNA", 129, 138], ["FIPV", "SPECIES", 129, 133], ["FIPV gene quantification", "TREATMENT", 129, 153]]], ["The viral RNA copy number was normalized using the feline \u03b2-2-microglobulin (\u03b22M) gene (GenBank; NM_001009876).", [["\u03b2-2-microglobulin", "GENE_OR_GENE_PRODUCT", 58, 75], ["\u03b22M", "GENE_OR_GENE_PRODUCT", 77, 80], ["feline \u03b2-2-microglobulin (\u03b22M) gene", "DNA", 51, 86], ["The viral RNA copy number", "TEST", 0, 25], ["viral RNA", "OBSERVATION", 4, 13]]], ["The \u03b22M gene derived from fcwf-4 cells was cloned by PCR amplification using the following primers: f\u03b22M-F 5\u2019-GGCGCGTTTTGTGGTCTTGGTC-3\u2019 and f\u03b22M-R 5\u2019-CACTTAACGACCTTGGGCTC-3\u2019.", [["fcwf-4 cells", "ANATOMY", 26, 38], ["\u03b22M", "GENE_OR_GENE_PRODUCT", 4, 7], ["fcwf-4 cells", "CELL", 26, 38], ["\u03b22M gene", "DNA", 4, 12], ["fcwf-4 cells", "CELL_LINE", 26, 38], ["f\u03b22M", "DNA", 140, 144], ["fcwf-4 cells", "TREATMENT", 26, 38], ["GGCGCGTTTTGTGGTCTTGGTC", "TEST", 110, 132], ["f\u03b22M", "TEST", 140, 144], ["CACTTAACGACCTTGGGCTC", "TEST", 150, 170]]], ["The amplified PCR products were subcloned into pTAC-1 plasmids (BioDynamics Laboratory Inc. Tokyo, Japan) to provide standards for the \u03b22M gene.", [["\u03b22M", "GENE_OR_GENE_PRODUCT", 135, 138], ["amplified PCR products", "DNA", 4, 26], ["pTAC-1 plasmids", "DNA", 47, 62], ["\u03b22M gene", "DNA", 135, 143], ["The amplified PCR products", "TREATMENT", 0, 26]]], ["We then quantified the feline \u03b22M gene by real-time PCR using the forward (5\u2019-CGCGTTTTGTGGTCTTGGTCTTGGT-3\u2019) and reverse (5\u2019-AAACCTGAACCTTTGGAGAATGC-3\u2019) primers for the \u03b22M gene and detected the gene using the TaqMan probe, TAMRA-CGGACTGCTCTATCTGTCCCACCTGGA-BHQ-2.Luciferase assay ::: Materials and methodsLuciferase activities were quantified using pGL4.30 [luc2P/NFAT-RE/Hygro] (Promega, Tokyo, Japan), pRL-SV40 vectors for the NF-AT response assay and the interferon stimulation response was determined using the plasmid pISRE-TK hRluc (F) provided by RIKEN BioResource Center (Tsukuba, Japan) and the pGL3 promoter (Promega).", [["feline", "ORGANISM", 23, 29], ["\u03b22M", "GENE_OR_GENE_PRODUCT", 30, 33], ["\u03b22M", "GENE_OR_GENE_PRODUCT", 168, 171], ["NFAT", "GENE_OR_GENE_PRODUCT", 364, 368], ["pRL", "GENE_OR_GENE_PRODUCT", 404, 407], ["SV40", "ORGANISM", 408, 412], ["NF-AT", "GENE_OR_GENE_PRODUCT", 429, 434], ["interferon", "GENE_OR_GENE_PRODUCT", 458, 468], ["pGL3", "GENE_OR_GENE_PRODUCT", 604, 608], ["feline \u03b22M gene", "DNA", 23, 38], ["\u03b22M gene", "DNA", 168, 176], ["TaqMan probe", "DNA", 209, 221], ["TAMRA-CGGACTGCTCTATCTGTCCCACCTGGA-BHQ-2", "DNA", 223, 262], ["pGL4", "PROTEIN", 349, 353], ["luc2P", "PROTEIN", 358, 363], ["NFAT", "PROTEIN", 364, 368], ["pRL-SV40 vectors", "DNA", 404, 420], ["interferon", "PROTEIN", 458, 468], ["pISRE", "DNA", 523, 528], ["TK hRluc", "DNA", 529, 537], ["pGL3 promoter", "DNA", 604, 617], ["CGCGTTTTGTGGTCTTGGTCTTGGT", "TEST", 78, 103], ["AAACCTGAACCTTTGGAGAATGC", "TEST", 124, 147], ["primers", "TREATMENT", 152, 159], ["the \u03b22M gene", "TREATMENT", 164, 176], ["the TaqMan probe", "TREATMENT", 205, 221], ["TAMRA-CGGACTGCTCTATCTGTCCCACCTGGA", "TEST", 223, 256], ["methodsLuciferase activities", "TEST", 298, 326], ["pGL4", "TEST", 349, 353], ["luc2P/NFAT", "TREATMENT", 358, 368], ["RE/Hygro]", "TREATMENT", 369, 378], ["Promega", "TREATMENT", 380, 387], ["pRL-SV40 vectors", "TREATMENT", 404, 420], ["the interferon stimulation response", "TREATMENT", 454, 489], ["the plasmid pISRE", "TREATMENT", 511, 528], ["the pGL3 promoter (Promega)", "TREATMENT", 600, 627]]], ["Briefly, the two reporter plasmids were co-transfected into fcwf-4 cells with or without CsA or FK506 for each assay.", [["plasmids", "ANATOMY", 26, 34], ["fcwf-4 cells", "ANATOMY", 60, 72], ["CsA", "CHEMICAL", 89, 92], ["FK506", "CHEMICAL", 96, 101], ["CsA", "CHEMICAL", 89, 92], ["FK506", "CHEMICAL", 96, 101], ["fcwf-4 cells", "CELL", 60, 72], ["CsA", "SIMPLE_CHEMICAL", 89, 92], ["FK506", "SIMPLE_CHEMICAL", 96, 101], ["reporter plasmids", "DNA", 17, 34], ["fcwf-4 cells", "CELL_LINE", 60, 72], ["the two reporter plasmids", "TREATMENT", 9, 34], ["CsA", "TREATMENT", 89, 92], ["FK506", "TREATMENT", 96, 101]]], ["Recombinant feline IFN\u03b1 (PBL Biomedical Laboratories, NJ, USA) was added at a concentration of 10 units/mL to the culture medium to evaluate the response to interferon (IFN).", [["feline", "ORGANISM", 12, 18], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 19, 23], ["interferon", "GENE_OR_GENE_PRODUCT", 157, 167], ["IFN", "GENE_OR_GENE_PRODUCT", 169, 172], ["interferon", "PROTEIN", 157, 167], ["IFN", "PROTEIN", 169, 172], ["feline", "SPECIES", 12, 18], ["the culture medium", "TEST", 110, 128], ["interferon (IFN)", "TREATMENT", 157, 173]]], ["Total cell lysates were prepared with Reporter Lysis buffer provided with the Dual-Luciferase Reporter Assay System at 48 h before the assay.", [["cell lysates", "ANATOMY", 6, 18], ["cell lysates", "ORGANISM_SUBSTANCE", 6, 18], ["Total cell lysates", "TREATMENT", 0, 18], ["Reporter Lysis buffer", "TREATMENT", 38, 59], ["the assay", "TEST", 131, 140], ["cell lysates", "OBSERVATION", 6, 18]]], ["Luciferase activities were quantified in triplicate assays using a Lumat LB9507 (Berthold Technologies, Tokyo, Japan).Western blotting ::: Materials and methodsThe cell membranes were disrupted with cell lysis buffer [10 mM Tris\u2013HCl, pH 7.8, 1 mM ethylenediamine tetraacetic acid (EDTA), 1 % NP-40, 0.15 M NaCl] including Complete Mini (Roche Diagnostics, Tokyo, Japan) at 20 h after infection.", [["cell membranes", "ANATOMY", 164, 178], ["cell", "ANATOMY", 199, 203], ["Tris\u2013HCl", "CHEMICAL", 224, 232], ["ethylenediamine tetraacetic acid", "CHEMICAL", 247, 279], ["EDTA", "CHEMICAL", 281, 285], ["NaCl", "CHEMICAL", 306, 310], ["infection", "DISEASE", 384, 393], ["Tris\u2013HCl", "CHEMICAL", 224, 232], ["ethylenediamine tetraacetic acid", "CHEMICAL", 247, 279], ["EDTA", "CHEMICAL", 281, 285], ["NaCl", "CHEMICAL", 306, 310], ["cell membranes", "CELLULAR_COMPONENT", 164, 178], ["cell", "CELL", 199, 203], ["Tris\u2013HCl", "SIMPLE_CHEMICAL", 224, 232], ["ethylenediamine tetraacetic acid", "SIMPLE_CHEMICAL", 247, 279], ["EDTA", "SIMPLE_CHEMICAL", 281, 285], ["NP-40", "SIMPLE_CHEMICAL", 292, 297], ["Luciferase activities", "TEST", 0, 21], ["cell lysis buffer", "TREATMENT", 199, 216], ["Tris\u2013HCl", "TEST", 224, 232], ["pH", "TEST", 234, 236], ["1 mM ethylenediamine tetraacetic acid", "TREATMENT", 242, 279], ["EDTA", "TEST", 281, 285], ["NP", "TEST", 292, 294], ["infection", "PROBLEM", 384, 393], ["cell membranes", "OBSERVATION", 164, 178], ["cell lysis", "OBSERVATION", 199, 209], ["infection", "OBSERVATION", 384, 393]]], ["The cell lysates were resolved by electrophoresis on 4-12 % Bis-Tris gels (Invitrogen, CA, USA) and Western blotted onto Immobilon-P membranes (Millipore, Tokyo, Japan).", [["cell lysates", "ANATOMY", 4, 16], ["Immobilon-P membranes", "ANATOMY", 121, 142], ["Bis-Tris", "CHEMICAL", 60, 68], ["Bis-Tris gels", "CHEMICAL", 60, 73], ["cell lysates", "CELL", 4, 16], ["Bis-Tris gels", "SIMPLE_CHEMICAL", 60, 73], ["The cell lysates", "TEST", 0, 16], ["electrophoresis", "TEST", 34, 49], ["Invitrogen", "TEST", 75, 85], ["Immobilon-P membranes (Millipore", "TREATMENT", 121, 153], ["cell lysates", "OBSERVATION", 4, 16]]], ["Non-specific protein binding was blocked with 5 % non-fat dry milk for 1 h and then the membranes were incubated with anti-feline coronavirus nucleocapsid (N) antibody (FIPV3-70; MyBioSource, CA, USA) or anti-\u03b2-actin (Sigma-Aldrich) for 1 h.", [["milk", "ANATOMY", 62, 66], ["membranes", "ANATOMY", 88, 97], ["anti-\u03b2-actin", "CHEMICAL", 204, 216], ["anti-\u03b2-actin", "CHEMICAL", 204, 216], ["milk", "ORGANISM_SUBSTANCE", 62, 66], ["membranes", "CELLULAR_COMPONENT", 88, 97], ["coronavirus nucleocapsid", "ORGANISM", 130, 154], ["anti-\u03b2-actin", "SIMPLE_CHEMICAL", 204, 216], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 218, 231], ["anti-feline coronavirus nucleocapsid (N) antibody", "PROTEIN", 118, 167], ["FIPV3", "PROTEIN", 169, 174], ["anti-\u03b2-actin", "PROTEIN", 204, 216], ["Non-specific protein binding", "PROBLEM", 0, 28], ["5 % non-fat dry milk", "TREATMENT", 46, 66], ["anti-feline coronavirus nucleocapsid", "PROBLEM", 118, 154], ["antibody", "TEST", 159, 167], ["FIPV3", "TEST", 169, 174], ["MyBioSource", "TREATMENT", 179, 190], ["anti-\u03b2-actin (Sigma-Aldrich)", "TREATMENT", 204, 232]]], ["Antigen signals were visualized by reacting proteins on the membranes with horseradish peroxidase-conjugated anti-mouse IgG antibody (Promega) followed by an enhanced chemiluminescence substrate (SuperSignal West Femto Maximum Sensitivity Substrate; Thermo Scientific, Tokyo, Japan) according to the manufacturer\u2019s protocol.Cell viability assay ::: Materials and methodsWe assayed WST-8 to evaluate cytotoxicity using the Cell Counting Kit-8 (Dojin Chemical Inc., Wako, Japan) according to the manufacturer\u2019s directions.Statistical analysis ::: Materials and methodsStatistical significance was determined using the Student\u2019s t test.", [["membranes", "ANATOMY", 60, 69], ["Cell", "ANATOMY", 324, 328], ["Cell", "ANATOMY", 422, 426], ["membranes", "CELLULAR_COMPONENT", 60, 69], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 75, 97], ["Cell", "CELL", 324, 328], ["WST-8", "CELL", 381, 386], ["Cell", "CELL", 422, 426], ["horseradish peroxidase", "PROTEIN", 75, 97], ["conjugated anti-mouse IgG antibody", "PROTEIN", 98, 132], ["WST", "PROTEIN", 381, 384], ["horseradish", "SPECIES", 75, 86], ["Antigen signals", "TEST", 0, 15], ["horseradish peroxidase", "TEST", 75, 97], ["conjugated anti-mouse IgG antibody", "TREATMENT", 98, 132], ["an enhanced chemiluminescence substrate", "TREATMENT", 155, 194], ["WST", "TEST", 381, 384], ["cytotoxicity", "TEST", 399, 411], ["the Cell Counting Kit", "TEST", 418, 439], ["Wako", "TREATMENT", 464, 468]]], ["For all data analyzed, a significance threshold of P < 0.05 was assumed.", [["all data", "TEST", 4, 12]]], ["The values are expressed in some figures as means \u00b1 standard deviation (SD).Inhibition of FIPV replication by CsA but not by FK506 ::: ResultsWe initially assessed the effects of CsA on FIPV RNA replication using cytotoxicity assays.", [["CsA", "CHEMICAL", 110, 113], ["FK506", "CHEMICAL", 125, 130], ["CsA", "CHEMICAL", 179, 182], ["CsA", "CHEMICAL", 110, 113], ["FK506", "CHEMICAL", 125, 130], ["CsA", "CHEMICAL", 179, 182], ["FIPV", "GENE_OR_GENE_PRODUCT", 90, 94], ["CsA", "SIMPLE_CHEMICAL", 110, 113], ["FK506", "SIMPLE_CHEMICAL", 125, 130], ["CsA", "SIMPLE_CHEMICAL", 179, 182], ["FIPV", "SIMPLE_CHEMICAL", 186, 190], ["FIPV", "SPECIES", 186, 190], ["FIPV replication", "TREATMENT", 90, 106], ["CsA", "TREATMENT", 179, 182], ["FIPV RNA replication", "TREATMENT", 186, 206], ["cytotoxicity assays", "TEST", 213, 232], ["FIPV replication", "OBSERVATION", 90, 106]]], ["Cyclosporin A at concentrations of 0\u20136.3 \u03bcM (cytotoxic dose50, 14.1 \u00b1 1.72 \u03bcM) did not affect fcwf-4 cell viability (Figure 1A) and dose-dependently reduced the numbers of FIPV plaques (Figure 1B), whereas 10 \u03bcM CsA was slightly cytotoxic.", [["fcwf-4 cell", "ANATOMY", 94, 105], ["Cyclosporin A", "CHEMICAL", 0, 13], ["CsA", "CHEMICAL", 212, 215], ["Cyclosporin A", "CHEMICAL", 0, 13], ["CsA", "CHEMICAL", 212, 215], ["Cyclosporin A", "SIMPLE_CHEMICAL", 0, 13], ["fcwf-4 cell", "CELL", 94, 105], ["CsA", "SIMPLE_CHEMICAL", 212, 215], ["FIPV", "SPECIES", 172, 176], ["Cyclosporin", "TREATMENT", 0, 11], ["FIPV plaques", "PROBLEM", 172, 184], ["CsA", "TEST", 212, 215], ["slightly cytotoxic", "PROBLEM", 220, 238], ["FIPV plaques", "OBSERVATION", 172, 184]]], ["Cyclosporin A blocks both the enzymatic activities of CyP that lead to the calcineurin (CN)-NF-AT and the P-glycoprotein pathway.", [["Cyclosporin A", "CHEMICAL", 0, 13], ["Cyclosporin A", "CHEMICAL", 0, 13], ["Cyclosporin A", "SIMPLE_CHEMICAL", 0, 13], ["CyP", "SIMPLE_CHEMICAL", 54, 57], ["calcineurin", "GENE_OR_GENE_PRODUCT", 75, 86], ["NF-AT", "GENE_OR_GENE_PRODUCT", 92, 97], ["CyP", "PROTEIN", 54, 57], ["calcineurin", "PROTEIN", 75, 86], ["CN", "PROTEIN", 88, 90], ["NF", "PROTEIN", 92, 94], ["glycoprotein", "PROTEIN", 108, 120], ["Cyclosporin A blocks", "TREATMENT", 0, 20], ["CyP", "TREATMENT", 54, 57], ["the calcineurin (CN", "TREATMENT", 71, 90], ["the P-glycoprotein pathway", "TREATMENT", 102, 128]]], ["We therefore assessed the effect of various concentrations of FK506, which also blocks the NF-AT pathway, on cell viability to confirm that CsA inhibited FIPV through this pathway.", [["cell", "ANATOMY", 109, 113], ["FK506", "CHEMICAL", 62, 67], ["CsA", "CHEMICAL", 140, 143], ["FIPV", "CHEMICAL", 154, 158], ["FK506", "CHEMICAL", 62, 67], ["CsA", "CHEMICAL", 140, 143], ["FK506", "SIMPLE_CHEMICAL", 62, 67], ["NF-AT", "GENE_OR_GENE_PRODUCT", 91, 96], ["cell", "CELL", 109, 113], ["CsA", "SIMPLE_CHEMICAL", 140, 143], ["FIPV", "GENE_OR_GENE_PRODUCT", 154, 158], ["FIPV", "PROTEIN", 154, 158], ["various concentrations of FK506", "TREATMENT", 36, 67], ["cell viability", "TREATMENT", 109, 123], ["CsA", "PROBLEM", 140, 143], ["this pathway", "TREATMENT", 167, 179]]], ["The cytopathic inhibitory effects did not significantly differ in the presence or absence of 0.08 - 10 \u03bcM FK506 (Figure 2B) and cell viability was not affected by 10 \u03bcM FK506 (Figure 2A).Inhibition of FIPV replication by CsA but not by FK506 ::: ResultsQuantitative RT-PCR showed that 0.63 - 10 \u03bcM CsA dose-dependently suppressed FIPV RNA replication, whereas FK506 did not exert significant inhibitory effects, except at 10 \u03bcM FK506 (approximately 30 % reduction compared to 0 \u03bcM FK506, P < 0.05; Figure 3A).", [["cell", "ANATOMY", 128, 132], ["FK506", "CHEMICAL", 106, 111], ["FK506", "CHEMICAL", 169, 174], ["CsA", "CHEMICAL", 221, 224], ["FK506", "CHEMICAL", 236, 241], ["CsA", "CHEMICAL", 298, 301], ["FK506", "CHEMICAL", 360, 365], ["FK506", "CHEMICAL", 428, 433], ["FK506", "CHEMICAL", 481, 486], ["FK506", "CHEMICAL", 106, 111], ["FK506", "CHEMICAL", 169, 174], ["CsA", "CHEMICAL", 221, 224], ["FK506", "CHEMICAL", 236, 241], ["CsA", "CHEMICAL", 298, 301], ["FK506", "CHEMICAL", 360, 365], ["FK506", "CHEMICAL", 428, 433], ["FK506", "CHEMICAL", 481, 486], ["FK506", "SIMPLE_CHEMICAL", 106, 111], ["cell", "CELL", 128, 132], ["FK506", "SIMPLE_CHEMICAL", 169, 174], ["FIPV", "GENE_OR_GENE_PRODUCT", 201, 205], ["CsA", "SIMPLE_CHEMICAL", 221, 224], ["FK506", "SIMPLE_CHEMICAL", 236, 241], ["CsA", "SIMPLE_CHEMICAL", 298, 301], ["FIPV", "GENE_OR_GENE_PRODUCT", 330, 334], ["FK506", "SIMPLE_CHEMICAL", 360, 365], ["FK506", "SIMPLE_CHEMICAL", 428, 433], ["FK506", "SIMPLE_CHEMICAL", 481, 486], ["FIPV RNA", "RNA", 330, 338], ["FIPV", "SPECIES", 330, 334], ["The cytopathic inhibitory effects", "PROBLEM", 0, 33], ["cell viability", "TEST", 128, 142], ["FIPV replication", "TREATMENT", 201, 217], ["PCR", "TEST", 269, 272], ["CsA dose", "TEST", 298, 306], ["dependently suppressed FIPV RNA replication", "TREATMENT", 307, 350], ["significant inhibitory effects", "PROBLEM", 380, 410], ["cytopathic", "OBSERVATION_MODIFIER", 4, 14], ["FIPV replication", "OBSERVATION", 201, 217]]], ["Western blotting showed that CsA, but not FK506 dose-dependently decreased FIPV-N protein (Figure 3B).Inhibition of FIPV replication by CsA but not by FK506 ::: ResultsWe then examined whether the suppressive effects of CsA on FIPV replication depend on the inhibitory NF-AT pathway or P-glycoprotein pathway by incubating FIPV-infected cells with CsH, which specifically blocks the P-glycoprotein pathway.", [["cells", "ANATOMY", 337, 342], ["CsA", "CHEMICAL", 29, 32], ["FK506", "CHEMICAL", 42, 47], ["CsA", "CHEMICAL", 136, 139], ["FK506", "CHEMICAL", 151, 156], ["CsA", "CHEMICAL", 220, 223], ["FIPV", "CHEMICAL", 323, 327], ["CsH", "CHEMICAL", 348, 351], ["CsA", "CHEMICAL", 29, 32], ["FK506", "CHEMICAL", 42, 47], ["CsA", "CHEMICAL", 136, 139], ["FK506", "CHEMICAL", 151, 156], ["CsA", "CHEMICAL", 220, 223], ["CsH", "CHEMICAL", 348, 351], ["CsA", "SIMPLE_CHEMICAL", 29, 32], ["FK506", "SIMPLE_CHEMICAL", 42, 47], ["FIPV-N", "GENE_OR_GENE_PRODUCT", 75, 81], ["FIPV", "GENE_OR_GENE_PRODUCT", 116, 120], ["CsA", "SIMPLE_CHEMICAL", 136, 139], ["FK506", "SIMPLE_CHEMICAL", 151, 156], ["CsA", "SIMPLE_CHEMICAL", 220, 223], ["FIPV", "SIMPLE_CHEMICAL", 227, 231], ["NF-AT", "GENE_OR_GENE_PRODUCT", 269, 274], ["FIPV", "GENE_OR_GENE_PRODUCT", 323, 327], ["cells", "CELL", 337, 342], ["CsH", "SIMPLE_CHEMICAL", 348, 351], ["FIPV", "PROTEIN", 75, 79], ["N protein", "PROTEIN", 80, 89], ["Figure 3B", "PROTEIN", 91, 100], ["glycoprotein", "PROTEIN", 288, 300], ["FIPV", "PROTEIN", 323, 327], ["CsH", "PROTEIN", 348, 351], ["P", "DNA", 383, 384], ["glycoprotein", "PROTEIN", 385, 397], ["Western blotting", "TEST", 0, 16], ["CsA", "TEST", 29, 32], ["dependently decreased FIPV", "PROBLEM", 53, 79], ["FIPV replication", "TREATMENT", 116, 132], ["CsA", "TREATMENT", 220, 223], ["FIPV replication", "TREATMENT", 227, 243], ["P-glycoprotein pathway", "TREATMENT", 286, 308], ["infected cells", "PROBLEM", 328, 342], ["CsH", "PROBLEM", 348, 351], ["FIPV replication", "OBSERVATION", 116, 132], ["infected cells", "OBSERVATION", 328, 342]]], ["The results show that no inhibition occurred (data not shown).CsA does not elicit either an interferon-stimulated response or a NF-AT response in fcwf-4 cells ::: ResultsTo determine whether the action of CsA and FK506 involves activation of interferon-stimulated gene responses in fcwf-4 cells, the ISRE-luciferase reporter plasmid, pISRE-TK hRluc (F) and pGL3 promoter plasmid as a normalization-control plasmid were transfected into fcwf-4 cells and cultured with feline interferon \u03b1, CsA or FK506.", [["fcwf-4 cells", "ANATOMY", 146, 158], ["fcwf-4 cells", "ANATOMY", 282, 294], ["plasmid", "ANATOMY", 406, 413], ["fcwf-4 cells", "ANATOMY", 436, 448], ["CsA", "CHEMICAL", 62, 65], ["CsA", "CHEMICAL", 205, 208], ["FK506", "CHEMICAL", 213, 218], ["CsA", "CHEMICAL", 488, 491], ["FK506", "CHEMICAL", 495, 500], ["CsA", "CHEMICAL", 62, 65], ["CsA", "CHEMICAL", 205, 208], ["FK506", "CHEMICAL", 213, 218], ["CsA", "CHEMICAL", 488, 491], ["FK506", "CHEMICAL", 495, 500], ["CsA", "SIMPLE_CHEMICAL", 62, 65], ["interferon", "GENE_OR_GENE_PRODUCT", 92, 102], ["NF-AT", "GENE_OR_GENE_PRODUCT", 128, 133], ["fcwf-4 cells", "CELL", 146, 158], ["CsA", "SIMPLE_CHEMICAL", 205, 208], ["FK506", "SIMPLE_CHEMICAL", 213, 218], ["interferon-stimulated gene", "GENE_OR_GENE_PRODUCT", 242, 268], ["fcwf-4 cells", "CELL", 282, 294], ["luciferase", "GENE_OR_GENE_PRODUCT", 305, 315], ["pISRE-TK hRluc (F)", "GENE_OR_GENE_PRODUCT", 334, 352], ["pGL3", "GENE_OR_GENE_PRODUCT", 357, 361], ["fcwf-4 cells", "CELL", 436, 448], ["feline", "ORGANISM", 467, 473], ["interferon \u03b1", "GENE_OR_GENE_PRODUCT", 474, 486], ["CsA", "SIMPLE_CHEMICAL", 488, 491], ["FK506", "SIMPLE_CHEMICAL", 495, 500], ["interferon", "PROTEIN", 92, 102], ["fcwf-4 cells", "CELL_LINE", 146, 158], ["interferon", "PROTEIN", 242, 252], ["fcwf-4 cells", "CELL_LINE", 282, 294], ["ISRE-luciferase reporter plasmid", "DNA", 300, 332], ["pISRE", "DNA", 334, 339], ["TK hRluc (F)", "DNA", 340, 352], ["pGL3 promoter plasmid", "DNA", 357, 378], ["normalization-control plasmid", "DNA", 384, 413], ["fcwf-4 cells", "CELL_LINE", 436, 448], ["inhibition", "PROBLEM", 25, 35], ["CsA", "TREATMENT", 205, 208], ["FK506", "TREATMENT", 213, 218], ["interferon", "TREATMENT", 242, 252], ["fcwf", "TEST", 282, 286], ["the ISRE", "TEST", 296, 304], ["plasmid", "TEST", 325, 332], ["pISRE", "TEST", 334, 339], ["pGL3 promoter plasmid", "TREATMENT", 357, 378], ["a normalization-control plasmid", "TREATMENT", 382, 413], ["feline interferon", "TREATMENT", 467, 484], ["CsA", "TREATMENT", 488, 491], ["FK506", "TREATMENT", 495, 500]]], ["The results of the dual-luciferase assay showed that none of these factors significantly affected luciferase activities at 48 h after transfection.", [["luciferase", "GENE_OR_GENE_PRODUCT", 24, 34], ["luciferase", "GENE_OR_GENE_PRODUCT", 98, 108], ["luciferase", "PROTEIN", 24, 34], ["luciferase", "PROTEIN", 98, 108], ["the dual-luciferase assay", "TEST", 15, 40], ["these factors", "PROBLEM", 61, 74]]], ["These results indicate that fcwf-4 cells are unresponsive, even to interferon \u03b1 (Figure 4A).", [["fcwf-4 cells", "ANATOMY", 28, 40], ["fcwf-4 cells", "CELL", 28, 40], ["interferon \u03b1", "GENE_OR_GENE_PRODUCT", 67, 79], ["Figure 4A", "GENE_OR_GENE_PRODUCT", 81, 90], ["fcwf-4 cells", "CELL_LINE", 28, 40], ["interferon \u03b1", "PROTEIN", 67, 79], ["Figure 4A", "PROTEIN", 81, 90], ["fcwf-4 cells", "PROBLEM", 28, 40], ["unresponsive", "PROBLEM", 45, 57]]], ["Consequently, the action of CsA on intracellular FIPV replication does not involve the activation of interferon-stimulated genes on fcwf-4 cells.", [["intracellular", "ANATOMY", 35, 48], ["fcwf-4 cells", "ANATOMY", 132, 144], ["CsA", "CHEMICAL", 28, 31], ["CsA", "CHEMICAL", 28, 31], ["CsA", "SIMPLE_CHEMICAL", 28, 31], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 35, 48], ["fcwf-4 cells", "CELL", 132, 144], ["interferon-stimulated genes", "DNA", 101, 128], ["fcwf-4 cells", "CELL_LINE", 132, 144], ["CsA", "TREATMENT", 28, 31], ["intracellular FIPV replication", "TREATMENT", 35, 65], ["interferon", "TREATMENT", 101, 111]]], ["Moreover, to evaluate the effects of CsA and FK506 on the calcineurin-NF-AT pathway in fcwf-4 cells, the NF-AT luciferase reporter plasmid, pGL4.30 [luc2P/NFAT-RE/Hygro] and pRL-SV40 as a normalization-control plasmid were transfected into fcwf-4 cells that had been incubated with CsA or FK506.", [["fcwf-4 cells", "ANATOMY", 87, 99], ["plasmid", "ANATOMY", 210, 217], ["fcwf-4 cells", "ANATOMY", 240, 252], ["CsA", "CHEMICAL", 37, 40], ["FK506", "CHEMICAL", 45, 50], ["CsA", "CHEMICAL", 282, 285], ["FK506", "CHEMICAL", 289, 294], ["CsA", "CHEMICAL", 37, 40], ["FK506", "CHEMICAL", 45, 50], ["CsA", "CHEMICAL", 282, 285], ["FK506", "CHEMICAL", 289, 294], ["CsA", "SIMPLE_CHEMICAL", 37, 40], ["FK506", "SIMPLE_CHEMICAL", 45, 50], ["calcineurin", "GENE_OR_GENE_PRODUCT", 58, 69], ["NF-AT", "GENE_OR_GENE_PRODUCT", 70, 75], ["fcwf-4 cells", "CELL", 87, 99], ["NF-AT luciferase", "GENE_OR_GENE_PRODUCT", 105, 121], ["pGL4.30", "GENE_OR_GENE_PRODUCT", 140, 147], ["luc2P", "GENE_OR_GENE_PRODUCT", 149, 154], ["NFAT-RE", "GENE_OR_GENE_PRODUCT", 155, 162], ["pRL-SV40", "GENE_OR_GENE_PRODUCT", 174, 182], ["fcwf-4 cells", "CELL", 240, 252], ["CsA", "SIMPLE_CHEMICAL", 282, 285], ["FK506", "SIMPLE_CHEMICAL", 289, 294], ["calcineurin", "PROTEIN", 58, 69], ["NF", "PROTEIN", 70, 72], ["fcwf-4 cells", "CELL_LINE", 87, 99], ["NF-AT luciferase reporter plasmid", "DNA", 105, 138], ["pGL4.30", "DNA", 140, 147], ["luc2P", "DNA", 149, 154], ["NFAT", "DNA", 155, 159], ["RE", "DNA", 160, 162], ["Hygro", "DNA", 163, 168], ["pRL", "DNA", 174, 177], ["SV40", "DNA", 178, 182], ["normalization-control plasmid", "DNA", 188, 217], ["fcwf-4 cells", "CELL_LINE", 240, 252], ["CsA", "TEST", 37, 40], ["FK506", "TREATMENT", 45, 50], ["the calcineurin", "TREATMENT", 54, 69], ["the NF", "TEST", 101, 107], ["plasmid", "TEST", 131, 138], ["pGL4", "TEST", 140, 144], ["luc2P/NFAT", "TREATMENT", 149, 159], ["RE/Hygro]", "TREATMENT", 160, 169], ["pRL", "TREATMENT", 174, 177], ["SV40", "TREATMENT", 178, 182], ["a normalization-control plasmid", "TREATMENT", 186, 217], ["CsA", "TREATMENT", 282, 285], ["FK506", "TREATMENT", 289, 294]]], ["Neither CsA nor FK506 affected NF-AT luciferase activities in fcwf-4 cells (Figure 4B).", [["fcwf-4 cells", "ANATOMY", 62, 74], ["CsA", "CHEMICAL", 8, 11], ["FK506", "CHEMICAL", 16, 21], ["CsA", "CHEMICAL", 8, 11], ["FK506", "CHEMICAL", 16, 21], ["CsA", "SIMPLE_CHEMICAL", 8, 11], ["FK506", "SIMPLE_CHEMICAL", 16, 21], ["NF-AT luciferase", "GENE_OR_GENE_PRODUCT", 31, 47], ["fcwf-4 cells", "CELL", 62, 74], ["luciferase", "PROTEIN", 37, 47], ["fcwf-4 cells", "CELL_LINE", 62, 74], ["CsA", "TEST", 8, 11], ["affected NF", "PROBLEM", 22, 33], ["fcwf", "TEST", 62, 66]]], ["These findings show that CsA does not influence the NF-AT pathway in fcwf-4 cells and that the inhibition of FIPV RNA replication by CsA is independent of the calcineurin NF-AT pathway.DiscussionWe discovered that CsA inhibits intracellular FIPV replication in vitro.", [["fcwf-4 cells", "ANATOMY", 69, 81], ["intracellular", "ANATOMY", 227, 240], ["CsA", "CHEMICAL", 25, 28], ["CsA", "CHEMICAL", 133, 136], ["CsA", "CHEMICAL", 214, 217], ["CsA", "CHEMICAL", 25, 28], ["CsA", "CHEMICAL", 133, 136], ["CsA", "CHEMICAL", 214, 217], ["CsA", "SIMPLE_CHEMICAL", 25, 28], ["NF-AT", "GENE_OR_GENE_PRODUCT", 52, 57], ["fcwf-4 cells", "CELL", 69, 81], ["FIPV", "GENE_OR_GENE_PRODUCT", 109, 113], ["CsA", "SIMPLE_CHEMICAL", 133, 136], ["calcineurin", "GENE_OR_GENE_PRODUCT", 159, 170], ["NF-AT", "GENE_OR_GENE_PRODUCT", 171, 176], ["CsA", "SIMPLE_CHEMICAL", 214, 217], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 227, 240], ["FIPV", "SIMPLE_CHEMICAL", 241, 245], ["fcwf-4 cells", "CELL_LINE", 69, 81], ["FIPV RNA", "RNA", 109, 117], ["calcineurin", "PROTEIN", 159, 170], ["NF", "PROTEIN", 171, 173], ["FIPV", "SPECIES", 109, 113], ["the NF", "PROBLEM", 48, 54], ["FIPV RNA replication", "TREATMENT", 109, 129], ["the calcineurin NF", "TREATMENT", 155, 173], ["intracellular FIPV replication", "TREATMENT", 227, 257], ["FIPV RNA", "OBSERVATION", 109, 117], ["FIPV replication", "OBSERVATION", 241, 257]]], ["The results of qRT-PCR and Western blotting showed that viral proliferation was strikingly inhibited at CsA concentrations between 0.16 and 10 \u03bcM.", [["CsA", "CHEMICAL", 104, 107], ["CsA", "CHEMICAL", 104, 107], ["CsA", "SIMPLE_CHEMICAL", 104, 107], ["qRT-PCR", "TEST", 15, 22], ["Western blotting", "TEST", 27, 43], ["viral proliferation", "PROBLEM", 56, 75], ["viral proliferation", "OBSERVATION", 56, 75]]], ["The results of cell viability assays showed that 10 \u03bcM CsA was slightly cytotoxic.", [["cell", "ANATOMY", 15, 19], ["CsA", "CHEMICAL", 55, 58], ["CsA", "CHEMICAL", 55, 58], ["cell", "CELL", 15, 19], ["CsA", "SIMPLE_CHEMICAL", 55, 58], ["cell viability assays", "TEST", 15, 36], ["CsA", "TEST", 55, 58], ["slightly cytotoxic", "PROBLEM", 63, 81], ["slightly", "OBSERVATION_MODIFIER", 63, 71], ["cytotoxic", "OBSERVATION_MODIFIER", 72, 81]]], ["The inhibitory effects at this concentration should therefore be considered in the light of cytotoxicity.", [["cytotoxicity", "PROBLEM", 92, 104]]], ["In contrast, immunosuppressive FK506 did not inhibit FIPV replication except at 10 \u03bcM according to the qRT-PCR findings.", [["FK506", "CHEMICAL", 31, 36], ["FK506", "CHEMICAL", 31, 36], ["FK506", "SIMPLE_CHEMICAL", 31, 36], ["FIPV", "SIMPLE_CHEMICAL", 53, 57], ["FIPV", "SPECIES", 53, 57], ["immunosuppressive FK506", "TREATMENT", 13, 36], ["FIPV replication", "TREATMENT", 53, 69], ["the qRT", "TEST", 99, 106]]], ["However, the inhibitory effects of 0.08 - 10 \u03bcM FK506 did not significantly differ on Western blots and the number of plaques did not significantly differ within the same concentration range of FK506.", [["plaques", "ANATOMY", 118, 125], ["FK506", "CHEMICAL", 48, 53], ["FK506", "CHEMICAL", 194, 199], ["FK506", "CHEMICAL", 48, 53], ["FK506", "CHEMICAL", 194, 199], ["FK506", "SIMPLE_CHEMICAL", 48, 53], ["FK506", "SIMPLE_CHEMICAL", 194, 199], ["Western blots", "TEST", 86, 99], ["plaques", "PROBLEM", 118, 125], ["FK506", "TREATMENT", 194, 199], ["plaques", "OBSERVATION", 118, 125]]], ["These findings might be related to the difference of the analytical detection sensitivity between qRT-PCR and Western blot assays.", [["the analytical detection sensitivity", "TEST", 53, 89], ["qRT", "TEST", 98, 101], ["Western blot assays", "TEST", 110, 129], ["might be related to", "UNCERTAINTY", 15, 34]]], ["Cyclosporin A binds cyclophilins, whereas FK506 binds cellular FKBP.", [["cellular", "ANATOMY", 54, 62], ["Cyclosporin A", "CHEMICAL", 0, 13], ["FK506", "CHEMICAL", 42, 47], ["Cyclosporin A", "CHEMICAL", 0, 13], ["FK506", "CHEMICAL", 42, 47], ["Cyclosporin A", "SIMPLE_CHEMICAL", 0, 13], ["cyclophilins", "SIMPLE_CHEMICAL", 20, 32], ["FK506", "SIMPLE_CHEMICAL", 42, 47], ["cellular FKBP", "GENE_OR_GENE_PRODUCT", 54, 67], ["FKBP", "PROTEIN", 63, 67], ["Cyclosporin A binds cyclophilins", "TREATMENT", 0, 32], ["cellular FKBP", "TEST", 54, 67], ["cellular FKBP", "OBSERVATION", 54, 67]]], ["Each complex independently inhibits the phosphatase activity of calcineurin that mediates the NF-AT pathway, which is critical to the expression of cytokines and their receptors [12,17].", [["calcineurin", "GENE_OR_GENE_PRODUCT", 64, 75], ["NF-AT", "GENE_OR_GENE_PRODUCT", 94, 99], ["phosphatase", "PROTEIN", 40, 51], ["calcineurin", "PROTEIN", 64, 75], ["cytokines", "PROTEIN", 148, 157], ["calcineurin", "TREATMENT", 64, 75]]], ["The results of NF-AT reporter assays indicate that neither CsA nor FK506 influenced NF-AT activities on fcwf-4 cells under our experimental conditions.", [["fcwf-4 cells", "ANATOMY", 104, 116], ["CsA", "CHEMICAL", 59, 62], ["FK506", "CHEMICAL", 67, 72], ["CsA", "CHEMICAL", 59, 62], ["FK506", "CHEMICAL", 67, 72], ["NF-AT", "GENE_OR_GENE_PRODUCT", 15, 20], ["CsA", "SIMPLE_CHEMICAL", 59, 62], ["FK506", "SIMPLE_CHEMICAL", 67, 72], ["NF-AT", "GENE_OR_GENE_PRODUCT", 84, 89], ["fcwf-4 cells", "CELL", 104, 116], ["fcwf-4 cells", "CELL_LINE", 104, 116], ["NF-AT reporter assays", "TEST", 15, 36], ["CsA", "TEST", 59, 62], ["fcwf", "TEST", 104, 108]]], ["Thus, the antiviral activity against FIPV is not involved in the suppression of gene responses regulated by NF-AT but instead is exerted through distinct mechanisms that are independent of FK506.", [["FIPV", "CHEMICAL", 37, 41], ["FK506", "CHEMICAL", 189, 194], ["FK506", "CHEMICAL", 189, 194], ["FIPV", "GENE_OR_GENE_PRODUCT", 37, 41], ["NF-AT", "GENE_OR_GENE_PRODUCT", 108, 113], ["FK506", "SIMPLE_CHEMICAL", 189, 194], ["FIPV", "PROTEIN", 37, 41], ["NF", "PROTEIN", 108, 110], ["FIPV", "SPECIES", 37, 41], ["FIPV", "PROBLEM", 37, 41]]], ["Pfefferle et al. recently described that SARS-coronavirus NSP1 overexpression increases signaling through the NF-AT pathway and enhances the induction of interleukin 2 [18].", [["SARS", "DISEASE", 41, 45], ["SARS-coronavirus", "ORGANISM", 41, 57], ["NSP1", "GENE_OR_GENE_PRODUCT", 58, 62], ["NF-AT", "GENE_OR_GENE_PRODUCT", 110, 115], ["interleukin 2", "GENE_OR_GENE_PRODUCT", 154, 167], ["NSP1", "PROTEIN", 58, 62], ["NF", "PROTEIN", 110, 112], ["interleukin 2", "PROTEIN", 154, 167], ["SARS-coronavirus", "SPECIES", 41, 57], ["SARS", "PROBLEM", 41, 45], ["coronavirus NSP1 overexpression", "PROBLEM", 46, 77], ["the induction of interleukin", "TREATMENT", 137, 165]]], ["Our data were somewhat inconsistent with these findings.", [["Our data", "TEST", 0, 8]]], ["The discrepancy might be explained in part by the fact that their experimental system included the addition of 13-O-Acetylphorbol 12-myristate (PMA) and ionomycin to the culture medium.", [["13-O-Acetylphorbol 12-myristate", "CHEMICAL", 111, 142], ["PMA", "CHEMICAL", 144, 147], ["ionomycin", "CHEMICAL", 153, 162], ["13-O-Acetylphorbol 12-myristate", "CHEMICAL", 111, 142], ["PMA", "CHEMICAL", 144, 147], ["ionomycin", "CHEMICAL", 153, 162], ["13-O-Acetylphorbol 12-myristate", "SIMPLE_CHEMICAL", 111, 142], ["PMA", "SIMPLE_CHEMICAL", 144, 147], ["ionomycin", "SIMPLE_CHEMICAL", 153, 162], ["Acetylphorbol 12-myristate (PMA)", "TREATMENT", 116, 148], ["ionomycin", "TREATMENT", 153, 162], ["the culture medium", "TEST", 166, 184]]], ["Further knockdown studies of the NF-AT gene would clarify its role in FIPV proliferation.", [["FIPV", "ANATOMY", 70, 74], ["NF-AT", "GENE_OR_GENE_PRODUCT", 33, 38], ["FIPV", "CELL", 70, 74], ["NF-AT gene", "DNA", 33, 43], ["Further knockdown studies", "TEST", 0, 25], ["the NF", "TEST", 29, 35], ["FIPV proliferation", "PROBLEM", 70, 88], ["FIPV proliferation", "OBSERVATION", 70, 88]]], ["Furthermore, IFN\u03b1 did not stimulate ISRE-promoter activities in fcwf-4 cells under these conditions.", [["fcwf-4 cells", "ANATOMY", 64, 76], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 13, 17], ["ISRE", "GENE_OR_GENE_PRODUCT", 36, 40], ["fcwf-4 cells", "CELL", 64, 76], ["IFN\u03b1", "PROTEIN", 13, 17], ["ISRE", "DNA", 36, 40], ["fcwf-4 cells", "CELL_LINE", 64, 76]]], ["These data suggest that the action of CsA on the intracellular replication of FIPV is independent of the IFN pathway.", [["intracellular", "ANATOMY", 49, 62], ["CsA", "CHEMICAL", 38, 41], ["CsA", "CHEMICAL", 38, 41], ["CsA", "SIMPLE_CHEMICAL", 38, 41], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 49, 62], ["FIPV", "GENE_OR_GENE_PRODUCT", 78, 82], ["IFN", "GENE_OR_GENE_PRODUCT", 105, 108], ["FIPV", "PROTEIN", 78, 82], ["IFN", "PROTEIN", 105, 108], ["These data", "TEST", 0, 10], ["CsA", "TREATMENT", 38, 41], ["the intracellular replication of FIPV", "TREATMENT", 45, 82], ["the IFN pathway", "TREATMENT", 101, 116]]], ["This cell line might not be responsive to IFN\u03b1 and would thus be useful for isolating feline coronavirus.DiscussionCyclophilins have PPIase activity [13,19-21], contribute to the maturation of several proteins, and are involved in cell signaling, mitochondrial function (ATP synthesis), molecular chaperone activity, RNA splicing, stress response, gene expression, cholesterol transport, and the regulation of kinase activity [22-25].", [["cell line", "ANATOMY", 5, 14], ["cell", "ANATOMY", 231, 235], ["mitochondrial", "ANATOMY", 247, 260], ["feline coronavirus", "DISEASE", 86, 104], ["ATP", "CHEMICAL", 271, 274], ["cholesterol", "CHEMICAL", 365, 376], ["ATP", "CHEMICAL", 271, 274], ["cholesterol", "CHEMICAL", 365, 376], ["cell line", "CELL", 5, 14], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 42, 46], ["feline coronavirus", "ORGANISM", 86, 104], ["DiscussionCyclophilins", "GENE_OR_GENE_PRODUCT", 105, 127], ["PPIase", "GENE_OR_GENE_PRODUCT", 133, 139], ["cell", "CELL", 231, 235], ["mitochondrial", "CELLULAR_COMPONENT", 247, 260], ["ATP", "SIMPLE_CHEMICAL", 271, 274], ["cholesterol", "SIMPLE_CHEMICAL", 365, 376], ["IFN\u03b1", "PROTEIN", 42, 46], ["PPIase", "PROTEIN", 133, 139], ["feline coronavirus", "SPECIES", 86, 104], ["feline coronavirus", "SPECIES", 86, 104], ["This cell line", "TREATMENT", 0, 14], ["IFN", "TREATMENT", 42, 45], ["isolating feline coronavirus", "PROBLEM", 76, 104], ["ATP synthesis", "TREATMENT", 271, 284], ["molecular chaperone activity", "PROBLEM", 287, 315], ["RNA splicing", "PROBLEM", 317, 329], ["stress response", "PROBLEM", 331, 346], ["cholesterol transport", "TEST", 365, 386], ["kinase activity", "TEST", 410, 425], ["cell line", "OBSERVATION", 5, 14], ["might not be", "UNCERTAINTY", 15, 27]]], ["Surface plasmon resonance technology and bioinformatics tools have found that the SARS coronavirus N protein binds to CyPA [26-28].", [["SARS coronavirus", "ORGANISM", 82, 98], ["CyPA", "GENE_OR_GENE_PRODUCT", 118, 122], ["SARS coronavirus N protein", "PROTEIN", 82, 108], ["CyPA", "PROTEIN", 118, 122], ["SARS coronavirus", "SPECIES", 82, 98], ["Surface plasmon resonance technology", "TEST", 0, 36], ["bioinformatics tools", "TEST", 41, 61], ["the SARS coronavirus N protein binds", "TEST", 78, 114], ["CyPA", "TEST", 118, 122]]], ["Therefore, the N protein of FIPV probably binds to CyP proteins to regulate viral replication.", [["FIPV", "GENE_OR_GENE_PRODUCT", 28, 32], ["CyP", "GENE_OR_GENE_PRODUCT", 51, 54], ["N protein", "PROTEIN", 15, 24], ["FIPV", "PROTEIN", 28, 32], ["CyP proteins", "PROTEIN", 51, 63], ["the N protein of FIPV", "TREATMENT", 11, 32], ["CyP proteins", "TREATMENT", 51, 63], ["viral replication", "TREATMENT", 76, 93], ["viral replication", "OBSERVATION", 76, 93]]], ["The roles of CyP in virus replication and the inhibitory effect by CsA on HCV and several other viruses have been studied [22-25].", [["CsA", "CHEMICAL", 67, 70], ["CsA", "CHEMICAL", 67, 70], ["CyP", "GENE_OR_GENE_PRODUCT", 13, 16], ["CsA", "SIMPLE_CHEMICAL", 67, 70], ["HCV", "ORGANISM", 74, 77], ["CyP", "PROTEIN", 13, 16], ["HCV", "SPECIES", 74, 77], ["CyP in virus replication", "TREATMENT", 13, 37], ["CsA", "PROBLEM", 67, 70], ["HCV", "PROBLEM", 74, 77], ["several other viruses", "PROBLEM", 82, 103], ["CyP", "ANATOMY", 13, 16]]], ["The proposed mechanisms of the inhibitory effect of CsA mainly involve CypA and CypB in virus replication [23,29,30].", [["CsA", "CHEMICAL", 52, 55], ["CsA", "CHEMICAL", 52, 55], ["CsA", "SIMPLE_CHEMICAL", 52, 55], ["CypA", "GENE_OR_GENE_PRODUCT", 71, 75], ["CypB", "GENE_OR_GENE_PRODUCT", 80, 84], ["CypA", "PROTEIN", 71, 75], ["CypB", "PROTEIN", 80, 84], ["CsA", "TREATMENT", 52, 55], ["CypA", "TEST", 71, 75], ["CypA", "OBSERVATION", 71, 75]]], ["Based on these earlier findings, we believe that interaction between the FIPV genome is likely or that viral and CyP proteins play critical roles in viral replication and transcription.", [["FIPV", "GENE_OR_GENE_PRODUCT", 73, 77], ["CyP", "GENE_OR_GENE_PRODUCT", 113, 116], ["FIPV genome", "DNA", 73, 84], ["viral and CyP proteins", "PROTEIN", 103, 125], ["the FIPV genome", "PROBLEM", 69, 84], ["viral and CyP proteins", "PROBLEM", 103, 125], ["viral replication", "TREATMENT", 149, 166], ["FIPV genome", "OBSERVATION", 73, 84], ["is likely", "UNCERTAINTY", 85, 94], ["viral replication", "OBSERVATION", 149, 166]]], ["Further studies are required to resolve which CyP is critical for viral replication and which viral protein is required to form replication complexes with CyP and/or other cellular proteins.DiscussionCats with clinically diagnosed FIP have very rarely been cured, although several therapeutic strategies have been attempted.", [["cellular", "ANATOMY", 172, 180], ["FIP", "DISEASE", 231, 234], ["CyP", "GENE_OR_GENE_PRODUCT", 46, 49], ["CyP", "GENE_OR_GENE_PRODUCT", 155, 158], ["cellular", "CELL", 172, 180], ["CyP", "PROTEIN", 46, 49], ["viral protein", "PROTEIN", 94, 107], ["replication complexes", "PROTEIN", 128, 149], ["CyP", "PROTEIN", 155, 158], ["cellular proteins", "PROTEIN", 172, 189], ["Further studies", "TEST", 0, 15], ["viral replication", "PROBLEM", 66, 83], ["viral protein", "PROBLEM", 94, 107], ["CyP", "TEST", 155, 158], ["other cellular proteins", "PROBLEM", 166, 189], ["FIP", "PROBLEM", 231, 234]]], ["Some cats treated with prednisolone and phenylalanine mustard or cyclophosphamide have gone into remission [26].", [["prednisolone", "CHEMICAL", 23, 35], ["phenylalanine mustard", "CHEMICAL", 40, 61], ["cyclophosphamide", "CHEMICAL", 65, 81], ["prednisolone", "CHEMICAL", 23, 35], ["phenylalanine", "CHEMICAL", 40, 53], ["cyclophosphamide", "CHEMICAL", 65, 81], ["cats", "ORGANISM", 5, 9], ["prednisolone", "SIMPLE_CHEMICAL", 23, 35], ["phenylalanine mustard", "SIMPLE_CHEMICAL", 40, 61], ["cyclophosphamide", "SIMPLE_CHEMICAL", 65, 81], ["cats", "SPECIES", 5, 9], ["prednisolone", "TREATMENT", 23, 35], ["phenylalanine mustard", "TREATMENT", 40, 61], ["cyclophosphamide", "TREATMENT", 65, 81]]], ["Various immunosuppressants, such as glucocorticoids and cyclophosphamide, may prolong life but do not alter the fatal outcome [4].DiscussionFurther investigations using PPIase dominant-negative assays and RNA interference methods are warranted to clarify the role of CsA against PPIase in FIPV replication in vitro.", [["glucocorticoids", "CHEMICAL", 36, 51], ["cyclophosphamide", "CHEMICAL", 56, 72], ["CsA", "CHEMICAL", 267, 270], ["cyclophosphamide", "CHEMICAL", 56, 72], ["cyclophosphamide", "SIMPLE_CHEMICAL", 56, 72], ["PPIase", "GENE_OR_GENE_PRODUCT", 169, 175], ["CsA", "SIMPLE_CHEMICAL", 267, 270], ["PPIase", "GENE_OR_GENE_PRODUCT", 279, 285], ["FIPV", "GENE_OR_GENE_PRODUCT", 289, 293], ["PPIase", "PROTEIN", 169, 175], ["PPIase", "PROTEIN", 279, 285], ["FIPV", "SPECIES", 289, 293], ["Various immunosuppressants", "TREATMENT", 0, 26], ["glucocorticoids", "TREATMENT", 36, 51], ["cyclophosphamide", "TREATMENT", 56, 72], ["DiscussionFurther investigations", "TEST", 130, 162], ["PPIase dominant", "TEST", 169, 184], ["RNA interference methods", "TEST", 205, 229], ["PPIase", "TREATMENT", 279, 285], ["FIPV replication", "TREATMENT", 289, 305], ["FIPV replication", "OBSERVATION", 289, 305]]], ["In addition, whether CsA could be useful as FIP treatment in vivo remains to be determinedCompeting interestsThe authors declare that they have no competing interests.Authors\u2019 contributionsYT carried out all experiments, participated in the data collection and analysis, and prepared the manuscript.", [["CsA", "CHEMICAL", 21, 24], ["CsA", "CHEMICAL", 21, 24], ["CsA", "SIMPLE_CHEMICAL", 21, 24], ["CsA", "TEST", 21, 24], ["FIP treatment", "TREATMENT", 44, 57], ["the data collection", "TEST", 237, 256]]], ["SO, MI, and ST carried out cell culture and virus preparation.", [["cell", "ANATOMY", 27, 31], ["MI", "DISEASE", 4, 6], ["SO", "SIMPLE_CHEMICAL", 0, 2], ["cell", "CELL", 27, 31], ["MI", "PROBLEM", 4, 6], ["cell culture", "TEST", 27, 39], ["virus preparation", "TREATMENT", 44, 61], ["MI", "ANATOMY", 4, 6]]], ["YS performed some of the biochemical experiments and TS carried out luciferase assays.", [["luciferase", "GENE_OR_GENE_PRODUCT", 68, 78], ["luciferase", "PROTEIN", 68, 78], ["the biochemical experiments", "TEST", 21, 48], ["luciferase assays", "TEST", 68, 85]]]], "d8ffe10c4c92236a38d1d27b1c0d7575b7672ed0": [["MethodsDuring April 2015-December 2017, we conducted a case-control study among severe acute malnourished (SAM) children aged <5 years admitted to the Dhaka hospital of International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b).", [["Diarrhoeal Disease", "DISEASE", 194, 212], ["children", "ORGANISM", 112, 120], ["children", "SPECIES", 112, 120], ["Diarrhoeal Disease", "PROBLEM", 194, 212], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["acute", "OBSERVATION_MODIFIER", 87, 92]]], ["We enrolled hospital admitted SAM children with clinical or radiological pneumonia as cases (during April 2015 to March 2017) and hospital admitted SAM children without any respiratory symptom in the past 10 days before admission as controls (during February 2016 to December 2017).", [["respiratory", "ANATOMY", 173, 184], ["pneumonia", "DISEASE", 73, 82], ["children", "ORGANISM", 34, 42], ["children", "ORGANISM", 152, 160], ["children", "SPECIES", 34, 42], ["children", "SPECIES", 152, 160], ["radiological pneumonia", "PROBLEM", 60, 82], ["any respiratory symptom", "PROBLEM", 169, 192], ["pneumonia", "OBSERVATION", 73, 82]]], ["We tested nasopharyngeal wash from both case and control for respiratory syncytial virus (RSV), human metapneumovirus (HMPV), influenza viruses, human parainfluenza viruses (HPIV), rhinovirus and adenovirus by singleplex real-time reverse transcriptase polymerase chain reaction.", [["nasopharyngeal", "ANATOMY", 10, 24], ["respiratory syncytial virus (RSV), human metapneumovirus (HMPV)", "DISEASE", 61, 124], ["influenza viruses", "DISEASE", 126, 143], ["human parainfluenza viruses", "DISEASE", 145, 172], ["respiratory syncytial virus", "ORGANISM", 61, 88], ["RSV", "ORGANISM", 90, 93], ["human", "ORGANISM", 96, 101], ["metapneumovirus", "ORGANISM", 102, 117], ["HMPV", "ORGANISM", 119, 123], ["influenza viruses", "ORGANISM", 126, 143], ["human", "ORGANISM", 145, 150], ["parainfluenza viruses", "ORGANISM", 151, 172], ["rhinovirus", "ORGANISM", 181, 191], ["adenovirus", "ORGANISM", 196, 206], ["reverse transcriptase", "PROTEIN", 231, 252], ["respiratory syncytial virus", "SPECIES", 61, 88], ["human", "SPECIES", 96, 101], ["metapneumovirus", "SPECIES", 102, 117], ["human", "SPECIES", 145, 150], ["parainfluenza viruses", "SPECIES", 151, 172], ["respiratory syncytial virus", "SPECIES", 61, 88], ["RSV", "SPECIES", 90, 93], ["human metapneumovirus", "SPECIES", 96, 117], ["HMPV", "SPECIES", 119, 123], ["human parainfluenza viruses", "SPECIES", 145, 172], ["HPIV", "SPECIES", 174, 178], ["adenovirus", "SPECIES", 196, 206], ["nasopharyngeal wash", "TREATMENT", 10, 29], ["respiratory syncytial virus", "PROBLEM", 61, 88], ["human metapneumovirus (HMPV", "PROBLEM", 96, 123], ["influenza viruses", "PROBLEM", 126, 143], ["human parainfluenza viruses", "PROBLEM", 145, 172], ["rhinovirus", "PROBLEM", 181, 191], ["adenovirus", "TREATMENT", 196, 206], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 231, 278], ["nasopharyngeal", "ANATOMY", 10, 24], ["respiratory syncytial", "ANATOMY", 61, 82]]], ["To identify the independent association of pneumonia with viral pathogens during February 2016 to March 2017, we used multivariable logistic regression for calculating adjusted odds ratios.ResultsWe enrolled 360 cases and 334 controls.", [["pneumonia", "DISEASE", 43, 52], ["pneumonia", "PROBLEM", 43, 52], ["viral pathogens", "PROBLEM", 58, 73], ["pneumonia", "OBSERVATION", 43, 52]]], ["For case and control the median age was 8 months (IQR: 5-13) and 11 months (IQR: 6-18) (p = 0.001) respectively.", [["IQR", "TEST", 76, 79]]], ["Weight/age Zscore was -4.3 (SD \u00b10.7) for cases and -4.1 (SD \u00b11.1) for controls (p = 0.01).", [["Weight", "TEST", 0, 6], ["Zscore", "TEST", 11, 17], ["cases", "TEST", 41, 46]]], ["Among cases 68% had both clinical and radiological pneumonia, 1% had clinical pneumonia and 31% had only radiological pneumonia.", [["pneumonia", "DISEASE", 51, 60], ["pneumonia", "DISEASE", 78, 87], ["pneumonia", "DISEASE", 118, 127], ["Among cases", "TEST", 0, 11], ["radiological pneumonia", "PROBLEM", 38, 60], ["clinical pneumonia", "PROBLEM", 69, 87], ["radiological pneumonia", "PROBLEM", 105, 127], ["pneumonia", "OBSERVATION", 51, 60], ["pneumonia", "OBSERVATION", 78, 87], ["pneumonia", "OBSERVATION", 118, 127]]], ["Respiratory virus detection was high in cases compared to controls [69.9% (251) vs. 44IntroductionPneumonia is the leading cause of morbidity and mortality among children aged less than five years in low and middle income countries [1] where it is commonly associated with malnutrition [2] .", [["Pneumonia", "DISEASE", 98, 107], ["malnutrition", "DISEASE", 273, 285], ["Respiratory virus", "ORGANISM", 0, 17], ["children", "ORGANISM", 162, 170], ["children", "SPECIES", 162, 170], ["Respiratory virus detection", "TEST", 0, 27], ["Pneumonia", "PROBLEM", 98, 107], ["morbidity", "PROBLEM", 132, 141], ["malnutrition", "PROBLEM", 273, 285], ["Pneumonia", "OBSERVATION", 98, 107], ["morbidity", "OBSERVATION", 132, 141]]], ["In 2016, one in every six childhood deaths was attributed to pneumonia [1] .", [["deaths", "DISEASE", 36, 42], ["pneumonia", "DISEASE", 61, 70], ["pneumonia", "PROBLEM", 61, 70], ["pneumonia", "OBSERVATION", 61, 70]]], ["In 2010, there were an estimated 120 million episodes of pneumonia in children aged less than five years of which 14 million developed severe complications requiring hospitalization [3] .", [["pneumonia", "DISEASE", 57, 66], ["children", "ORGANISM", 70, 78], ["children", "SPECIES", 70, 78], ["pneumonia", "PROBLEM", 57, 66], ["severe complications", "PROBLEM", 135, 155], ["pneumonia", "OBSERVATION", 57, 66], ["severe", "OBSERVATION_MODIFIER", 135, 141], ["complications", "OBSERVATION", 142, 155]]], ["Pneumonia is a common co-morbidity in children presenting with malnutrition and can increase the risk of death 15 fold [2] .", [["Pneumonia", "DISEASE", 0, 9], ["malnutrition", "DISEASE", 63, 75], ["death", "DISEASE", 105, 110], ["children", "ORGANISM", 38, 46], ["children", "SPECIES", 38, 46], ["Pneumonia", "PROBLEM", 0, 9], ["malnutrition", "PROBLEM", 63, 75]]], ["Malnourished children might have a blunted inflammatory response, leading to an inability to produce clinical sign-symptoms, despite having infections like pneumonia [4] .", [["infections", "DISEASE", 140, 150], ["pneumonia", "DISEASE", 156, 165], ["children", "ORGANISM", 13, 21], ["children", "SPECIES", 13, 21], ["a blunted inflammatory response", "PROBLEM", 33, 64], ["symptoms", "PROBLEM", 115, 123], ["infections", "PROBLEM", 140, 150], ["pneumonia", "PROBLEM", 156, 165], ["blunted", "OBSERVATION_MODIFIER", 35, 42], ["inflammatory", "OBSERVATION", 43, 55], ["pneumonia", "OBSERVATION", 156, 165]]], ["An atypical presentation of pneumonia can delay diagnosis and appropriate care, thus increasing the risk of morbidity and mortality in such populations [5] .", [["pneumonia", "DISEASE", 28, 37], ["pneumonia", "PROBLEM", 28, 37], ["morbidity", "PROBLEM", 108, 117], ["atypical", "OBSERVATION_MODIFIER", 3, 11], ["pneumonia", "OBSERVATION", 28, 37]]], ["In Bangladesh, co-morbidity of pneumonia and malnutrition is prevalent and frequently associated with case fatality [6] .", [["pneumonia", "DISEASE", 31, 40], ["malnutrition", "DISEASE", 45, 57], ["pneumonia", "PROBLEM", 31, 40], ["malnutrition", "PROBLEM", 45, 57], ["pneumonia", "OBSERVATION", 31, 40], ["malnutrition", "OBSERVATION", 45, 57]]], ["Pneumonia accounts for approximately 15% of 1,19,000 deaths among Bangladeshi children aged less than five years [7] .", [["Pneumonia", "DISEASE", 0, 9], ["deaths", "DISEASE", 53, 59], ["children", "ORGANISM", 78, 86], ["children", "SPECIES", 78, 86], ["Pneumonia", "PROBLEM", 0, 9]]], ["In Bangladesh, 36% of children aged less than five years are malnourished and 12% of them have severe acute malnutrition (SAM) [8] .", [["acute malnutrition", "DISEASE", 102, 120], ["children", "ORGANISM", 22, 30], ["children", "SPECIES", 22, 30], ["severe acute malnutrition (SAM)", "PROBLEM", 95, 126], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["acute", "OBSERVATION_MODIFIER", 102, 107], ["malnutrition", "OBSERVATION", 108, 120]]], ["Two-thirds of the malnourished children admitted to hospital are diagnosed with pneumonia [9] .", [["pneumonia", "DISEASE", 80, 89], ["children", "ORGANISM", 31, 39], ["children", "SPECIES", 31, 39], ["pneumonia", "PROBLEM", 80, 89], ["pneumonia", "OBSERVATION", 80, 89]]], ["It is crucial to target malnourished children with pneumonia with the highest risk of death to have a significant impact on global child mortality through proper pneumonia case management [10] .", [["pneumonia", "DISEASE", 51, 60], ["death", "DISEASE", 86, 91], ["pneumonia", "DISEASE", 162, 171], ["children", "ORGANISM", 37, 45], ["children", "SPECIES", 37, 45], ["pneumonia", "PROBLEM", 51, 60], ["death", "PROBLEM", 86, 91], ["proper pneumonia case management", "TREATMENT", 155, 187], ["pneumonia", "OBSERVATION", 51, 60], ["significant", "OBSERVATION_MODIFIER", 102, 113], ["pneumonia", "OBSERVATION", 162, 171]]], ["There are scarcity of data about the etiology of pneumonia in children with SAM [2] .", [["pneumonia", "DISEASE", 49, 58], ["children", "ORGANISM", 62, 70], ["children", "SPECIES", 62, 70], ["pneumonia", "PROBLEM", 49, 58], ["scarcity", "OBSERVATION_MODIFIER", 10, 18], ["pneumonia", "OBSERVATION", 49, 58]]], ["Studies suggest that the etiology of pneumonia in malnourished children might be different from that of well-nourished children and predominantly associated with gram-negative bacteria while considering bacterial etiology [2, 5] .IntroductionIn the failure of antibiotics in treating severe pneumonia, one possibility could be non-bacterial aetiology of pneumonia in under-five children.", [["pneumonia", "DISEASE", 37, 46], ["malnourished", "DISEASE", 50, 62], ["pneumonia", "DISEASE", 291, 300], ["pneumonia", "DISEASE", 354, 363], ["children", "ORGANISM", 63, 71], ["children", "ORGANISM", 119, 127], ["children", "ORGANISM", 378, 386], ["children", "SPECIES", 63, 71], ["children", "SPECIES", 119, 127], ["children", "SPECIES", 378, 386], ["pneumonia", "PROBLEM", 37, 46], ["gram-negative bacteria", "PROBLEM", 162, 184], ["antibiotics", "TREATMENT", 260, 271], ["severe pneumonia", "PROBLEM", 284, 300], ["pneumonia", "PROBLEM", 354, 363], ["pneumonia", "OBSERVATION", 37, 46], ["negative bacteria", "OBSERVATION_MODIFIER", 167, 184], ["severe", "OBSERVATION_MODIFIER", 284, 290], ["pneumonia", "OBSERVATION", 291, 300], ["one possibility could be", "UNCERTAINTY", 302, 326], ["non-bacterial", "OBSERVATION_MODIFIER", 327, 340], ["pneumonia", "OBSERVATION", 354, 363]]], ["Respiratory viruses are a major cause of childhood pneumonia, especially in young age.", [["Respiratory viruses", "DISEASE", 0, 19], ["pneumonia", "DISEASE", 51, 60], ["Respiratory viruses", "SPECIES", 0, 19], ["Respiratory viruses", "PROBLEM", 0, 19], ["childhood pneumonia", "PROBLEM", 41, 60], ["viruses", "OBSERVATION", 12, 19], ["childhood", "OBSERVATION_MODIFIER", 41, 50], ["pneumonia", "OBSERVATION", 51, 60]]], ["It has been estimated that seventy-seven percent of pneumonias among Bangladeshi children aged <2 years were associated with respiratory viral pathogens [11] .", [["pneumonias", "DISEASE", 52, 62], ["respiratory viral pathogens", "DISEASE", 125, 152], ["children", "ORGANISM", 81, 89], ["children", "SPECIES", 81, 89], ["pneumonias", "PROBLEM", 52, 62], ["respiratory viral pathogens", "PROBLEM", 125, 152], ["pneumonias", "OBSERVATION", 52, 62]]], ["The annual incidence of respiratory virus associated hospitalization is approximately 11 per 1000 children aged <5 years and is predominantly associated with respiratory syncytial virus (RSV) illness [12] .", [["respiratory virus", "DISEASE", 24, 41], ["respiratory syncytial virus (RSV) illness", "DISEASE", 158, 199], ["respiratory syncytial virus", "ORGANISM", 158, 185], ["RSV", "ORGANISM", 187, 190], ["children", "SPECIES", 98, 106], ["respiratory syncytial virus", "SPECIES", 158, 185], ["respiratory syncytial virus", "SPECIES", 158, 185], ["RSV", "SPECIES", 187, 190], ["respiratory virus", "PROBLEM", 24, 41], ["respiratory syncytial virus (RSV) illness", "PROBLEM", 158, 199], ["respiratory virus", "OBSERVATION", 24, 41], ["predominantly associated with", "UNCERTAINTY", 128, 157], ["respiratory syncytial virus", "OBSERVATION", 158, 185]]], ["Other commonly identified respiratory viruses include influenza viruses, rhinoviruses, adenoviruses, human para influenza viruses (HPIV), and human metapneumoviruses (HMPV) [12] .", [["respiratory viruses", "DISEASE", 26, 45], ["influenza viruses", "DISEASE", 54, 71], ["rhinoviruses", "DISEASE", 73, 85], ["human para influenza viruses", "DISEASE", 101, 129], ["influenza viruses", "ORGANISM", 54, 71], ["rhinoviruses", "ORGANISM", 73, 85], ["adenoviruses", "ORGANISM", 87, 99], ["human para influenza viruses", "ORGANISM", 101, 129], ["HPIV", "CANCER", 131, 135], ["human", "ORGANISM", 142, 147], ["HMPV", "ORGANISM", 167, 171], ["human", "SPECIES", 101, 106], ["para influenza viruses", "SPECIES", 107, 129], ["human", "SPECIES", 142, 147], ["human para influenza viruses", "SPECIES", 101, 129], ["HPIV", "SPECIES", 131, 135], ["human", "SPECIES", 142, 147], ["HMPV", "SPECIES", 167, 171], ["respiratory viruses", "PROBLEM", 26, 45], ["influenza viruses", "PROBLEM", 54, 71], ["rhinoviruses", "PROBLEM", 73, 85], ["adenoviruses", "PROBLEM", 87, 99], ["human para influenza viruses", "PROBLEM", 101, 129], ["respiratory viruses", "OBSERVATION", 26, 45], ["influenza viruses", "OBSERVATION", 54, 71]]], ["Relatively little is known, however, about the etiology of viral pneumonia among children with SAM [6] .IntroductionAntivirals to treat influenza, and influenza vaccines, and monoclonal antibodies to prevent RSV illness are available but seldom used in Bangladesh [13] .", [["viral pneumonia", "DISEASE", 59, 74], ["influenza", "DISEASE", 136, 145], ["influenza", "DISEASE", 151, 160], ["RSV illness", "DISEASE", 208, 219], ["children", "ORGANISM", 81, 89], ["RSV", "ORGANISM", 208, 211], ["monoclonal antibodies", "PROTEIN", 175, 196], ["children", "SPECIES", 81, 89], ["RSV", "SPECIES", 208, 211], ["RSV", "SPECIES", 208, 211], ["viral pneumonia", "PROBLEM", 59, 74], ["IntroductionAntivirals", "TREATMENT", 104, 126], ["influenza", "PROBLEM", 136, 145], ["influenza vaccines", "TREATMENT", 151, 169], ["monoclonal antibodies", "TREATMENT", 175, 196], ["RSV illness", "PROBLEM", 208, 219], ["viral", "OBSERVATION_MODIFIER", 59, 64], ["pneumonia", "OBSERVATION", 65, 74]]], ["New antivirals, vaccines, and monoclonal antibodies are also in the primitive stage of development for treating influenza, RSV, and HPIV-3infection [14, 15] .", [["influenza", "DISEASE", 112, 121], ["RSV", "DISEASE", 123, 126], ["RSV", "ORGANISM", 123, 126], ["HPIV-3infection", "ORGANISM", 132, 147], ["monoclonal antibodies", "PROTEIN", 30, 51], ["RSV", "SPECIES", 123, 126], ["HPIV", "SPECIES", 132, 136], ["New antivirals", "TREATMENT", 0, 14], ["vaccines", "TREATMENT", 16, 24], ["monoclonal antibodies", "TREATMENT", 30, 51], ["influenza", "PROBLEM", 112, 121], ["RSV", "PROBLEM", 123, 126], ["antivirals", "OBSERVATION", 4, 14], ["primitive stage", "OBSERVATION_MODIFIER", 68, 83]]], ["Information about the relative contribution of respiratory pathogens might help health officials to explore the value of targeting such pharmaceuticals to children with severe pneumonia and SAM and to avoid unnecessary antibiotic use.", [["pneumonia", "DISEASE", 176, 185], ["children", "ORGANISM", 155, 163], ["children", "SPECIES", 155, 163], ["respiratory pathogens", "PROBLEM", 47, 68], ["severe pneumonia and SAM", "PROBLEM", 169, 193], ["unnecessary antibiotic use", "TREATMENT", 207, 233], ["pneumonia", "OBSERVATION", 176, 185]]], ["To fill this knowledge gap, we aimed to determine the viral etiology of pneumonia among young children with SAM at an urban hospital in Bangladesh and to also identify the outcome of pneumonia according to different viral etiology within 30 days of hospital admission.Study setting and patient enrollmentWe conducted a case-control study in which we prospectively screened all severely malnourished children aged <5 years admitted to the Dhaka Hospital of International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b) from April 2015 to December 2017.", [["pneumonia", "DISEASE", 72, 81], ["pneumonia", "DISEASE", 183, 192], ["Diarrhoeal Disease", "DISEASE", 481, 499], ["children", "ORGANISM", 94, 102], ["patient", "ORGANISM", 286, 293], ["children", "ORGANISM", 399, 407], ["children", "SPECIES", 94, 102], ["patient", "SPECIES", 286, 293], ["children", "SPECIES", 399, 407], ["pneumonia", "PROBLEM", 72, 81], ["pneumonia", "PROBLEM", 183, 192], ["Diarrhoeal Disease", "PROBLEM", 481, 499], ["pneumonia", "OBSERVATION", 72, 81], ["pneumonia", "OBSERVATION", 183, 192]]], ["The Dhaka hospital of icddr,b provides care and treatment for approximately 140,000 patients annually mostly from low-socioeconomic urban or peri-urban communities in Dhaka.", [["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["treatment", "TREATMENT", 48, 57]]], ["Sixty percent of patients are aged <5 years admitted with diarrhea only or with diarrhea and other co-morbidities [16] .", [["diarrhea", "DISEASE", 58, 66], ["diarrhea", "DISEASE", 80, 88], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["diarrhea", "PROBLEM", 58, 66], ["diarrhea", "PROBLEM", 80, 88], ["other co-morbidities", "PROBLEM", 93, 113]]], ["According to data from Dhaka hospital of icddr,b during 2017, among 6,035 children <5 years with diarrhoea and other co-morbidities around 23% (1,408) were severely malnourished, 24% (1,453) children had pneumonia and 6% (354) had both SAM and pneumonia.Study setting and patient enrollmentDuring April 2015 to March 2017, we enrolled children as cases if they were aged <5 years (0-59 months), severely malnourished (i.e., WHO criteria <-3 z score from the median of weight for height/length, weight for age, or nutritional edema) [17] and met WHO clinical criteria for pneumonia [18] .", [["diarrhoea", "DISEASE", 97, 106], ["pneumonia", "DISEASE", 204, 213], ["pneumonia", "DISEASE", 244, 253], ["nutritional edema", "DISEASE", 513, 530], ["pneumonia", "DISEASE", 571, 580], ["children", "ORGANISM", 74, 82], ["children", "ORGANISM", 191, 199], ["patient", "ORGANISM", 272, 279], ["children", "ORGANISM", 335, 343], ["edema", "PATHOLOGICAL_FORMATION", 525, 530], ["children", "SPECIES", 74, 82], ["children", "SPECIES", 191, 199], ["patient", "SPECIES", 272, 279], ["children", "SPECIES", 335, 343], ["diarrhoea", "PROBLEM", 97, 106], ["other co-morbidities", "PROBLEM", 111, 131], ["severely malnourished", "PROBLEM", 156, 177], ["pneumonia", "PROBLEM", 204, 213], ["pneumonia", "PROBLEM", 244, 253], ["severely malnourished", "PROBLEM", 395, 416], ["length", "TEST", 486, 492], ["weight", "TEST", 494, 500], ["nutritional edema", "PROBLEM", 513, 530], ["pneumonia", "PROBLEM", 571, 580], ["pneumonia", "OBSERVATION", 204, 213], ["pneumonia", "OBSERVATION", 244, 253], ["edema", "OBSERVATION", 525, 530], ["pneumonia", "OBSERVATION", 571, 580]]], ["We also enrolled children as cases if they had SAM, cough, and radiological pneumonia.", [["cough", "DISEASE", 52, 57], ["pneumonia", "DISEASE", 76, 85], ["children", "ORGANISM", 17, 25], ["children", "SPECIES", 17, 25], ["cough", "PROBLEM", 52, 57], ["radiological pneumonia", "PROBLEM", 63, 85], ["cough", "OBSERVATION", 52, 57], ["pneumonia", "OBSERVATION", 76, 85]]], ["During February 2016 to December 2017, we enrolled SAM children with no pneumonia on admission as controls if they did not have any additional respiratory symptoms and/or signs of pneumonia as classified by the WHO within the past 10 days prior to admission.", [["respiratory", "ANATOMY", 143, 154], ["pneumonia", "DISEASE", 72, 81], ["respiratory symptoms", "DISEASE", 143, 163], ["pneumonia", "DISEASE", 180, 189], ["children", "ORGANISM", 55, 63], ["children", "SPECIES", 55, 63], ["pneumonia", "PROBLEM", 72, 81], ["any additional respiratory symptoms", "PROBLEM", 128, 163], ["pneumonia", "PROBLEM", 180, 189], ["no", "UNCERTAINTY", 69, 71], ["pneumonia", "OBSERVATION", 72, 81], ["pneumonia", "OBSERVATION", 180, 189]]], ["The only match that was done for our case and control was severe malnutrition and it was done at recruitment.", [["malnutrition", "DISEASE", 65, 77], ["severe malnutrition", "PROBLEM", 58, 77], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["malnutrition", "OBSERVATION", 65, 77]]], ["Children who might have chance of migration to outside Dhaka city within a one-month period from admission were not enrolled in the study as we followed-up with enrolled participants during that period to evaluate the death outcome of children with pneumonia related to different viral etiology.", [["death", "DISEASE", 218, 223], ["pneumonia", "DISEASE", 249, 258], ["Children", "ORGANISM", 0, 8], ["children", "ORGANISM", 235, 243], ["Children", "SPECIES", 0, 8], ["participants", "SPECIES", 170, 182], ["children", "SPECIES", 235, 243], ["the study", "TEST", 128, 137], ["pneumonia", "PROBLEM", 249, 258], ["different viral etiology", "PROBLEM", 270, 294], ["pneumonia", "OBSERVATION", 249, 258], ["viral", "OBSERVATION", 280, 285]]], ["Information on chance of migration was validated from the statement of parents/ caregivers.Study setting and patient enrollmentA child with severe malnutrition with cough or respiratory difficulty with the presence of end point consolidation or other infiltrates, or pleural effusion in chest X-ray defined by WHO, as assessed by a qualified radiologist [20] .Study setting and patient enrollmentClinical characteristics of pneumonia: According to WHO, a child with a history of cough with respiratory difficulty or age-specific fast breathing or lower chest wall indrawing will be defined as pneumonia [18] .Study setting and patient enrollmentOr According to WHO, a child with a history of cough and/or respiratory difficulty plus oxygen saturation < 90% or central cyanosis, or severe respiratory distress (grunting, very severe chest in-drawing), or signs of pneumonia with a general danger sign (inability to breastfeed or drink, lethargy or reduced level of consciousness, convulsions), auscultatory findings of decreased or bronchial breath sounds or signs of pleural effusion or empyema will be defined as severe pneumonia [18] .Clinical approachStudy physicians examined each child for chest auscultation and measured length, weight, respiratory rate, oxygen saturation, and axillary temperature.", [["respiratory", "ANATOMY", 174, 185], ["pleural", "ANATOMY", 267, 274], ["respiratory", "ANATOMY", 490, 501], ["lower chest wall", "ANATOMY", 547, 563], ["respiratory", "ANATOMY", 705, 716], ["respiratory", "ANATOMY", 788, 799], ["chest", "ANATOMY", 832, 837], ["bronchial breath", "ANATOMY", 1031, 1047], ["pleural", "ANATOMY", 1067, 1074], ["chest", "ANATOMY", 1195, 1200], ["axillary", "ANATOMY", 1284, 1292], ["malnutrition", "DISEASE", 147, 159], ["cough", "DISEASE", 165, 170], ["respiratory difficulty", "DISEASE", 174, 196], ["pleural effusion", "DISEASE", 267, 283], ["pneumonia", "DISEASE", 424, 433], ["cough", "DISEASE", 479, 484], ["respiratory difficulty", "DISEASE", 490, 512], ["pneumonia", "DISEASE", 593, 602], ["cough", "DISEASE", 692, 697], ["respiratory difficulty", "DISEASE", 705, 727], ["oxygen", "CHEMICAL", 733, 739], ["cyanosis", "DISEASE", 768, 776], ["respiratory distress", "DISEASE", 788, 808], ["grunting", "DISEASE", 810, 818], ["pneumonia", "DISEASE", 863, 872], ["lethargy", "DISEASE", 935, 943], ["convulsions", "DISEASE", 979, 990], ["pleural effusion", "DISEASE", 1067, 1083], ["empyema", "DISEASE", 1087, 1094], ["pneumonia", "DISEASE", 1121, 1130], ["oxygen", "CHEMICAL", 1261, 1267], ["oxygen", "CHEMICAL", 733, 739], ["oxygen", "CHEMICAL", 1261, 1267], ["patient", "ORGANISM", 109, 116], ["pleural", "ORGAN", 267, 274], ["patient", "ORGANISM", 378, 385], ["chest wall", "MULTI-TISSUE_STRUCTURE", 553, 563], ["patient", "ORGANISM", 627, 634], ["oxygen", "SIMPLE_CHEMICAL", 733, 739], ["pleural", "ORGAN", 1067, 1074], ["chest", "ORGANISM_SUBDIVISION", 1195, 1200], ["oxygen", "SIMPLE_CHEMICAL", 1261, 1267], ["patient", "SPECIES", 109, 116], ["patient", "SPECIES", 378, 385], ["patient", "SPECIES", 627, 634], ["severe malnutrition", "PROBLEM", 140, 159], ["cough", "PROBLEM", 165, 170], ["respiratory difficulty", "PROBLEM", 174, 196], ["end point consolidation", "PROBLEM", 218, 241], ["other infiltrates", "PROBLEM", 245, 262], ["pleural effusion", "PROBLEM", 267, 283], ["pneumonia", "PROBLEM", 424, 433], ["cough", "PROBLEM", 479, 484], ["respiratory difficulty", "PROBLEM", 490, 512], ["specific fast breathing", "PROBLEM", 520, 543], ["lower chest wall indrawing", "PROBLEM", 547, 573], ["pneumonia", "PROBLEM", 593, 602], ["cough", "PROBLEM", 692, 697], ["respiratory difficulty", "PROBLEM", 705, 727], ["oxygen saturation", "TEST", 733, 750], ["central cyanosis", "PROBLEM", 760, 776], ["severe respiratory distress", "PROBLEM", 781, 808], ["grunting", "PROBLEM", 810, 818], ["very severe chest in-drawing)", "PROBLEM", 820, 849], ["pneumonia", "PROBLEM", 863, 872], ["a general danger sign", "PROBLEM", 878, 899], ["lethargy", "PROBLEM", 935, 943], ["reduced level of consciousness", "PROBLEM", 947, 977], ["convulsions", "PROBLEM", 979, 990], ["auscultatory findings", "TEST", 993, 1014], ["decreased or bronchial breath sounds", "PROBLEM", 1018, 1054], ["pleural effusion", "PROBLEM", 1067, 1083], ["empyema", "PROBLEM", 1087, 1094], ["severe pneumonia", "PROBLEM", 1114, 1130], ["chest auscultation", "TEST", 1195, 1213], ["length", "TEST", 1227, 1233], ["weight", "TEST", 1235, 1241], ["respiratory rate", "TEST", 1243, 1259], ["oxygen saturation", "TEST", 1261, 1278], ["axillary temperature", "TEST", 1284, 1304], ["severe", "OBSERVATION_MODIFIER", 140, 146], ["malnutrition", "OBSERVATION", 147, 159], ["cough", "OBSERVATION", 165, 170], ["consolidation", "OBSERVATION", 228, 241], ["other", "OBSERVATION_MODIFIER", 245, 250], ["infiltrates", "OBSERVATION", 251, 262], ["pleural", "ANATOMY", 267, 274], ["effusion", "OBSERVATION", 275, 283], ["chest", "ANATOMY", 287, 292], ["pneumonia", "OBSERVATION", 424, 433], ["cough", "OBSERVATION", 479, 484], ["lower", "ANATOMY_MODIFIER", 547, 552], ["chest wall", "ANATOMY", 553, 563], ["pneumonia", "OBSERVATION", 593, 602], ["cough", "OBSERVATION", 692, 697], ["respiratory", "ANATOMY", 705, 716], ["central", "OBSERVATION_MODIFIER", 760, 767], ["cyanosis", "OBSERVATION", 768, 776], ["severe", "OBSERVATION_MODIFIER", 781, 787], ["respiratory distress", "OBSERVATION", 788, 808], ["chest", "ANATOMY", 832, 837], ["pneumonia", "OBSERVATION", 863, 872], ["decreased", "OBSERVATION_MODIFIER", 1018, 1027], ["bronchial", "ANATOMY", 1031, 1040], ["pleural", "ANATOMY", 1067, 1074], ["effusion", "OBSERVATION", 1075, 1083], ["empyema", "OBSERVATION", 1087, 1094], ["severe", "OBSERVATION_MODIFIER", 1114, 1120], ["pneumonia", "OBSERVATION", 1121, 1130], ["chest", "ANATOMY", 1195, 1200], ["oxygen saturation", "OBSERVATION", 1261, 1278], ["axillary", "ANATOMY", 1284, 1292]]], ["Children with severe malnutrition having cough or respiratory difficulty without any additional sign of pneumonia were evaluated for radiological pneumonia through chest X-ray.", [["respiratory", "ANATOMY", 50, 61], ["malnutrition", "DISEASE", 21, 33], ["cough", "DISEASE", 41, 46], ["respiratory difficulty", "DISEASE", 50, 72], ["pneumonia", "DISEASE", 104, 113], ["pneumonia", "DISEASE", 146, 155], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["severe malnutrition", "PROBLEM", 14, 33], ["cough", "PROBLEM", 41, 46], ["respiratory difficulty", "PROBLEM", 50, 72], ["pneumonia", "PROBLEM", 104, 113], ["radiological pneumonia", "PROBLEM", 133, 155], ["chest X-ray", "TEST", 164, 175], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["malnutrition", "OBSERVATION", 21, 33], ["cough", "OBSERVATION", 41, 46], ["pneumonia", "OBSERVATION", 104, 113], ["pneumonia", "OBSERVATION", 146, 155], ["chest", "ANATOMY", 164, 169]]], ["These children were enrolled into the study if they met WHO radiological classification of pneumonia [21].", [["pneumonia", "DISEASE", 91, 100], ["children", "ORGANISM", 6, 14], ["children", "SPECIES", 6, 14], ["the study", "TEST", 34, 43], ["pneumonia", "PROBLEM", 91, 100], ["pneumonia", "OBSERVATION", 91, 100]]], ["Children with known congenital heart disease presented with features of pneumonia (cough, fast breathing, chest in-drawing and even cyanosis) secondary to congestive cardiac failure.", [["heart", "ANATOMY", 31, 36], ["chest", "ANATOMY", 106, 111], ["cardiac", "ANATOMY", 166, 173], ["congenital heart disease", "DISEASE", 20, 44], ["pneumonia", "DISEASE", 72, 81], ["cough", "DISEASE", 83, 88], ["cyanosis", "DISEASE", 132, 140], ["congestive cardiac failure", "DISEASE", 155, 181], ["Children", "ORGANISM", 0, 8], ["heart", "ORGAN", 31, 36], ["cardiac", "ORGAN", 166, 173], ["Children", "SPECIES", 0, 8], ["known congenital heart disease", "PROBLEM", 14, 44], ["pneumonia", "PROBLEM", 72, 81], ["cough", "PROBLEM", 83, 88], ["fast breathing", "PROBLEM", 90, 104], ["even cyanosis", "PROBLEM", 127, 140], ["congestive cardiac failure", "PROBLEM", 155, 181], ["congenital", "OBSERVATION", 20, 30], ["heart", "ANATOMY", 31, 36], ["disease", "OBSERVATION", 37, 44], ["pneumonia", "OBSERVATION", 72, 81], ["cough", "OBSERVATION", 83, 88], ["chest", "ANATOMY", 106, 111], ["cyanosis", "OBSERVATION", 132, 140], ["congestive", "OBSERVATION_MODIFIER", 155, 165], ["cardiac", "ANATOMY", 166, 173], ["failure", "OBSERVATION", 174, 181]]], ["Therefore, these children were further evaluated through chest x-ray and auscultatory findings to diagnose pneumonia.", [["chest", "ANATOMY", 57, 62], ["pneumonia", "DISEASE", 107, 116], ["children", "ORGANISM", 17, 25], ["children", "SPECIES", 17, 25], ["chest x-ray", "TEST", 57, 68], ["auscultatory findings", "TEST", 73, 94], ["pneumonia", "PROBLEM", 107, 116], ["chest", "ANATOMY", 57, 62], ["pneumonia", "OBSERVATION", 107, 116]]], ["According to the established clinical guidelines of the Dhaka hospital study children were provided nutritional rehabilitation, and treatment of severe pneumonia and hypoxemia (defined as SpO2<90% on pulse oximetry) [18, 22] .", [["pneumonia", "DISEASE", 152, 161], ["hypoxemia", "DISEASE", 166, 175], ["children", "ORGANISM", 77, 85], ["children", "SPECIES", 77, 85], ["nutritional rehabilitation", "TREATMENT", 100, 126], ["severe pneumonia", "PROBLEM", 145, 161], ["hypoxemia", "PROBLEM", 166, 175], ["SpO2", "TEST", 188, 192], ["pulse oximetry", "TEST", 200, 214], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["pneumonia", "OBSERVATION", 152, 161], ["hypoxemia", "OBSERVATION", 166, 175]]], ["Children with severe malnutrition and pneumonia were treated with parenteral ampicillin and gentamicin as the first line of treatment.", [["malnutrition", "DISEASE", 21, 33], ["pneumonia", "DISEASE", 38, 47], ["ampicillin", "CHEMICAL", 77, 87], ["gentamicin", "CHEMICAL", 92, 102], ["ampicillin", "CHEMICAL", 77, 87], ["gentamicin", "CHEMICAL", 92, 102], ["Children", "ORGANISM", 0, 8], ["ampicillin", "SIMPLE_CHEMICAL", 77, 87], ["gentamicin", "SIMPLE_CHEMICAL", 92, 102], ["Children", "SPECIES", 0, 8], ["severe malnutrition", "PROBLEM", 14, 33], ["pneumonia", "PROBLEM", 38, 47], ["parenteral ampicillin", "TREATMENT", 66, 87], ["gentamicin", "TREATMENT", 92, 102], ["the first line of treatment", "TREATMENT", 106, 133], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["malnutrition", "OBSERVATION", 21, 33], ["pneumonia", "OBSERVATION", 38, 47]]], ["For those children who did not respond (no improvement within 48 hours or presented deterioration of clinical sign symptoms of pneumonia within 24 hours of initiation of antibiotics) antibiotics were changed to ceftriaxone and levofloxacin according to Dhaka Hospital protocol [23].Data collectionStudy physicians additionally gathered demographic characteristics including medical history, clinical examination at enrollment, radiological findings, vaccinations and outcome using a structured, pretested case record form.", [["pneumonia", "DISEASE", 127, 136], ["ceftriaxone", "CHEMICAL", 211, 222], ["levofloxacin", "CHEMICAL", 227, 239], ["ceftriaxone", "CHEMICAL", 211, 222], ["levofloxacin", "CHEMICAL", 227, 239], ["children", "ORGANISM", 10, 18], ["ceftriaxone", "SIMPLE_CHEMICAL", 211, 222], ["levofloxacin", "SIMPLE_CHEMICAL", 227, 239], ["children", "SPECIES", 10, 18], ["clinical sign symptoms", "PROBLEM", 101, 123], ["pneumonia", "PROBLEM", 127, 136], ["antibiotics", "TREATMENT", 170, 181], ["antibiotics", "TREATMENT", 183, 194], ["ceftriaxone", "TREATMENT", 211, 222], ["levofloxacin", "TREATMENT", 227, 239], ["clinical examination", "TEST", 391, 411], ["radiological findings", "TEST", 427, 448], ["pneumonia", "OBSERVATION", 127, 136]]], ["Households with a monthly income of <120 USD were considered of low socioeconomic status.", [["low socioeconomic status", "PROBLEM", 64, 88]]], ["The study physician followed up with children within 30 days of admission to assess the outcome of their pneumonia even after discharge from hospital.", [["pneumonia", "DISEASE", 105, 114], ["children", "ORGANISM", 37, 45], ["children", "SPECIES", 37, 45], ["their pneumonia", "PROBLEM", 99, 114], ["pneumonia", "OBSERVATION", 105, 114]]], ["After recovery and completion of nutritional rehabilitation phase, patients were discharged.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["nutritional rehabilitation phase", "TREATMENT", 33, 65]]], ["The study physician asked caregivers to make weekly follow-up visits to the hospital after discharge from hospital until completion of 30 days from admission in order to monitor the death outcome according to different viral etiology of pneumonia.", [["death", "DISEASE", 182, 187], ["pneumonia", "DISEASE", 237, 246], ["the death outcome", "PROBLEM", 178, 195], ["pneumonia", "PROBLEM", 237, 246], ["pneumonia", "OBSERVATION", 237, 246]]], ["At each follow up visit the study physician asked the mother/caregiver whether there was any sign or symptoms of specific morbidities since the previous visit.", [["symptoms", "PROBLEM", 101, 109], ["specific morbidities", "PROBLEM", 113, 133]]], ["Morbidity information like respiratory (runny nose, cough, fever, breathing difficulty, chest indrawing, auscultatory findings), diarrhoeal or others (eye, ear and skin infection, thrush, passage of worms etc) was recorded.", [["respiratory", "ANATOMY", 27, 38], ["chest", "ANATOMY", 88, 93], ["eye", "ANATOMY", 151, 154], ["ear", "ANATOMY", 156, 159], ["skin", "ANATOMY", 164, 168], ["cough", "DISEASE", 52, 57], ["fever", "DISEASE", 59, 64], ["breathing difficulty", "DISEASE", 66, 86], ["chest indrawing", "DISEASE", 88, 103], ["diarrhoeal or others (eye, ear and skin infection", "DISEASE", 129, 178], ["thrush", "DISEASE", 180, 186], ["nose", "ORGANISM_SUBDIVISION", 46, 50], ["eye", "ORGAN", 151, 154], ["ear", "ORGAN", 156, 159], ["skin", "ORGAN", 164, 168], ["thrush", "ORGANISM_SUBDIVISION", 180, 186], ["worms", "SPECIES", 199, 204], ["respiratory (runny nose", "PROBLEM", 27, 50], ["cough", "PROBLEM", 52, 57], ["fever", "PROBLEM", 59, 64], ["breathing difficulty", "PROBLEM", 66, 86], ["chest indrawing, auscultatory findings", "PROBLEM", 88, 126], ["diarrhoeal or others (eye, ear and skin infection", "PROBLEM", 129, 178], ["thrush", "PROBLEM", 180, 186], ["respiratory", "ANATOMY", 27, 38], ["chest", "ANATOMY", 88, 93], ["eye", "ANATOMY", 151, 154], ["ear", "ANATOMY", 156, 159], ["skin", "ANATOMY", 164, 168], ["infection", "OBSERVATION", 169, 178], ["thrush", "OBSERVATION", 180, 186]]], ["Vital signs including z-scores, oedema were recorded at each visit.Data collectionFollowing discharge the mother/caregiver was advised to consult with the study physician over cell phone or return to the hospital at any time if any sign or symptoms of illness develop within the scheduled follow up visit.Sample collection and laboratory analysisWe collected nasopharyngeal wash (NPW) samples for respiratory viral testing by real-time reverse transcriptase polymerase chain reaction (rRT-PCR) by a trained study physician from 694 cases and controls.", [["cell", "ANATOMY", 176, 180], ["nasopharyngeal", "ANATOMY", 359, 373], ["samples", "ANATOMY", 385, 392], ["oedema", "DISEASE", 32, 38], ["illness", "DISEASE", 252, 259], ["cell", "CELL", 176, 180], ["reverse transcriptase", "PROTEIN", 436, 457], ["Vital signs", "TEST", 0, 11], ["z-scores", "TEST", 22, 30], ["oedema", "PROBLEM", 32, 38], ["symptoms", "PROBLEM", 240, 248], ["illness", "PROBLEM", 252, 259], ["Sample collection", "TEST", 305, 322], ["laboratory analysisWe", "TEST", 327, 348], ["respiratory viral testing", "TEST", 397, 422], ["transcriptase polymerase chain reaction", "PROBLEM", 444, 483], ["oedema", "OBSERVATION", 32, 38], ["nasopharyngeal", "ANATOMY", 359, 373]]], ["Of these collected samples, 5 were invalid samples that were insufficient for testing (1 in case and 4 in controls).", [["samples", "ANATOMY", 19, 26], ["samples", "ANATOMY", 43, 50], ["samples", "CANCER", 19, 26], ["these collected samples", "TEST", 3, 26], ["invalid samples", "TEST", 35, 50], ["testing", "TEST", 78, 85]]], ["Due to higher sensitivity for virus collection NPW was considered as standard specimen collection method instead of nasopharyngeal swab in clinical setting [24] .", [["specimen", "ANATOMY", 78, 86], ["nasopharyngeal swab", "ANATOMY", 116, 135], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 116, 135], ["virus collection NPW", "PROBLEM", 30, 50], ["standard specimen collection method", "TEST", 69, 104], ["nasopharyngeal swab", "TEST", 116, 135], ["nasopharyngeal", "ANATOMY", 116, 130]]], ["For sample collection the distal end of the butterfly catheter (needle and butterfly) extension set was cut off so that about 2-3 inches of tubing were left attached to the hub.", [["sample", "ANATOMY", 4, 10], ["sample collection", "PROBLEM", 4, 21], ["the butterfly catheter (needle and butterfly) extension set", "TREATMENT", 40, 99], ["2-3 inches of tubing", "TREATMENT", 126, 146], ["distal", "OBSERVATION_MODIFIER", 26, 32], ["end", "OBSERVATION_MODIFIER", 33, 36], ["butterfly", "OBSERVATION_MODIFIER", 44, 53], ["catheter", "OBSERVATION", 54, 62], ["tubing", "OBSERVATION", 140, 146], ["hub", "ANATOMY", 173, 176]]], ["For the procedure study physician washed hands, wore gown, mask and gloves.", [["the procedure study", "TEST", 4, 23], ["mask", "TREATMENT", 59, 63], ["gloves", "TREATMENT", 68, 74]]], ["Then drew up 4 mls of sterile bacteriostatic saline (0.9% NaCl) in a 5 ml syringe and attached the syringe with the bulb of the catheter.", [["bulb", "ANATOMY", 116, 120], ["NaCl", "CHEMICAL", 58, 62], ["NaCl", "CHEMICAL", 58, 62], ["saline", "SIMPLE_CHEMICAL", 45, 51], ["bulb", "ORGANISM_SUBDIVISION", 116, 120], ["sterile bacteriostatic saline", "TREATMENT", 22, 51], ["0.9% NaCl)", "TREATMENT", 53, 63], ["a 5 ml syringe", "TREATMENT", 67, 81], ["the syringe", "TREATMENT", 95, 106], ["the bulb of the catheter", "TREATMENT", 112, 136], ["bulb", "OBSERVATION_MODIFIER", 116, 120], ["catheter", "OBSERVATION", 128, 136]]], ["Child was placed in upright position in the mother's/caregiver's lap and the mother/caregiver restrained arms and legs of the child.", [["legs", "ANATOMY", 114, 118], ["arms", "ORGANISM_SUBDIVISION", 105, 109], ["legs", "ORGANISM_SUBDIVISION", 114, 118], ["legs", "ANATOMY", 114, 118]]], ["Assistant stabilized the child's head against the mother's/caregiver's chest and tilted the subject's head slightly (70\u02da).", [["head", "ANATOMY", 33, 37], ["chest", "ANATOMY", 71, 76], ["head", "ANATOMY", 102, 106], ["head", "ORGANISM_SUBDIVISION", 33, 37], ["chest", "ORGAN", 71, 76], ["head", "ORGANISM_SUBDIVISION", 102, 106], ["child", "SPECIES", 25, 30], ["chest", "ANATOMY", 71, 76], ["head", "ANATOMY", 102, 106]]], ["Then physician inserted the cannula 1.5-2 cm into the nostril parallel to the palate, flushed the saline into posterior nasopharynx, and immediately aspirated back into the syringe and withdrew the cannula.", [["nostril", "ANATOMY", 54, 61], ["palate", "ANATOMY", 78, 84], ["posterior nasopharynx", "ANATOMY", 110, 131], ["nostril", "ORGAN", 54, 61], ["palate", "ORGAN", 78, 84], ["nasopharynx", "ORGAN", 120, 131], ["the cannula", "TREATMENT", 24, 35], ["the saline into posterior nasopharynx", "TREATMENT", 94, 131], ["the syringe", "TREATMENT", 169, 180], ["the cannula", "TREATMENT", 194, 205], ["nostril", "ANATOMY", 54, 61], ["palate", "ANATOMY", 78, 84], ["flushed", "OBSERVATION", 86, 93], ["posterior", "ANATOMY_MODIFIER", 110, 119], ["nasopharynx", "ANATOMY", 120, 131], ["cannula", "OBSERVATION_MODIFIER", 198, 205]]], ["Physician assessed the subject, especially respiratory rate and effort and auscultated the chest; removed the cannula and put aspirate into 2 ml viral transport media (VTM) up to the maximum graduation mark of the collection tube.Sample collection and laboratory analysisThe samples were kept in cool box with ice packs at approximately 4\u02daC before being transported to virology laboratory of icddr,b within one hour of sample collection for testing.", [["respiratory", "ANATOMY", 43, 54], ["chest", "ANATOMY", 91, 96], ["samples", "ANATOMY", 275, 282], ["sample", "ANATOMY", 419, 425], ["chest", "ORGANISM_SUBDIVISION", 91, 96], ["tube", "TISSUE", 225, 229], ["C", "GENE_OR_GENE_PRODUCT", 339, 340], ["auscultated the chest", "PROBLEM", 75, 96], ["the cannula", "TREATMENT", 106, 117], ["2 ml viral transport media", "TREATMENT", 140, 166], ["the collection tube", "TREATMENT", 210, 229], ["Sample collection", "TEST", 230, 247], ["laboratory analysis", "TEST", 252, 271], ["The samples", "TEST", 271, 282], ["ice packs", "TREATMENT", 310, 319], ["sample collection", "TEST", 419, 436], ["testing", "TEST", 441, 448], ["chest", "ANATOMY", 91, 96], ["collection tube", "OBSERVATION", 214, 229]]], ["In virology laboratory two aliquots were prepared from each sample, one was processed for testing and one stored in -80\u02daC freezer for future analysis if needed.", [["sample", "ANATOMY", 60, 66], ["testing", "TEST", 90, 97], ["future analysis", "TEST", 134, 149]]], ["Total nucleic acid was extracted from nasopharyngeal wash and rRT-PCR was performed for detecting respiratory viruses using fluorescent Taqman probes.", [["nasopharyngeal", "ANATOMY", 38, 52], ["nucleic acid", "CHEMICAL", 6, 18], ["nasopharyngeal", "ORGANISM_SUBDIVISION", 38, 52], ["Total nucleic acid", "TREATMENT", 0, 18], ["nasopharyngeal wash", "TREATMENT", 38, 57], ["rRT-PCR", "TEST", 62, 69], ["respiratory viruses", "PROBLEM", 98, 117], ["fluorescent Taqman probes", "TREATMENT", 124, 149], ["nucleic acid", "OBSERVATION", 6, 18], ["nasopharyngeal", "ANATOMY", 38, 52], ["respiratory viruses", "OBSERVATION", 98, 117]]], ["Following this procedure we detected influenza A and B, and their subtypes as well as other common respiratory viruses including respiratory syncytial virus (RSV), adenovirus, rhinovirus, human parainfluenza viruses (HPIV) types1, 2 and 3 and human metapneumovirus (HMPV) using primers and probes designed by CDC (Centers for Disease Control and Prevention), Atlanta as described previously [25, 26] .", [["influenza A and B", "DISEASE", 37, 54], ["respiratory viruses", "DISEASE", 99, 118], ["respiratory syncytial virus (RSV)", "DISEASE", 129, 162], ["human parainfluenza viruses", "DISEASE", 188, 215], ["B", "GENE_OR_GENE_PRODUCT", 53, 54], ["respiratory viruses", "ORGANISM", 99, 118], ["respiratory syncytial virus", "ORGANISM", 129, 156], ["RSV", "ORGANISM", 158, 161], ["adenovirus", "ORGANISM", 164, 174], ["rhinovirus", "ORGANISM", 176, 186], ["human parainfluenza viruses", "ORGANISM", 188, 215], ["(HPIV) types1, 2", "GENE_OR_GENE_PRODUCT", 216, 232], ["3", "GENE_OR_GENE_PRODUCT", 237, 238], ["human metapneumovirus", "ORGANISM", 243, 264], ["HMPV", "ORGANISM", 266, 270], ["respiratory syncytial virus", "SPECIES", 129, 156], ["rhinovirus", "SPECIES", 176, 186], ["human", "SPECIES", 188, 193], ["parainfluenza viruses", "SPECIES", 194, 215], ["human", "SPECIES", 243, 248], ["metapneumovirus", "SPECIES", 249, 264], ["respiratory syncytial virus", "SPECIES", 129, 156], ["RSV", "SPECIES", 158, 161], ["adenovirus", "SPECIES", 164, 174], ["human parainfluenza viruses", "SPECIES", 188, 215], ["HPIV", "SPECIES", 217, 221], ["human metapneumovirus", "SPECIES", 243, 264], ["HMPV", "SPECIES", 266, 270], ["this procedure", "TREATMENT", 10, 24], ["influenza", "PROBLEM", 37, 46], ["other common respiratory viruses", "PROBLEM", 86, 118], ["respiratory syncytial virus (RSV)", "PROBLEM", 129, 162], ["adenovirus", "PROBLEM", 164, 174], ["rhinovirus", "PROBLEM", 176, 186], ["human parainfluenza viruses", "PROBLEM", 188, 215], ["types1", "TEST", 223, 229], ["human metapneumovirus (HMPV", "PROBLEM", 243, 270], ["primers", "TREATMENT", 278, 285], ["Disease Control", "TREATMENT", 326, 341], ["respiratory", "ANATOMY", 129, 140], ["syncytial virus", "OBSERVATION", 141, 156], ["parainfluenza viruses", "OBSERVATION", 194, 215]]], ["Chest X-ray and blood culture were obtained only from the case patients.Statistical analysisAssuming 80% power, an alpha of 5%, and 10% drop out among participants, we calculated that we would need 350 cases and controls to distinguish a respiratory viral pathogen detectable in 35% of severely malnourished children with pneumonia and 25% in severely malnourished children without pneumonia [27] .", [["blood", "ANATOMY", 16, 21], ["respiratory viral pathogen", "DISEASE", 238, 264], ["malnourished", "DISEASE", 295, 307], ["pneumonia", "DISEASE", 322, 331], ["malnourished", "DISEASE", 352, 364], ["pneumonia", "DISEASE", 382, 391], ["blood", "ORGANISM_SUBSTANCE", 16, 21], ["patients", "ORGANISM", 63, 71], ["children", "ORGANISM", 308, 316], ["children", "ORGANISM", 365, 373], ["patients", "SPECIES", 63, 71], ["participants", "SPECIES", 151, 163], ["children", "SPECIES", 308, 316], ["children", "SPECIES", 365, 373], ["Chest X-ray", "TEST", 0, 11], ["blood culture", "TEST", 16, 29], ["Statistical analysisAssuming", "TEST", 72, 100], ["an alpha", "TEST", 112, 120], ["a respiratory viral pathogen", "PROBLEM", 236, 264], ["severely malnourished children", "PROBLEM", 286, 316], ["pneumonia", "PROBLEM", 322, 331], ["pneumonia", "PROBLEM", 382, 391], ["pneumonia", "OBSERVATION", 322, 331], ["pneumonia", "OBSERVATION", 382, 391]]], ["We entered data using SPSS for Windows version 20.0 (SPSS Inc, Chicago, IL), and analyzed it using STATA version 13.", [["Windows version", "TEST", 31, 46], ["Chicago, IL)", "TREATMENT", 63, 75], ["STATA version", "TEST", 99, 112]]], ["We conducted descriptive analysis to summarize the baseline demographic and clinical characteristics and reported frequencies and proportions for categorical variables.", [["descriptive analysis", "TEST", 13, 33], ["categorical variables", "TEST", 146, 167]]], ["To examine the statistical significance between case and control patients, we used Chi-squared tests in baseline characteristics.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["Chi-squared tests", "TEST", 83, 100]]], ["We conducted stratified analysis by age (infants aged < = 12 months and toddlers aged 13-60 months) and performed univariate analysis in etiological characteristics to examine the statistical significance between case (178 children) and control (174 children) enrolled during February 2016 to March 2017.", [["infants", "ORGANISM", 41, 48], ["children", "ORGANISM", 223, 231], ["children", "ORGANISM", 250, 258], ["infants", "SPECIES", 41, 48], ["children", "SPECIES", 223, 231], ["children", "SPECIES", 250, 258], ["univariate analysis", "TEST", 114, 133]]], ["Parainfluenza types 1, 2, and 3 were merged into one category, and influenza virus types A and B were combined into another category for analysis.", [["influenza virus", "ORGANISM", 67, 82], ["influenza virus", "SPECIES", 67, 82], ["influenza virus", "SPECIES", 67, 82], ["Parainfluenza types", "TEST", 0, 19], ["influenza virus types A and B", "PROBLEM", 67, 96], ["analysis", "TEST", 137, 145]]], ["The monthly detection of respiratory viral pathogens was generated in a trend graph to describe the seasonality among case patients.", [["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["respiratory viral pathogens", "PROBLEM", 25, 52], ["respiratory", "ANATOMY", 25, 36], ["viral pathogens", "OBSERVATION", 37, 52]]], ["To identify the independent association of pneumonia with viral pathogens during February 2016 to March 2017, we used multivariable logistic regression for calculating adjusted odds ratios (OR) and 95% confidence intervals (CI).", [["pneumonia", "DISEASE", 43, 52], ["pneumonia", "PROBLEM", 43, 52], ["viral pathogens", "PROBLEM", 58, 73], ["CI", "TEST", 224, 226], ["pneumonia", "OBSERVATION", 43, 52]]], ["We adjusted for age, PCV vaccination, duration from illness onset to hospitalization, and use of antibiotics prior to hospitalization.", [["illness", "DISEASE", 52, 59], ["PCV vaccination", "TREATMENT", 21, 36], ["antibiotics", "TREATMENT", 97, 108]]], ["Any association with a p value <0.05 was considered statistically significant.Ethical considerationWe obtained written informed consent from a parent or a caregiver of the participating children before enrolling them into the study.", [["children", "ORGANISM", 186, 194], ["children", "SPECIES", 186, 194], ["a p value", "TEST", 21, 30], ["the study", "TEST", 222, 231]]], ["The study protocol was reviewed and approved by the institutional review boards (IRB; named as Research Review Committee and Ethical Review Committee) of icddr,b.", [["The study protocol", "TEST", 0, 18]]], ["CDC relied on icddr,b's IRB review.ResultsWe screened a total of 656 SAM children for pneumonia and 507 SAM children with the same criteria for no pneumonia.", [["pneumonia", "DISEASE", 86, 95], ["pneumonia", "DISEASE", 147, 156], ["children", "ORGANISM", 73, 81], ["children", "ORGANISM", 108, 116], ["children", "SPECIES", 73, 81], ["children", "SPECIES", 108, 116], ["pneumonia", "PROBLEM", 86, 95], ["pneumonia", "PROBLEM", 147, 156], ["pneumonia", "OBSERVATION", 86, 95], ["pneumonia", "OBSERVATION", 147, 156]]], ["Of those, 360 children were enrolled as cases and 334 were controls for our study (Fig 1) .ResultsAmong cases, 68% (245) had both clinical pneumonia and radiological pneumonia, 1% (4) had clinical pneumonia and 31% (111) had only radiological pneumonia.", [["pneumonia", "DISEASE", 139, 148], ["pneumonia", "DISEASE", 166, 175], ["pneumonia", "DISEASE", 197, 206], ["pneumonia", "DISEASE", 243, 252], ["children", "ORGANISM", 14, 22], ["children", "SPECIES", 14, 22], ["our study", "TEST", 72, 81], ["both clinical pneumonia", "PROBLEM", 125, 148], ["radiological pneumonia", "PROBLEM", 153, 175], ["clinical pneumonia", "PROBLEM", 188, 206], ["radiological pneumonia", "PROBLEM", 230, 252], ["pneumonia", "OBSERVATION", 139, 148], ["pneumonia", "OBSERVATION", 166, 175], ["pneumonia", "OBSERVATION", 197, 206], ["pneumonia", "OBSERVATION", 243, 252]]], ["Ninety-nine percent (356) of cases had cough with a median duration of 5 days (IQR: 3-7), 19% (46) had runny nose with a median duration of 3 days (IQR: 2-5), 48% (174) had tachypnoea, 24% (86) had chest indrawing and 13% (45) had hypoxaemia.ResultsFor the case and control, median age was 8 months (IQR: 5-13) and 11 months (IQR: 6-18) (p = 0.001) and 62% and 61% were male (p = 0.7), respectively.", [["chest", "ANATOMY", 198, 203], ["cough", "DISEASE", 39, 44], ["tachypnoea", "DISEASE", 173, 183], ["chest indrawing", "DISEASE", 198, 213], ["hypoxaemia", "DISEASE", 231, 241], ["nose", "ORGAN", 109, 113], ["cough", "PROBLEM", 39, 44], ["runny nose", "PROBLEM", 103, 113], ["tachypnoea", "PROBLEM", 173, 183], ["chest indrawing", "TEST", 198, 213], ["hypoxaemia", "PROBLEM", 231, 241], ["IQR", "TEST", 326, 329], ["chest", "ANATOMY", 198, 203], ["hypoxaemia", "OBSERVATION", 231, 241]]], ["Younger in age (8 months vs. 11 months, p = 0.001), lower Z score of weight for age (p = 0.01), congenital heart disease (p<0.001), exposure to cigarette smoke at home (p = 0.04), and getting antibiotics before hospitalization (p<0.001) were more common among the cases compared to the controls (Table 1) .", [["heart", "ANATOMY", 107, 112], ["congenital heart disease", "DISEASE", 96, 120], ["smoke", "CHEMICAL", 154, 159], ["heart", "ORGAN", 107, 112], ["lower Z score of weight", "PROBLEM", 52, 75], ["congenital heart disease", "PROBLEM", 96, 120], ["antibiotics", "TREATMENT", 192, 203], ["heart", "ANATOMY", 107, 112], ["disease", "OBSERVATION", 113, 120]]], ["Pneumococcal Conjugate Vaccine (PCV) vaccination was higher (case: 37% vs. control 61%; p = <0.001)) among controls (Table 1) .", [["Pneumococcal Conjugate Vaccine", "TREATMENT", 0, 30], ["PCV) vaccination", "TREATMENT", 32, 48], ["control", "TEST", 75, 82]]], ["There was no difference in gender, maternal education and occupation, exclusive breast feeding, weight for height and Bacille Calmette Guerin (BCG) vaccination between cases and controls.", [["breast", "ANATOMY", 80, 86], ["Bacille Calmette Guerin", "CHEMICAL", 118, 141], ["breast", "ORGANISM_SUBDIVISION", 80, 86], ["Bacille Calmette Guerin", "ORGANISM", 118, 141], ["exclusive breast feeding", "TREATMENT", 70, 94], ["height", "TEST", 107, 113], ["Bacille Calmette Guerin (BCG) vaccination", "TREATMENT", 118, 159], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23]]], ["A similar proportion of cases and controls had a history of respiratory tract infection (RTI) among family members in last 14 days, household cooked in bedroom, low socioeconomic status, and were slum dwellers ( Bacterial pathogens were isolated from blood culture in 4% (16) cases.", [["respiratory tract", "ANATOMY", 60, 77], ["blood", "ANATOMY", 251, 256], ["respiratory tract infection", "DISEASE", 60, 87], ["RTI", "DISEASE", 89, 92], ["respiratory tract", "ORGANISM_SUBDIVISION", 60, 77], ["blood", "ORGANISM_SUBSTANCE", 251, 256], ["respiratory tract infection", "PROBLEM", 60, 87], ["low socioeconomic status", "PROBLEM", 161, 185], ["Bacterial pathogens", "PROBLEM", 212, 231], ["blood culture", "TEST", 251, 264], ["respiratory tract", "ANATOMY", 60, 77], ["infection", "OBSERVATION", 78, 87]]], ["Isolates identified Pseudomonas 25% (4), Enterococcus 12.5% (2), Salmonella typhi 12.5% (2), Streptococcus pneumoniae 6.3% (1), Staphylococcus aureus 6.3% (1), Klebsiella 6.3% (1), Streptococcus spp 6.3% (1), Corynebacterium spp 6.3% (1),and Beta-hemolytic streptococcus 6.3% (1).", [["Streptococcus pneumoniae", "DISEASE", 93, 117], ["Staphylococcus aureus", "DISEASE", 128, 149], ["Streptococcus spp", "DISEASE", 181, 198], ["Beta-hemolytic streptococcus", "DISEASE", 242, 270], ["Salmonella typhi", "ORGANISM", 65, 81], ["Streptococcus pneumoniae", "ORGANISM", 93, 117], ["Staphylococcus aureus", "ORGANISM", 128, 149], ["Klebsiella 6.3", "ORGANISM", 160, 174], ["Streptococcus spp", "ORGANISM", 181, 198], ["Corynebacterium spp", "ORGANISM", 209, 228], ["Beta-hemolytic streptococcus", "ORGANISM", 242, 270], ["Salmonella typhi", "SPECIES", 65, 81], ["Streptococcus pneumoniae", "SPECIES", 93, 117], ["Staphylococcus aureus", "SPECIES", 128, 149], ["Streptococcus spp", "SPECIES", 181, 198], ["Corynebacterium spp", "SPECIES", 209, 228], ["Beta-hemolytic streptococcus", "SPECIES", 242, 270], ["Pseudomonas 25", "SPECIES", 20, 34], ["Salmonella typhi", "SPECIES", 65, 81], ["Streptococcus pneumoniae", "SPECIES", 93, 117], ["Staphylococcus aureus", "SPECIES", 128, 149], ["Klebsiella 6.3", "SPECIES", 160, 174], ["Streptococcus spp 6.3", "SPECIES", 181, 202], ["Corynebacterium spp 6.3", "SPECIES", 209, 232], ["Isolates", "TEST", 0, 8], ["Pseudomonas", "TEST", 20, 31], ["Enterococcus", "TEST", 41, 53], ["Salmonella typhi", "TEST", 65, 81], ["Streptococcus pneumoniae", "TEST", 93, 117], ["Staphylococcus aureus", "TEST", 128, 149], ["Klebsiella", "TEST", 160, 170], ["Streptococcus spp", "TEST", 181, 198], ["Corynebacterium spp", "TEST", 209, 228], ["Beta-hemolytic streptococcus", "TEST", 242, 270]]], ["Coagulase-negative Staphylococcus which might be a contaminant was also isolated in 12.5% (2) of children.", [["Coagulase-negative Staphylococcus", "GENE_OR_GENE_PRODUCT", 0, 33], ["children", "ORGANISM", 97, 105], ["children", "SPECIES", 97, 105], ["Coagulase", "TEST", 0, 9], ["Staphylococcus", "PROBLEM", 19, 33], ["negative Staphylococcus", "OBSERVATION", 10, 33]]], ["Antibiotic usage prior to admission was reported in 50% (8) 34 .5% (60); p = 0.003] was higher in controls when compared to cases (Fig 2) .", [["Antibiotic usage", "TREATMENT", 0, 16]]], ["Respiratory viral pathogens such as RSV [3.9% (7) (8)] were detected more frequently among younger children (< = 12 months vs. 13-60 months) of the cases (Fig 2) .ResultsAmong the cases, fever was most frequent in children with influenza and subsequently in RSV, HPIV, adenovirus, and HMPV; all the children with respiratory viruses had cough except for those with adenovirus (90%).", [["fever", "DISEASE", 187, 192], ["influenza", "DISEASE", 228, 237], ["respiratory viruses", "DISEASE", 313, 332], ["cough", "DISEASE", 337, 342], ["RSV", "ORGANISM", 36, 39], ["children", "ORGANISM", 99, 107], ["children", "ORGANISM", 214, 222], ["RSV", "ORGANISM", 258, 261], ["adenovirus", "ORGANISM", 269, 279], ["HMPV", "ORGANISM", 285, 289], ["children", "ORGANISM", 299, 307], ["adenovirus", "ORGANISM", 365, 375], ["children", "SPECIES", 99, 107], ["children", "SPECIES", 214, 222], ["children", "SPECIES", 299, 307], ["RSV", "SPECIES", 36, 39], ["RSV", "SPECIES", 258, 261], ["HPIV", "SPECIES", 263, 267], ["adenovirus", "SPECIES", 269, 279], ["HMPV", "SPECIES", 285, 289], ["Respiratory viral pathogens", "PROBLEM", 0, 27], ["RSV", "TEST", 36, 39], ["fever", "PROBLEM", 187, 192], ["influenza", "PROBLEM", 228, 237], ["RSV", "PROBLEM", 258, 261], ["HPIV", "PROBLEM", 263, 267], ["adenovirus", "PROBLEM", 269, 279], ["HMPV", "PROBLEM", 285, 289], ["respiratory viruses", "PROBLEM", 313, 332], ["cough", "PROBLEM", 337, 342], ["adenovirus", "PROBLEM", 365, 375]]], ["Compared to other respiratory viruses detected, tachypnea and chest in-drawing were higher in children with RSV; hypoxemia (SpO2<90%), grunting and head nodding were more common in children with HMPV; temperature was higher in children with influenza virus; and rales were more common in children with RSV and HMPV ( Table 2) .", [["chest", "ANATOMY", 62, 67], ["head", "ANATOMY", 148, 152], ["respiratory viruses", "DISEASE", 18, 37], ["tachypnea", "DISEASE", 48, 57], ["RSV", "DISEASE", 108, 111], ["hypoxemia", "DISEASE", 113, 122], ["grunting", "DISEASE", 135, 143], ["HMPV", "DISEASE", 195, 199], ["influenza virus", "DISEASE", 241, 256], ["HMPV", "DISEASE", 310, 314], ["chest", "ORGANISM_SUBDIVISION", 62, 67], ["children", "ORGANISM", 94, 102], ["RSV", "ORGANISM", 108, 111], ["head", "ORGANISM_SUBDIVISION", 148, 152], ["children", "ORGANISM", 181, 189], ["HMPV", "ORGANISM", 195, 199], ["children", "ORGANISM", 227, 235], ["influenza virus", "ORGANISM", 241, 256], ["children", "ORGANISM", 288, 296], ["RSV", "ORGANISM", 302, 305], ["children", "SPECIES", 94, 102], ["children", "SPECIES", 181, 189], ["children", "SPECIES", 227, 235], ["influenza virus", "SPECIES", 241, 256], ["children", "SPECIES", 288, 296], ["RSV", "SPECIES", 108, 111], ["HMPV", "SPECIES", 195, 199], ["RSV", "SPECIES", 302, 305], ["HMPV", "SPECIES", 310, 314], ["other respiratory viruses", "PROBLEM", 12, 37], ["tachypnea", "PROBLEM", 48, 57], ["RSV", "PROBLEM", 108, 111], ["hypoxemia", "PROBLEM", 113, 122], ["SpO2", "TEST", 124, 128], ["grunting", "PROBLEM", 135, 143], ["head nodding", "PROBLEM", 148, 160], ["HMPV", "PROBLEM", 195, 199], ["influenza virus", "PROBLEM", 241, 256], ["rales", "PROBLEM", 262, 267], ["RSV", "PROBLEM", 302, 305], ["HMPV", "PROBLEM", 310, 314], ["respiratory", "ANATOMY", 18, 29], ["viruses", "OBSERVATION", 30, 37], ["chest", "ANATOMY", 62, 67], ["hypoxemia", "OBSERVATION", 113, 122], ["head", "ANATOMY", 148, 152]]], ["Pulmonary infiltration was reported in all cases of influenza and adenovirus detected.", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary infiltration", "DISEASE", 0, 22], ["influenza", "DISEASE", 52, 61], ["Pulmonary", "ORGAN", 0, 9], ["adenovirus", "ORGANISM", 66, 76], ["adenovirus", "SPECIES", 66, 76], ["Pulmonary infiltration", "PROBLEM", 0, 22], ["influenza", "PROBLEM", 52, 61], ["adenovirus", "PROBLEM", 66, 76], ["infiltration", "OBSERVATION", 10, 22], ["influenza", "OBSERVATION", 52, 61], ["adenovirus", "OBSERVATION", 66, 76]]], ["Consolidation was reported mostly in HMPV (Table 2) .ResultsOf the enrolled children, 3.7% (26/694; 24 cases and 2 controls) died in the hospital and another 2.0% (14/694; 12 case and 2 control) of the children died during post-discharge follow up period.", [["children", "ORGANISM", 76, 84], ["children", "ORGANISM", 202, 210], ["children", "SPECIES", 76, 84], ["children", "SPECIES", 202, 210], ["HMPV", "SPECIES", 37, 41], ["Consolidation", "PROBLEM", 0, 13]]], ["We had 6.6% (24) inpatient and 3.3% (12) post-discharge deaths among the cases.", [["deaths", "DISEASE", 56, 62]]], ["Among inpatient deaths according to different viral etiology mortality was higher among Fig 3.", [["deaths", "DISEASE", 16, 22]]], ["RSV was detected constantly from September 2015 to August 2016, with a peak in winter from December 2015 to February 2016.", [["RSV", "ORGANISM", 0, 3], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3]]], ["Influenza virus was detected during the already defined influenza season in Bangladesh (May to October).", [["Influenza", "DISEASE", 0, 9], ["influenza", "DISEASE", 56, 65], ["Influenza virus", "ORGANISM", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "PROBLEM", 0, 15], ["virus", "OBSERVATION", 10, 15]]], ["HPIV was detected throughout the year, with a first peak in May 2015 and a second peak in March 2016.", [["HPIV", "SPECIES", 0, 4]]], ["HMPV was detected from August to October in 2015 with a peak in September and from December 2016 to March 2017 with a peak in February.", [["HMPV", "ORGANISM", 0, 4], ["HMPV", "SPECIES", 0, 4], ["HMPV", "PROBLEM", 0, 4]]], ["Adenoviruses and rhinoviruses were detected throughout the year without any seasonal variation.ResultsAfter adjusting for age, PCV vaccination, duration of illness onset to hospitalization, and use of antibiotics prior to hospitalization, RSV (OR 13.1; 95% CI: 1.6, 106.1), influenza (OR 8.7; 95% CI: 1.0, 78.9), HPIV (3.8; 95% CI: 1.0, 14.8), and HMPV (2.7; 95% CI: 1.3, 5.5) were Table 2Multiple virus (n = 63) n (%) No No virus (n = 109) n (%)Bronchial breath sound identified as the independent viral pathogens for pneumonia in severely malnourished children (Table 3 ).Chest X-ray findingsNormal 1 (3) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 2(Consolidation 2 (6) 0 (0) 0 (0) 3 (4) 1 (6) 2 (13) 3 (5) 4 (4) Other 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 1 (1)DiscussionThe most important observation of this study was the independent association of RSV, Influenza, HPIV, and HMPV with pneumonia among children with SAM.", [["illness", "DISEASE", 156, 163], ["RSV", "DISEASE", 239, 242], ["influenza", "DISEASE", 274, 283], ["pneumonia", "DISEASE", 519, 528], ["malnourished", "DISEASE", 541, 553], ["RSV", "DISEASE", 851, 854], ["Influenza", "DISEASE", 856, 865], ["pneumonia", "DISEASE", 887, 896], ["rhinoviruses", "ORGANISM", 17, 29], ["RSV", "ORGANISM", 239, 242], ["children", "ORGANISM", 554, 562], ["RSV", "ORGANISM", 851, 854], ["Influenza", "ORGANISM", 856, 865], ["HMPV", "ORGANISM", 877, 881], ["children", "ORGANISM", 903, 911], ["children", "SPECIES", 554, 562], ["children", "SPECIES", 903, 911], ["RSV", "SPECIES", 239, 242], ["HMPV", "SPECIES", 348, 352], ["RSV", "SPECIES", 851, 854], ["HPIV", "SPECIES", 867, 871], ["HMPV", "SPECIES", 877, 881], ["Adenoviruses", "PROBLEM", 0, 12], ["rhinoviruses", "PROBLEM", 17, 29], ["PCV vaccination", "TREATMENT", 127, 142], ["illness", "PROBLEM", 156, 163], ["antibiotics", "TREATMENT", 201, 212], ["RSV", "TEST", 239, 242], ["CI", "TEST", 257, 259], ["influenza", "TEST", 274, 283], ["CI", "TEST", 297, 299], ["HPIV", "TEST", 313, 317], ["CI", "TEST", 328, 330], ["HMPV", "TEST", 348, 352], ["CI", "TEST", 363, 365], ["virus", "TEST", 398, 403], ["virus", "PROBLEM", 425, 430], ["Bronchial breath sound", "TEST", 446, 468], ["the independent viral pathogens", "PROBLEM", 483, 514], ["pneumonia", "PROBLEM", 519, 528], ["Chest X-ray", "TEST", 574, 585], ["Consolidation", "TEST", 645, 658], ["this study", "TEST", 805, 815], ["RSV", "PROBLEM", 851, 854], ["Influenza", "PROBLEM", 856, 865], ["HPIV", "TREATMENT", 867, 871], ["HMPV", "PROBLEM", 877, 881], ["pneumonia", "PROBLEM", 887, 896], ["rhinoviruses", "OBSERVATION", 17, 29], ["Bronchial", "ANATOMY", 446, 455], ["viral pathogens", "OBSERVATION", 499, 514], ["pneumonia", "OBSERVATION", 519, 528], ["Consolidation", "OBSERVATION", 645, 658], ["RSV", "OBSERVATION", 851, 854], ["pneumonia", "OBSERVATION", 887, 896]]], ["Our observation was consistent with previous studies that showed the same association in well-nourished children while compared to healthy controls [28] [29] [30] [31] [32] .", [["children", "ORGANISM", 104, 112], ["[28] [29] [30] [31", "SIMPLE_CHEMICAL", 148, 166], ["children", "SPECIES", 104, 112], ["Our observation", "TEST", 0, 15], ["previous studies", "TEST", 36, 52]]], ["We detected at least one laboratory confirmed respiratory virus in 70% of the study children hospitalized with pneumonia and in 44% of the study children without pneumonia.", [["respiratory virus", "DISEASE", 46, 63], ["pneumonia", "DISEASE", 111, 120], ["pneumonia", "DISEASE", 162, 171], ["children", "ORGANISM", 84, 92], ["children", "ORGANISM", 145, 153], ["children", "SPECIES", 84, 92], ["children", "SPECIES", 145, 153], ["respiratory virus", "PROBLEM", 46, 63], ["the study", "TEST", 74, 83], ["pneumonia", "PROBLEM", 111, 120], ["the study", "TEST", 135, 144], ["pneumonia", "PROBLEM", 162, 171], ["respiratory virus", "OBSERVATION", 46, 63], ["pneumonia", "OBSERVATION", 111, 120], ["without", "UNCERTAINTY", 154, 161], ["pneumonia", "OBSERVATION", 162, 171]]], ["To our knowledge our study was the first prospective casecontrol study that described the common respiratory viral pathogens associated with pneumonia in severely malnourished <5 children living in Bangladesh.", [["respiratory viral pathogens", "DISEASE", 97, 124], ["pneumonia", "DISEASE", 141, 150], ["children", "ORGANISM", 179, 187], ["children", "SPECIES", 179, 187], ["our study", "TEST", 17, 26], ["prospective casecontrol study", "TEST", 41, 70], ["the common respiratory viral pathogens", "PROBLEM", 86, 124], ["pneumonia", "PROBLEM", 141, 150], ["severely malnourished", "PROBLEM", 154, 175], ["viral pathogens", "OBSERVATION", 109, 124], ["pneumonia", "OBSERVATION", 141, 150], ["severely", "OBSERVATION_MODIFIER", 154, 162], ["malnourished", "OBSERVATION", 163, 175]]], ["The only other study on viral etiology of pneumonia in malnourished children was conducted in Gambia in 1994 and detected 35% viral etiology in malnourished children with pneumonia and 25% in children without pneumonia, which is much lower than what we have found in our investigation [27] .", [["pneumonia", "DISEASE", 42, 51], ["viral etiology", "DISEASE", 126, 140], ["malnourished", "DISEASE", 144, 156], ["pneumonia", "DISEASE", 171, 180], ["pneumonia", "DISEASE", 209, 218], ["children", "ORGANISM", 68, 76], ["children", "ORGANISM", 157, 165], ["children", "ORGANISM", 192, 200], ["children", "SPECIES", 68, 76], ["children", "SPECIES", 157, 165], ["children", "SPECIES", 192, 200], ["other study", "TEST", 9, 20], ["pneumonia", "PROBLEM", 42, 51], ["pneumonia", "PROBLEM", 171, 180], ["pneumonia", "PROBLEM", 209, 218], ["pneumonia", "OBSERVATION", 42, 51], ["pneumonia", "OBSERVATION", 171, 180], ["pneumonia", "OBSERVATION", 209, 218]]], ["A recent study in Ecuadorian children also found an association between being underweight and increased odds of RSV [33] .", [["underweight", "DISEASE", 78, 89], ["RSV", "DISEASE", 112, 115], ["children", "ORGANISM", 29, 37], ["RSV", "ORGANISM", 112, 115], ["children", "SPECIES", 29, 37], ["RSV", "SPECIES", 112, 115], ["A recent study", "TEST", 0, 14], ["RSV", "PROBLEM", 112, 115]]], ["The detection of influenza virus among our study population is also found to be consistent with previous studies involving children with severe pneumonia [33, 34] .", [["influenza virus", "DISEASE", 17, 32], ["pneumonia", "DISEASE", 144, 153], ["influenza virus", "ORGANISM", 17, 32], ["children", "ORGANISM", 123, 131], ["influenza virus", "SPECIES", 17, 32], ["children", "SPECIES", 123, 131], ["influenza virus", "SPECIES", 17, 32], ["influenza virus", "PROBLEM", 17, 32], ["our study population", "TEST", 39, 59], ["severe pneumonia", "PROBLEM", 137, 153], ["influenza virus", "OBSERVATION", 17, 32], ["severe", "OBSERVATION_MODIFIER", 137, 143], ["pneumonia", "OBSERVATION", 144, 153]]], ["It is important to note that in developed countries respiratory viruses were detected in up to 81% of young children with pneumonia, with RSVbeing the most frequently detected virus in most studies, ranging from 7% to 48% [35] [36] [37] .", [["respiratory viruses", "DISEASE", 52, 71], ["pneumonia", "DISEASE", 122, 131], ["children", "ORGANISM", 108, 116], ["children", "SPECIES", 108, 116], ["respiratory viruses", "PROBLEM", 52, 71], ["pneumonia", "PROBLEM", 122, 131], ["RSVbeing", "TREATMENT", 138, 146], ["pneumonia", "OBSERVATION", 122, 131]]], ["HMPV was more frequently detected in community acquired pneumonia in high-income countries, ranging from 23% in USA to 15% in Sweden [33, 38, 39] , and was less frequent in low-and middle-income countries [40, 41] , which coincides with our study findings.", [["pneumonia", "DISEASE", 56, 65], ["HMPV", "ORGANISM", 0, 4], ["HMPV", "SPECIES", 0, 4], ["HMPV", "PROBLEM", 0, 4], ["community acquired pneumonia", "PROBLEM", 37, 65], ["our study findings", "TEST", 237, 255], ["pneumonia", "OBSERVATION", 56, 65], ["high", "OBSERVATION_MODIFIER", 69, 73]]], ["In developing countries studies have shown 37% to 97% detection of respiratory viruses in children with pneumonia and 7% to 82% in children without any respiratory symptom [28] [29] [30] [31] [32] .", [["respiratory", "ANATOMY", 152, 163], ["respiratory viruses", "DISEASE", 67, 86], ["pneumonia", "DISEASE", 104, 113], ["children", "ORGANISM", 90, 98], ["children", "ORGANISM", 131, 139], ["children", "SPECIES", 90, 98], ["children", "SPECIES", 131, 139], ["respiratory viruses", "PROBLEM", 67, 86], ["pneumonia", "PROBLEM", 104, 113], ["any respiratory symptom", "PROBLEM", 148, 171], ["respiratory viruses", "OBSERVATION", 67, 86], ["pneumonia", "OBSERVATION", 104, 113]]], ["As our main aim was to evaluate viral etiology of pneumonia in SAM children because of lack of previous data, our study results demonstrate that RSV was the most common viral pathogen causing pneumonia.", [["pneumonia", "DISEASE", 50, 59], ["RSV", "DISEASE", 145, 148], ["pneumonia", "DISEASE", 192, 201], ["children", "ORGANISM", 67, 75], ["RSV", "ORGANISM", 145, 148], ["children", "SPECIES", 67, 75], ["RSV", "SPECIES", 145, 148], ["pneumonia", "PROBLEM", 50, 59], ["our study", "TEST", 110, 119], ["RSV", "PROBLEM", 145, 148], ["pneumonia", "PROBLEM", 192, 201], ["pneumonia", "OBSERVATION", 50, 59], ["RSV", "OBSERVATION", 145, 148], ["pneumonia", "OBSERVATION", 192, 201]]], ["Although we did not have any control of well nourished children with pneumonia recently published PERCH data from Bangladesh site and other developing countries revealed the predominance of RSV as the main viral pathogen causing pneumonia [42] .", [["pneumonia", "DISEASE", 69, 78], ["RSV", "DISEASE", 190, 193], ["pneumonia", "DISEASE", 229, 238], ["children", "ORGANISM", 55, 63], ["RSV", "ORGANISM", 190, 193], ["children", "SPECIES", 55, 63], ["RSV", "SPECIES", 190, 193], ["pneumonia", "PROBLEM", 69, 78], ["Bangladesh site", "PROBLEM", 114, 129], ["RSV", "PROBLEM", 190, 193], ["pneumonia", "PROBLEM", 229, 238], ["pneumonia", "OBSERVATION", 69, 78], ["RSV", "OBSERVATION", 190, 193], ["main", "OBSERVATION_MODIFIER", 201, 205], ["viral pathogen", "OBSERVATION", 206, 220], ["pneumonia", "OBSERVATION", 229, 238]]], ["The spectrum and frequency of other pathogens detected such as HMPV, HPIV, influenza virus were consistent with PERCH data.", [["influenza", "DISEASE", 75, 84], ["HMPV", "ORGANISM", 63, 67], ["HPIV", "GENE_OR_GENE_PRODUCT", 69, 73], ["influenza virus", "ORGANISM", 75, 90], ["influenza virus", "SPECIES", 75, 90], ["HMPV", "SPECIES", 63, 67], ["HPIV", "SPECIES", 69, 73], ["other pathogens", "PROBLEM", 30, 45], ["HMPV", "PROBLEM", 63, 67], ["HPIV", "PROBLEM", 69, 73], ["influenza virus", "PROBLEM", 75, 90]]], ["The wide range of respiratory viruses detected among asymptomatic control children raises the concern of independent respiratory virus associated pneumonia.", [["respiratory viruses", "DISEASE", 18, 37], ["respiratory virus", "DISEASE", 117, 134], ["pneumonia", "DISEASE", 146, 155], ["children", "ORGANISM", 74, 82], ["respiratory virus", "ORGANISM", 117, 134], ["children", "SPECIES", 74, 82], ["respiratory viruses", "PROBLEM", 18, 37], ["independent respiratory virus associated pneumonia", "PROBLEM", 105, 155], ["wide", "OBSERVATION_MODIFIER", 4, 8], ["range", "OBSERVATION_MODIFIER", 9, 14], ["respiratory viruses", "OBSERVATION", 18, 37], ["respiratory virus", "OBSERVATION", 117, 134], ["pneumonia", "OBSERVATION", 146, 155]]], ["Rhinovirus and adenovirus were the most frequently detected viruses and their rates of detection were similar in both the cases and the controls.", [["Rhinovirus", "GENE_OR_GENE_PRODUCT", 0, 10], ["adenovirus", "ORGANISM", 15, 25], ["Rhinovirus", "SPECIES", 0, 10], ["adenovirus", "SPECIES", 15, 25], ["Rhinovirus", "PROBLEM", 0, 10], ["adenovirus", "PROBLEM", 15, 25], ["adenovirus", "OBSERVATION", 15, 25]]], ["Rhinovirus was detected in nearly one-third of all study children indicating a lower likelihood of rhinovirus being a casual pathogen of pneumonia in severely malnourished children.", [["rhinovirus", "DISEASE", 99, 109], ["pneumonia", "DISEASE", 137, 146], ["malnourished", "DISEASE", 159, 171], ["children", "ORGANISM", 57, 65], ["rhinovirus", "ORGANISM", 99, 109], ["children", "ORGANISM", 172, 180], ["children", "SPECIES", 57, 65], ["children", "SPECIES", 172, 180], ["Rhinovirus", "SPECIES", 0, 10], ["Rhinovirus", "PROBLEM", 0, 10], ["rhinovirus", "PROBLEM", 99, 109], ["pneumonia", "PROBLEM", 137, 146], ["severely malnourished children", "PROBLEM", 150, 180], ["lower likelihood", "OBSERVATION_MODIFIER", 79, 95], ["rhinovirus", "OBSERVATION", 99, 109], ["pneumonia", "OBSERVATION", 137, 146]]], ["Similarly, in the USA and Alaska respectively, rhinovirus was detected in 27% and 44% of children with pneumonia requiring hospitalization and 17% and 33% in asymptomatic control children [28, 36] .", [["pneumonia", "DISEASE", 103, 112], ["rhinovirus", "ORGANISM", 47, 57], ["children", "ORGANISM", 89, 97], ["children", "ORGANISM", 179, 187], ["children", "SPECIES", 89, 97], ["children", "SPECIES", 179, 187], ["rhinovirus", "PROBLEM", 47, 57], ["pneumonia", "PROBLEM", 103, 112], ["rhinovirus", "OBSERVATION", 47, 57], ["pneumonia", "OBSERVATION", 103, 112]]], ["Despite literature supporting the association of human rhinovirus with pneumonia [43] , the continued shedding of human rhinovirus even two weeks after infection makes it challenging to infer a causal association between rhinovirus and pneumonia [44] .", [["pneumonia", "DISEASE", 71, 80], ["infection", "DISEASE", 152, 161], ["rhinovirus", "DISEASE", 221, 231], ["pneumonia", "DISEASE", 236, 245], ["human", "ORGANISM", 49, 54], ["rhinovirus", "ORGANISM", 55, 65], ["human", "ORGANISM", 114, 119], ["rhinovirus", "ORGANISM", 120, 130], ["rhinovirus", "ORGANISM", 221, 231], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 114, 119], ["human rhinovirus", "SPECIES", 49, 65], ["human rhinovirus", "SPECIES", 114, 130], ["human rhinovirus", "PROBLEM", 49, 65], ["pneumonia", "PROBLEM", 71, 80], ["human rhinovirus", "PROBLEM", 114, 130], ["infection", "PROBLEM", 152, 161], ["rhinovirus", "PROBLEM", 221, 231], ["pneumonia", "PROBLEM", 236, 245], ["rhinovirus", "OBSERVATION", 55, 65], ["pneumonia", "OBSERVATION", 71, 80], ["pneumonia", "OBSERVATION", 236, 245]]], ["Adenovirus was detected in almost onefourth of all study children and thus could not be associated with pneumonia.", [["pneumonia", "DISEASE", 104, 113], ["Adenovirus", "ORGANISM", 0, 10], ["children", "ORGANISM", 57, 65], ["children", "SPECIES", 57, 65], ["Adenovirus", "SPECIES", 0, 10], ["Adenovirus", "PROBLEM", 0, 10], ["pneumonia", "PROBLEM", 104, 113], ["could not be associated with", "UNCERTAINTY", 75, 103], ["pneumonia", "OBSERVATION", 104, 113]]], ["Similarly, previous studies have shown detection of adenovirus in 21 to 30% of children with pneumonia and in16% of children without any respiratory symptoms [28, 45] , despite adenovirus being a potential cause of pneumonia in young children [46] .", [["respiratory", "ANATOMY", 137, 148], ["pneumonia", "DISEASE", 93, 102], ["respiratory symptoms", "DISEASE", 137, 157], ["pneumonia", "DISEASE", 215, 224], ["adenovirus", "ORGANISM", 52, 62], ["children", "ORGANISM", 79, 87], ["children", "ORGANISM", 116, 124], ["adenovirus", "ORGANISM", 177, 187], ["children", "ORGANISM", 234, 242], ["children", "SPECIES", 79, 87], ["children", "SPECIES", 116, 124], ["children", "SPECIES", 234, 242], ["adenovirus", "SPECIES", 52, 62], ["adenovirus", "SPECIES", 177, 187], ["previous studies", "TEST", 11, 27], ["adenovirus", "PROBLEM", 52, 62], ["pneumonia", "PROBLEM", 93, 102], ["any respiratory symptoms", "PROBLEM", 133, 157], ["adenovirus", "PROBLEM", 177, 187], ["pneumonia", "PROBLEM", 215, 224], ["pneumonia", "OBSERVATION", 93, 102], ["pneumonia", "OBSERVATION", 215, 224]]], ["We found that three-fourths of our study children with pneumonia and all children in the control group without pneumonia had acute diarrhoea.", [["pneumonia", "DISEASE", 55, 64], ["pneumonia", "DISEASE", 111, 120], ["diarrhoea", "DISEASE", 131, 140], ["children", "ORGANISM", 41, 49], ["children", "ORGANISM", 73, 81], ["children", "SPECIES", 41, 49], ["children", "SPECIES", 73, 81], ["pneumonia", "PROBLEM", 55, 64], ["pneumonia", "PROBLEM", 111, 120], ["acute diarrhoea", "PROBLEM", 125, 140], ["pneumonia", "OBSERVATION", 55, 64], ["pneumonia", "OBSERVATION", 111, 120], ["acute", "OBSERVATION_MODIFIER", 125, 130], ["diarrhoea", "OBSERVATION", 131, 140]]], ["As adenovirus is known to be an important viral cause of acute diarrhoea [47] , its detection in the control group might be due to acute diarrhoea or due to co-infections with other viral and bacterial pathogens [33] .", [["diarrhoea", "DISEASE", 63, 72], ["diarrhoea", "DISEASE", 137, 146], ["co-infections", "DISEASE", 157, 170], ["adenovirus", "ORGANISM", 3, 13], ["adenovirus", "SPECIES", 3, 13], ["adenovirus", "PROBLEM", 3, 13], ["acute diarrhoea", "PROBLEM", 57, 72], ["acute diarrhoea", "PROBLEM", 131, 146], ["co-infections", "PROBLEM", 157, 170], ["other viral and bacterial pathogens", "PROBLEM", 176, 211], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["diarrhoea", "OBSERVATION", 63, 72], ["acute", "OBSERVATION_MODIFIER", 131, 136], ["diarrhoea", "OBSERVATION", 137, 146]]], ["However, we did not test stool samples from our study population to explore an association between adenovirus and diarrhoea.", [["stool samples", "ANATOMY", 25, 38], ["diarrhoea", "DISEASE", 114, 123], ["adenovirus", "ORGANISM", 99, 109], ["adenovirus", "SPECIES", 99, 109], ["stool samples", "TEST", 25, 38], ["our study population", "TEST", 44, 64], ["adenovirus", "PROBLEM", 99, 109], ["diarrhoea", "PROBLEM", 114, 123], ["diarrhoea", "OBSERVATION", 114, 123]]], ["The contribution of rhinovirus and adenovirus to independent etiology of pneumonia in malnourished children remains uncertain and needs further investigation.DiscussionThe presence of respiratory viral pathogens in asymptomatic healthy children in case control studies makes interpreting causative pathogens for pneumonia challenging and obscures its clinical significance [48] .", [["pneumonia", "DISEASE", 73, 82], ["malnourished", "DISEASE", 86, 98], ["respiratory viral pathogens", "DISEASE", 184, 211], ["pneumonia", "DISEASE", 312, 321], ["rhinovirus", "ORGANISM", 20, 30], ["adenovirus", "ORGANISM", 35, 45], ["children", "ORGANISM", 99, 107], ["children", "ORGANISM", 236, 244], ["children", "SPECIES", 99, 107], ["children", "SPECIES", 236, 244], ["rhinovirus", "PROBLEM", 20, 30], ["adenovirus", "PROBLEM", 35, 45], ["pneumonia", "PROBLEM", 73, 82], ["further investigation", "TEST", 136, 157], ["respiratory viral pathogens", "PROBLEM", 184, 211], ["causative pathogens", "PROBLEM", 288, 307], ["pneumonia", "PROBLEM", 312, 321], ["rhinovirus", "OBSERVATION", 20, 30], ["adenovirus", "OBSERVATION", 35, 45], ["pneumonia", "OBSERVATION", 73, 82]]], ["This draws attention to the importance of representative controls as a reference when assessing the impact of respiratory viruses on the development of pneumonia.", [["respiratory viruses", "DISEASE", 110, 129], ["pneumonia", "DISEASE", 152, 161], ["respiratory viruses", "PROBLEM", 110, 129], ["pneumonia", "PROBLEM", 152, 161], ["respiratory viruses", "OBSERVATION", 110, 129], ["pneumonia", "OBSERVATION", 152, 161]]], ["However, it might be interesting to correlate the threshold cycle (Ct) values obtained from RT-PCR to identify more precisely the relationship between a detected viral pathogen and pneumonia etiology [49] .DiscussionDifferent respiratory viral pathogens were detected more frequently in cases less than 1 year of age highlighting the importance of vaccination in younger age groups.", [["viral pathogen", "DISEASE", 162, 176], ["pneumonia", "DISEASE", 181, 190], ["the threshold cycle", "TEST", 46, 65], ["Ct) values", "TEST", 67, 77], ["RT-PCR", "TEST", 92, 98], ["a detected viral pathogen", "PROBLEM", 151, 176], ["pneumonia", "PROBLEM", 181, 190], ["DiscussionDifferent respiratory viral pathogens", "PROBLEM", 206, 253], ["vaccination", "TREATMENT", 348, 359], ["viral", "OBSERVATION_MODIFIER", 162, 167], ["pathogen", "OBSERVATION", 168, 176], ["pneumonia", "OBSERVATION", 181, 190]]], ["In Ecuadorian children RSV and HPIV were significantly higher among younger children [33] .", [["children", "ORGANISM", 14, 22], ["RSV", "ORGANISM", 23, 26], ["children", "ORGANISM", 76, 84], ["children", "SPECIES", 14, 22], ["RSV", "SPECIES", 23, 26], ["children", "SPECIES", 76, 84], ["RSV", "SPECIES", 23, 26], ["HPIV", "SPECIES", 31, 35]]], ["Another study in Kenya reported the highest incidence of respiratory virus associated admission for pneumonia among infants [30] .", [["respiratory virus", "DISEASE", 57, 74], ["pneumonia", "DISEASE", 100, 109], ["infants", "ORGANISM", 116, 123], ["infants", "SPECIES", 116, 123], ["Another study", "TEST", 0, 13], ["respiratory virus", "PROBLEM", 57, 74], ["pneumonia", "PROBLEM", 100, 109], ["respiratory virus", "OBSERVATION", 57, 74], ["pneumonia", "OBSERVATION", 100, 109]]], ["Our study findings of 6.7% inpatient death in SAM children with pneumonia were similar to other developing countries, such as Kenya (5.9%) and India (8.2%) [50, 51] .", [["death", "DISEASE", 37, 42], ["pneumonia", "DISEASE", 64, 73], ["children", "ORGANISM", 50, 58], ["children", "SPECIES", 50, 58], ["Our study", "TEST", 0, 9], ["6.7% inpatient death", "PROBLEM", 22, 42], ["pneumonia", "PROBLEM", 64, 73], ["Kenya", "TEST", 126, 131], ["India", "TEST", 143, 148], ["pneumonia", "OBSERVATION", 64, 73]]], ["According to viral etiology, mortality was higher among cases with HPIV (14%) and HMPV (13%).", [["HMPV", "DISEASE", 82, 86], ["HPIV", "SPECIES", 67, 71], ["HMPV", "SPECIES", 82, 86], ["HPIV", "TEST", 67, 71], ["HMPV", "TEST", 82, 86]]], ["Studies have shown HMPV infection was associated with higher severity of illness in hospitalized children with pneumonia with fatal outcome [52, 53] .", [["HMPV infection", "DISEASE", 19, 33], ["illness", "DISEASE", 73, 80], ["pneumonia", "DISEASE", 111, 120], ["HMPV", "ORGANISM", 19, 23], ["children", "ORGANISM", 97, 105], ["children", "SPECIES", 97, 105], ["HMPV", "SPECIES", 19, 23], ["HMPV infection", "PROBLEM", 19, 33], ["pneumonia", "PROBLEM", 111, 120], ["fatal outcome", "PROBLEM", 126, 139], ["HMPV", "OBSERVATION_MODIFIER", 19, 23], ["infection", "OBSERVATION", 24, 33], ["pneumonia", "OBSERVATION", 111, 120]]], ["Hypoxemia, grunting and head nodding were more common in HMPV infection compared to other respiratory viruses indicating higher disease severity.", [["head", "ANATOMY", 24, 28], ["Hypoxemia", "DISEASE", 0, 9], ["grunting", "DISEASE", 11, 19], ["HMPV infection", "DISEASE", 57, 71], ["respiratory viruses", "DISEASE", 90, 109], ["head", "ORGANISM_SUBDIVISION", 24, 28], ["HMPV", "ORGANISM", 57, 61], ["HMPV", "SPECIES", 57, 61], ["Hypoxemia", "PROBLEM", 0, 9], ["grunting", "PROBLEM", 11, 19], ["head nodding", "PROBLEM", 24, 36], ["HMPV infection", "PROBLEM", 57, 71], ["other respiratory viruses", "PROBLEM", 84, 109], ["higher disease severity", "PROBLEM", 121, 144], ["grunting", "OBSERVATION", 11, 19], ["head", "ANATOMY", 24, 28], ["HMPV", "OBSERVATION", 57, 61], ["higher", "OBSERVATION_MODIFIER", 121, 127], ["disease", "OBSERVATION", 128, 135]]], ["In contrast, though mortality was higher in HPIV, hypoxemia, grunting, and head nodding on admission in terms of disease severity was not higher in this group compared to other respiratory viral pathogens.", [["head", "ANATOMY", 75, 79], ["hypoxemia", "DISEASE", 50, 59], ["grunting", "DISEASE", 61, 69], ["respiratory viral pathogens", "DISEASE", 177, 204], ["head", "ORGANISM_SUBDIVISION", 75, 79], ["HPIV", "SPECIES", 44, 48], ["mortality", "PROBLEM", 20, 29], ["hypoxemia", "PROBLEM", 50, 59], ["grunting", "PROBLEM", 61, 69], ["head nodding", "PROBLEM", 75, 87], ["disease severity", "PROBLEM", 113, 129], ["other respiratory viral pathogens", "PROBLEM", 171, 204], ["higher", "OBSERVATION_MODIFIER", 34, 40], ["hypoxemia", "OBSERVATION", 50, 59], ["grunting", "OBSERVATION", 61, 69], ["head", "ANATOMY", 75, 79], ["disease", "OBSERVATION", 113, 120], ["higher", "OBSERVATION_MODIFIER", 138, 144], ["respiratory", "ANATOMY", 177, 188], ["viral pathogens", "OBSERVATION", 189, 204]]], ["Apart from HMPV clinical signs of chest indrawing, however, hopoxemia and head nodding were common in cases with RSV infection compared to other respiratory viruses but no death was observed in this group.", [["chest", "ANATOMY", 34, 39], ["head", "ANATOMY", 74, 78], ["chest indrawing", "DISEASE", 34, 49], ["hopoxemia", "DISEASE", 60, 69], ["RSV infection", "DISEASE", 113, 126], ["respiratory viruses", "DISEASE", 145, 164], ["death", "DISEASE", 172, 177], ["chest", "ORGANISM_SUBDIVISION", 34, 39], ["head", "ORGANISM_SUBDIVISION", 74, 78], ["RSV", "ORGANISM", 113, 116], ["HMPV", "SPECIES", 11, 15], ["RSV", "SPECIES", 113, 116], ["HMPV clinical signs of chest indrawing", "PROBLEM", 11, 49], ["hopoxemia", "PROBLEM", 60, 69], ["head nodding", "PROBLEM", 74, 86], ["RSV infection", "PROBLEM", 113, 126], ["other respiratory viruses", "PROBLEM", 139, 164], ["death", "PROBLEM", 172, 177], ["HMPV", "OBSERVATION", 11, 15], ["chest", "ANATOMY", 34, 39], ["infection", "OBSERVATION", 117, 126], ["respiratory", "ANATOMY", 145, 156], ["viruses", "OBSERVATION", 157, 164], ["no", "UNCERTAINTY", 169, 171]]], ["RSV was found to be associated with disease severity in children with pneumonia [30] .DiscussionIt was surprising that in this study, RSV was detected simultaneously for only a year within the two-year study period of children hospitalized with pneumonia.", [["pneumonia", "DISEASE", 70, 79], ["pneumonia", "DISEASE", 245, 254], ["RSV", "ORGANISM", 0, 3], ["children", "ORGANISM", 56, 64], ["RSV", "ORGANISM", 134, 137], ["children", "ORGANISM", 218, 226], ["children", "SPECIES", 56, 64], ["children", "SPECIES", 218, 226], ["RSV", "SPECIES", 0, 3], ["RSV", "SPECIES", 134, 137], ["RSV", "PROBLEM", 0, 3], ["disease severity", "PROBLEM", 36, 52], ["pneumonia", "PROBLEM", 70, 79], ["this study", "TEST", 122, 132], ["RSV", "PROBLEM", 134, 137], ["pneumonia", "PROBLEM", 245, 254], ["pneumonia", "OBSERVATION", 70, 79], ["pneumonia", "OBSERVATION", 245, 254]]], ["However, peak was observed in winter during December to February, which was similar to what some other countries reported in a recent review article on RSV seasonality [54] .", [["RSV", "ORGANISM", 152, 155], ["RSV", "SPECIES", 152, 155]]], ["The review article reported that, epidemic in different countries were consistent between different years with some changes between seasons observed from year to year.", [["epidemic", "PROBLEM", 34, 42]]], ["Nevertheless, other countries reported irregular patterns of RSV seasonality as 2 different seasons for RSV and also followed a twoyear cycle for RSV.", [["RSV", "DISEASE", 104, 107], ["RSV", "DISEASE", 146, 149], ["RSV", "ORGANISM", 61, 64], ["RSV", "ORGANISM", 104, 107], ["RSV", "ORGANISM", 146, 149], ["RSV", "SPECIES", 61, 64], ["RSV", "SPECIES", 104, 107], ["RSV", "SPECIES", 146, 149], ["RSV seasonality", "PROBLEM", 61, 76], ["RSV", "PROBLEM", 104, 107], ["RSV", "PROBLEM", 146, 149], ["irregular", "OBSERVATION_MODIFIER", 39, 48], ["RSV seasonality", "OBSERVATION", 61, 76]]], ["Influenza virus was detected mostly during the influenza epidemic (May to September) in Bangladesh identified through the influenza surveillance system [55] .", [["Influenza", "DISEASE", 0, 9], ["influenza", "DISEASE", 47, 56], ["Influenza virus", "ORGANISM", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "PROBLEM", 0, 15], ["the influenza epidemic", "PROBLEM", 43, 65], ["virus", "OBSERVATION", 10, 15]]], ["No definite seasonal pattern was observed for other respiratory viruses.DiscussionDespite the inclusion of the PCV and Hib vaccines in the EPI programme in Bangladesh, viral pneumonia continues to be a major contributor of childhood pneumonia.", [["viral pneumonia", "DISEASE", 168, 183], ["pneumonia", "DISEASE", 233, 242], ["Hib", "ORGANISM", 119, 122], ["definite seasonal pattern", "PROBLEM", 3, 28], ["other respiratory viruses", "PROBLEM", 46, 71], ["the PCV", "TREATMENT", 107, 114], ["Hib vaccines", "TREATMENT", 119, 131], ["the EPI programme", "TREATMENT", 135, 152], ["viral pneumonia", "PROBLEM", 168, 183], ["childhood pneumonia", "PROBLEM", 223, 242], ["definite", "UNCERTAINTY", 3, 11], ["seasonal pattern", "OBSERVATION", 12, 28], ["respiratory viruses", "OBSERVATION", 52, 71], ["viral", "OBSERVATION_MODIFIER", 168, 173], ["pneumonia", "OBSERVATION", 174, 183], ["childhood", "OBSERVATION_MODIFIER", 223, 232], ["pneumonia", "OBSERVATION", 233, 242]]], ["The treatment of viral infections is often challenging due to the empirical use of antibiotics or antivirals.", [["viral infections", "DISEASE", 17, 33], ["viral infections", "PROBLEM", 17, 33], ["antibiotics", "TREATMENT", 83, 94], ["antivirals", "TREATMENT", 98, 108], ["viral", "OBSERVATION_MODIFIER", 17, 22], ["infections", "OBSERVATION", 23, 33]]], ["Currently, the development of an RSV vaccine is in progress and is modified for target populations such as infants, children, and pregnant women [56] .", [["RSV", "ORGANISM", 33, 36], ["infants", "ORGANISM", 107, 114], ["children", "ORGANISM", 116, 124], ["women", "ORGANISM", 139, 144], ["infants", "SPECIES", 107, 114], ["children", "SPECIES", 116, 124], ["women", "SPECIES", 139, 144], ["RSV", "SPECIES", 33, 36], ["an RSV vaccine", "TREATMENT", 30, 44], ["RSV", "OBSERVATION", 33, 36]]], ["In developing countries, RSV causes significant morbidity and mortality, as well as economic burden among children highlighting the crucial need for RSV vaccine implementation [57] .", [["RSV", "DISEASE", 25, 28], ["RSV", "ORGANISM", 25, 28], ["children", "ORGANISM", 106, 114], ["RSV", "ORGANISM", 149, 152], ["children", "SPECIES", 106, 114], ["RSV", "SPECIES", 25, 28], ["RSV", "SPECIES", 149, 152], ["RSV", "PROBLEM", 25, 28], ["significant morbidity", "PROBLEM", 36, 57], ["RSV vaccine implementation", "TREATMENT", 149, 175], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["morbidity", "OBSERVATION", 48, 57]]], ["In developed countries, the influenza vaccine is recommended for children, but vaccination coverage remains inadequate [58] .", [["influenza", "DISEASE", 28, 37], ["children", "ORGANISM", 65, 73], ["children", "SPECIES", 65, 73], ["the influenza vaccine", "TREATMENT", 24, 45], ["vaccination coverage", "TREATMENT", 79, 99]]], ["In developing countries with a high burden of childhood pneumonia, such as Bangladesh, the necessity for influenza vaccination among children needs to be considered [59] .", [["pneumonia", "DISEASE", 56, 65], ["influenza", "DISEASE", 105, 114], ["children", "ORGANISM", 133, 141], ["children", "SPECIES", 133, 141], ["childhood pneumonia", "PROBLEM", 46, 65], ["influenza vaccination", "TREATMENT", 105, 126], ["pneumonia", "OBSERVATION", 56, 65]]], ["For the treatment and prevention of pneumonia among severely malnourished children our study has generated imperative substantiation for physicians and policy-makers to plan and develop enhanced strategies through targeting vaccines and antivirals for common causative respiratory viral pathogens of pneumonia.", [["pneumonia", "DISEASE", 36, 45], ["respiratory viral pathogens", "DISEASE", 269, 296], ["pneumonia", "DISEASE", 300, 309], ["children", "ORGANISM", 74, 82], ["children", "SPECIES", 74, 82], ["the treatment", "TREATMENT", 4, 17], ["pneumonia", "PROBLEM", 36, 45], ["our study", "TEST", 83, 92], ["enhanced strategies", "TREATMENT", 186, 205], ["targeting vaccines", "TREATMENT", 214, 232], ["antivirals", "TREATMENT", 237, 247], ["common causative respiratory viral pathogens", "PROBLEM", 252, 296], ["pneumonia", "PROBLEM", 300, 309], ["pneumonia", "OBSERVATION", 36, 45], ["pneumonia", "OBSERVATION", 300, 309]]], ["Further research should be in consideration targeting vaccines or drugs to reduce the pneumonia burden in this specific population.LimitationsThe main limitation of our study was that we failed to enroll well-nourished controls.", [["pneumonia", "DISEASE", 86, 95], ["controls", "ORGANISM", 219, 227], ["targeting vaccines", "TREATMENT", 44, 62], ["drugs", "TREATMENT", 66, 71], ["the pneumonia burden", "PROBLEM", 82, 102], ["our study", "TEST", 165, 174], ["pneumonia", "OBSERVATION", 86, 95], ["main", "OBSERVATION_MODIFIER", 146, 150]]], ["This may reduce the generalizability of the causality from microbiological findings.", [["microbiological findings", "TEST", 59, 83]]], ["On the other hand, introduction of hospital-based controls which differs in exposure compared to the cases may weaken the causality from a microbiological point of view.", [["hospital-based controls", "TREATMENT", 35, 58]]], ["Another limitation of our study was that we did not enroll both the case and control during the same time period and the seasonal circulation of respiratory pathogens may have impacted our findings.", [["our study", "TEST", 22, 31], ["respiratory pathogens", "PROBLEM", 145, 166], ["respiratory pathogens", "OBSERVATION", 145, 166]]], ["However, we have a one year (February 2016 to March 2017) overlapping time period for both case and control enrollment and thereby we conducted analysis during this time period to identify etiological and independent causal associations of pneumonia.", [["pneumonia", "DISEASE", 240, 249], ["pneumonia", "PROBLEM", 240, 249], ["pneumonia", "OBSERVATION", 240, 249]]], ["Moreover, we did not subtype the predominant rhinoviruses and adenoviruses to identify the pathogenic subtype causing pneumonia.", [["pneumonia", "DISEASE", 118, 127], ["rhinoviruses", "ORGANISM", 45, 57], ["adenoviruses", "ORGANISM", 62, 74], ["the predominant rhinoviruses", "PROBLEM", 29, 57], ["adenoviruses", "TREATMENT", 62, 74], ["pneumonia", "PROBLEM", 118, 127], ["predominant", "OBSERVATION_MODIFIER", 33, 44], ["rhinoviruses", "OBSERVATION", 45, 57], ["pneumonia", "OBSERVATION", 118, 127]]], ["Another limitation of our study was that we did not test for other respiratory viruses such as bocavirus, coronavirus, cytomegalovirus and enterovirus which also might have an impact in our study findings.", [["coronavirus, cytomegalovirus and enterovirus", "DISEASE", 106, 150], ["bocavirus", "GENE_OR_GENE_PRODUCT", 95, 104], ["coronavirus", "ORGANISM", 106, 117], ["cytomegalovirus", "ORGANISM", 119, 134], ["enterovirus", "ORGANISM", 139, 150], ["our study", "TEST", 22, 31], ["other respiratory viruses", "PROBLEM", 61, 86], ["bocavirus", "PROBLEM", 95, 104], ["coronavirus", "PROBLEM", 106, 117], ["cytomegalovirus", "PROBLEM", 119, 134], ["enterovirus", "PROBLEM", 139, 150], ["our study findings", "TEST", 186, 204], ["respiratory", "ANATOMY", 67, 78], ["viruses", "OBSERVATION", 79, 86], ["cytomegalovirus", "OBSERVATION", 119, 134]]], ["Another limitation of the study is to perform bacterial culture only for blood which has traditionally low yield and not to perform bacterial culture for all NPW that were used for viral culture and thus, the chance of bacterial co-infection in these children with pneumonia could not be eliminated.", [["blood", "ANATOMY", 73, 78], ["bacterial co-infection", "DISEASE", 219, 241], ["pneumonia", "DISEASE", 265, 274], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["NPW", "SIMPLE_CHEMICAL", 158, 161], ["children", "ORGANISM", 251, 259], ["children", "SPECIES", 251, 259], ["NPW", "SPECIES", 158, 161], ["the study", "TEST", 22, 31], ["bacterial culture", "TEST", 46, 63], ["blood", "PROBLEM", 73, 78], ["bacterial culture", "TEST", 132, 149], ["all NPW", "TEST", 154, 161], ["viral culture", "TEST", 181, 194], ["bacterial co-infection", "PROBLEM", 219, 241], ["pneumonia", "PROBLEM", 265, 274], ["bacterial", "OBSERVATION_MODIFIER", 219, 228], ["co-infection", "OBSERVATION", 229, 241], ["pneumonia", "OBSERVATION", 265, 274]]], ["Finally, as the study was conducted in a diarrheal disease hospital in Dhaka city, the external validity of our study is limited.LimitationsThe major strength of our study was the study design, in particular the inclusion of respiratory symptom-free controls, to assess the pneumonia etiology by comparing the detection of pathogens in both groups, as inclusion of control in searching for the viral etiology of pneumonia specifically in severely malnourished children is happening for the first time.", [["diarrheal disease", "DISEASE", 41, 58], ["pneumonia", "DISEASE", 274, 283], ["pneumonia", "DISEASE", 412, 421], ["children", "ORGANISM", 460, 468], ["children", "SPECIES", 460, 468], ["the study", "TEST", 12, 21], ["our study", "TEST", 108, 117], ["our study", "TEST", 162, 171], ["the study", "TEST", 176, 185], ["respiratory symptom", "PROBLEM", 225, 244], ["the pneumonia", "PROBLEM", 270, 283], ["the detection", "TEST", 306, 319], ["pathogens", "PROBLEM", 323, 332], ["pneumonia", "PROBLEM", 412, 421], ["pneumonia", "OBSERVATION", 274, 283], ["viral", "OBSERVATION_MODIFIER", 394, 399], ["pneumonia", "OBSERVATION", 412, 421], ["severely", "OBSERVATION_MODIFIER", 438, 446], ["malnourished", "OBSERVATION", 447, 459]]], ["Another strength of this study was the well-trained team that evaluated and documented respiratory sign symptoms and used the standardized definition of pneumonia and laboratory measurement techniques.ConclusionPneumonia in severely malnourished children was mainly attributable to RSV, influenza, HPIV and HMPV.", [["respiratory", "ANATOMY", 87, 98], ["pneumonia", "DISEASE", 153, 162], ["ConclusionPneumonia", "CHEMICAL", 201, 220], ["malnourished", "DISEASE", 233, 245], ["influenza", "DISEASE", 287, 296], ["children", "ORGANISM", 246, 254], ["RSV", "ORGANISM", 282, 285], ["HMPV", "ORGANISM", 307, 311], ["children", "SPECIES", 246, 254], ["RSV", "SPECIES", 282, 285], ["HPIV", "SPECIES", 298, 302], ["HMPV", "SPECIES", 307, 311], ["this study", "TEST", 20, 30], ["respiratory sign symptoms", "PROBLEM", 87, 112], ["pneumonia", "PROBLEM", 153, 162], ["laboratory measurement techniques", "TEST", 167, 200], ["ConclusionPneumonia", "PROBLEM", 201, 220], ["severely malnourished children", "PROBLEM", 224, 254], ["RSV", "PROBLEM", 282, 285], ["influenza", "PROBLEM", 287, 296], ["HPIV", "TREATMENT", 298, 302], ["HMPV", "PROBLEM", 307, 311], ["pneumonia", "OBSERVATION", 153, 162], ["severely", "OBSERVATION_MODIFIER", 224, 232], ["malnourished", "OBSERVATION", 233, 245], ["mainly attributable to", "UNCERTAINTY", 259, 281], ["RSV", "OBSERVATION", 282, 285], ["HMPV", "OBSERVATION", 307, 311]]], ["Rhinovirus and adenovirus were detected in over two-thirds of the respiratory symptom-free control children, so identifying their contribution to pneumonia etiology was challenging.", [["pneumonia", "DISEASE", 146, 155], ["Rhinovirus", "GENE_OR_GENE_PRODUCT", 0, 10], ["adenovirus", "ORGANISM", 15, 25], ["children", "ORGANISM", 99, 107], ["children", "SPECIES", 99, 107], ["Rhinovirus", "SPECIES", 0, 10], ["adenovirus", "SPECIES", 15, 25], ["Rhinovirus", "PROBLEM", 0, 10], ["adenovirus", "PROBLEM", 15, 25], ["the respiratory symptom", "PROBLEM", 62, 85], ["pneumonia", "PROBLEM", 146, 155], ["adenovirus", "OBSERVATION", 15, 25], ["pneumonia", "OBSERVATION", 146, 155]]], ["This study provides important evidence for clinicians as well as for the public health policy makers to plan and develop improved strategies for the treatment and prevention of pneumonia among severely malnourished children.", [["pneumonia", "DISEASE", 177, 186], ["children", "ORGANISM", 215, 223], ["children", "SPECIES", 215, 223], ["This study", "TEST", 0, 10], ["the treatment", "TREATMENT", 145, 158], ["pneumonia", "PROBLEM", 177, 186], ["severely malnourished children", "PROBLEM", 193, 223], ["pneumonia", "OBSERVATION", 177, 186]]], ["Our study findings may help in planning further studies targeting vaccines or drugs against common viruses responsible for pneumonia in these children.", [["pneumonia", "DISEASE", 123, 132], ["children", "ORGANISM", 142, 150], ["children", "SPECIES", 142, 150], ["Our study", "TEST", 0, 9], ["further studies", "TEST", 40, 55], ["targeting vaccines", "TREATMENT", 56, 74], ["drugs", "TREATMENT", 78, 83], ["common viruses", "PROBLEM", 92, 106], ["pneumonia", "PROBLEM", 123, 132], ["pneumonia", "OBSERVATION", 123, 132]]]], "PMC5341368": [["BackgroundHuman adenoviruses (HAdVs) have been linked to a number of respiratory, gastrointestinal, ocular, genitourinary and neurologic diseases [1].", [["respiratory", "ANATOMY", 69, 80], ["gastrointestinal", "ANATOMY", 82, 98], ["ocular", "ANATOMY", 100, 106], ["genitourinary", "ANATOMY", 108, 121], ["neurologic", "ANATOMY", 126, 136], ["respiratory, gastrointestinal, ocular, genitourinary and neurologic diseases", "DISEASE", 69, 145], ["BackgroundHuman adenoviruses", "ORGANISM", 0, 28], ["HAdVs", "GENE_OR_GENE_PRODUCT", 30, 35], ["gastrointestinal", "ANATOMICAL_SYSTEM", 82, 98], ["BackgroundHuman adenoviruses (HAdVs)", "PROBLEM", 0, 36], ["respiratory, gastrointestinal, ocular, genitourinary and neurologic diseases", "PROBLEM", 69, 145], ["adenoviruses", "OBSERVATION", 16, 28], ["respiratory", "ANATOMY", 69, 80], ["gastrointestinal", "ANATOMY", 82, 98], ["ocular", "ANATOMY", 100, 106], ["genitourinary", "ANATOMY", 108, 121]]], ["There are currently 60 serotypes of HAdVs identified, which are grouped into 7 species based on their morphologic, immunogenic and genomic properties [2, 3].", [["HAdVs", "GENE_OR_GENE_PRODUCT", 36, 41], ["HAdVs", "PROBLEM", 36, 41]]], ["HAdV infections have been linked to mild upper respiratory tract infections such as pharyngitis or coryza, as well as to more severe lower respiratory tract infections (LRTIs) such as bronchiolitis, croup and pneumonia [4].", [["upper respiratory tract", "ANATOMY", 41, 64], ["lower respiratory tract", "ANATOMY", 133, 156], ["HAdV infections", "DISEASE", 0, 15], ["respiratory tract infections", "DISEASE", 47, 75], ["pharyngitis", "DISEASE", 84, 95], ["coryza", "DISEASE", 99, 105], ["lower respiratory tract infections", "DISEASE", 133, 167], ["LRTIs", "DISEASE", 169, 174], ["bronchiolitis", "DISEASE", 184, 197], ["croup", "DISEASE", 199, 204], ["pneumonia", "DISEASE", 209, 218], ["HAdV", "ORGANISM", 0, 4], ["upper", "ORGANISM_SUBDIVISION", 41, 46], ["respiratory tract", "ORGANISM_SUBDIVISION", 47, 64], ["tract", "ORGANISM_SUBDIVISION", 151, 156], ["HAdV infections", "PROBLEM", 0, 15], ["mild upper respiratory tract infections", "PROBLEM", 36, 75], ["pharyngitis", "PROBLEM", 84, 95], ["coryza", "PROBLEM", 99, 105], ["severe lower respiratory tract infections", "PROBLEM", 126, 167], ["bronchiolitis", "PROBLEM", 184, 197], ["croup", "PROBLEM", 199, 204], ["pneumonia", "PROBLEM", 209, 218], ["infections", "OBSERVATION", 5, 15], ["mild", "OBSERVATION_MODIFIER", 36, 40], ["upper", "ANATOMY_MODIFIER", 41, 46], ["respiratory tract", "ANATOMY", 47, 64], ["infections", "OBSERVATION", 65, 75], ["pharyngitis", "OBSERVATION", 84, 95], ["coryza", "OBSERVATION", 99, 105], ["severe", "OBSERVATION_MODIFIER", 126, 132], ["lower", "ANATOMY_MODIFIER", 133, 138], ["respiratory tract", "ANATOMY", 139, 156], ["infections", "OBSERVATION", 157, 167], ["LRTIs", "OBSERVATION", 169, 174], ["bronchiolitis", "OBSERVATION", 184, 197], ["pneumonia", "OBSERVATION", 209, 218]]], ["Approximately one-fifth of all HAdV infections were shown to be caused by HAdV-7, which is associated with serious LRTIs [5].", [["HAdV infections", "DISEASE", 31, 46], ["LRTIs", "DISEASE", 115, 120], ["HAdV", "ORGANISM", 31, 35], ["HAdV-7", "ORGANISM", 74, 80], ["HAdV-7", "SPECIES", 74, 80], ["all HAdV infections", "PROBLEM", 27, 46], ["HAdV", "PROBLEM", 74, 78], ["serious LRTIs", "PROBLEM", 107, 120], ["HAdV", "OBSERVATION_MODIFIER", 31, 35], ["infections", "OBSERVATION", 36, 46], ["associated with", "UNCERTAINTY", 91, 106], ["serious", "OBSERVATION_MODIFIER", 107, 114], ["LRTIs", "OBSERVATION", 115, 120]]], ["Although treatment of severe adenovirus infection is mainly supportive, antiviral agents such as acyclovir, ganciclovir, ribavirin, and cidofovir have been investigated for non-immunocompromised individuals [6, 7].", [["adenovirus infection", "DISEASE", 29, 49], ["acyclovir", "CHEMICAL", 97, 106], ["ganciclovir", "CHEMICAL", 108, 119], ["ribavirin", "CHEMICAL", 121, 130], ["cidofovir", "CHEMICAL", 136, 145], ["acyclovir", "CHEMICAL", 97, 106], ["ganciclovir", "CHEMICAL", 108, 119], ["ribavirin", "CHEMICAL", 121, 130], ["cidofovir", "CHEMICAL", 136, 145], ["adenovirus", "ORGANISM", 29, 39], ["acyclovir", "SIMPLE_CHEMICAL", 97, 106], ["ganciclovir", "SIMPLE_CHEMICAL", 108, 119], ["ribavirin", "SIMPLE_CHEMICAL", 121, 130], ["cidofovir", "SIMPLE_CHEMICAL", 136, 145], ["adenovirus", "SPECIES", 29, 39], ["severe adenovirus infection", "PROBLEM", 22, 49], ["antiviral agents", "TREATMENT", 72, 88], ["acyclovir", "TREATMENT", 97, 106], ["ganciclovir", "TREATMENT", 108, 119], ["ribavirin", "TREATMENT", 121, 130], ["cidofovir", "TREATMENT", 136, 145], ["non-immunocompromised individuals", "PROBLEM", 173, 206], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["adenovirus", "OBSERVATION_MODIFIER", 29, 39], ["infection", "OBSERVATION", 40, 49]]], ["Therapeutic strategies such as extracorporeal membrane oxygenation (ECMO) with or without high frequency oscillatory ventilation (HFOV) have also been evaluated in patients with severe disease [8, 9].BackgroundChildren, immunocompromised individuals, and people in crowded environments such as military recruits and hospitalized or institutionalized individuals have been shown to have a higher susceptibility to HAdV infections, especially HAdV-7 [10\u201313].", [["extracorporeal membrane", "ANATOMY", 31, 54], ["HAdV infections", "DISEASE", 413, 428], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 31, 54], ["patients", "ORGANISM", 164, 172], ["Children", "ORGANISM", 210, 218], ["people", "ORGANISM", 255, 261], ["individuals", "ORGANISM", 350, 361], ["HAdV", "ORGANISM", 413, 417], ["HAdV-7", "ORGANISM", 441, 447], ["patients", "SPECIES", 164, 172], ["Children", "SPECIES", 210, 218], ["people", "SPECIES", 255, 261], ["HAdV", "SPECIES", 413, 417], ["HAdV-7", "SPECIES", 441, 447], ["Therapeutic strategies", "TREATMENT", 0, 22], ["extracorporeal membrane oxygenation", "TREATMENT", 31, 66], ["high frequency oscillatory ventilation", "TREATMENT", 90, 128], ["severe disease", "PROBLEM", 178, 192], ["immunocompromised individuals", "PROBLEM", 220, 249], ["HAdV infections", "PROBLEM", 413, 428], ["severe", "OBSERVATION_MODIFIER", 178, 184], ["disease", "OBSERVATION", 185, 192], ["immunocompromised", "OBSERVATION", 220, 237], ["infections", "OBSERVATION", 418, 428]]], ["HAdVs 1, 2 and 5 are usually implicated in endemic or sporadic cases, while HAdVs 7 and to a lesser extent HAdV-3 have been isolated from epidemics of adenovirus LRTIs in healthy children [11, 14].", [["adenovirus LRTIs", "DISEASE", 151, 167], ["HAdVs 1", "GENE_OR_GENE_PRODUCT", 0, 7], ["2", "GENE_OR_GENE_PRODUCT", 9, 10], ["5", "GENE_OR_GENE_PRODUCT", 15, 16], ["HAdVs 7", "ORGANISM", 76, 83], ["HAdV-3", "ORGANISM", 107, 113], ["adenovirus", "ORGANISM", 151, 161], ["children", "ORGANISM", 179, 187], ["children", "SPECIES", 179, 187], ["adenovirus", "SPECIES", 151, 161], ["adenovirus LRTIs", "OBSERVATION", 151, 167]]], ["HAdV-11 and HAdV-7 were the most frequently identified pathogens in a 2011 study of community-acquired pneumonia in Beijing, China [15].", [["pneumonia", "DISEASE", 103, 112], ["HAdV-11", "ORGANISM", 0, 7], ["HAdV-7", "ORGANISM", 12, 18], ["HAdV-11", "SPECIES", 0, 7], ["HAdV-7", "SPECIES", 12, 18], ["HAdV", "TEST", 0, 4], ["HAdV", "PROBLEM", 12, 16], ["community-acquired pneumonia", "PROBLEM", 84, 112], ["pathogens", "OBSERVATION", 55, 64], ["pneumonia", "OBSERVATION", 103, 112]]], ["HAdV-7 was also reported as the primary pathogen in an outbreak of severe LRTI among infants in Shaanxi Province, China in 2009, and Singapore in 2012 [5, 16].", [["LRTI", "DISEASE", 74, 78], ["HAdV-7", "ORGANISM", 0, 6], ["infants", "ORGANISM", 85, 92], ["infants", "SPECIES", 85, 92], ["HAdV-7", "SPECIES", 0, 6], ["HAdV", "PROBLEM", 0, 4]]], ["A number of adenovirus outbreaks involving HAdV-7, HAdV-3, and HAdV-4 have been reported from Taiwan between 1999 and 2005 [17, 18].", [["adenovirus", "ORGANISM", 12, 22], ["HAdV-7", "ORGANISM", 43, 49], ["HAdV-3", "ORGANISM", 51, 57], ["HAdV-4", "ORGANISM", 63, 69], ["HAdV-7", "SPECIES", 43, 49], ["HAdV-3", "SPECIES", 51, 57], ["HAdV-4", "SPECIES", 63, 69], ["adenovirus outbreaks", "PROBLEM", 12, 32], ["HAdV", "TEST", 43, 47], ["HAdV", "TEST", 51, 55], ["HAdV", "TEST", 63, 67], ["adenovirus outbreaks", "OBSERVATION", 12, 32]]], ["The largest reported community outbreak which occurred in Taiwan in 2011 involved co-circulating HAdV-3 and HAdV-7 [19].", [["HAdV-3", "ORGANISM", 97, 103], ["HAdV-7", "ORGANISM", 108, 114], ["HAdV", "TEST", 97, 101], ["HAdV", "TEST", 108, 112], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["community", "OBSERVATION_MODIFIER", 21, 30], ["outbreak", "OBSERVATION", 31, 39]]], ["Although the 2011 outbreak was associated with HAdV-3 as well as HAdV-7, patients infected with HAdV-7 had a higher fatality rate [20].", [["HAdV-3", "ORGANISM", 47, 53], ["HAdV-7", "ORGANISM", 65, 71], ["patients", "ORGANISM", 73, 81], ["HAdV-7", "ORGANISM", 96, 102], ["patients", "SPECIES", 73, 81], ["HAdV-3", "SPECIES", 47, 53], ["HAdV-7", "SPECIES", 65, 71], ["HAdV-7", "SPECIES", 96, 102], ["HAdV", "PROBLEM", 47, 51], ["HAdV", "PROBLEM", 65, 69], ["HAdV", "TEST", 96, 100]]], ["HAdV-7 isolated from the 2011 outbreak was shown to have the highest homology with HAdV-7d and HAdV-7d2, strains which had not been seen in Taiwan prior to 2011 [19].BackgroundCellular immunity plays an important role in viral infections, and severe adenovirus infections are commonly seen in immunocompromised individuals.", [["Cellular", "ANATOMY", 176, 184], ["viral infections", "DISEASE", 221, 237], ["adenovirus infections", "DISEASE", 250, 271], ["HAdV-7", "ORGANISM", 0, 6], ["HAdV-7d", "ORGANISM", 83, 90], ["HAdV-7d2", "ORGANISM", 95, 103], ["Cellular", "CELL", 176, 184], ["adenovirus", "ORGANISM", 250, 260], ["HAdV-7", "SPECIES", 0, 6], ["HAdV-7d2", "SPECIES", 95, 103], ["adenovirus", "SPECIES", 250, 260], ["HAdV", "PROBLEM", 0, 4], ["HAdV", "PROBLEM", 83, 87], ["HAdV", "PROBLEM", 95, 99], ["strains", "PROBLEM", 105, 112], ["viral infections", "PROBLEM", 221, 237], ["severe adenovirus infections", "PROBLEM", 243, 271], ["immunocompromised individuals", "PROBLEM", 293, 322], ["Cellular immunity", "OBSERVATION", 176, 193], ["viral infections", "OBSERVATION", 221, 237], ["severe", "OBSERVATION_MODIFIER", 243, 249], ["adenovirus infections", "OBSERVATION", 250, 271], ["immunocompromised individuals", "OBSERVATION", 293, 322]]], ["The mechanisms underlying the pathogenesis of severe adenovirus infections in non-immunocompromised individuals remain unclear.", [["adenovirus infections", "DISEASE", 53, 74], ["adenovirus", "ORGANISM", 53, 63], ["adenovirus", "SPECIES", 53, 63], ["severe adenovirus infections", "PROBLEM", 46, 74], ["non-immunocompromised individuals", "PROBLEM", 78, 111], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["adenovirus", "OBSERVATION_MODIFIER", 53, 63], ["infections", "OBSERVATION", 64, 74]]], ["Production of chemokines and cytokines in response to HAdV-7 infection was shown to damage lung tissue, and result in recruitment of inflammatory cells such as neutrophils, monocytes and lymphocytes [21, 22].", [["lung tissue", "ANATOMY", 91, 102], ["inflammatory cells", "ANATOMY", 133, 151], ["neutrophils", "ANATOMY", 160, 171], ["monocytes", "ANATOMY", 173, 182], ["lymphocytes", "ANATOMY", 187, 198], ["infection", "DISEASE", 61, 70], ["HAdV-7", "ORGANISM", 54, 60], ["lung tissue", "TISSUE", 91, 102], ["inflammatory cells", "CELL", 133, 151], ["neutrophils", "CELL", 160, 171], ["monocytes", "CELL", 173, 182], ["lymphocytes", "CELL", 187, 198], ["chemokines", "PROTEIN", 14, 24], ["cytokines", "PROTEIN", 29, 38], ["inflammatory cells", "CELL_TYPE", 133, 151], ["neutrophils", "CELL_TYPE", 160, 171], ["monocytes", "CELL_TYPE", 173, 182], ["lymphocytes", "CELL_TYPE", 187, 198], ["HAdV-7", "SPECIES", 54, 60], ["chemokines", "PROBLEM", 14, 24], ["cytokines", "PROBLEM", 29, 38], ["HAdV", "PROBLEM", 54, 58], ["7 infection", "PROBLEM", 59, 70], ["damage lung tissue", "PROBLEM", 84, 102], ["inflammatory cells", "PROBLEM", 133, 151], ["neutrophils", "TEST", 160, 171], ["monocytes", "TEST", 173, 182], ["lymphocytes", "TEST", 187, 198], ["chemokines", "OBSERVATION_MODIFIER", 14, 24], ["infection", "OBSERVATION", 61, 70], ["lung tissue", "ANATOMY", 91, 102], ["recruitment", "OBSERVATION_MODIFIER", 118, 129], ["inflammatory cells", "OBSERVATION", 133, 151]]], ["Interestingly, a recent report reviewed 19 studies which evaluated immunocompetent patients with adenovirus pneumonia and showed that more than half the patients were lymphopenic [23].", [["adenovirus pneumonia", "DISEASE", 97, 117], ["patients", "ORGANISM", 83, 91], ["adenovirus", "ORGANISM", 97, 107], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 153, 161], ["19 studies", "TEST", 40, 50], ["adenovirus pneumonia", "PROBLEM", 97, 117], ["lymphopenic", "PROBLEM", 167, 178], ["pneumonia", "OBSERVATION", 108, 117], ["lymphopenic", "OBSERVATION", 167, 178]]], ["A recent retrospective study also showed that non-immunocompromised patients with severe adenovirus pneumonia had lower hemoglobin levels, leucopenia, thrombocytopenia and elevated liver enzymes, suggesting a distinctive mechanism of immunopathogenesis which may contribute to the severity of the infection [7].BackgroundWe hypothesized that the host immunological response determines the severity of adenoviral infection.", [["liver", "ANATOMY", 181, 186], ["adenovirus pneumonia", "DISEASE", 89, 109], ["leucopenia", "DISEASE", 139, 149], ["thrombocytopenia", "DISEASE", 151, 167], ["elevated liver enzymes", "DISEASE", 172, 194], ["infection", "DISEASE", 297, 306], ["adenoviral infection", "DISEASE", 401, 421], ["patients", "ORGANISM", 68, 76], ["adenovirus", "ORGANISM", 89, 99], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 120, 130], ["liver", "ORGAN", 181, 186], ["adenoviral", "ORGANISM", 401, 411], ["hemoglobin", "PROTEIN", 120, 130], ["liver enzymes", "PROTEIN", 181, 194], ["patients", "SPECIES", 68, 76], ["adenoviral", "SPECIES", 401, 411], ["A recent retrospective study", "TEST", 0, 28], ["severe adenovirus pneumonia", "PROBLEM", 82, 109], ["lower hemoglobin levels", "PROBLEM", 114, 137], ["leucopenia", "PROBLEM", 139, 149], ["thrombocytopenia", "PROBLEM", 151, 167], ["elevated liver enzymes", "PROBLEM", 172, 194], ["immunopathogenesis", "PROBLEM", 234, 252], ["the infection", "PROBLEM", 293, 306], ["adenoviral infection", "PROBLEM", 401, 421], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["adenovirus", "OBSERVATION_MODIFIER", 89, 99], ["pneumonia", "OBSERVATION", 100, 109], ["leucopenia", "OBSERVATION", 139, 149], ["thrombocytopenia", "OBSERVATION", 151, 167], ["liver", "ANATOMY", 181, 186], ["immunopathogenesis", "OBSERVATION", 234, 252], ["infection", "OBSERVATION", 297, 306], ["adenoviral", "ANATOMY", 401, 411], ["infection", "OBSERVATION", 412, 421]]], ["Additionally, we observed that adenovirus pneumonia was associated with pleural effusion in a number of patients from the 2011 outbreak.", [["pleural effusion", "ANATOMY", 72, 88], ["adenovirus pneumonia", "DISEASE", 31, 51], ["pleural effusion", "DISEASE", 72, 88], ["adenovirus", "ORGANISM", 31, 41], ["pleural", "PATHOLOGICAL_FORMATION", 72, 79], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["adenovirus pneumonia", "PROBLEM", 31, 51], ["pleural effusion", "PROBLEM", 72, 88], ["adenovirus", "OBSERVATION_MODIFIER", 31, 41], ["pneumonia", "OBSERVATION", 42, 51], ["pleural", "ANATOMY", 72, 79], ["effusion", "OBSERVATION", 80, 88]]], ["We hypothesized that similar to bacterial pneumonia, patients diagnosed with adenovirus pneumonia who have pleural effusion are more severely and systemically infected, and may have a more protracted disease course.", [["pleural effusion", "ANATOMY", 107, 123], ["pneumonia", "DISEASE", 42, 51], ["adenovirus pneumonia", "DISEASE", 77, 97], ["pleural effusion", "DISEASE", 107, 123], ["patients", "ORGANISM", 53, 61], ["adenovirus", "ORGANISM", 77, 87], ["pleural effusion", "CANCER", 107, 123], ["patients", "SPECIES", 53, 61], ["bacterial pneumonia", "PROBLEM", 32, 51], ["adenovirus pneumonia", "PROBLEM", 77, 97], ["pleural effusion", "PROBLEM", 107, 123], ["a more protracted disease course", "PROBLEM", 182, 214], ["bacterial", "OBSERVATION_MODIFIER", 32, 41], ["pneumonia", "OBSERVATION", 42, 51], ["adenovirus", "OBSERVATION_MODIFIER", 77, 87], ["pneumonia", "OBSERVATION", 88, 97], ["pleural", "ANATOMY", 107, 114], ["effusion", "OBSERVATION", 115, 123], ["severely", "OBSERVATION_MODIFIER", 133, 141], ["systemically", "OBSERVATION_MODIFIER", 146, 158], ["infected", "OBSERVATION", 159, 167], ["more", "OBSERVATION_MODIFIER", 184, 188], ["protracted", "OBSERVATION_MODIFIER", 189, 199], ["disease", "OBSERVATION", 200, 207]]], ["In this retrospective case series study, we evaluated the clinical manifestations of adenoviral pneumonia in a convenience sample of 27 patients from the 2011 outbreak in South Taiwan and compared clinical features and laboratory data between patients with or without parapneumonic effusion.Materials ::: MethodsBlood cultures were done using the BACTEC Fx System (BD Biosciences, USA).", [["Blood cultures", "ANATOMY", 312, 326], ["adenoviral pneumonia", "DISEASE", 85, 105], ["parapneumonic effusion", "DISEASE", 268, 290], ["adenoviral", "ORGANISM", 85, 95], ["patients", "ORGANISM", 136, 144], ["patients", "ORGANISM", 243, 251], ["patients", "SPECIES", 136, 144], ["patients", "SPECIES", 243, 251], ["adenoviral", "SPECIES", 85, 95], ["series study", "TEST", 27, 39], ["adenoviral pneumonia", "PROBLEM", 85, 105], ["laboratory data", "TEST", 219, 234], ["parapneumonic effusion", "PROBLEM", 268, 290], ["MethodsBlood cultures", "TEST", 305, 326], ["the BACTEC Fx System", "TEST", 343, 363], ["adenoviral", "ANATOMY", 85, 95], ["pneumonia", "OBSERVATION", 96, 105], ["without", "UNCERTAINTY", 260, 267], ["parapneumonic", "OBSERVATION_MODIFIER", 268, 281], ["effusion", "OBSERVATION", 282, 290]]], ["Urine pneumococcal antigen tests were done with the BinaxNOW\u00ae Streptococcus pneumoniae Antigen Card (Alere Ltd, Stockport, UK), and urine Legionella antigen tests were done with the BinaxNOW Legionella Urinary Antigen Card (Alere Ltd, Stockport, UK).", [["Urine", "ANATOMY", 0, 5], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["Streptococcus pneumoniae", "ORGANISM", 62, 86], ["urine", "ORGANISM_SUBSTANCE", 132, 137], ["Streptococcus pneumoniae", "SPECIES", 62, 86], ["pneumococcal", "SPECIES", 6, 18], ["Streptococcus pneumoniae", "SPECIES", 62, 86], ["Urine pneumococcal antigen tests", "TEST", 0, 32], ["Streptococcus pneumoniae Antigen", "TEST", 62, 94], ["urine Legionella antigen tests", "TEST", 132, 162], ["the BinaxNOW Legionella", "TEST", 178, 201], ["pneumococcal", "OBSERVATION", 6, 18]]], ["The Cryptococcus antigen test was done with the CALAS\u00ae Cryptococcal Antigen latex agglutination system (Meridian Bioscience, Inc, Cincinnati, Ohio, USA).", [["Cryptococcus antigen", "GENE_OR_GENE_PRODUCT", 4, 24], ["CALAS", "PROTEIN", 48, 53], ["The Cryptococcus antigen test", "TEST", 0, 29], ["Cryptococcal Antigen", "TEST", 55, 75]]], ["Mycoplasma antibodies were detected using the Serodia Myco II gelatin particle agglutination kit (Fujirebio, Tokyo, Japan).", [["Mycoplasma antibodies", "PROTEIN", 0, 21], ["Mycoplasma antibodies", "TEST", 0, 21], ["the Serodia Myco II gelatin", "TREATMENT", 42, 69]]], ["The influenza rapid test was performed with the Directigen Flu A + B test (Directigen; BD Diagnostic Systems, Sparks, MD.)", [["The influenza rapid test", "TEST", 0, 24]]], ["CDC-validated FDA-approved real time RT-PCR assays were used to detect human influenza virus (CDC influenza division, USA).", [["influenza virus", "DISEASE", 77, 92], ["human", "ORGANISM", 71, 76], ["influenza virus", "ORGANISM", 77, 92], ["human", "SPECIES", 71, 76], ["influenza virus", "SPECIES", 77, 92], ["human influenza virus", "SPECIES", 71, 92], ["CDC", "TEST", 0, 3], ["RT-PCR assays", "TEST", 37, 50], ["human influenza virus", "PROBLEM", 71, 92]]], ["The respiratory syncytial virus (RSV) antigen test was a direct fluorescent-antibody assay (DFA) by Diagnostic Hybrids Inc. (DHI; Athens, OH).Patients ::: MethodsThis retrospective, single-center, observational case series included a total of 27 patients who presented with severe adenovirus LRTIs at the National Cheng Kung University (NCKU) Hospital in southern Taiwan between December 2010 and October 2011.", [["respiratory syncytial virus", "DISEASE", 4, 31], ["adenovirus LRTIs", "DISEASE", 281, 297], ["OH", "CHEMICAL", 138, 140], ["respiratory syncytial virus", "ORGANISM", 4, 31], ["RSV", "ORGANISM", 33, 36], ["Patients", "ORGANISM", 142, 150], ["patients", "ORGANISM", 246, 254], ["adenovirus", "ORGANISM", 281, 291], ["Patients", "SPECIES", 142, 150], ["patients", "SPECIES", 246, 254], ["respiratory syncytial virus", "SPECIES", 4, 31], ["RSV", "SPECIES", 33, 36], ["The respiratory syncytial virus (RSV) antigen test", "TEST", 0, 50], ["a direct fluorescent", "TEST", 55, 75], ["antibody assay", "TEST", 76, 90], ["DFA", "TEST", 92, 95], ["severe adenovirus LRTIs", "PROBLEM", 274, 297], ["respiratory syncytial", "ANATOMY", 4, 25], ["severe", "OBSERVATION_MODIFIER", 274, 280], ["adenovirus LRTIs", "OBSERVATION", 281, 297]]], ["Inclusion criteria were 1) presence of multifocal patchy infiltrates, lobar consolidation or reticular interstitial opacities in chest X-rays, and 2) presence of adenovirus isolated from respiratory specimens.", [["lobar", "ANATOMY", 70, 75], ["reticular interstitial opacities", "ANATOMY", 93, 125], ["respiratory specimens", "ANATOMY", 187, 208], ["interstitial opacities", "DISEASE", 103, 125], ["adenovirus", "ORGANISM", 162, 172], ["multifocal patchy infiltrates", "PROBLEM", 39, 68], ["lobar consolidation", "PROBLEM", 70, 89], ["reticular interstitial opacities", "PROBLEM", 93, 125], ["chest X-rays", "TEST", 129, 141], ["adenovirus", "PROBLEM", 162, 172], ["respiratory specimens", "TEST", 187, 208], ["multifocal", "OBSERVATION_MODIFIER", 39, 49], ["patchy", "OBSERVATION_MODIFIER", 50, 56], ["infiltrates", "OBSERVATION", 57, 68], ["lobar", "OBSERVATION_MODIFIER", 70, 75], ["consolidation", "OBSERVATION", 76, 89], ["reticular", "ANATOMY_MODIFIER", 93, 102], ["interstitial", "ANATOMY_MODIFIER", 103, 115], ["opacities", "OBSERVATION", 116, 125], ["chest", "ANATOMY", 129, 134], ["adenovirus", "OBSERVATION", 162, 172], ["respiratory specimens", "OBSERVATION", 187, 208]]], ["Pleural effusion and diagnosis of adenoviral pneumonia was confirmed in all study patients using chest echography, which is an ultrasound technique.", [["Pleural", "ANATOMY", 0, 7], ["Pleural effusion", "DISEASE", 0, 16], ["adenoviral pneumonia", "DISEASE", 34, 54], ["Pleural", "PATHOLOGICAL_FORMATION", 0, 7], ["adenoviral", "ORGANISM", 34, 44], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["adenoviral", "SPECIES", 34, 44], ["Pleural effusion", "PROBLEM", 0, 16], ["adenoviral pneumonia", "PROBLEM", 34, 54], ["all study", "TEST", 72, 81], ["chest echography", "TEST", 97, 113], ["an ultrasound technique", "TEST", 124, 147], ["effusion", "OBSERVATION", 8, 16], ["adenoviral", "OBSERVATION_MODIFIER", 34, 44], ["pneumonia", "OBSERVATION", 45, 54], ["chest", "ANATOMY", 97, 102]]], ["Chest echography at the NCKU hospital is mainly performed by senior pediatric residents with at least three years of pediatric training.", [["Chest echography", "TEST", 0, 16], ["pediatric training", "TREATMENT", 117, 135]]], ["The results are subsequently confirmed by the attending pediatrician and another pediatric chest specialist.Patients ::: MethodsAll throat swabs were examined for the presence of influenza virus using PCR assays, and for the presence of RSV antigen using a direct fluorescent-antibody assay.", [["chest", "ANATOMY", 91, 96], ["throat swabs", "ANATOMY", 132, 144], ["chest", "ORGANISM_SUBDIVISION", 91, 96], ["Patients", "ORGANISM", 108, 116], ["RSV", "ORGANISM", 237, 240], ["RSV antigen", "PROTEIN", 237, 248], ["Patients", "SPECIES", 108, 116], ["influenza virus", "SPECIES", 179, 194], ["influenza virus", "SPECIES", 179, 194], ["RSV", "SPECIES", 237, 240], ["Methods", "TEST", 121, 128], ["All throat swabs", "TEST", 128, 144], ["influenza virus", "PROBLEM", 179, 194], ["PCR assays", "TEST", 201, 211], ["RSV antigen", "PROBLEM", 237, 248], ["a direct fluorescent-antibody assay", "TEST", 255, 290], ["chest", "ANATOMY", 91, 96]]], ["All specimens were negative for influenza and RSV.", [["specimens", "ANATOMY", 4, 13], ["influenza", "DISEASE", 32, 41], ["RSV", "DISEASE", 46, 49], ["specimens", "CANCER", 4, 13], ["RSV", "ORGANISM", 46, 49], ["RSV", "SPECIES", 46, 49], ["All specimens", "TEST", 0, 13], ["influenza", "PROBLEM", 32, 41], ["RSV", "PROBLEM", 46, 49], ["negative for", "UNCERTAINTY", 19, 31]]], ["Co-infections were excluded using blood cultures, sputum cultures, pleural effusion cultures, the urine pneumococcal antigen test, the urine Legionella antigen test, the influenza rapid test, the RSV rapid test, PCR assay for influenza and the Cryptococcus and Mycoplasma tests.", [["blood", "ANATOMY", 34, 39], ["sputum cultures", "ANATOMY", 50, 65], ["pleural effusion cultures", "ANATOMY", 67, 92], ["urine", "ANATOMY", 98, 103], ["urine", "ANATOMY", 135, 140], ["pleural effusion", "DISEASE", 67, 83], ["influenza", "DISEASE", 226, 235], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["urine", "ORGANISM_SUBSTANCE", 98, 103], ["urine", "ORGANISM_SUBSTANCE", 135, 140], ["RSV", "ORGANISM", 196, 199], ["pneumococcal", "SPECIES", 104, 116], ["RSV", "SPECIES", 196, 199], ["Co-infections", "PROBLEM", 0, 13], ["blood cultures", "TEST", 34, 48], ["sputum cultures", "TEST", 50, 65], ["pleural effusion cultures", "TEST", 67, 92], ["the urine pneumococcal antigen test", "TEST", 94, 129], ["the urine Legionella antigen test", "TEST", 131, 164], ["the influenza rapid test", "TEST", 166, 190], ["the RSV rapid test", "TEST", 192, 210], ["PCR assay", "TEST", 212, 221], ["influenza", "PROBLEM", 226, 235], ["the Cryptococcus", "TEST", 240, 256], ["Mycoplasma tests", "TEST", 261, 277], ["pleural", "ANATOMY", 67, 74], ["effusion", "OBSERVATION", 75, 83]]], ["Data for presence of Mycoplasma antibodies were available for 21 patients (19 patients were negative and 2 patients were positive for Mycoplasma).", [["Mycoplasma", "ORGANISM", 21, 31], ["patients", "ORGANISM", 65, 73], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 107, 115], ["Mycoplasma antibodies", "PROTEIN", 21, 42], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 107, 115], ["Mycoplasma antibodies", "PROBLEM", 21, 42], ["Mycoplasma", "PROBLEM", 134, 144]]], ["Data for Legionella antibodies were only available for 3 patients, all of whom were negative for Legionella.", [["patients", "ORGANISM", 57, 65], ["Legionella antibodies", "PROTEIN", 9, 30], ["patients", "SPECIES", 57, 65], ["Legionella antibodies", "TEST", 9, 30], ["Legionella", "PROBLEM", 97, 107]]], ["Only two cases with significantly elevated levels of mycoplasma antibody presented with simple adenovirus pneumonia.", [["pneumonia", "DISEASE", 106, 115], ["adenovirus", "ORGANISM", 95, 105], ["mycoplasma antibody", "PROTEIN", 53, 72], ["significantly elevated levels", "PROBLEM", 20, 49], ["mycoplasma antibody", "PROBLEM", 53, 72], ["simple adenovirus pneumonia", "PROBLEM", 88, 115], ["mycoplasma antibody", "OBSERVATION", 53, 72], ["simple", "OBSERVATION_MODIFIER", 88, 94], ["adenovirus", "OBSERVATION_MODIFIER", 95, 105], ["pneumonia", "OBSERVATION", 106, 115]]], ["Since our results would not have changed even if we had excluded these two cases, we retained these two cases in the adenovirus pneumonia without pleural effusion group.", [["pleural effusion", "ANATOMY", 146, 162], ["pneumonia", "DISEASE", 128, 137], ["pleural effusion", "DISEASE", 146, 162], ["adenovirus", "ORGANISM", 117, 127], ["pleural effusion", "PATHOLOGICAL_FORMATION", 146, 162], ["the adenovirus pneumonia", "PROBLEM", 113, 137], ["pleural effusion group", "PROBLEM", 146, 168], ["adenovirus", "ANATOMY", 117, 127], ["pneumonia", "OBSERVATION", 128, 137], ["without", "UNCERTAINTY", 138, 145], ["pleural", "ANATOMY", 146, 153], ["effusion", "OBSERVATION", 154, 162]]], ["All other viral cultures only showed the presence of adenovirus.", [["adenovirus", "ORGANISM", 53, 63], ["All other viral cultures", "TEST", 0, 24], ["adenovirus", "PROBLEM", 53, 63], ["adenovirus", "OBSERVATION", 53, 63]]], ["Although the antibiotic regimen varied from patient to patient, most patients were on ampicillin/sulbactam.", [["ampicillin", "CHEMICAL", 86, 96], ["sulbactam", "CHEMICAL", 97, 106], ["ampicillin", "CHEMICAL", 86, 96], ["sulbactam", "CHEMICAL", 97, 106], ["patient", "ORGANISM", 44, 51], ["patient", "ORGANISM", 55, 62], ["patients", "ORGANISM", 69, 77], ["ampicillin", "SIMPLE_CHEMICAL", 86, 96], ["sulbactam", "SIMPLE_CHEMICAL", 97, 106], ["patient", "SPECIES", 44, 51], ["patient", "SPECIES", 55, 62], ["patients", "SPECIES", 69, 77], ["the antibiotic regimen", "TREATMENT", 9, 31], ["ampicillin", "TREATMENT", 86, 96], ["sulbactam", "TREATMENT", 97, 106]]], ["All patient data were recorded soon after hospitalization.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["It is important to note that at the NCKU Hospital, all pediatric patients except those with walking/atypical pneumonia (caused by mycoplasma) are hospitalized for evaluation and treatment, and their medical data are accessible using administrative hospital data.", [["pneumonia", "DISEASE", 109, 118], ["mycoplasma", "DISEASE", 130, 140], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["atypical pneumonia", "PROBLEM", 100, 118], ["mycoplasma", "PROBLEM", 130, 140], ["evaluation", "TEST", 163, 173], ["treatment", "TREATMENT", 178, 187], ["pneumonia", "OBSERVATION", 109, 118]]], ["This decreases the likelihood of selection bias within this sample of hospitalized patients.Patients ::: MethodsThis study sample was a convenience sample.", [["patients", "ORGANISM", 83, 91], ["Patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 83, 91], ["Patients", "SPECIES", 92, 100], ["selection bias", "TEST", 33, 47], ["Methods", "TREATMENT", 105, 112], ["This study", "TEST", 112, 122], ["a convenience sample", "TEST", 134, 154]]], ["Patients with adenovirus pneumonia usually have prolonged fever and severe respiratory symptoms, which increases the likelihood of seeking medical care.", [["respiratory", "ANATOMY", 75, 86], ["adenovirus pneumonia", "DISEASE", 14, 34], ["fever", "DISEASE", 58, 63], ["respiratory symptoms", "DISEASE", 75, 95], ["Patients", "ORGANISM", 0, 8], ["adenovirus", "ORGANISM", 14, 24], ["Patients", "SPECIES", 0, 8], ["adenovirus pneumonia", "PROBLEM", 14, 34], ["prolonged fever", "PROBLEM", 48, 63], ["severe respiratory symptoms", "PROBLEM", 68, 95], ["adenovirus", "ANATOMY", 14, 24], ["pneumonia", "OBSERVATION", 25, 34], ["prolonged", "OBSERVATION_MODIFIER", 48, 57], ["fever", "OBSERVATION", 58, 63], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["respiratory symptoms", "OBSERVATION", 75, 95]]], ["Most patients were referred by their local practitioners if their fever did not subside on the 3rd or 4th day.", [["fever", "DISEASE", 66, 71], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["their fever", "PROBLEM", 60, 71]]], ["Our hospital is one of the biggest and largest pediatric tertiary referral centers in southern Taiwan, and even when the study cases are sampled by convenience, they are likely to closely reflect the population of patients hospitalized with severe adenoviral infection.Patients ::: MethodsThis study was approved by the Institutional Review Board of the National Cheng Kung University (NCKU) Hospital.Statistical analysis ::: MethodsContinuous data for the two groups of patients (patients with or without pleural effusion) were represented as either (i) mean \u00b1 SD and compared using the two-sample t-test if the data followed normal distribution or (ii) median (IQR: 1st, 3rd quartiles) and compared using the Mann-Whitney U test if the data didn\u2019t follow normal distribution.", [["pleural", "ANATOMY", 506, 513], ["adenoviral infection", "DISEASE", 248, 268], ["pleural effusion", "DISEASE", 506, 522], ["patients", "ORGANISM", 214, 222], ["adenoviral", "ORGANISM", 248, 258], ["Patients", "ORGANISM", 269, 277], ["patients", "ORGANISM", 471, 479], ["patients", "ORGANISM", 481, 489], ["pleural", "ORGAN", 506, 513], ["patients", "SPECIES", 214, 222], ["Patients", "SPECIES", 269, 277], ["patients", "SPECIES", 471, 479], ["patients", "SPECIES", 481, 489], ["adenoviral", "SPECIES", 248, 258], ["the study", "TEST", 117, 126], ["severe adenoviral infection", "PROBLEM", 241, 268], ["Methods", "TREATMENT", 282, 289], ["This study", "TEST", 289, 299], ["MethodsContinuous data", "TEST", 426, 448], ["pleural effusion", "PROBLEM", 506, 522], ["the two-sample t-test", "TEST", 584, 605], ["the data", "TEST", 609, 617], ["Whitney U test", "TEST", 716, 730], ["the data", "TEST", 734, 742], ["severe", "OBSERVATION_MODIFIER", 241, 247], ["adenoviral", "ANATOMY", 248, 258], ["infection", "OBSERVATION", 259, 268], ["pleural", "ANATOMY", 506, 513], ["effusion", "OBSERVATION", 514, 522]]], ["Categorical data were represented as n (%) in the two groups of patients and compared using the Fisher\u2019s exact test.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["Categorical data", "TEST", 0, 16]]], ["All statistical assessments were two-tailed and p values <0.05 were considered significant.", [["All statistical assessments", "TEST", 0, 27], ["p values", "TEST", 48, 56]]], ["All statistical analyses were carried out with IBM SPSS statistical software version 22 for Windows (IBM Corp., New York, USA).ResultsThis case series included a total of 27 patients who were admitted to the NCKU hospital with adenovirus pneumonia during the 2011 epidemic.", [["adenovirus pneumonia", "DISEASE", 227, 247], ["patients", "ORGANISM", 174, 182], ["adenovirus", "ORGANISM", 227, 237], ["patients", "SPECIES", 174, 182], ["All statistical analyses", "TEST", 0, 24], ["adenovirus pneumonia", "PROBLEM", 227, 247], ["adenovirus", "ANATOMY", 227, 237], ["pneumonia", "OBSERVATION", 238, 247]]], ["Figure 1 represents the number of patients per month from whom adenoviruses were isolated at the NCKU hospital between 2007 and 2012.", [["patients", "ORGANISM", 34, 42], ["adenoviruses", "ORGANISM", 63, 75], ["patients", "SPECIES", 34, 42], ["adenoviruses", "PROBLEM", 63, 75]]]], "PMC7129822": [["The studyIt has been reported that PCV2 entered wild boar from avian species, and subsequently transmitted to pigs(Firth et al., 2009).", [["PCV2", "ORGANISM", 35, 39], ["wild boar", "ORGANISM", 48, 57], ["avian", "ORGANISM", 63, 68], ["pigs", "ORGANISM", 110, 114], ["boar", "SPECIES", 53, 57], ["pigs", "SPECIES", 110, 114], ["pigs", "SPECIES", 110, 114], ["The study", "TEST", 0, 9], ["PCV2", "PROBLEM", 35, 39], ["PCV2", "OBSERVATION", 35, 39]]], ["Despite an increasing number of available sequences, the origin and transmission patterns of PCVs remain obscure.", [["PCVs", "GENE_OR_GENE_PRODUCT", 93, 97], ["PCVs", "PROBLEM", 93, 97], ["increasing", "OBSERVATION_MODIFIER", 11, 21], ["PCVs", "OBSERVATION", 93, 97]]], ["At the same time, there is controversy regarding the evolutionary relationship between circoviruses and their hosts.", [["circoviruses", "GENE_OR_GENE_PRODUCT", 87, 99]]], ["While particular studies have suggested co-speciation between circovirus and host (Johne et al., 2006), other studies indicate that these viruses may be introduced to new hosts through cross-species transmission (Firth et al., 2009; He et al., 2019a).", [["circovirus", "ORGANISM", 62, 72], ["circovirus", "SPECIES", 62, 72], ["circovirus", "SPECIES", 62, 72], ["particular studies", "TEST", 6, 24], ["co-speciation", "PROBLEM", 40, 53], ["circovirus", "PROBLEM", 62, 72], ["other studies", "TEST", 104, 117], ["these viruses", "PROBLEM", 132, 145], ["viruses", "OBSERVATION", 138, 145]]], ["The increasing availability of sampling and sequences data offers an important opportunity to reconstruct the origin and transmission patterns of PCVs.", [["PCVs", "GENE_OR_GENE_PRODUCT", 146, 150], ["sampling and sequences data", "TEST", 31, 58], ["PCVs", "TEST", 146, 150], ["increasing", "OBSERVATION_MODIFIER", 4, 14]]], ["Here, we analysed 95 circovirus Rep from different hosts retrieved from GenBank (https://www.ncbi.nlm.nih.gov/) to trace the origin and evolutionary history of PCV (Table S1).", [["circovirus", "ORGANISM", 21, 31], ["Rep", "GENE_OR_GENE_PRODUCT", 32, 35], ["circovirus Rep", "PROTEIN", 21, 35]]], ["Based on a maximum likelihood (ML) tree of the conserved Rep sequences from multiple hosts inferred using RAxML (v4.8.10), we found that PCV1 and PCV2 cluster together, while PCV3 represents a more divergent lineage from PCV1 and PCV2 (Fig. 1a) (Stamatakis, 2014).", [["Rep", "GENE_OR_GENE_PRODUCT", 57, 60], ["PCV1", "GENE_OR_GENE_PRODUCT", 137, 141], ["PCV2", "ORGANISM", 146, 150], ["PCV1", "CANCER", 221, 225], ["PCV2", "ORGANISM", 230, 234], ["Rep sequences", "DNA", 57, 70], ["PCV1", "DNA", 137, 141], ["PCV3", "DNA", 175, 179], ["RAxML", "TEST", 106, 111], ["PCV1", "TEST", 137, 141], ["PCV2 cluster", "OBSERVATION", 146, 158]]], ["Additionally, PCV1 and PCV2 may have originated from bat circovirus (BatCV), however not from the bat clade 2 because they are related to a novel bat genotype (Wu et al., 2016).", [["PCV1", "GENE_OR_GENE_PRODUCT", 14, 18], ["PCV2", "ORGANISM", 23, 27], ["bat circovirus", "ORGANISM", 53, 67], ["BatCV", "ORGANISM", 69, 74], ["bat", "ORGANISM", 146, 149], ["PCV1", "PROTEIN", 14, 18], ["bat circovirus", "SPECIES", 53, 67], ["PCV1", "SPECIES", 14, 18], ["PCV2", "SPECIES", 23, 27], ["bat circovirus", "SPECIES", 53, 67], ["BatCV", "SPECIES", 69, 74], ["PCV1", "TEST", 14, 18], ["PCV2", "PROBLEM", 23, 27], ["PCV2", "OBSERVATION", 23, 27]]], ["These results are also confirmed by a Bayesian tree reconstructed using MrBayes (v3.8.2) with a mixed model and a sample size of 2,000,000 and a sample frequency of 200 (Fig. 1b).", [["a sample size", "TEST", 112, 125], ["a sample frequency", "TEST", 143, 161], ["size", "OBSERVATION_MODIFIER", 121, 125]]], ["In addition, we performed selection analysis based on the ML tree and we identified positive selection in some branches (Fig. 1).", [["selection analysis", "TEST", 26, 44], ["positive selection", "OBSERVATION", 84, 102], ["branches", "ANATOMY_MODIFIER", 111, 119]]], ["In particular, we found positive selection in the branch (red branch) of the diversification of BatCV and PCV (Fig. 1) using DATAMONKEY (http://www.datamonkey.org/), suggesting that the transmission of circovirus between bats and the porcine host resulted in adaptation to pigs.", [["BatCV", "GENE_OR_GENE_PRODUCT", 96, 101], ["circovirus", "ORGANISM", 202, 212], ["bats", "ORGANISM", 221, 225], ["porcine", "ORGANISM", 234, 241], ["pigs", "ORGANISM", 273, 277], ["BatCV", "PROTEIN", 96, 101], ["circovirus", "SPECIES", 202, 212], ["porcine", "SPECIES", 234, 241], ["pigs", "SPECIES", 273, 277], ["circovirus", "SPECIES", 202, 212], ["pigs", "SPECIES", 273, 277], ["BatCV", "TREATMENT", 96, 101], ["PCV", "TREATMENT", 106, 109], ["circovirus", "PROBLEM", 202, 212], ["the porcine host", "TREATMENT", 230, 246], ["positive selection", "OBSERVATION", 24, 42], ["branch", "ANATOMY_MODIFIER", 50, 56], ["branch", "ANATOMY_MODIFIER", 62, 68], ["diversification", "OBSERVATION_MODIFIER", 77, 92]]], ["Then PCV diverged into PCV1 and PCV2, moreover causing huge economic losses to the pig industry.The studyWe also detected recombination between BatCV and PCV using RDP4 (p value <.05) and Simplot (similarity plot) (Fig. 2a) (Lole et al., 1999; Martin et al., 2015).", [["PCV2", "ORGANISM", 32, 36], ["pig", "ORGANISM", 83, 86], ["pig", "SPECIES", 83, 86], ["PCV1", "SPECIES", 23, 27], ["PCV2", "SPECIES", 32, 36], ["pig", "SPECIES", 83, 86], ["PCV", "TREATMENT", 5, 8], ["PCV1", "TREATMENT", 23, 27], ["PCV2", "TREATMENT", 32, 36], ["huge economic losses", "PROBLEM", 55, 75], ["the pig industry", "TREATMENT", 79, 95], ["PCV", "TREATMENT", 154, 157], ["RDP4", "TREATMENT", 164, 168], ["huge", "OBSERVATION_MODIFIER", 55, 59], ["economic losses", "OBSERVATION", 60, 75]]], ["After RDP4 analysis, one bat circovirus was detected by a potential recombinant between BatCV and PCV2.", [["bat", "ORGANISM", 25, 28], ["circovirus", "ORGANISM", 29, 39], ["BatCV", "GENE_OR_GENE_PRODUCT", 88, 93], ["PCV2", "ORGANISM", 98, 102], ["RDP4", "PROTEIN", 6, 10], ["BatCV", "PROTEIN", 88, 93], ["circovirus", "SPECIES", 29, 39], ["bat circovirus", "SPECIES", 25, 39], ["BatCV", "SPECIES", 88, 93], ["RDP4 analysis", "TEST", 6, 19], ["one bat circovirus", "PROBLEM", 21, 39], ["BatCV", "TREATMENT", 88, 93], ["PCV2", "TREATMENT", 98, 102], ["PCV2", "OBSERVATION", 98, 102]]], ["To confirm this, we observed the sequences characteristic and reconstructed a phylogenetic tree using recombined and non-recombined regions separated by the potential recombination breakpoint (the 777th nucleotide) (Fig. 2b).", [["recombined and non-recombined regions", "DNA", 102, 139], ["777th nucleotide", "DNA", 197, 213], ["the sequences", "TEST", 29, 42], ["recombined and non-recombined regions", "PROBLEM", 102, 139], ["recombination breakpoint", "OBSERVATION", 167, 191]]], ["The position of the BatCV (YN/ZQ924) sequence varies in the two trees.", [["BatCV", "GENE_OR_GENE_PRODUCT", 20, 25], ["BatCV (YN/ZQ924) sequence", "DNA", 20, 45], ["the BatCV (YN/ZQ924) sequence", "TREATMENT", 16, 45], ["position", "OBSERVATION_MODIFIER", 4, 12]]], ["The non-recombined region of the BatCV (YN/ZQ924) sequence clusters with other BatCVs.", [["BatCV", "GENE_OR_GENE_PRODUCT", 33, 38], ["BatCVs", "GENE_OR_GENE_PRODUCT", 79, 85], ["BatCV (YN/ZQ924) sequence", "DNA", 33, 58], ["BatCVs", "DNA", 79, 85], ["the BatCV (YN/ZQ924)", "TREATMENT", 29, 49], ["other BatCVs", "TREATMENT", 73, 85]]], ["However, the recombined region clusters with PCV2.", [["PCV2", "ORGANISM", 45, 49], ["PCV2", "PROBLEM", 45, 49], ["region", "OBSERVATION_MODIFIER", 24, 30], ["clusters", "OBSERVATION_MODIFIER", 31, 39], ["PCV2", "OBSERVATION", 45, 49]]], ["This indicates that BatCV recombined with PCV2 in the REP gene, suggesting that bats might be co-infected with PCV to form a new BatCV.", [["BatCV", "GENE_OR_GENE_PRODUCT", 20, 25], ["PCV2", "ORGANISM", 42, 46], ["REP", "GENE_OR_GENE_PRODUCT", 54, 57], ["bats", "ORGANISM", 80, 84], ["BatCV", "CANCER", 129, 134], ["BatCV", "DNA", 20, 25], ["REP gene", "DNA", 54, 62], ["BatCV", "DNA", 129, 134], ["PCV2", "PROBLEM", 42, 46], ["PCV", "TREATMENT", 111, 114], ["a new BatCV", "PROBLEM", 123, 134]]], ["Although it is not clear if this recombination facilitated the cross-species transmission of the virus, it suggests that virus transmission and recombination occurred between bats and pigs (Zhou et al., 2018).", [["pigs", "ORGANISM", 184, 188], ["pigs", "SPECIES", 184, 188], ["the virus", "PROBLEM", 93, 102], ["virus transmission", "PROBLEM", 121, 139], ["virus", "OBSERVATION", 121, 126]]], ["We can speculate that bat-originated DNA viruses can recombine and cross-species transmission concomitant with the migration, co-roosting and intra- or inter-species contact of other hosts.", [["DNA", "CELLULAR_COMPONENT", 37, 40], ["DNA viruses", "PROBLEM", 37, 48]]], ["Our result suggests that the emergence and host range expansion of circoviruses could be the result of the close contact of domestic and wild pigs.", [["circoviruses", "GENE_OR_GENE_PRODUCT", 67, 79], ["pigs", "ORGANISM", 142, 146], ["pigs", "SPECIES", 142, 146], ["circoviruses", "PROBLEM", 67, 79]]], ["Indeed, PCVs are highly prevalent in China while closely-related bat CVs have been sequenced from Southern China (Fig. 1 and Table S1) where there is a large number of pig slaughterhouses and a wide distribution and diversity of bat species displaying unique behaviour including characteristic flight patterns, mobility, diet, and roosting.", [["PCVs", "GENE_OR_GENE_PRODUCT", 8, 12], ["bat", "ORGANISM", 65, 68], ["CVs", "ORGANISM", 69, 72], ["pig", "ORGANISM", 168, 171], ["PCVs", "PROTEIN", 8, 12], ["pig", "SPECIES", 168, 171], ["pig", "SPECIES", 168, 171], ["PCVs", "PROBLEM", 8, 12], ["pig slaughterhouses", "TREATMENT", 168, 187], ["a wide distribution and diversity of bat species", "PROBLEM", 192, 240], ["PCVs", "OBSERVATION", 8, 12], ["large", "OBSERVATION_MODIFIER", 152, 157], ["number", "OBSERVATION_MODIFIER", 158, 164], ["pig slaughterhouses", "OBSERVATION", 168, 187], ["wide", "OBSERVATION_MODIFIER", 194, 198], ["distribution", "OBSERVATION_MODIFIER", 199, 211], ["bat species", "OBSERVATION", 229, 240]]], ["This, together with the constant interaction of pig and humans, presents a potential threat to the pig industry and public health.Conclusion", [["pig", "ORGANISM", 48, 51], ["humans", "ORGANISM", 56, 62], ["pig", "ORGANISM", 99, 102], ["pig", "SPECIES", 48, 51], ["humans", "SPECIES", 56, 62], ["pig", "SPECIES", 99, 102], ["pig", "SPECIES", 48, 51], ["humans", "SPECIES", 56, 62], ["pig", "SPECIES", 99, 102]]]], "0aa15f39018240133a9b40985dd986838fba5cb0": [["IntroductionDelirium is one of the great geriatric syndromes and a challenge for health professionals caring for older patients.", [["IntroductionDelirium", "DISEASE", 0, 20], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["IntroductionDelirium", "TREATMENT", 0, 20], ["the great geriatric syndromes", "PROBLEM", 31, 60]]], ["It is a medical emergency characterized by a disturbance in attention, awareness and cognitive function, developed over a short period of time [1, 2] .", [["disturbance in attention, awareness and cognitive function", "DISEASE", 45, 103]]], ["Although delirium can also develop in children and younger adults, its prevalence 1 3 is much higher in older people.", [["delirium", "DISEASE", 9, 17], ["children", "ORGANISM", 38, 46], ["people", "ORGANISM", 110, 116], ["children", "SPECIES", 38, 46], ["people", "SPECIES", 110, 116], ["delirium", "PROBLEM", 9, 17], ["delirium", "OBSERVATION", 9, 17]]], ["Several studies have reported that up to one third of patients over 70 years of age admitted to any medical unit develop delirium [2] , a percentage that increases up to 50% in surgical units and up to 85% in palliative care units [3] .", [["delirium", "DISEASE", 121, 129], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["Several studies", "TEST", 0, 15], ["delirium", "PROBLEM", 121, 129], ["delirium", "OBSERVATION", 121, 129]]], ["The importance of delirium is not only due to its high incidence, but also on the serious consequences for those who suffer it.", [["delirium", "DISEASE", 18, 26], ["delirium", "PROBLEM", 18, 26], ["delirium", "OBSERVATION", 18, 26]]], ["It has a negative impact on quality of life, increasing morbidity, functional dependence [4, 5] , the risk of institutionalization [6] and mortality [6] [7] [8] [9] .", [["increasing morbidity", "PROBLEM", 45, 65], ["functional dependence", "PROBLEM", 67, 88], ["negative", "OBSERVATION_MODIFIER", 9, 17], ["impact", "OBSERVATION_MODIFIER", 18, 24], ["increasing", "OBSERVATION_MODIFIER", 45, 55], ["morbidity", "OBSERVATION", 56, 65]]], ["Moreover, delirium has been associated with longer hospital stays [10] and higher economic costs [11] .", [["delirium", "DISEASE", 10, 18], ["delirium", "PROBLEM", 10, 18], ["delirium", "OBSERVATION", 10, 18]]], ["The association with all these negative results has been shown independent of possible confusing variables such as age, sex, comorbidities or severity of illnesses and dementia.IntroductionAmong older people, it is well known that exercise and physical activity have an important role in maintaining independent living [12] functional capacity (maintaining muscle mass, strength and balance) [13, 14] , prevention of chronic diseases [15] and maintaining quality of life [16] .", [["muscle", "ANATOMY", 357, 363], ["dementia", "DISEASE", 168, 176], ["chronic diseases", "DISEASE", 417, 433], ["people", "ORGANISM", 201, 207], ["muscle", "ORGAN", 357, 363], ["people", "SPECIES", 201, 207], ["confusing variables", "PROBLEM", 87, 106], ["severity of illnesses", "PROBLEM", 142, 163], ["dementia", "PROBLEM", 168, 176], ["chronic diseases", "PROBLEM", 417, 433], ["dementia", "OBSERVATION", 168, 176], ["muscle", "ANATOMY", 357, 363], ["mass", "OBSERVATION", 364, 368], ["chronic", "OBSERVATION_MODIFIER", 417, 424], ["diseases", "OBSERVATION", 425, 433]]], ["Regarding the care of disabling acute or chronic conditions, physical therapy and rehabilitation are a pivotal part of the multidisciplinary and multifactorial approach.", [["disabling acute or chronic conditions", "PROBLEM", 22, 59], ["physical therapy", "TREATMENT", 61, 77], ["rehabilitation", "TREATMENT", 82, 96], ["disabling", "OBSERVATION_MODIFIER", 22, 31], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["chronic", "OBSERVATION_MODIFIER", 41, 48]]], ["Available literature demonstrates not only that physical activity is correlated to a better cognitive function and to a reduced risk of developing cognitive impairment [17, 18] , but also that the performance of physical exercise or rehabilitation can improve cognitive function in older population [19, 20] , even in persons with preexisting dementia [21] .IntroductionRegarding delirium, the evidence shows positive influences and benefits of physical exercise on this geriatric syndrome.", [["cognitive impairment", "DISEASE", 147, 167], ["dementia", "DISEASE", 343, 351], ["delirium", "DISEASE", 380, 388], ["geriatric syndrome", "DISEASE", 471, 489], ["persons", "ORGANISM", 318, 325], ["persons", "SPECIES", 318, 325], ["developing cognitive impairment", "PROBLEM", 136, 167], ["rehabilitation", "TREATMENT", 233, 247], ["preexisting dementia", "PROBLEM", 331, 351], ["delirium", "PROBLEM", 380, 388], ["positive influences", "PROBLEM", 409, 428], ["this geriatric syndrome", "PROBLEM", 466, 489], ["dementia", "OBSERVATION", 343, 351]]], ["In fact, delirium and physical function are closely related, since disability, immobility and functional decline are identified as risk factors of delirium [22, 23] , and, on the other hand, all of them might be direct consequences of delirium [4, 5] .", [["delirium", "DISEASE", 9, 17], ["disability", "DISEASE", 67, 77], ["immobility", "DISEASE", 79, 89], ["delirium", "DISEASE", 147, 155], ["delirium", "DISEASE", 235, 243], ["delirium", "PROBLEM", 9, 17], ["physical function", "PROBLEM", 22, 39], ["disability", "PROBLEM", 67, 77], ["immobility", "PROBLEM", 79, 89], ["functional decline", "PROBLEM", 94, 112], ["delirium", "PROBLEM", 147, 155], ["delirium", "PROBLEM", 235, 243], ["delirium", "OBSERVATION", 9, 17]]], ["So that, physical exercise is also part of many strategies which have been demonstrated as useful for preventing delirium [24] , as well as multicomponent interventions [25] .IntroductionThe relationship between delirium and physical exercise is highly complex and presents several specificities.", [["delirium", "DISEASE", 113, 121], ["delirium", "DISEASE", 212, 220], ["delirium", "PROBLEM", 113, 121], ["delirium", "PROBLEM", 212, 220]]], ["Understanding this relationship may help developing health strategies to improve the care of delirium patients, both in the prevention and treatment of this syndrome.", [["delirium", "DISEASE", 93, 101], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["delirium", "PROBLEM", 93, 101], ["treatment", "TREATMENT", 139, 148], ["this syndrome", "PROBLEM", 152, 165]]], ["This article aims to track down and analyze the points, where delirium, physical exercise, and rehabilitation intersect, to better understand their interrelation and the gaps in knowledge, to visualize future lines of research.MethodologyFor this narrative review, we have reviewed studies that examine the relationship between delirium and physical function, physical exercise or rehabilitation.", [["delirium", "DISEASE", 62, 70], ["delirium", "DISEASE", 328, 336], ["delirium", "PROBLEM", 62, 70], ["delirium", "PROBLEM", 328, 336], ["rehabilitation", "TREATMENT", 381, 395]]], ["After an overview of brain neurophysiology and function, as common substrates to understand this relationship, we have explored, the evidence in the available literature supporting: (1) physical dysfunction as a risk factor for delirium;Methodology(2) physical dysfunction as a symptom of delirium and (3) functional consequences related to delirium.", [["brain", "ANATOMY", 21, 26], ["physical dysfunction", "DISEASE", 186, 206], ["delirium", "DISEASE", 228, 236], ["physical dysfunction", "DISEASE", 252, 272], ["delirium", "DISEASE", 289, 297], ["delirium", "DISEASE", 341, 349], ["brain", "ORGAN", 21, 26], ["brain neurophysiology", "TEST", 21, 42], ["physical dysfunction", "PROBLEM", 186, 206], ["delirium", "PROBLEM", 228, 236], ["physical dysfunction", "PROBLEM", 252, 272], ["delirium", "PROBLEM", 289, 297], ["functional consequences", "PROBLEM", 306, 329], ["delirium", "PROBLEM", 341, 349]]], ["Then, we have reviewed intervention studies, centered on multicomponent interventions, including rehabilitation, which have shown to be effective in managing delirium.", [["delirium", "DISEASE", 158, 166], ["intervention studies", "TEST", 23, 43], ["multicomponent interventions", "TREATMENT", 57, 85], ["rehabilitation", "TREATMENT", 97, 111], ["managing delirium", "PROBLEM", 149, 166]]], ["For this purpose, we did a search in PubMed Database using a combination of terms representing delirium prevention, multicomponent intervention, non-pharmacologic intervention, and Hospital Elder Life Program.", [["delirium", "DISEASE", 95, 103], ["delirium prevention", "TREATMENT", 95, 114], ["multicomponent intervention", "TREATMENT", 116, 143], ["non-pharmacologic intervention", "TREATMENT", 145, 175], ["delirium", "OBSERVATION", 95, 103]]], ["Studies were included if they were randomized control trials and mean age of subject was \u2265 65 years.", [["Studies", "TEST", 0, 7]]], ["We excluded those articles which intervention did not incorporate physical strategies.", [["intervention", "TREATMENT", 33, 45]]], ["Finally, we have examined how frailty, delirium and physical exercise interact with each other.Effect of delirium and physical exercise on brain neurophysiology and function(a) Delirium pathophysiologyEffect of delirium and physical exercise on brain neurophysiology and functionThe pathophysiology of delirium is complex and poorly understood, with several hypothesis described in the literature: the neuronal aging, neuroinflammatory hypothesis, oxidative stress theory, neuroendocrine dysregulation, circadian dysregulation, neurotransmitter hypothesis\u2026.", [["brain", "ANATOMY", 139, 144], ["brain", "ANATOMY", 245, 250], ["neuronal", "ANATOMY", 402, 410], ["neuroendocrine", "ANATOMY", 473, 487], ["delirium", "DISEASE", 39, 47], ["delirium", "DISEASE", 105, 113], ["Delirium", "DISEASE", 177, 185], ["delirium", "DISEASE", 211, 219], ["delirium", "DISEASE", 302, 310], ["neuronal aging", "DISEASE", 402, 416], ["brain", "ORGAN", 139, 144], ["brain", "ORGAN", 245, 250], ["neuronal", "CELL", 402, 410], ["delirium", "PROBLEM", 39, 47], ["delirium", "PROBLEM", 105, 113], ["brain neurophysiology", "TEST", 139, 160], ["Delirium pathophysiology", "PROBLEM", 177, 201], ["delirium", "PROBLEM", 211, 219], ["physical exercise", "TEST", 224, 241], ["brain neurophysiology", "TEST", 245, 266], ["delirium", "PROBLEM", 302, 310], ["neuroinflammatory hypothesis", "PROBLEM", 418, 446], ["oxidative stress theory", "PROBLEM", 448, 471], ["neuroendocrine dysregulation", "PROBLEM", 473, 501], ["circadian dysregulation", "PROBLEM", 503, 526], ["neurotransmitter hypothesis", "PROBLEM", 528, 555], ["delirium", "OBSERVATION", 105, 113], ["delirium", "OBSERVATION", 211, 219], ["delirium", "OBSERVATION", 302, 310], ["neuroinflammatory hypothesis", "OBSERVATION", 418, 446], ["neuroendocrine dysregulation", "OBSERVATION", 473, 501]]], ["Given the development of different hypotheses, the large number of precipitating and substrate factors, as well as the many phenotypic presentations and the interaction between different biological factors, it seems that a single hypothesis may not be sufficient to explain delirium and that all these hypothesis may be complementary and not mutually exclusive [26] .", [["delirium", "DISEASE", 274, 282], ["substrate factors", "PROTEIN", 85, 102], ["different hypotheses", "PROBLEM", 25, 45], ["precipitating and substrate factors", "PROBLEM", 67, 102], ["a single hypothesis", "PROBLEM", 221, 240], ["delirium", "PROBLEM", 274, 282], ["different", "OBSERVATION_MODIFIER", 25, 34], ["hypotheses", "OBSERVATION", 35, 45], ["large", "OBSERVATION_MODIFIER", 51, 56], ["number", "OBSERVATION_MODIFIER", 57, 63]]], ["In summary, there is a complex interaction between different systems, including immune, hormonal and neuronal homeostasis in delirium.Effect of delirium and physical exercise on brain neurophysiology and functionBased on published scientific evidence, various cerebral structures are involved in delirium development [27] , such as the brainstem, especially the ascending reticular activating system (ARAS), basal ganglia, thalamus and frontal, parietal and temporal cortices.", [["neuronal", "ANATOMY", 101, 109], ["brain", "ANATOMY", 178, 183], ["cerebral structures", "ANATOMY", 260, 279], ["brainstem", "ANATOMY", 336, 345], ["ascending reticular activating system", "ANATOMY", 362, 399], ["ARAS", "ANATOMY", 401, 405], ["basal ganglia", "ANATOMY", 408, 421], ["thalamus", "ANATOMY", 423, 431], ["frontal", "ANATOMY", 436, 443], ["parietal", "ANATOMY", 445, 453], ["temporal cortices", "ANATOMY", 458, 475], ["delirium", "DISEASE", 125, 133], ["delirium", "DISEASE", 144, 152], ["delirium", "DISEASE", 296, 304], ["neuronal", "CELL", 101, 109], ["brain", "ORGAN", 178, 183], ["cerebral structures", "MULTI-TISSUE_STRUCTURE", 260, 279], ["brainstem", "CANCER", 336, 345], ["ARAS", "CANCER", 401, 405], ["basal ganglia", "MULTI-TISSUE_STRUCTURE", 408, 421], ["thalamus", "MULTI-TISSUE_STRUCTURE", 423, 431], ["frontal", "MULTI-TISSUE_STRUCTURE", 436, 443], ["parietal", "MULTI-TISSUE_STRUCTURE", 445, 453], ["temporal cortices", "MULTI-TISSUE_STRUCTURE", 458, 475], ["a complex interaction between different systems", "PROBLEM", 21, 68], ["immune, hormonal and neuronal homeostasis", "PROBLEM", 80, 121], ["delirium", "PROBLEM", 125, 133], ["delirium", "PROBLEM", 144, 152], ["physical exercise", "TEST", 157, 174], ["brain neurophysiology", "TEST", 178, 199], ["delirium development", "PROBLEM", 296, 316], ["ARAS), basal ganglia, thalamus and frontal, parietal and temporal cortices", "PROBLEM", 401, 475], ["complex", "OBSERVATION_MODIFIER", 23, 30], ["interaction", "OBSERVATION", 31, 42], ["neuronal homeostasis", "OBSERVATION", 101, 121], ["delirium", "OBSERVATION", 125, 133], ["delirium", "OBSERVATION", 144, 152], ["cerebral", "ANATOMY", 260, 268], ["brainstem", "ANATOMY", 336, 345], ["ascending", "ANATOMY_MODIFIER", 362, 371], ["reticular", "ANATOMY_MODIFIER", 372, 381], ["ARAS", "ANATOMY", 401, 405], ["basal", "ANATOMY_MODIFIER", 408, 413], ["ganglia", "ANATOMY", 414, 421], ["thalamus", "ANATOMY_MODIFIER", 423, 431], ["frontal", "ANATOMY_MODIFIER", 436, 443], ["parietal", "ANATOMY_MODIFIER", 445, 453], ["temporal cortices", "ANATOMY", 458, 475]]], ["For example, strokes affecting specific structures can just cause delirium [28] .", [["strokes", "DISEASE", 13, 20], ["delirium", "DISEASE", 66, 74], ["strokes affecting specific structures", "PROBLEM", 13, 50], ["delirium", "PROBLEM", 66, 74], ["strokes", "OBSERVATION", 13, 20]]], ["Interestingly, these areas are also part of the complex control of gait pathways, which includes brainstem, cerebellum, basal ganglia, thalamus, amygdala, hippocampus and cortical regions such as the supplementary motor area, motor and premotor cortex, parietal and visual cortex [29] .", [["brainstem", "ANATOMY", 97, 106], ["cerebellum", "ANATOMY", 108, 118], ["basal ganglia", "ANATOMY", 120, 133], ["thalamus", "ANATOMY", 135, 143], ["amygdala", "ANATOMY", 145, 153], ["hippocampus", "ANATOMY", 155, 166], ["cortical regions", "ANATOMY", 171, 187], ["supplementary motor area", "ANATOMY", 200, 224], ["motor", "ANATOMY", 226, 231], ["premotor cortex", "ANATOMY", 236, 251], ["parietal", "ANATOMY", 253, 261], ["visual cortex", "ANATOMY", 266, 279], ["brainstem", "MULTI-TISSUE_STRUCTURE", 97, 106], ["cerebellum", "MULTI-TISSUE_STRUCTURE", 108, 118], ["basal ganglia", "MULTI-TISSUE_STRUCTURE", 120, 133], ["thalamus", "MULTI-TISSUE_STRUCTURE", 135, 143], ["amygdala", "MULTI-TISSUE_STRUCTURE", 145, 153], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 155, 166], ["cortical regions", "MULTI-TISSUE_STRUCTURE", 171, 187], ["motor area", "MULTI-TISSUE_STRUCTURE", 214, 224], ["premotor cortex", "MULTI-TISSUE_STRUCTURE", 236, 251], ["parietal", "MULTI-TISSUE_STRUCTURE", 253, 261], ["brainstem, cerebellum, basal ganglia, thalamus, amygdala, hippocampus and cortical regions", "PROBLEM", 97, 187], ["areas", "OBSERVATION_MODIFIER", 21, 26], ["complex", "OBSERVATION_MODIFIER", 48, 55], ["gait pathways", "OBSERVATION", 67, 80], ["brainstem", "ANATOMY", 97, 106], ["cerebellum", "ANATOMY", 108, 118], ["basal ganglia", "ANATOMY", 120, 133], ["thalamus", "ANATOMY_MODIFIER", 135, 143], ["amygdala", "ANATOMY_MODIFIER", 145, 153], ["hippocampus", "ANATOMY", 155, 166], ["cortical", "ANATOMY_MODIFIER", 171, 179], ["regions", "ANATOMY_MODIFIER", 180, 187], ["supplementary", "ANATOMY_MODIFIER", 200, 213], ["motor area", "ANATOMY", 214, 224], ["motor", "ANATOMY_MODIFIER", 226, 231], ["premotor cortex", "ANATOMY", 236, 251], ["parietal", "ANATOMY_MODIFIER", 253, 261], ["visual cortex", "ANATOMY", 266, 279]]], ["Specifically, the prefrontal cortex is involved in the planning and control of movements [30] , while is also considered as a key region for attention [31] , one of the main cognitive functions altered in delirium.", [["prefrontal cortex", "ANATOMY", 18, 35], ["delirium", "DISEASE", 205, 213], ["prefrontal cortex", "MULTI-TISSUE_STRUCTURE", 18, 35], ["delirium", "PROBLEM", 205, 213], ["prefrontal cortex", "ANATOMY", 18, 35], ["delirium", "OBSERVATION", 205, 213]]], ["Since attention is one of the cognitive features necessary for a safety walking, disturbances in this area can be directly correlated with motor function disorders and falls [32] .", [["falls", "DISEASE", 168, 173], ["disturbances in this area", "PROBLEM", 81, 106], ["motor function disorders", "PROBLEM", 139, 163]]], ["It is important to note that for a safe and effective gait, in addition to good sensorimotor systems, a correct integration between executive, cognitive and affective dimensions is essential [32] .Effect of delirium and physical exercise on brain neurophysiology and functionFurthermore, imbalances between acetylcholine and other neurotransmitters such as serotonin, and dopamine play an important role in delirium and are directly associated with cognitive disturbances and motor disorders [33] .", [["brain", "ANATOMY", 241, 246], ["delirium", "DISEASE", 207, 215], ["acetylcholine", "CHEMICAL", 307, 320], ["serotonin", "CHEMICAL", 357, 366], ["dopamine", "CHEMICAL", 372, 380], ["delirium", "DISEASE", 407, 415], ["cognitive disturbances", "DISEASE", 449, 471], ["motor disorders", "DISEASE", 476, 491], ["acetylcholine", "CHEMICAL", 307, 320], ["serotonin", "CHEMICAL", 357, 366], ["dopamine", "CHEMICAL", 372, 380], ["brain", "ORGAN", 241, 246], ["acetylcholine", "SIMPLE_CHEMICAL", 307, 320], ["serotonin", "GENE_OR_GENE_PRODUCT", 357, 366], ["dopamine", "SIMPLE_CHEMICAL", 372, 380], ["delirium", "PROBLEM", 207, 215], ["physical exercise", "PROBLEM", 220, 237], ["brain neurophysiology", "TEST", 241, 262], ["acetylcholine", "TREATMENT", 307, 320], ["other neurotransmitters", "TREATMENT", 325, 348], ["serotonin", "TREATMENT", 357, 366], ["dopamine", "TREATMENT", 372, 380], ["delirium", "PROBLEM", 407, 415], ["cognitive disturbances", "PROBLEM", 449, 471], ["motor disorders", "PROBLEM", 476, 491], ["delirium", "OBSERVATION", 207, 215]]], ["During normal aging, concentrations of acetylcholine in the central nervous system are decreased, leading to a vulnerable brain that can easily develop delirium with the use of anticholinergic medication.", [["central nervous system", "ANATOMY", 60, 82], ["brain", "ANATOMY", 122, 127], ["acetylcholine", "CHEMICAL", 39, 52], ["delirium", "DISEASE", 152, 160], ["acetylcholine", "CHEMICAL", 39, 52], ["acetylcholine", "SIMPLE_CHEMICAL", 39, 52], ["central nervous system", "ANATOMICAL_SYSTEM", 60, 82], ["brain", "ORGAN", 122, 127], ["acetylcholine", "TREATMENT", 39, 52], ["a vulnerable brain", "PROBLEM", 109, 127], ["delirium", "PROBLEM", 152, 160], ["anticholinergic medication", "TREATMENT", 177, 203], ["central", "ANATOMY_MODIFIER", 60, 67], ["nervous system", "ANATOMY", 68, 82], ["decreased", "OBSERVATION_MODIFIER", 87, 96], ["brain", "ANATOMY", 122, 127]]], ["Since reductions in acetylcholine concentration have been also associated to frontal and executive dysfunctions [34], it has been hypothesized that motor disturbances as the manifestations of delirium may be caused by the inability to plan and perform movements, due to this neurotransmitter dysregulation [35].(b) Physical exercise and cognitive functionThe benefits of physical exercise, a subset of physical activity that is planned, structured and repetitive [36] , are widely known in older adults.", [["frontal", "ANATOMY", 77, 84], ["acetylcholine", "CHEMICAL", 20, 33], ["frontal and executive dysfunctions", "DISEASE", 77, 111], ["motor disturbances", "DISEASE", 148, 166], ["delirium", "DISEASE", 192, 200], ["acetylcholine", "CHEMICAL", 20, 33], ["acetylcholine", "SIMPLE_CHEMICAL", 20, 33], ["frontal", "MULTI-TISSUE_STRUCTURE", 77, 84], ["acetylcholine concentration", "TREATMENT", 20, 47], ["frontal and executive dysfunctions", "PROBLEM", 77, 111], ["motor disturbances", "PROBLEM", 148, 166], ["delirium", "PROBLEM", 192, 200], ["this neurotransmitter dysregulation", "PROBLEM", 270, 305], ["cognitive function", "TEST", 337, 355], ["reductions", "OBSERVATION_MODIFIER", 6, 16], ["acetylcholine concentration", "OBSERVATION", 20, 47]]], ["These include not only maintaining physical function, preventing or delaying disability and a better control of chronic illnesses (i.e., cardiovascular disease risk, bone health, respiratory function in chronic pulmonary obstructive disease) [37, 38], but also protecting against cognitive decline and dementia [39] .", [["cardiovascular", "ANATOMY", 137, 151], ["bone", "ANATOMY", 166, 170], ["respiratory", "ANATOMY", 179, 190], ["pulmonary", "ANATOMY", 211, 220], ["disability", "DISEASE", 77, 87], ["cardiovascular disease", "DISEASE", 137, 159], ["chronic pulmonary obstructive disease", "DISEASE", 203, 240], ["cognitive decline", "DISEASE", 280, 297], ["dementia", "DISEASE", 302, 310], ["cardiovascular", "ANATOMICAL_SYSTEM", 137, 151], ["bone", "TISSUE", 166, 170], ["pulmonary", "ORGAN", 211, 220], ["delaying disability", "PROBLEM", 68, 87], ["chronic illnesses", "PROBLEM", 112, 129], ["cardiovascular disease risk", "PROBLEM", 137, 164], ["bone health", "PROBLEM", 166, 177], ["respiratory function", "PROBLEM", 179, 199], ["chronic pulmonary obstructive disease", "PROBLEM", 203, 240], ["cognitive decline", "PROBLEM", 280, 297], ["dementia", "PROBLEM", 302, 310], ["chronic", "OBSERVATION_MODIFIER", 112, 119], ["illnesses", "OBSERVATION", 120, 129], ["bone", "ANATOMY", 166, 170], ["chronic", "OBSERVATION_MODIFIER", 203, 210], ["pulmonary", "ANATOMY", 211, 220], ["obstructive", "OBSERVATION", 221, 232]]], ["Moreover, recent studies have also demonstrated that physical exercise not only can prevent cognitive decline, it can also reverse the cognitive impairment associated to the hospitalization of older patients, improving specifically executive function and verbal fluency [40] .(b) Physical exercise and cognitive functionSince exercise can modify cardiovascular risk factors such as hypertension, dyslipidemia, diabetes mellitus and metabolic syndrome, it also improves cerebral vascular function and reduces inflammation, acting as a protective agent against cognitive deterioration.(b) Physical exercise and cognitive functionNeurobiological studies have suggested that exercise can influence the brain at a supramolecular and molecular level [41] .", [["cardiovascular", "ANATOMY", 346, 360], ["cerebral vascular", "ANATOMY", 469, 486], ["brain", "ANATOMY", 698, 703], ["cognitive decline", "DISEASE", 92, 109], ["cognitive impairment", "DISEASE", 135, 155], ["hypertension", "DISEASE", 382, 394], ["dyslipidemia", "DISEASE", 396, 408], ["diabetes mellitus", "DISEASE", 410, 427], ["metabolic syndrome", "DISEASE", 432, 450], ["inflammation", "DISEASE", 508, 520], ["cognitive deterioration", "DISEASE", 559, 582], ["patients", "ORGANISM", 199, 207], ["cardiovascular", "ANATOMICAL_SYSTEM", 346, 360], ["cerebral vascular", "MULTI-TISSUE_STRUCTURE", 469, 486], ["brain", "ORGAN", 698, 703], ["patients", "SPECIES", 199, 207], ["recent studies", "TEST", 10, 24], ["cognitive decline", "PROBLEM", 92, 109], ["the cognitive impairment", "PROBLEM", 131, 155], ["cardiovascular risk factors", "PROBLEM", 346, 373], ["hypertension", "PROBLEM", 382, 394], ["dyslipidemia", "PROBLEM", 396, 408], ["diabetes mellitus", "PROBLEM", 410, 427], ["metabolic syndrome", "PROBLEM", 432, 450], ["cerebral vascular function", "PROBLEM", 469, 495], ["reduces inflammation", "PROBLEM", 500, 520], ["a protective agent", "TREATMENT", 532, 550], ["cognitive deterioration", "PROBLEM", 559, 582], ["cognitive function", "TEST", 609, 627], ["Neurobiological studies", "TEST", 627, 650], ["hypertension", "OBSERVATION", 382, 394], ["dyslipidemia", "OBSERVATION", 396, 408], ["metabolic syndrome", "OBSERVATION", 432, 450], ["vascular", "ANATOMY", 478, 486], ["inflammation", "OBSERVATION", 508, 520], ["brain", "ANATOMY", 698, 703]]], ["In a supramolecular level, physical exercise stimulates angiogenesis, neurogenesis, and synaptogenesis.", [["neurogenesis", "PROBLEM", 70, 82], ["synaptogenesis", "PROBLEM", 88, 102]]], ["Several cerebral structural changes have been described, such as decrease in white matter hyperintensities and increase in different cerebral regions [42] .", [["cerebral", "ANATOMY", 8, 16], ["white matter", "ANATOMY", 77, 89], ["cerebral", "ANATOMY", 133, 141], ["white matter hyperintensities", "DISEASE", 77, 106], ["cerebral", "MULTI-TISSUE_STRUCTURE", 8, 16], ["cerebral", "ORGAN", 133, 141], ["Several cerebral structural changes", "PROBLEM", 0, 35], ["decrease in white matter hyperintensities", "PROBLEM", 65, 106], ["increase in different cerebral regions", "PROBLEM", 111, 149], ["cerebral", "ANATOMY", 8, 16], ["structural", "OBSERVATION", 17, 27], ["decrease", "OBSERVATION_MODIFIER", 65, 73], ["white matter hyperintensities", "OBSERVATION", 77, 106], ["increase", "OBSERVATION_MODIFIER", 111, 119], ["different", "OBSERVATION_MODIFIER", 123, 132], ["cerebral", "ANATOMY", 133, 141], ["regions", "ANATOMY_MODIFIER", 142, 149]]], ["At a molecular level, exercise produces changes in molecular growth factors such as brainderived neurotrophic factor (BDNF), which plays a crucial role in neuroplasticity and neuroprotection, and increases the production of insulin-like growth factor 1 (IGF-1), involved in both neurogenesis and angiogenesis [43] .", [["brainderived neurotrophic factor", "GENE_OR_GENE_PRODUCT", 84, 116], ["BDNF", "GENE_OR_GENE_PRODUCT", 118, 122], ["insulin-like growth factor 1", "GENE_OR_GENE_PRODUCT", 224, 252], ["IGF-1", "GENE_OR_GENE_PRODUCT", 254, 259], ["molecular growth factors", "PROTEIN", 51, 75], ["brainderived neurotrophic factor", "PROTEIN", 84, 116], ["BDNF", "PROTEIN", 118, 122], ["insulin-like growth factor 1", "PROTEIN", 224, 252], ["IGF", "PROTEIN", 254, 257], ["molecular growth factors", "PROBLEM", 51, 75], ["brainderived neurotrophic factor (BDNF)", "PROBLEM", 84, 123], ["neuroprotection", "TREATMENT", 175, 190], ["insulin", "TREATMENT", 224, 231], ["IGF", "TEST", 254, 257]]], ["Animal and human studies suggest that greater engagement in physical activity may preserve cortical gray matter structure and slow the accumulation of A\u03b2 and tau burden [44] .Relationship between delirium and physical functionPhysical function is central to maintain an independent life, its assessment is also key in the comprehensive geriatric assessment and it is directly related to multiple health outcomes (post-surgical complications, functional dependence, cognitive impairment, institutionalization and mortality among others) [45] [46] [47] .", [["cortical gray matter", "ANATOMY", 91, 111], ["delirium", "DISEASE", 196, 204], ["cognitive impairment", "DISEASE", 465, 485], ["human", "ORGANISM", 11, 16], ["cortical gray matter", "MULTI-TISSUE_STRUCTURE", 91, 111], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 151, 153], ["tau", "GENE_OR_GENE_PRODUCT", 158, 161], ["A\u03b2", "PROTEIN", 151, 153], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["Animal and human studies", "TEST", 0, 24], ["slow the accumulation of A\u03b2 and tau burden", "PROBLEM", 126, 168], ["delirium", "PROBLEM", 196, 204], ["its assessment", "TEST", 288, 302], ["the comprehensive geriatric assessment", "TEST", 318, 356], ["post-surgical complications", "PROBLEM", 413, 440], ["functional dependence", "PROBLEM", 442, 463], ["cognitive impairment", "PROBLEM", 465, 485], ["greater", "OBSERVATION_MODIFIER", 38, 45], ["cortical gray matter", "OBSERVATION", 91, 111], ["slow", "OBSERVATION_MODIFIER", 126, 130]]], ["Therefore, it is not surprising that physical function is also strongly associated with delirium, as can be seen throughout the process of an entire episode of delirium: physical dysfunction as a risk factor before delirium, as a symptom during delirium and as negative consequence after the delirium.", [["delirium", "DISEASE", 88, 96], ["delirium", "DISEASE", 160, 168], ["physical dysfunction", "DISEASE", 170, 190], ["delirium", "DISEASE", 215, 223], ["delirium", "DISEASE", 245, 253], ["delirium", "DISEASE", 292, 300], ["delirium", "PROBLEM", 88, 96], ["delirium", "PROBLEM", 160, 168], ["physical dysfunction", "PROBLEM", 170, 190], ["a risk factor", "PROBLEM", 194, 207], ["delirium", "PROBLEM", 215, 223], ["a symptom", "PROBLEM", 228, 237], ["delirium", "PROBLEM", 245, 253], ["the delirium", "PROBLEM", 288, 300], ["delirium", "OBSERVATION", 160, 168]]], ["In this section, we will analyze those three different moments in which physical dysfunction and delirium are related ( Fig. 1) .(a) Disorders in physical function as risk factors for deliriumFor delirium development, several factors are usually required, especially in older people.", [["physical dysfunction", "DISEASE", 72, 92], ["delirium", "DISEASE", 97, 105], ["delirium", "DISEASE", 184, 192], ["delirium", "DISEASE", 196, 204], ["people", "ORGANISM", 276, 282], ["people", "SPECIES", 276, 282], ["physical dysfunction", "PROBLEM", 72, 92], ["delirium", "PROBLEM", 97, 105], ["a) Disorders in physical function", "PROBLEM", 130, 163], ["delirium", "PROBLEM", 184, 192], ["delirium", "PROBLEM", 196, 204]]], ["This widely accepted multifactorial delirium model includes a complex relationship between vulnerable people (with predisposing factors) and their exposure to adverse events (precipitating factors) [48] .", [["delirium", "DISEASE", 36, 44], ["people", "ORGANISM", 102, 108], ["people", "SPECIES", 102, 108], ["multifactorial delirium model", "PROBLEM", 21, 50], ["adverse events", "PROBLEM", 159, 173], ["multifactorial", "OBSERVATION_MODIFIER", 21, 35], ["delirium", "OBSERVATION", 36, 44]]], ["In both categories, predisposing and precipitating factor, physical function plays a major role.(a) Disorders in physical function as risk factors for deliriumThere are two factors related to physical function that have been identified as predisposing factors for delirium.", [["delirium", "DISEASE", 151, 159], ["delirium", "DISEASE", 264, 272], ["a) Disorders in physical function", "PROBLEM", 97, 130], ["delirium", "PROBLEM", 151, 159], ["delirium", "PROBLEM", 264, 272]]], ["On one hand, disability or prior functional impairment (understood as the inability to complete one or more activities of daily life (ADLs)) is one of the main and persistent predisposing factors, conferring up to a fourfold increased risk of delirium [2] .", [["disability", "DISEASE", 13, 23], ["functional impairment", "DISEASE", 33, 54], ["delirium", "DISEASE", 243, 251], ["prior functional impairment", "PROBLEM", 27, 54], ["delirium", "PROBLEM", 243, 251], ["persistent", "OBSERVATION_MODIFIER", 164, 174], ["delirium", "OBSERVATION", 243, 251]]], ["Moreover, as the disability increases, the greater the risk of delirium, regardless of other factors [49] .", [["disability", "DISEASE", 17, 27], ["delirium", "DISEASE", 63, 71], ["delirium", "PROBLEM", 63, 71], ["delirium", "OBSERVATION", 63, 71]]], ["On the other hand, a poor usual physical activity or patient's mobility before hospitalization has also been identified as an independent risk factor for developing postoperative delirium [50] .(a) Disorders in physical function as risk factors for deliriumWhen analyzing the precipitating factors, immobility and specially the use of physical restraints are pointed as independent risk factors for delirium [2, 51] .", [["postoperative delirium", "DISEASE", 165, 187], ["delirium", "DISEASE", 399, 407], ["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["postoperative delirium", "PROBLEM", 165, 187], ["a) Disorders in physical function", "PROBLEM", 195, 228], ["the precipitating factors", "PROBLEM", 272, 297], ["immobility", "PROBLEM", 299, 309], ["physical restraints", "TREATMENT", 335, 354], ["delirium", "PROBLEM", 399, 407]]], ["Bedrest and low levels of mobility, common in hospitalized older patients, are a well-documented problem associated with many adverse outcomes, including pressure ulcers, venous stasis and an increased risk of hospital-associated pneumonia [52] [53] [54] .", [["venous", "ANATOMY", 171, 177], ["ulcers", "DISEASE", 163, 169], ["venous stasis", "DISEASE", 171, 184], ["pneumonia", "DISEASE", 230, 239], ["patients", "ORGANISM", 65, 73], ["venous", "MULTI-TISSUE_STRUCTURE", 171, 177], ["patients", "SPECIES", 65, 73], ["Bedrest", "TREATMENT", 0, 7], ["many adverse outcomes", "PROBLEM", 121, 142], ["pressure ulcers", "PROBLEM", 154, 169], ["venous stasis", "PROBLEM", 171, 184], ["hospital-associated pneumonia", "PROBLEM", 210, 239], ["low levels", "OBSERVATION_MODIFIER", 12, 22], ["pressure", "OBSERVATION_MODIFIER", 154, 162], ["ulcers", "OBSERVATION", 163, 169], ["venous", "ANATOMY", 171, 177], ["stasis", "OBSERVATION", 178, 184], ["increased", "OBSERVATION_MODIFIER", 192, 201], ["pneumonia", "OBSERVATION", 230, 239]]], ["Prolonged hospital immobility is also associated with significant reductions in muscle mass and strength, leading to functional decline, longer hospital length of stay, institutionalization, and death [54] [55] [56] .", [["muscle", "ANATOMY", 80, 86], ["death", "DISEASE", 195, 200], ["muscle", "ORGAN", 80, 86], ["Prolonged hospital immobility", "PROBLEM", 0, 29], ["significant reductions in muscle mass", "PROBLEM", 54, 91], ["functional decline", "PROBLEM", 117, 135], ["muscle", "ANATOMY", 80, 86], ["mass", "OBSERVATION", 87, 91]]], ["In addition to this strong impact on the health of hospitalized patients, immobility and its direct consequences (pressure ulcers, infectious complications and functional decline) have in turn been associated to delirium development [57, 58] .(a) Disorders in physical function as risk factors for deliriumAs we analyze in-hospital mobility of older patients, most of the time is spent lying in bed (83%), with only 3% of the time standing or walking, despite an ability to walk independently [55] .", [["ulcers", "DISEASE", 123, 129], ["delirium", "DISEASE", 212, 220], ["delirium", "DISEASE", 298, 306], ["patients", "ORGANISM", 64, 72], ["patients", "ORGANISM", 350, 358], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 350, 358], ["immobility", "PROBLEM", 74, 84], ["pressure ulcers", "PROBLEM", 114, 129], ["infectious complications", "PROBLEM", 131, 155], ["functional decline", "PROBLEM", 160, 178], ["delirium development", "PROBLEM", 212, 232], ["a) Disorders in physical function", "PROBLEM", 244, 277], ["delirium", "PROBLEM", 298, 306], ["pressure", "OBSERVATION_MODIFIER", 114, 122], ["ulcers", "OBSERVATION", 123, 129], ["infectious", "OBSERVATION_MODIFIER", 131, 141]]], ["In a part of these patients, the mobility is involuntary limited by bedrest orders from health professionals, although those orders are not always justified [56] .(a) Disorders in physical function as risk factors for deliriumUse of physical restraints, which includes belts, bedrails or other devices limiting the person's mobility, is not only associated to delirium (increasing by 4.4 times the risk of developing delirium) [2, 59] , but also to many other complications such as pressure ulcers, infections or urinary incontinence [60] [61] [62] .", [["urinary", "ANATOMY", 513, 520], ["delirium", "DISEASE", 360, 368], ["delirium", "DISEASE", 417, 425], ["ulcers", "DISEASE", 491, 497], ["infections", "DISEASE", 499, 509], ["urinary incontinence", "DISEASE", 513, 533], ["patients", "ORGANISM", 19, 27], ["urinary", "ORGANISM_SUBDIVISION", 513, 520], ["patients", "SPECIES", 19, 27], ["person", "SPECIES", 315, 321], ["a) Disorders in physical function", "PROBLEM", 164, 197], ["physical restraints", "TREATMENT", 233, 252], ["other devices", "TREATMENT", 288, 301], ["delirium", "PROBLEM", 360, 368], ["developing delirium", "PROBLEM", 406, 425], ["many other complications", "PROBLEM", 449, 473], ["pressure ulcers", "PROBLEM", 482, 497], ["infections", "PROBLEM", 499, 509], ["urinary incontinence", "PROBLEM", 513, 533], ["pressure", "OBSERVATION_MODIFIER", 482, 490], ["ulcers", "OBSERVATION", 491, 497]]], ["Although restraints can be helpful in managing agitation and preventing patients' and staff injury during an episode of severe agitation [63] , the recent available literature emphasizes the dangers associated to physical restraints, the importance of using restraints only as a last resource, and the promotion of restraint reduction initiatives [62] .", [["agitation", "DISEASE", 47, 56], ["agitation", "DISEASE", 127, 136], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["restraints", "TREATMENT", 9, 19], ["agitation", "PROBLEM", 47, 56], ["patients' and staff injury", "PROBLEM", 72, 98], ["severe agitation", "PROBLEM", 120, 136], ["physical restraints", "TREATMENT", 213, 232], ["restraints", "TREATMENT", 258, 268], ["restraint reduction initiatives", "TREATMENT", 315, 346]]], ["Despite these recommendations, the prevalence of physical restraint can reach 53%, depending on the country, institution, patient's characteristics and professional knowledge of alternatives [64, 65] .(a) Disorders in physical function as risk factors for delirium(b) Motor dysfunction as symptom of delirium Although the diagnosis of delirium pivots on cognitive disturbances such as attention and awareness disorders, there is an objective pattern of fluctuating motor performance that occurs in parallel to these cognitive disorders [35] .", [["delirium", "DISEASE", 256, 264], ["Motor dysfunction", "DISEASE", 268, 285], ["delirium", "DISEASE", 300, 308], ["delirium", "DISEASE", 335, 343], ["cognitive disturbances", "DISEASE", 354, 376], ["attention and awareness disorders", "DISEASE", 385, 418], ["cognitive disorders", "DISEASE", 516, 535], ["patient", "ORGANISM", 122, 129], ["patient", "SPECIES", 122, 129], ["physical restraint", "TREATMENT", 49, 67], ["a) Disorders in physical function", "PROBLEM", 202, 235], ["delirium", "PROBLEM", 256, 264], ["Motor dysfunction", "PROBLEM", 268, 285], ["delirium", "PROBLEM", 300, 308], ["delirium", "PROBLEM", 335, 343], ["cognitive disturbances", "PROBLEM", 354, 376], ["awareness disorders", "PROBLEM", 399, 418], ["fluctuating motor performance", "PROBLEM", 453, 482], ["these cognitive disorders", "PROBLEM", 510, 535]]], ["Several studies point out that these motor disorders are a clinical sign of delirium and not only a consequence, suggesting that delirium is not exclusively a cognitive disease, but also a motor disorder [35, 66] .(a) Disorders in physical function as risk factors for deliriumIn fact, when analyzing motor function, impairments of worse motor function can be identified in patients with delirium in comparison with those without delirium, independently of the presence of underlying dementia [67] .", [["motor disorders", "DISEASE", 37, 52], ["delirium", "DISEASE", 76, 84], ["delirium", "DISEASE", 129, 137], ["cognitive disease", "DISEASE", 159, 176], ["motor disorder", "DISEASE", 189, 203], ["delirium", "DISEASE", 388, 396], ["delirium", "DISEASE", 430, 438], ["dementia", "DISEASE", 484, 492], ["patients", "ORGANISM", 374, 382], ["patients", "SPECIES", 374, 382], ["Several studies", "TEST", 0, 15], ["these motor disorders", "PROBLEM", 31, 52], ["delirium", "PROBLEM", 76, 84], ["delirium", "PROBLEM", 129, 137], ["a cognitive disease", "PROBLEM", 157, 176], ["a motor disorder", "PROBLEM", 187, 203], ["a) Disorders in physical function", "PROBLEM", 215, 248], ["deliriumIn fact", "PROBLEM", 269, 284], ["worse motor function", "PROBLEM", 332, 352], ["delirium", "PROBLEM", 388, 396], ["delirium", "PROBLEM", 430, 438], ["underlying dementia", "PROBLEM", 473, 492], ["dementia", "OBSERVATION", 484, 492]]], ["These features have been used to improve the diagnosis of delirium superimposed on dementia (DSD), using only motor tools like the Tinetti scale or the Hierarchical Assessment of Balance and Mobility (HABAM) [35, 67] .(a) Disorders in physical function as risk factors for deliriumAnother characteristic that supports the idea of delirium, as also a motor disease is the classification of its subtypes.", [["delirium", "DISEASE", 58, 66], ["dementia", "DISEASE", 83, 91], ["DSD", "DISEASE", 93, 96], ["delirium", "DISEASE", 330, 338], ["delirium", "PROBLEM", 58, 66], ["dementia", "PROBLEM", 83, 91], ["DSD", "TREATMENT", 93, 96], ["the Tinetti scale", "TREATMENT", 127, 144], ["a) Disorders in physical function", "PROBLEM", 219, 252], ["delirium", "PROBLEM", 330, 338], ["a motor disease", "PROBLEM", 348, 363], ["delirium", "OBSERVATION", 58, 66], ["dementia", "OBSERVATION", 83, 91], ["motor disease", "OBSERVATION", 350, 363]]], ["Although it can be divided according to its duration or intensity of symptoms, it is usual to classify delirium according to the associated motor disorder: hyperactive or hypoactive (identified by a marked increase or decrease in motor activity), mixed (which combines moments of increase and decrease in motor activity throughout the day) and the non-motor delirium subtype (which has no motor activity disorders).", [["delirium", "DISEASE", 103, 111], ["motor disorder", "DISEASE", 140, 154], ["hyperactive or hypoactive", "DISEASE", 156, 181], ["non-motor delirium", "DISEASE", 348, 366], ["symptoms", "PROBLEM", 69, 77], ["delirium", "PROBLEM", 103, 111], ["the associated motor disorder", "PROBLEM", 125, 154], ["hyperactive or hypoactive", "PROBLEM", 156, 181], ["a marked increase", "PROBLEM", 197, 214], ["decrease in motor activity)", "PROBLEM", 218, 245], ["decrease in motor activity", "PROBLEM", 293, 319], ["the non-motor delirium subtype", "PROBLEM", 344, 374], ["motor activity disorders", "PROBLEM", 389, 413], ["hyperactive", "OBSERVATION", 156, 167], ["hypoactive", "OBSERVATION", 171, 181], ["marked", "OBSERVATION_MODIFIER", 199, 205], ["increase", "OBSERVATION_MODIFIER", 206, 214], ["decrease", "OBSERVATION_MODIFIER", 218, 226], ["motor activity", "OBSERVATION_MODIFIER", 230, 244], ["decrease", "OBSERVATION_MODIFIER", 293, 301], ["motor activity", "OBSERVATION_MODIFIER", 305, 319]]], ["The evidence suggests that patients with more disability are at higher risk of an hypoactive delirium, which is independently associated with higher a mortality [68] [69] [70] and a higher global functional decline compared to mixed and hyperactive delirium [70] .(a) Disorders in physical function as risk factors for deliriumFinally, the strong association between falls and delirium is another aspect supporting the idea of motor disorders as symptoms of delirium.", [["disability", "DISEASE", 46, 56], ["delirium", "DISEASE", 93, 101], ["hyperactive delirium", "DISEASE", 237, 257], ["falls", "DISEASE", 367, 372], ["delirium", "DISEASE", 377, 385], ["motor disorders", "DISEASE", 427, 442], ["delirium", "DISEASE", 458, 466], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["an hypoactive delirium", "PROBLEM", 79, 101], ["a higher global functional decline", "PROBLEM", 180, 214], ["hyperactive delirium", "PROBLEM", 237, 257], ["a) Disorders in physical function", "PROBLEM", 265, 298], ["deliriumFinally", "PROBLEM", 319, 334], ["delirium", "PROBLEM", 377, 385], ["motor disorders", "PROBLEM", 427, 442], ["symptoms", "PROBLEM", 446, 454], ["delirium", "PROBLEM", 458, 466], ["hypoactive", "OBSERVATION_MODIFIER", 82, 92], ["delirium", "OBSERVATION", 93, 101]]], ["In a systematic review by Sillner et al. [71] , on one hand, delirium is a persistent risk factor for falls with an relative risk that ranges from 1.4 to 12.6.", [["delirium", "DISEASE", 61, 69], ["falls", "DISEASE", 102, 107], ["delirium", "PROBLEM", 61, 69], ["a persistent risk factor", "PROBLEM", 73, 97], ["falls", "PROBLEM", 102, 107], ["delirium", "OBSERVATION", 61, 69]]], ["On the other hand, delirium is also frequent (24-96%) in patients that have fallen.", [["delirium", "DISEASE", 19, 27], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["delirium", "PROBLEM", 19, 27], ["delirium", "OBSERVATION", 19, 27]]], ["Motor disturbances, in addition to the impaired attention linked to delirium, are factors contributing to falls.", [["Motor disturbances", "DISEASE", 0, 18], ["delirium", "DISEASE", 68, 76], ["falls", "DISEASE", 106, 111], ["Motor disturbances", "PROBLEM", 0, 18], ["delirium", "PROBLEM", 68, 76], ["falls", "PROBLEM", 106, 111]]], ["Disturbances of attention (which is the key in the control of gait and posture, especially under challenging circumstances [72] ) contribute to reduce the ability to maintain gait with multiple environmental stimuli, increasing automatically the risk of falling.", [["multiple environmental stimuli", "TEST", 185, 215]]], ["Furthermore, other delirium symptoms such as disorientation and alteration in perception, together with motor disturbances, create an environment favorable to falls.", [["delirium", "DISEASE", 19, 27], ["disorientation", "DISEASE", 45, 59], ["falls", "DISEASE", 159, 164], ["other delirium symptoms", "PROBLEM", 13, 36], ["disorientation", "PROBLEM", 45, 59], ["alteration in perception", "PROBLEM", 64, 88], ["motor disturbances", "PROBLEM", 104, 122]]], ["In fact, there is evidence demonstrating that preventing delirium prevents falls [73] .(a) Disorders in physical function as risk factors for delirium(c) Functional impairment and disability as consequences of delirium(a) Disorders in physical function as risk factors for deliriumWhen delirium occurs, patients develop a sudden functional decline, which, although it can improve at the same time that delirium does, leads to poor functional and recovery outcomes compared to those who did not develop delirium [4, 5] .", [["delirium", "DISEASE", 57, 65], ["falls", "DISEASE", 75, 80], ["delirium", "DISEASE", 142, 150], ["Functional impairment", "DISEASE", 154, 175], ["disability", "DISEASE", 180, 190], ["delirium", "DISEASE", 210, 218], ["delirium", "DISEASE", 286, 294], ["sudden functional decline", "DISEASE", 322, 347], ["delirium", "DISEASE", 402, 410], ["delirium", "DISEASE", 502, 510], ["patients", "ORGANISM", 303, 311], ["patients", "SPECIES", 303, 311], ["delirium", "PROBLEM", 57, 65], ["a) Disorders in physical function", "PROBLEM", 88, 121], ["delirium", "PROBLEM", 142, 150], ["Functional impairment and disability", "PROBLEM", 154, 190], ["delirium", "PROBLEM", 210, 218], ["Disorders in physical function", "PROBLEM", 222, 252], ["deliriumWhen delirium", "PROBLEM", 273, 294], ["a sudden functional decline", "PROBLEM", 320, 347], ["delirium", "PROBLEM", 402, 410], ["delirium", "PROBLEM", 502, 510]]], ["In fact, the evidence shows that the longer the delirium lasts, the greater the functional loss [74, 75] .", [["delirium", "DISEASE", 48, 56], ["the longer the delirium", "PROBLEM", 33, 56], ["delirium", "OBSERVATION", 48, 56], ["greater", "OBSERVATION_MODIFIER", 68, 75]]], ["Despite the evidence of worse functional recovery related to delirium is overwhelming at discharge and in the first months after delirium [76] [77] [78] , the functional consequences of delirium beyond 12 months are less known and even sometimes contradictory.", [["delirium", "DISEASE", 61, 69], ["delirium", "DISEASE", 129, 137], ["delirium", "DISEASE", 186, 194], ["worse functional recovery", "PROBLEM", 24, 49], ["delirium", "PROBLEM", 61, 69], ["delirium", "PROBLEM", 129, 137], ["delirium", "PROBLEM", 186, 194]]], ["Some publications consider physical function after 6-12 months to be comparable in patients who did and did not develop delirium [5, 76, 79] , while other studies point to a maintenance of the functional loss during more than 12 months after delirium [80] .", [["delirium", "DISEASE", 120, 128], ["functional loss", "DISEASE", 193, 208], ["delirium", "DISEASE", 242, 250], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["delirium", "PROBLEM", 120, 128], ["the functional loss", "PROBLEM", 189, 208], ["delirium", "PROBLEM", 242, 250]]], ["Table 1 shows the short and long-term functional outcomes associated to delirium observed in different hospital settings.Physical therapy, one of the main strategies in multicomponent interventions strategies to prevent deliriumSince delirium has a multifactorial etiology, a single component approach is not recommended.", [["delirium", "DISEASE", 72, 80], ["delirium", "DISEASE", 234, 242], ["the short and long-term functional outcomes", "PROBLEM", 14, 57], ["delirium", "PROBLEM", 72, 80], ["Physical therapy", "TREATMENT", 121, 137], ["multicomponent interventions strategies", "TREATMENT", 169, 208], ["deliriumSince delirium", "PROBLEM", 220, 242]]], ["For this reason, interventions that have proven effective in preventing or treating delirium are multicomponent strategies that act on different risk factors of delirium, such as cognitive impairment, sleep deprivation, immobility, dehydration, and vision or hearing impairment [2, 57] .", [["delirium", "DISEASE", 84, 92], ["delirium", "DISEASE", 161, 169], ["cognitive impairment", "DISEASE", 179, 199], ["sleep deprivation", "DISEASE", 201, 218], ["immobility", "DISEASE", 220, 230], ["dehydration", "DISEASE", 232, 243], ["hearing impairment", "DISEASE", 259, 277], ["interventions", "TREATMENT", 17, 30], ["delirium", "PROBLEM", 84, 92], ["multicomponent strategies", "TREATMENT", 97, 122], ["delirium", "PROBLEM", 161, 169], ["cognitive impairment", "PROBLEM", 179, 199], ["sleep deprivation", "PROBLEM", 201, 218], ["immobility", "PROBLEM", 220, 230], ["dehydration", "PROBLEM", 232, 243], ["vision or hearing impairment", "PROBLEM", 249, 277]]], ["The Hospital Elder Life Program (HELP) [57] , widely disseminated, is the first multicomponent evidence-based intervention that showed efficacy in preventing delirium in a cost-effective manner.", [["delirium", "DISEASE", 158, 166], ["based intervention", "TREATMENT", 104, 122], ["delirium", "PROBLEM", 158, 166], ["disseminated", "OBSERVATION", 53, 65], ["delirium", "OBSERVATION", 158, 166]]], ["The effectiveness of multicomponent nonpharmacological programs Delirium is associated with functional decline at 1 month but not at 3 and 12 months [91] has been observed above all in the prevention and reduction of delirium incidence, reaching a significant relative 40% reduction [92] , with also a reduction of falls and a tendency to decrease length of stay and avoidance of institutionalization [51, 57] .", [["Delirium", "DISEASE", 64, 72], ["delirium", "DISEASE", 217, 225], ["falls", "DISEASE", 315, 320], ["multicomponent nonpharmacological programs", "TREATMENT", 21, 63], ["Delirium", "PROBLEM", 64, 72], ["functional decline", "PROBLEM", 92, 110], ["delirium incidence", "PROBLEM", 217, 235], ["a reduction of falls", "PROBLEM", 300, 320], ["a tendency", "PROBLEM", 325, 335], ["falls", "OBSERVATION", 315, 320]]], ["Moreover, thanks to these programs we know that a significant amount of delirium cases is preventable, without entailing a high economic cost or high technological complexity.", [["delirium", "DISEASE", 72, 80], ["delirium cases", "PROBLEM", 72, 86], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["amount", "OBSERVATION_MODIFIER", 62, 68], ["delirium", "OBSERVATION", 72, 80]]], ["Given the importance of physical function and mobility in the development of delirium, almost all multicomponent interventions have included, among other aspects, functional strategies to reduce immobility and enhance physical exercise during hospitalization.", [["delirium", "DISEASE", 77, 85], ["delirium", "PROBLEM", 77, 85], ["functional strategies", "TREATMENT", 163, 184], ["immobility", "PROBLEM", 195, 205], ["delirium", "OBSERVATION", 77, 85]]], ["The different functional strategies range from early mobilization, encourage walking (with assistance, if necessary), increase mobilizations in bed, promote autonomy in ADLs, perform physical exercises with static bicycles, and in parallel suggest to avoid the use of immobilizing equipment (e.g., bladder catheters, i.v. equipment or physical restraints), among others.", [["bladder", "ANATOMY", 298, 305], ["bladder", "ORGAN", 298, 305], ["early mobilization", "TREATMENT", 47, 65], ["physical exercises", "TREATMENT", 183, 201], ["static bicycles", "TREATMENT", 207, 222], ["immobilizing equipment", "TREATMENT", 268, 290], ["bladder catheters", "TREATMENT", 298, 315], ["i.v. equipment", "TREATMENT", 317, 331], ["physical restraints", "TREATMENT", 335, 354], ["bladder", "ANATOMY", 298, 305], ["catheters", "OBSERVATION", 306, 315]]], ["Table 2 illustrates rehabilitation strategies carried out in multicomponent interventions that have demonstrated efficacy in managing delirium.", [["delirium", "DISEASE", 134, 142], ["rehabilitation strategies", "TREATMENT", 20, 45], ["multicomponent interventions", "TREATMENT", 61, 89], ["managing delirium", "PROBLEM", 125, 142]]], ["Apart from specific rehabilitation strategies or mobilization protocols, the studies highlight the importance of encouraging or motivating patients to stay physically active, within its possibilities, as a way of empowering patients that is also associated with better clinical outcomes [93] .Delirium prevention by targeting frailty with physical exerciseFrailty is a dysregulation of several physiological systems that generates a progressive decline in our homeostatic capacity [103] .", [["Delirium", "DISEASE", 293, 301], ["frailty", "DISEASE", 326, 333], ["patients", "ORGANISM", 139, 147], ["patients", "ORGANISM", 224, 232], ["patients", "SPECIES", 139, 147], ["patients", "SPECIES", 224, 232], ["specific rehabilitation strategies", "TREATMENT", 11, 45], ["mobilization protocols", "TREATMENT", 49, 71], ["the studies", "TEST", 73, 84], ["Delirium", "PROBLEM", 293, 301], ["a dysregulation of several physiological systems", "PROBLEM", 367, 415], ["a progressive decline", "PROBLEM", 431, 452], ["progressive", "OBSERVATION_MODIFIER", 433, 444], ["decline", "OBSERVATION_MODIFIER", 445, 452]]], ["This condition implies, in the person suffering from it, a state of increased vulnerability associated with many negative health-related outcomes, including an increase in morbidity, mortality and disability [104] .", [["disability", "DISEASE", 197, 207], ["person", "SPECIES", 31, 37], ["increased vulnerability", "PROBLEM", 68, 91], ["an increase in morbidity", "PROBLEM", 157, 181], ["increase", "OBSERVATION_MODIFIER", 160, 168], ["morbidity", "OBSERVATION", 172, 181]]], ["A classic definition of frailty is centered on a reduction of physical performance (low gait speed, low strength, reduced physical activity and exhaustion,) and malnutrition.", [["frailty", "DISEASE", 24, 31], ["malnutrition", "DISEASE", 161, 173], ["physical performance", "TEST", 62, 82], ["low gait speed", "PROBLEM", 84, 98], ["low strength", "PROBLEM", 100, 112], ["reduced physical activity", "PROBLEM", 114, 139], ["exhaustion", "PROBLEM", 144, 154], ["malnutrition", "PROBLEM", 161, 173], ["frailty", "OBSERVATION", 24, 31]]], ["To detect it, both specific frailty scales, such as the Clinical Frailty Scale (CSF), specific Frailty Index or the Fried's frailty phenotype, can be used, as well as physical function test such as the Short-Physical Performance Battery (SPPB) or the Timed Up and Go test (TUG) [105, 106] .", [["the Clinical Frailty Scale", "TEST", 52, 78], ["specific Frailty Index", "TEST", 86, 108], ["the Fried's frailty phenotype", "PROBLEM", 112, 141], ["physical function test", "TEST", 167, 189]]], ["Frailty represents a critical moment in older adults, leading to a progressive decrease in global capacity.", [["Frailty", "DISEASE", 0, 7], ["a progressive decrease in global capacity", "PROBLEM", 65, 106], ["progressive", "OBSERVATION_MODIFIER", 67, 78], ["decrease", "OBSERVATION_MODIFIER", 79, 87], ["global capacity", "OBSERVATION", 91, 106]]], ["In fact, to prevent disability during aging is essential to recognize and manage frailty in the community [107, 108] .Delirium prevention by targeting frailty with physical exerciseSince frailty is a factor that compromises the ability to cope with internal and external stressful elements, it is easy to understand why from 2010 frailty has also been related to delirium [109] [110] [111] , and has been confirmed as a predisposing factor for delirium in a meta-analysis by Persico et al. [112] , although the paucity of studies.Delirium prevention by targeting frailty with physical exerciseFrailty, as well as delirium, is also a reversible condition that can be prevented and treated.", [["disability", "DISEASE", 20, 30], ["frailty", "DISEASE", 81, 88], ["Delirium", "DISEASE", 118, 126], ["frailty", "DISEASE", 187, 194], ["delirium", "DISEASE", 363, 371], ["delirium", "DISEASE", 444, 452], ["Delirium", "DISEASE", 530, 538], ["delirium", "DISEASE", 613, 621], ["disability", "PROBLEM", 20, 30], ["Delirium", "PROBLEM", 118, 126], ["internal and external stressful elements", "PROBLEM", 249, 289], ["delirium", "PROBLEM", 363, 371], ["delirium", "PROBLEM", 444, 452], ["Delirium", "PROBLEM", 530, 538], ["delirium", "PROBLEM", 613, 621], ["a reversible condition", "PROBLEM", 631, 653]]], ["In the last years, many community interventions have tried to reverse frailty successfully [113] [114] [115] .Delirium prevention by targeting frailty with physical exerciseGiven that frailty has a multifactorial cause, its approach cannot be exhaustively a physical intervention, and multicomponent strategies are needed.", [["Delirium", "DISEASE", 110, 118], ["frailty", "DISEASE", 184, 191], ["many community interventions", "TREATMENT", 19, 47], ["Delirium", "PROBLEM", 110, 118], ["a physical intervention", "TREATMENT", 256, 279], ["multicomponent strategies", "TREATMENT", 285, 310]]], ["However, programs including physical exercise are essential in the prevention and treatment of frailty, according to the available scientific evidence, and are likely to be effective if undertaken on a regular basis over a prolonged period [116, 117] .Delirium prevention by targeting frailty with physical exerciseAfter observing that physical exercise can reduce frailty, clinicians have used this knowledge to include physical exercise in prehabilitation programs for older frail adults undergoing scheduled surgery, as a way to optimize their physical condition and decrease possible negative outcomes linked to surgery and hospitalization.", [["frailty", "DISEASE", 95, 102], ["Delirium", "DISEASE", 252, 260], ["frailty", "DISEASE", 365, 372], ["physical exercise", "TEST", 28, 45], ["frailty", "PROBLEM", 95, 102], ["Delirium", "PROBLEM", 252, 260], ["prehabilitation programs", "TREATMENT", 442, 466], ["scheduled surgery", "TREATMENT", 501, 518], ["surgery", "TREATMENT", 616, 623]]], ["Usual prehabilitation programs that include physical and nutritional interventions have demonstrated to reduce the incidence of post-operative complications, shorten hospital stay and improve healthrelated quality of life [118, 119] , also in frail patients [120] .", [["patients", "ORGANISM", 249, 257], ["patients", "SPECIES", 249, 257], ["Usual prehabilitation programs", "TREATMENT", 0, 30], ["physical and nutritional interventions", "TREATMENT", 44, 82], ["post-operative complications", "PROBLEM", 128, 156]]], ["Regarding delirium, we are beginning to observe positive effects of prehabilitation programs with a reduction in delirium incidence [121] , although more studies are needed.ConclusionsDelirium and physical function are closely related; therefore, it is not surprising that physical exercise is widely used in delirium preventive strategies.", [["delirium", "DISEASE", 10, 18], ["delirium", "DISEASE", 113, 121], ["Delirium", "DISEASE", 184, 192], ["delirium", "DISEASE", 309, 317], ["delirium", "PROBLEM", 10, 18], ["prehabilitation programs", "TREATMENT", 68, 92], ["delirium incidence", "PROBLEM", 113, 131], ["Delirium", "PROBLEM", 184, 192], ["delirium preventive strategies", "TREATMENT", 309, 339]]], ["Although delirium is catalogued as a neurocognitive disorder, we believe that scientific evidence shows that it is also a motor disorder, which is to be expected, since a vast body of literature already supports an interaction between motor and cognitive function.", [["delirium", "DISEASE", 9, 17], ["neurocognitive disorder", "DISEASE", 37, 60], ["motor disorder", "DISEASE", 122, 136], ["delirium", "PROBLEM", 9, 17], ["a neurocognitive disorder", "PROBLEM", 35, 60], ["a motor disorder", "PROBLEM", 120, 136], ["delirium", "OBSERVATION", 9, 17], ["motor disorder", "OBSERVATION", 122, 136]]], ["This motor component of delirium should be take into account when designing interventions or strategies to address delirium.", [["delirium", "DISEASE", 24, 32], ["delirium", "DISEASE", 115, 123], ["delirium", "PROBLEM", 24, 32], ["interventions", "TREATMENT", 76, 89], ["delirium", "PROBLEM", 115, 123], ["delirium", "OBSERVATION", 24, 32]]], ["This interventions may have a special importance in frail older adults.", [["This interventions", "TREATMENT", 0, 18]]], ["We cannot forget that delirium etiology is multifactorial and that interventions to diminish their risk must also be multicomponent, including, of course, rehabilitation strategies with the indispensable competence of a rehabilitation team that will increase the probability of success.", [["delirium", "DISEASE", 22, 30], ["delirium", "PROBLEM", 22, 30], ["interventions", "TREATMENT", 67, 80], ["rehabilitation strategies", "TREATMENT", 155, 180]]], ["(4)", [["(4)", "CHEMICAL", 0, 3]]]], "PMC7529396": [["IntroductionIt is widely known that the COVID-19 pandemic does not differentiate between nationality, gender, religion, wealth or the economies and markets it affects.", [["the COVID", "TEST", 36, 45]]], ["Dramatic challenges have impacted businesses in every country.", [["impacted", "OBSERVATION_MODIFIER", 25, 33], ["businesses", "OBSERVATION", 34, 44]]], ["In recent years, Micro, Small and Medium-scale Enterprises (MSMEs) were recognised by the Indian Government as the backbone of the economy, as, they provide about 30% of India\u2019s economy (Ministry of MSME website, 2013).", [["Micro", "TEST", 17, 22], ["Small", "OBSERVATION_MODIFIER", 24, 29]]], ["It provides extensive employment opportunities and contributes socially and economically to India\u2019s stability.", [["extensive", "OBSERVATION_MODIFIER", 12, 21], ["employment", "OBSERVATION", 22, 32]]], ["With the importance MSMEs have in India, revision in the definition of MSMEs has been needed for a long time.", [["MSMEs", "DISEASE", 71, 76], ["revision", "TREATMENT", 41, 49]]], ["This revision came at the time of the pandemic when the industries were in dire need of the help from the Government.", [["This revision", "TREATMENT", 0, 13], ["revision", "OBSERVATION", 5, 13]]], ["This is an important step as their survival has been dramatically challenged by the COVID-19 virus that was first detected in Wuhan, China in November 2019.", [["COVID-19 virus", "ORGANISM", 84, 98], ["COVID-19 virus", "SPECIES", 84, 98], ["the COVID-19 virus", "PROBLEM", 80, 98]]], ["It has people in the entire world in the first half of 2020 because of which, the COVID-19 virus outbreak was declared a pandemic and a public health emergency of International Concern on 30 January 2020 (Euro surveillance Editorial Team, 2020).", [["people", "ORGANISM", 7, 13], ["COVID-19 virus", "ORGANISM", 82, 96], ["people", "SPECIES", 7, 13], ["COVID-19 virus", "SPECIES", 82, 96], ["the COVID-19 virus outbreak", "PROBLEM", 78, 105]]], ["Till July, 2020, there has been 11.4 million cases of COVID-19 and more than 535,000 people have lost their lives (World Health Organization, 2020).", [["people", "ORGANISM", 85, 91], ["people", "SPECIES", 85, 91], ["COVID", "TEST", 54, 59]]], ["Figure 1depicts the global deaths due to COVID-19.", [["deaths", "DISEASE", 27, 33], ["COVID-19", "CHEMICAL", 41, 49], ["COVID-19", "DNA", 41, 49], ["the global deaths", "PROBLEM", 16, 33], ["COVID", "TEST", 41, 46]]], ["The data is till 22nd May, 2020 and the graph shown in Figure 1 does not constitute deaths from cardiovascular diseases or cancer, which according to World Economic Forum, are the top causes of deaths in the world.IntroductionThe COVID-19 pandemic hangs over societies\u2019 futures, like a spectre.", [["cardiovascular", "ANATOMY", 96, 110], ["cancer", "ANATOMY", 123, 129], ["deaths", "DISEASE", 84, 90], ["cardiovascular diseases", "DISEASE", 96, 119], ["cancer", "DISEASE", 123, 129], ["deaths", "DISEASE", 194, 200], ["cardiovascular", "ANATOMICAL_SYSTEM", 96, 110], ["cancer", "CANCER", 123, 129], ["the graph", "TEST", 36, 45], ["cardiovascular diseases", "PROBLEM", 96, 119], ["cancer", "PROBLEM", 123, 129], ["The COVID", "TREATMENT", 226, 235], ["cardiovascular", "ANATOMY", 96, 110], ["diseases", "OBSERVATION", 111, 119], ["cancer", "OBSERVATION", 123, 129]]], ["This pandemic has brought economic activity to a standstill, and has resulted in dramatic declines in global trade and growth (Haleem et al., 2020).", [["dramatic declines", "PROBLEM", 81, 98], ["dramatic", "OBSERVATION_MODIFIER", 81, 89], ["declines", "OBSERVATION_MODIFIER", 90, 98], ["global trade", "OBSERVATION", 102, 114]]], ["The International Labour Organisation (ILO) described the pandemic as the most serious challenge since Second World War; it has forecasted that the pandemic will infect 2.7 billion workers, or 81% of the world\u2019s workforce (Livemint, 2020a).IntroductionThe loss of livelihood, social isolation, and fear of contracting the virus have created fear and anxiety among the people which has led to mental illnesses and other types of severe illnesses.", [["loss of livelihood, social isolation", "DISEASE", 256, 292], ["anxiety", "DISEASE", 350, 357], ["people", "ORGANISM", 368, 374], ["people", "SPECIES", 368, 374], ["social isolation", "TREATMENT", 276, 292], ["contracting the virus", "PROBLEM", 306, 327], ["anxiety", "PROBLEM", 350, 357], ["mental illnesses", "PROBLEM", 392, 408], ["severe illnesses", "PROBLEM", 428, 444], ["loss", "OBSERVATION_MODIFIER", 256, 260], ["severe", "OBSERVATION_MODIFIER", 428, 434], ["illnesses", "OBSERVATION", 435, 444]]], ["Even though, COVID-19 was, at first considered to be a physical health crisis, it has given rise to mental health risks as well as it expands globally into a severe pandemic (United Nations Organisation, 2020).", [["COVID", "TEST", 13, 18], ["severe", "OBSERVATION_MODIFIER", 158, 164]]], ["The physical and mental health illnesses have caused increased risks of the survival to millions of people.", [["people", "ORGANISM", 100, 106], ["people", "SPECIES", 100, 106]]], ["Therefore, focus should be on incorporating the approaches which would be able to restore the environment and to improve the health of humans which are vital for sustainable development of society (Song et al., 2015).", [["humans", "ORGANISM", 135, 141], ["humans", "SPECIES", 135, 141], ["humans", "SPECIES", 135, 141]]], ["The impacts evolving from COVID-19 pandemic are documenting that this pandemic is causing extensive social, psychological and economic damage.", [["COVID", "TEST", 26, 31], ["economic damage", "PROBLEM", 126, 141], ["extensive", "OBSERVATION_MODIFIER", 90, 99]]], ["The estimation by the ILO stated that in India, more than 90% of the workers work in the informal sector and they are at risk of moving deep into poverty because of the pandemic, which will adversely affect overall societal development (I.L.O., 2020).IntroductionThis pandemic has increased the urgency to incorporate all three aspects of sustainability, social, environmental, and economic goals into all dimensions of supply chain management including coordinating inter-organisational business practices to ensure improvement in performances of all of the firms in all supply chains (Hussain et al., 2018; Khurana et al., 2019).", [["the pandemic", "PROBLEM", 165, 177], ["the urgency", "PROBLEM", 291, 302], ["supply chain management", "TREATMENT", 420, 443], ["coordinating inter-organisational business practices", "TREATMENT", 454, 506], ["improvement", "OBSERVATION_MODIFIER", 517, 528]]], ["Moreover, in the current economic scenario, the success of any firm should be based, not only on profitability, but also on its capacity to contribute to the future of people and planet (Bubicz et al., 2019).", [["people", "ORGANISM", 168, 174], ["people", "SPECIES", 168, 174], ["firm", "OBSERVATION", 63, 67]]], ["This pandemic has disrupted millions of supply chains, filled hospitals with millions of sick and dying people, closed schools; and highlighted the urgency to consider the social aspects of sustainability along with ways to increase productivity of companies, i.e. to make them COVID-19 resilient (P.I.B, 2020a).", [["people", "SPECIES", 104, 110], ["the urgency", "PROBLEM", 144, 155], ["millions", "OBSERVATION_MODIFIER", 28, 36], ["supply", "OBSERVATION_MODIFIER", 40, 46], ["chains", "OBSERVATION_MODIFIER", 47, 53]]], ["Although the \u201cHuman Dimension\u201d is urgent, it must be balanced with the ecological and economic dimensions of all countries.", [["Human", "ORGANISM", 14, 19], ["Human", "SPECIES", 14, 19]]], ["But, unless improvement stimulus support also includes policies focussing on climate change mitigation, there is a high probability that firms will return to their high polluting practices when the pandemic fades (Spratt and Armistead, 2020).", [["climate change mitigation", "TREATMENT", 77, 102]]], ["The pressures from stakeholders for equity should act as a catalyst for company leaders to transition their companies to have sustainable performance at all levels.", [["The pressures", "TEST", 0, 13], ["a catalyst", "TREATMENT", 57, 67], ["pressures", "OBSERVATION_MODIFIER", 4, 13]]], ["Therefore, it is urgent to recognise and bring to the forefront the factors, which can help companies to reduce their losses, incorporate sustainable practices and to increase their resilience to this crisis and to future crises (Amankwah-Amoah, 2020).IntroductionThe COVID-19 has given every country many new lessons, which if implemented will help the countries to reduce the negative impact of this crisis and of future pandemics.", [["sustainable practices", "TREATMENT", 138, 159], ["this crisis", "PROBLEM", 196, 207], ["this crisis", "PROBLEM", 397, 408]]], ["As societal reactions to this pandemic have shown, many businesses have been closed leading to loss of livelihood.", [["loss of livelihood", "PROBLEM", 95, 113]]], ["Many people who have lost their jobs are suffering from mental illnesses and others have developed fear because of uncertainties for their future (Nicola et al., 2020).", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11], ["mental illnesses", "PROBLEM", 56, 72]]], ["Therefore, the challenge which needs to be addressed is how to save the lives of people from being killed by the virus or dying due to lack of work, money and food.IntroductionThis can be done by upgrading the healthcare system of the country.", [["people", "ORGANISM", 81, 87], ["people", "SPECIES", 81, 87]]], ["For this, one of the obstacles to overcome lies in improving the numerous supply chains of the country (Farooque et al., 2019).", [["numerous", "OBSERVATION_MODIFIER", 65, 73], ["supply", "OBSERVATION_MODIFIER", 74, 80], ["chains", "OBSERVATION_MODIFIER", 81, 87]]], ["All aspects of supply chains are interlinked.", [["supply chains", "OBSERVATION", 15, 28]]], ["Disruption of supply chains cause businesses to close which in return lead to loss of livelihood which affects the mental and physical health of individuals and of society, overall.", [["Disruption of supply chains", "PROBLEM", 0, 27], ["loss of livelihood", "PROBLEM", 78, 96], ["chains", "OBSERVATION_MODIFIER", 21, 27]]], ["As people switch to drugs and alcohol, the abuse at home increases.", [["alcohol", "CHEMICAL", 30, 37], ["alcohol", "CHEMICAL", 30, 37], ["people", "ORGANISM", 3, 9], ["alcohol", "SIMPLE_CHEMICAL", 30, 37], ["people", "SPECIES", 3, 9], ["drugs", "TREATMENT", 20, 25]]], ["Therefore, how companies cope with the problems associated with supply chain disruptions due to this and other pandemics needs to be addressed.", [["the problems", "PROBLEM", 35, 47], ["supply chain disruptions", "PROBLEM", 64, 88]]], ["Previous research on COVID-19 has been performed in the context of medical science.", [["COVID-19", "CHEMICAL", 21, 29], ["COVID-19", "DNA", 21, 29], ["COVID", "TEST", 21, 26]]], ["But, a production and operations management perspective of the pandemic is missing (Kumar et al., 2020).", [["operations management", "TREATMENT", 22, 43]]], ["Therefore, to proceed on this journey and address these issues, the authors of paper had the objective to identify the factors, which would help to rebuild resilient industries and societies in the post COVID-19 era.", [["COVID", "TEST", 203, 208]]], ["Consequently, the objectives of the research were:\u2022To identify the factors which are important in helping India\u2019s companies to become more resilient and effective in overcoming the impacts of COVID-19, climate changes and other crises;\u2022To rank the priorities of the identified factors, which are important in helping companies to recover from such shocks; and\u2022To perform sensitivity, analyses to test the strength of the identified factors under different weighting categories.", [["COVID", "TEST", 192, 197], ["other crises", "PROBLEM", 222, 234], ["sensitivity", "TEST", 371, 382], ["analyses", "TEST", 384, 392]]]], "PMC7315403": [["Dear Sirs,", [["Sirs", "OBSERVATION", 5, 9]]]], "PMC5210549": [["The Virus Variation model ::: INTRODUCTIONThe NCBI Virus Variation Resource provides users with a convenient way in which to search, download, and analyze viral nucleotide and protein sequences.", [["nucleotide", "CHEMICAL", 161, 171], ["nucleotide", "CHEMICAL", 161, 171], ["viral nucleotide and protein sequences", "DNA", 155, 193], ["viral nucleotide and protein sequences", "TEST", 155, 193], ["Virus Variation", "OBSERVATION", 4, 19]]], ["The resource includes data processing pipelines that retrieve sequences from GenBank, provide standardized gene and protein annotation, and map sequence source descriptors (i.e. metadata) to uniform vocabularies.", [["protein annotation", "TEST", 116, 134], ["map sequence source descriptors", "TEST", 140, 171]]], ["There are currently seven discrete Virus Variation modules\u2014Dengue virus, Ebolavirus, influenza virus, MERS coronavirus, Rotavirus A, West Nile virus, and Zika virus\u2014and these include a total of nearly 550 000 nucleotide sequences (see Table 2).", [["Dengue", "DISEASE", 59, 65], ["influenza virus", "DISEASE", 85, 100], ["MERS coronavirus", "DISEASE", 102, 118], ["Rotavirus A", "DISEASE", 120, 131], ["nucleotide", "CHEMICAL", 209, 219], ["Dengue virus", "ORGANISM", 59, 71], ["Ebolavirus, influenza virus", "ORGANISM", 73, 100], ["MERS coronavirus", "ORGANISM", 102, 118], ["Rotavirus A", "ORGANISM", 120, 131], ["West Nile virus", "ORGANISM", 133, 148], ["Zika virus\u2014and", "ORGANISM", 154, 168], ["Dengue virus", "SPECIES", 59, 71], ["influenza virus", "SPECIES", 85, 100], ["MERS coronavirus", "SPECIES", 102, 118], ["West Nile virus", "SPECIES", 133, 148], ["Dengue virus", "SPECIES", 59, 71], ["MERS coronavirus", "SPECIES", 102, 118], ["Rotavirus A", "SPECIES", 120, 131], ["West Nile virus", "SPECIES", 133, 148], ["seven discrete Virus Variation modules", "PROBLEM", 20, 58], ["Dengue virus", "PROBLEM", 59, 71], ["Ebolavirus", "PROBLEM", 73, 83], ["influenza virus", "PROBLEM", 85, 100], ["MERS coronavirus", "PROBLEM", 102, 118], ["Rotavirus", "PROBLEM", 120, 129], ["West Nile virus", "PROBLEM", 133, 148], ["nucleotide sequences", "TEST", 209, 229], ["seven", "OBSERVATION_MODIFIER", 20, 25], ["discrete", "OBSERVATION_MODIFIER", 26, 34], ["Virus Variation", "OBSERVATION", 35, 50]]], ["Example usages of the resources for dengue virus, Ebolavirus, and rotavirus are Klema et al. (15), Bell et al. (16), Agbemabiese et al. (17), respectively.Rapid deployment model ::: INTRODUCTIONCurrent development efforts have focused on expanding the Virus Variation model to include more viruses, enhancing the functionality of the resource and providing rapid support to emergent sequencing efforts.", [["dengue", "DISEASE", 36, 42], ["rotavirus", "DISEASE", 66, 75], ["dengue virus", "ORGANISM", 36, 48], ["dengue virus", "SPECIES", 36, 48], ["dengue virus", "SPECIES", 36, 48], ["dengue virus", "PROBLEM", 36, 48], ["Ebolavirus", "PROBLEM", 50, 60], ["rotavirus", "PROBLEM", 66, 75], ["INTRODUCTIONCurrent development efforts", "TREATMENT", 182, 221], ["expanding the Virus Variation model", "TREATMENT", 238, 273], ["rapid support", "TREATMENT", 357, 370], ["emergent sequencing efforts", "TREATMENT", 374, 401]]], ["This last point has been particularly relevant over the past several years as emerging viral outbreaks of Ebola and Zika viruses and others have quickly led to large sequencing efforts.", [["Ebola and Zika viruses", "DISEASE", 106, 128], ["Ebola", "ORGANISM", 106, 111], ["Zika viruses", "ORGANISM", 116, 128], ["Ebola", "SPECIES", 106, 111], ["Ebola", "PROBLEM", 106, 111], ["Zika viruses", "PROBLEM", 116, 128]]], ["There was a clear need to support these sequencing efforts with bioinformatics resources, but timelines prevented traditional development paths where new virus modules and features were added over the course of months.", [["bioinformatics resources", "TREATMENT", 64, 88], ["new virus modules", "PROBLEM", 150, 167], ["new", "OBSERVATION_MODIFIER", 150, 153], ["virus modules", "OBSERVATION", 154, 167]]], ["The first rapid deployment of a Virus Variation module was during the western African Ebola virus outbreak that began in December of 2013.", [["Ebola virus", "DISEASE", 86, 97], ["Virus", "ORGANISM", 32, 37], ["Ebola virus", "SPECIES", 86, 97], ["African Ebola virus", "SPECIES", 78, 97], ["a Virus Variation module", "PROBLEM", 30, 54], ["Virus Variation", "OBSERVATION", 32, 47]]], ["By September, a Virus Variation Resource specific to Ebolaviruses was available to help access the sequences that had begun to pour into the INSDC databases.", [["Ebolaviruses", "DNA", 53, 65], ["INSDC databases", "DNA", 141, 156], ["the sequences", "TEST", 95, 108]]], ["Similarly, a Virus Variation Resource module was developed in September 2014 in response to the outbreak of Middle East respiratory syndrome-related coronavirus (MERS-CoV).", [["Middle East respiratory syndrome", "DISEASE", 108, 140], ["Middle East respiratory syndrome-related coronavirus", "ORGANISM", 108, 160], ["MERS-CoV", "ORGANISM", 162, 170], ["Middle East respiratory syndrome-related coronavirus", "SPECIES", 108, 160], ["MERS-CoV", "SPECIES", 162, 170], ["a Virus Variation Resource module", "PROBLEM", 11, 44], ["Middle East respiratory syndrome", "PROBLEM", 108, 140], ["coronavirus", "PROBLEM", 149, 160], ["Virus", "OBSERVATION", 13, 18], ["Middle", "ANATOMY_MODIFIER", 108, 114], ["respiratory syndrome", "OBSERVATION", 120, 140], ["coronavirus", "OBSERVATION", 149, 160]]], ["Most recently, this rapid response model was repeated for the Zika virus module, which was put in place in March 2016.", [["Zika virus", "SPECIES", 62, 72], ["the Zika virus module", "PROBLEM", 58, 79]]], ["This need-based deployment strategy is likely a model for future efforts, and much of our current development is geared toward harmonizing processes and interfaces among individual data and software modules so as to provide more support for more virus species within the resource and to respond more efficiently to emergent large-scale sequencing efforts.Sequence annotation ::: INTRODUCTIONAccurate gene and protein annotation is necessary both to identify sequences of interest and to analyze them.", [["INTRODUCTIONAccurate gene", "DNA", 379, 404], ["based deployment strategy", "TREATMENT", 10, 35], ["software modules", "PROBLEM", 190, 206], ["more virus species", "PROBLEM", 241, 259], ["emergent large-scale sequencing efforts", "TREATMENT", 315, 354], ["protein annotation", "TEST", 409, 427]]], ["The Virus Variation Resource employs annotation pipelines that support consistent gene and protein naming.", [["The Virus Variation", "TREATMENT", 0, 19], ["annotation pipelines", "TREATMENT", 37, 57]]], ["Retrieved sequences are compared to nucleotide references for that virus group using BLASTN, and the best match is determined (8,13,18).", [["nucleotide", "CHEMICAL", 36, 46], ["nucleotide", "CHEMICAL", 36, 46], ["BLASTN", "TEST", 85, 91]]], ["This step confirms species taxonomy, identifies segment assignment if applicable and provides information about the lineage, genotype, type or subtype.", [["species taxonomy", "OBSERVATION", 19, 35]]], ["The first pipeline uses a reference protein guided approach based on the Prosplign tool as described previously (8,13,18).", [["a reference protein guided approach", "TREATMENT", 24, 59]]], ["Here, protein reference sequences are aligned with potential translations of the query sequence.", [["protein reference sequences", "DNA", 6, 33], ["protein reference sequences", "TEST", 6, 33], ["the query sequence", "TEST", 77, 95]]], ["The highest scoring translation alignment to any protein reference is then chosen and parsed to determine that it meets specific criteria \u2013 the presence of a start codon, exact matches to mature peptide cleavage sites or premature stop sites.", [["start codon", "DNA", 158, 169], ["premature stop sites", "DNA", 221, 241], ["a start codon", "TREATMENT", 156, 169], ["mature peptide cleavage sites", "PROBLEM", 188, 217], ["premature stop sites", "PROBLEM", 221, 241]]], ["Post transcriptional and translational exceptions can be accounted for by this tool by adjusting parameters and allowing multiple transitions from different open reading frames to be assembled into a single alignment.", [["open reading frames", "DNA", 157, 176], ["multiple transitions", "PROBLEM", 121, 141], ["different open reading frames", "TREATMENT", 147, 176]]], ["One advantage of this approach is that new viruses can be incorporated by adding new reference protein sequences and adjusting the criteria used for validating a particular translation.", [["this approach", "TREATMENT", 17, 30], ["new viruses", "PROBLEM", 39, 50], ["new reference protein sequences", "TEST", 81, 112], ["new", "OBSERVATION_MODIFIER", 39, 42], ["viruses", "OBSERVATION", 43, 50]]], ["Such was the case for Zika virus annotation where the existing dengue virus pipeline was updated with new Zika virus reference sequences (see Table 3).Sequence annotation ::: INTRODUCTIONA second approach to gene and protein annotation was implemented in the Ebola virus and MERS coronavirus rapid deployment modules.", [["dengue", "DISEASE", 63, 69], ["Zika virus", "ORGANISM", 22, 32], ["Ebola virus", "ORGANISM", 259, 270], ["MERS coronavirus", "ORGANISM", 275, 291], ["Zika virus reference sequences", "DNA", 106, 136], ["Ebola virus", "SPECIES", 259, 270], ["Zika virus", "SPECIES", 22, 32], ["dengue virus", "SPECIES", 63, 75], ["Zika virus", "SPECIES", 106, 116], ["Ebola virus", "SPECIES", 259, 270], ["MERS coronavirus", "SPECIES", 275, 291], ["Zika virus annotation", "PROBLEM", 22, 43], ["the existing dengue virus pipeline", "TREATMENT", 50, 84], ["protein annotation", "TEST", 217, 235], ["the Ebola virus", "PROBLEM", 255, 270], ["MERS coronavirus rapid deployment modules", "TREATMENT", 275, 316], ["Ebola virus", "OBSERVATION", 259, 270]]], ["To accomplish this, a BLAST-based pipeline was developed that compares genes and proteins as annotated on GenBank records to reference proteins derived from the best reference nucleotide match.", [["nucleotide", "CHEMICAL", 176, 186], ["a BLAST-based pipeline", "PROBLEM", 20, 42]]], ["Genes are validated in the same manner using BLASTN and reference nucleotide sequences.", [["nucleotide", "CHEMICAL", 66, 76], ["nucleotide", "CHEMICAL", 66, 76], ["BLASTN and reference nucleotide sequences", "DNA", 45, 86], ["reference nucleotide sequences", "TEST", 56, 86]]], ["Ultimately these approaches support both search and analysis functionality but are not capable of generating standardized annotation across all sequences belonging to a particular virus.Sequence annotation ::: INTRODUCTIONOur experience has emphasized the importance of accurate annotation pipelines that can be applied to new viruses rapidly in response to emergent needs.", [["analysis functionality", "TEST", 52, 74], ["a particular virus", "PROBLEM", 167, 185], ["accurate annotation pipelines", "TREATMENT", 270, 299], ["new viruses", "PROBLEM", 323, 334]]], ["Though our current pipelines are effective, they are also very specific to particular viruses and application to new viruses requires much work developing reference sequences, defining processing parameters and manually reviewing annotation results.", [["particular viruses", "PROBLEM", 75, 93], ["new viruses", "PROBLEM", 113, 124]]], ["The nucleotide and protein sequences within these records can be invaluable for the unambiguous assignment of sequences to defined groups and can also serve as repositories of reference sequence feature annotation maintained by in-house curation efforts often in collaboration with other scientists (20\u201324).", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 4, 14], ["The nucleotide and protein sequences", "TEST", 0, 36]]], ["Second, this approach includes a comprehensive list of error flags that provide extensive information about sequences and can provide warnings about potential problems.", [["error flags", "PROBLEM", 55, 66], ["potential problems", "PROBLEM", 149, 167]]], ["This error coding not only allows staff to quickly sort through thousands of annotations during the development of new pipelines, but also provides potential criteria for the selection or filtering of sequences to resource users.Sequence annotation ::: INTRODUCTIONThis new approach was used to annotate polyprotein and mature peptide genomic intervals in West Nile virus (WNV), and this annotation will be available soon through the Virus Variation Resource.", [["West Nile virus", "ORGANISM", 356, 371], ["WNV", "ORGANISM", 373, 376], ["West Nile virus", "SPECIES", 356, 371], ["West Nile virus", "SPECIES", 356, 371], ["WNV", "SPECIES", 373, 376], ["the selection", "TREATMENT", 171, 184], ["INTRODUCTIONThis new approach", "TREATMENT", 253, 282], ["annotate polyprotein", "TREATMENT", 295, 315]]], ["These annotations were calculated as follows: First, GenBank West Nile sequences were classified as one of the two common lineages of WNV (lineage 1 or lineage 2) using a combination of BLASTN (25) against the two RefSeq sequences and expert knowledge.", [["WNV", "DISEASE", 134, 137], ["WNV", "ORGANISM", 134, 137], ["GenBank West Nile sequences", "DNA", 53, 80], ["RefSeq sequences", "DNA", 214, 230], ["GenBank West Nile", "SPECIES", 53, 70], ["WNV", "SPECIES", 134, 137], ["a combination of BLASTN", "TREATMENT", 169, 192], ["WNV", "OBSERVATION", 134, 137]]], ["The principal characteristic that distinguishes lineage 1 from lineage 2 is that the additional protein WARF4 occurs only in lineage 1 WNV genomes and is believed to occur in most of them (7).", [["lineage 1", "CELL", 48, 57], ["lineage 2", "CELL", 63, 72], ["WARF4", "GENE_OR_GENE_PRODUCT", 104, 109], ["WARF4", "PROTEIN", 104, 109], ["lineage 1 WNV genomes", "DNA", 125, 146], ["protein WARF4", "OBSERVATION", 96, 109], ["WNV genomes", "OBSERVATION", 135, 146]]], ["There is some evidence that a small proportion of WNV genomes do not fit neatly into lineage 1 or lineage 2 (7), but these were classified as lineage 2 in our annotations.", [["WNV", "ORGANISM", 50, 53], ["WNV genomes", "DNA", 50, 61], ["WNV", "SPECIES", 50, 53], ["a small proportion of WNV genomes", "PROBLEM", 28, 61], ["small", "OBSERVATION_MODIFIER", 30, 35], ["WNV", "OBSERVATION", 50, 53]]], ["Second, the annotation pipeline built a covariance model (CM) for each of 16 mature peptides present in the NC_009942 RefSeq annotation and for the 15 mature peptides in the NC_001563 RefSeq.", [["NC_009942 RefSeq", "RNA", 108, 124], ["NC", "ANATOMY", 174, 176]]], ["The CMs are built using the cmbuild program of the Infernal homology search software package (26).", [["CMs", "ANATOMY", 4, 7], ["CMs", "CELL", 4, 7], ["CMs", "CELL_TYPE", 4, 7], ["CMs", "OBSERVATION", 4, 7]]], ["Infernal is typically used for modeling the sequence and secondary structure of RNAs, and because the sequences we are modeling lack structure (i.e. basepairs between positions), the CMs we created are effectively identical to sequence-only profile hidden Markov models.", [["RNAs", "RNA", 80, 84], ["modeling the sequence", "TEST", 31, 52], ["secondary structure of RNAs", "PROBLEM", 57, 84], ["the sequences", "TEST", 98, 111], ["modeling lack structure", "PROBLEM", 119, 142], ["RNAs", "OBSERVATION", 80, 84]]], ["In the current version of our pipeline, each model was derived from the single RefSeq nucleotide sequence encoding each mature peptide.", [["nucleotide", "CHEMICAL", 86, 96], ["nucleotide", "CHEMICAL", 86, 96], ["RefSeq nucleotide sequence", "DNA", 79, 105], ["the single RefSeq nucleotide sequence", "TREATMENT", 68, 105]]], ["Third, the CMs built from the RefSeq to which that genome was assigned were used to predict each mature peptide coding sequence using Infernal's cmscan program.Sequence annotation ::: INTRODUCTIONThe annotation software then runs a variety of validation checks and produces error codes that assist in curation of sequences.", [["CMs", "ANATOMY", 11, 14], ["CMs", "DNA", 11, 14], ["validation checks", "TEST", 243, 260], ["error codes", "PROBLEM", 274, 285]]], ["For example, the pipeline checks for the existence of any in-frame stop codons within the predicted regions.", [["the pipeline checks", "TEST", 13, 32]]], ["If one or more is found, the prediction boundaries are modified to terminate at the 5\u2032-most stop found.", [["5\u2032-most stop", "DNA", 84, 96]]], ["Lineage 1 (NC_009942) has three CDSs and lineage 2 (NC_001563) has two CDSs.", [["NC_001563", "CHEMICAL", 52, 61]]], ["For each CDS, the predictions for the corresponding mature peptides that make up each CDS are tested for consistency by ensuring that mature peptide coding sequences that are adjacent (separated by 0 nucleotides) in the RefSeq are also adjacent in the predictions.", [["CDS", "DNA", 9, 12], ["CDS", "DNA", 86, 89], ["RefSeq", "DNA", 220, 226]]], ["The start position of the first mature peptide and end position of the final mature peptide that comprise each CDS are then used as the start and stop position for that CDS.", [["CDS", "DNA", 111, 114], ["the first mature peptide", "TREATMENT", 22, 46], ["the final mature peptide", "TREATMENT", 67, 91]]], ["CDS annotations are not made if the mature peptide consistency check fails.", [["CDS annotations", "TEST", 0, 15], ["the mature peptide consistency", "TEST", 32, 62]]], ["In addition to checking for early stop codons and the adjacency of mature peptide coding sequences, the annotation pipeline identifies other unusual or unexpected features in each sequence and reports those as \u2018error codes\u2019.", [["early stop codons", "DNA", 28, 45], ["early stop codons", "PROBLEM", 28, 45], ["mature peptide coding sequences", "PROBLEM", 67, 98]]], ["There are 17 possible error codes, which provide an easy way for users to gauge the quality of each sequence and its annotations, and should facilitate the selection of subsets of the sequence data that meet specific user-defined quality standards.", [["the sequence data", "TEST", 180, 197]]], ["A more detailed description of the new annotation pipeline and error flags will be included in full detail eventually in a separate manuscript, as well as in the help documents available at the Virus Variation Resource.Source metadata processing ::: INTRODUCTIONAnother important aspect of sequence analysis is to place a given sequence within biological, temporal and geospatial contexts.", [["error flags", "PROBLEM", 63, 74], ["sequence analysis", "TEST", 290, 307]]], ["Such associations can provide profound health policy and scientific insights, but unfortunately, descriptors that provide information about the source of nucleotide sequences are notoriously inconsistent.", [["nucleotide", "CHEMICAL", 154, 164], ["nucleotide", "CHEMICAL", 154, 164], ["nucleotide sequences", "TEST", 154, 174]]], ["To resolve this issue, the Virus Variation database loading pipeline parses GenBank records, identifies important metadata terms, such as sample isolation host, date, country and source, and maps these to a standardized vocabulary using a hierarchical approach.", [["the Virus", "PROBLEM", 23, 32], ["a hierarchical approach", "TREATMENT", 237, 260]]], ["For example, isolation host terms are first identified in the host field and failing that, then isolate or strain fields, then isolation source, note and finally organism name.Source metadata processing ::: INTRODUCTIONThis vocabulary mapping strategy follows the INSDC practice of separating isolation host from source.", [["isolation host terms", "PROBLEM", 13, 33], ["INTRODUCTIONThis vocabulary mapping strategy", "TREATMENT", 207, 251]]], ["For human pathogens isolation source often refers to a host tissue or bodily fluid, and the Virus Variation vocabulary mapping strategy attempts to combine similar clinical terms into biologically relevant groups.", [["tissue", "ANATOMY", 60, 66], ["bodily fluid", "ANATOMY", 70, 82], ["human", "ORGANISM", 4, 9], ["tissue", "TISSUE", 60, 66], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["human pathogens isolation source", "PROBLEM", 4, 36], ["bodily fluid", "TEST", 70, 82], ["the Virus Variation vocabulary mapping strategy", "TREATMENT", 88, 135]]], ["For example, the parsed terms \u2018serum,\u2019 \u2018plasma\u2019 and \u2018lymphocytes\u2019 are all mapped to the standardized vocabulary term \u2018blood\u2019.", [["serum", "ANATOMY", 31, 36], ["plasma", "ANATOMY", 40, 46], ["\u2018lymphocytes", "ANATOMY", 52, 64], ["blood", "ANATOMY", 118, 123], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["plasma", "ORGANISM_SUBSTANCE", 40, 46], ["\u2018lymphocytes", "CELL", 52, 64], ["blood", "ORGANISM_SUBSTANCE", 118, 123], ["lymphocytes", "CELL_TYPE", 53, 64], ["serum", "TEST", 31, 36], ["plasma\u2019", "TEST", 40, 47], ["lymphocytes", "TEST", 53, 64], ["lymphocytes", "OBSERVATION", 53, 64]]], ["To support more efficient data retrieval, host terms are mapped in a hierarchy, and once a species term such as \u2018Accipiter cooperii\u2019 is identified, it is mapped to both the group name \u2018Bird\u2019 and the common name \u2018Accipiter.\u2019Source metadata processing ::: INTRODUCTIONOther metadata terms such as those for disease associations and clinical/laboratory manipulations are more difficult to parse.", [["Accipiter cooperii", "SPECIES", 113, 131], ["disease associations", "PROBLEM", 305, 325], ["clinical/laboratory manipulations", "TEST", 330, 363]]], ["To this end, laboratory isolates, vaccine strains and environmental samples are identified by searching for key terms, such as \u2018tissue culture\u2019 or \u2018sewage,\u2019 from all fields.", [["samples", "ANATOMY", 68, 75], ["tissue", "ANATOMY", 128, 134], ["laboratory isolates", "TEST", 13, 32], ["vaccine strains", "TREATMENT", 34, 49], ["environmental samples", "TEST", 54, 75], ["\u2018tissue culture", "TEST", 127, 142]]], ["Disease terms for dengue virus are also found using a similar strategy.", [["dengue", "DISEASE", 18, 24], ["dengue virus", "ORGANISM", 18, 30], ["dengue virus", "SPECIES", 18, 30], ["Disease terms", "PROBLEM", 0, 13], ["dengue virus", "PROBLEM", 18, 30]]], ["In all cases these strategies require extensive examination of sequence records and documentation of specific terms that can be accurately mapped to controlled vocabulary gleaned from established ontologies such as the Environmental Ontology (https://bioportal.bioontology.org/ontologies/ENVO) and the Infectious Disease Ontology (https://bioportal.bioontology.org/ontologies/IDO).", [["extensive examination of sequence records", "TEST", 38, 79]]], ["This process is supported by a curation interface that lists records where parsing fails to identify expected terms, leading to good old-fashioned manual curation and the identification of new terms, common misspellings, regional spelling differences and the manual incorporation of metadata from relevant literature into the Virus Variation database.", [["common misspellings", "PROBLEM", 200, 219], ["regional spelling differences", "PROBLEM", 221, 250], ["the manual incorporation of metadata", "TREATMENT", 255, 291], ["new", "OBSERVATION_MODIFIER", 189, 192], ["regional spelling", "OBSERVATION", 221, 238]]], ["In total, these vocabulary remapping strategies can have a profound impact on data usability as large numbers of parsed terms can be mapped to controlled vocabularies (Table 4).Search interface ::: INTRODUCTIONThe Virus Variation annotation and metadata mapping pipelines create standardized terms that can then be leveraged by the resource search interface.", [["these vocabulary remapping strategies", "TREATMENT", 10, 47], ["data usability", "TEST", 78, 92], ["The Virus Variation annotation", "TREATMENT", 210, 240], ["metadata mapping pipelines", "TREATMENT", 245, 271], ["large", "OBSERVATION_MODIFIER", 96, 101], ["Virus Variation", "OBSERVATION", 214, 229]]], ["A link to this interface can be found on the home page of each virus module, which also includes links to help documents, other NCBI resources, and relevant external resources (for an example, please see http://www.ncbi.nlm.nih.gov/genome/viruses/variation/dengue/).", [["each virus module", "PROBLEM", 58, 75]]], ["To access the search interface from the module home page, select the link to \u2018Search nucleotide and protein sequences.\u2019", [["nucleotide", "CHEMICAL", 85, 95], ["nucleotide", "CHEMICAL", 85, 95], ["Search nucleotide and protein sequences", "DNA", 78, 117], ["Search nucleotide and protein sequences", "TEST", 78, 117]]], ["Here, users can select between protein and nucleotide searches (see Figure 1).", [["nucleotide", "CHEMICAL", 43, 53], ["nucleotide searches", "TEST", 43, 62]]], ["When searching protein sequences, selecting \u2018Full-length sequences only\u2019 filter, limits retrieved sequences to those with a complete coding region as determined to the relevant reference.", [["\u2018Full-length sequences", "DNA", 44, 66], ["searching protein sequences", "TEST", 5, 32], ["filter", "TREATMENT", 73, 79]]], ["The same filter limits nucleotide searches to full-length genomes, where the completeness of a given genome is operationally determined by comparing the genes/proteins present on a given sequence to those on the relevant, full-length reference genome.", [["nucleotide", "CHEMICAL", 23, 33], ["nucleotide", "CHEMICAL", 23, 33], ["full-length reference genome", "DNA", 222, 250], ["The same filter", "TREATMENT", 0, 15], ["filter", "OBSERVATION", 9, 15]]], ["Currently, non-coding, terminal regions are not included in this determination.Search interface ::: INTRODUCTIONDuring both protein and nucleotide searches, users can define explicitly the genomic regions present on retrieved sequences using drop-down menus that support multiple selections.", [["nucleotide", "CHEMICAL", 136, 146], ["non-coding, terminal regions", "DNA", 11, 39], ["genomic regions", "DNA", 189, 204], ["nucleotide searches", "TEST", 136, 155], ["drop-down menus", "TREATMENT", 242, 257], ["non-coding", "OBSERVATION", 11, 21], ["terminal", "OBSERVATION_MODIFIER", 23, 31], ["not included", "UNCERTAINTY", 44, 56]]], ["In addition to these common filters, there are module-specific filters for species, types, and disease for Ebolaviruses and dengue virus respectively.", [["Ebolaviruses", "DISEASE", 107, 119], ["dengue", "DISEASE", 124, 130], ["dengue virus", "ORGANISM", 124, 136], ["dengue virus", "SPECIES", 124, 136], ["these common filters", "TREATMENT", 15, 35], ["module-specific filters", "TREATMENT", 47, 70], ["species", "PROBLEM", 75, 82], ["disease", "PROBLEM", 95, 102], ["Ebolaviruses", "PROBLEM", 107, 119], ["dengue virus", "PROBLEM", 124, 136], ["common filters", "OBSERVATION", 21, 35], ["specific filters", "OBSERVATION", 54, 70]]], ["The influenza virus module also provides some module-specific search options.", [["influenza virus", "ORGANISM", 4, 19], ["The influenza virus module", "PROBLEM", 0, 26], ["influenza virus", "OBSERVATION", 4, 19]]], ["For example, a user can select \u2018Full length only\u2019 to include sequences with complete coding regions or \u2018Full length plus\u2019 to include sequences with complete coding regions, but no start and/or stop codon.", [["coding regions", "DNA", 85, 99], ["coding regions", "DNA", 157, 171], ["start and/or stop codon", "DNA", 180, 203]]], ["Several other specific filters are also available on the influenza module search interface, such as H and N subtypes, minimum or maximum sequence lengths, and inclusion or exclusion of pandemic H1N1 viruses.Search interface ::: INTRODUCTIONA second set of functions and filters is included within the \u2018Additional filters\u2019 menu.", [["pandemic H1N1 viruses", "ORGANISM", 185, 206], ["pandemic H1N1 viruses", "SPECIES", 185, 206], ["Several other specific filters", "TREATMENT", 0, 30], ["pandemic H1N1 viruses", "PROBLEM", 185, 206], ["filters", "TREATMENT", 270, 277], ["filters", "OBSERVATION", 23, 30], ["pandemic", "OBSERVATION_MODIFIER", 185, 193], ["H1N1 viruses", "OBSERVATION", 194, 206]]], ["There are also filters to include or exclude laboratory isolates, vaccine strains, and environmental isolates.", [["filters", "TREATMENT", 15, 22], ["laboratory isolates", "TEST", 45, 64], ["vaccine strains", "TREATMENT", 66, 81], ["filters", "OBSERVATION", 15, 22]]], ["One can also select specific rotavirus segment types based on assignment by the Rotavirus Classification Working Group (27,28), or by selecting specific sequences by GenBank accession.", [["Rotavirus", "DISEASE", 80, 89], ["specific rotavirus segment types", "PROBLEM", 20, 52], ["rotavirus", "OBSERVATION", 29, 38]]], ["Several searches can be run and added to the query builder where the combination of filters and number of retrieved sequences is displayed for each search.", [["filters", "TREATMENT", 84, 91]]], ["The number of unique sequences can be displayed using the \u2018collapse identical sequences\u2019 checkbox.", [["\u2018collapse identical sequences", "DNA", 58, 87], ["the \u2018collapse", "TREATMENT", 54, 67], ["collapse", "OBSERVATION", 59, 67]]], ["Individual searches can then be selected and/or combined and sent to the results page for further refinement and analysis.Results page ::: INTRODUCTIONThe results page supports selection of sequences from the search set for analysis or download.", [["further refinement and analysis", "TEST", 90, 121], ["the search", "TEST", 205, 215], ["analysis", "TEST", 224, 232]]], ["Search parameters are displayed at the top of the results page, and a table displays retrieved sequences and associated metadata.", [["Search parameters", "TEST", 0, 17]]], ["The individual columns within the table can be selected to display specific sets of metadata and hyperlinked GenBank and BioSample accessions (29).", [["columns", "OBSERVATION_MODIFIER", 15, 22]]], ["BioSample records store an extended set of sample descriptors and are linked to Sequence Read Archive (SRA) (30) records, allowing users to easily find sequence read data associated with retrieved GenBank sequences when available.", [["GenBank sequences", "DNA", 197, 214], ["GenBank sequences", "TEST", 197, 214]]], ["One new feature is the ability to collapse identical retrieved sequences for all viruses as described in the preceding section.", [["all viruses", "PROBLEM", 77, 88], ["new", "OBSERVATION_MODIFIER", 4, 7], ["collapse", "OBSERVATION", 34, 42], ["viruses", "OBSERVATION", 81, 88]]], ["When identical sequences are collapsed on the query page, they will be represented by a single sequence on the results page with the number of collapsed sequences shown in the \u2018Identical sequences\u2019 column (see Figure 2).", [["collapsed sequences", "TEST", 143, 162], ["collapsed", "OBSERVATION", 29, 38]]], ["Clicking the arrows in the \u2018Identical sequences\u2019 column displays the individual sequences and makes them selectable.", [["Clicking the arrows", "PROBLEM", 0, 19], ["the individual sequences", "TEST", 65, 89]]], ["Users can now customize sequence titles including the FASTA defline of downloaded sequences and tree labels using the \u2018Customize label\u2019 tool.", [["downloaded sequences", "DNA", 71, 91]]], ["The defline can be modified to include various types of data such as the sequence accession number, calculated genomic region, host, isolation source, collection date or country, as well as field-separators such as pipes or slashes.", [["calculated genomic region", "PROBLEM", 100, 125]]], ["User-selected titles will also be displayed in multi-sequence alignments and trees as described in the following section.Analysis tools ::: INTRODUCTIONUsers can build multiple sequence alignments or trees from selected sequences, and these in turn can be downloaded in various formats.", [["selected sequences", "TEST", 211, 229]]], ["The influenza module uses previously described tools for these functions (8,13,31), but a new set of tools has been developed for other viruses.", [["The influenza module", "PROBLEM", 0, 20], ["these functions", "TEST", 57, 72], ["other viruses", "PROBLEM", 130, 143], ["influenza", "OBSERVATION", 4, 13]]], ["Multiple sequence alignments are constructed using an optimized version of MUSCLE, and rooted trees are generated using the Unweighted Pair Group Method with six base nucleotide or amino acid k-mers (32) (see Figure 3).", [["nucleotide", "CHEMICAL", 167, 177], ["amino acid", "CHEMICAL", 181, 191], ["nucleotide", "CHEMICAL", 167, 177], ["amino acid", "CHEMICAL", 181, 191], ["Multiple sequence alignments", "TEST", 0, 28], ["the Unweighted Pair Group Method", "TREATMENT", 120, 152], ["six base nucleotide", "TREATMENT", 158, 177], ["amino acid k-mers", "TREATMENT", 181, 198], ["MUSCLE", "ANATOMY", 75, 81]]], ["The multiple sequence alignment display includes a navigation map above the alignment, a variation histogram and a consensus sequence.", [["consensus sequence", "DNA", 115, 133], ["The multiple sequence alignment", "TEST", 0, 31], ["a variation histogram", "TEST", 87, 108], ["a consensus sequence", "TEST", 113, 133]]], ["Characters are colored to indicate variable positions.", [["colored", "OBSERVATION", 15, 22], ["variable", "OBSERVATION_MODIFIER", 35, 43], ["positions", "OBSERVATION_MODIFIER", 44, 53]]], ["The tree display supports a variety of layouts including rectangular and slanted cladograms, radial trees and circular trees, the image can be downloaded as a PDF, and the tree file can be downloaded in ASN text or binary, Newick, or NEXUS formats.", [["PDF", "DNA", 159, 162], ["rectangular and slanted cladograms", "TREATMENT", 57, 91], ["a PDF", "TEST", 157, 162], ["tree", "ANATOMY_MODIFIER", 4, 8], ["variety", "OBSERVATION_MODIFIER", 28, 35], ["radial", "ANATOMY_MODIFIER", 93, 99], ["trees", "ANATOMY_MODIFIER", 100, 105], ["circular trees", "OBSERVATION", 110, 124]]], ["The data labels on multi-sequence alignments and trees can be customized from the results table before the tree is calculated using the \u2018Customize label\u2019 options, making it easier to identify the distribution of sample/sequence characteristics.", [["multi-sequence alignments", "DNA", 19, 44], ["multi-sequence alignments", "TEST", 19, 44], ["sample/sequence characteristics", "TEST", 212, 243]]], ["A URL is also provided to make sharing a tree easy.FUTURE DIRECTIONSThe Virus Variation Resource described here provides a number of features that improve the usability of archival sequence data.", [["archival sequence data", "TEST", 172, 194]]], ["The resource now includes more than 20% of the GenBank sequences that are assigned viral taxonomy.", [["GenBank sequences", "DNA", 47, 64], ["the GenBank sequences", "TEST", 43, 64], ["viral taxonomy", "OBSERVATION", 83, 97]]], ["Our plan is to increase the pace at which new virus species are added to the Virus Variation Resource, and we are currently developing layers of data processing \u2013 the least transformative of which could be applied across all viral sequences but still provide basic information about a sequence.", [["viral sequences", "DNA", 225, 240], ["the pace", "TREATMENT", 24, 32], ["new virus species", "PROBLEM", 42, 59], ["all viral sequences", "TEST", 221, 240]]], ["The search interface and data displays will be revised so that they better support user-required comparative genomic functions across a much larger number of viral species from the same query page.", [["comparative genomic functions", "PROBLEM", 97, 126], ["viral species", "PROBLEM", 158, 171], ["viral species", "OBSERVATION", 158, 171]]], ["We also intend to support searches based on author names and more detailed sample information, such as clinical symptoms or laboratory handling.", [["clinical symptoms", "PROBLEM", 103, 120]]], ["Though we will begin parsing the potentially rich metadata data sets from BioSample records, the success of this effort will ultimately rest on improved community awareness and more consistent submission of metadata to public databases.FUTURE DIRECTIONSGiven the unbridled growth and clear potential of nucleotide sequencing efforts, one must assume the current Virus Variation Resource is just scratching the surface of future bioinformatic needs.", [["nucleotide", "CHEMICAL", 303, 313], ["nucleotide", "CHEMICAL", 303, 313], ["nucleotide sequencing efforts", "TREATMENT", 303, 332]]], ["The current resource model is suited to viruses that have experimentally validated annotation, and similar modules are in development for additional viral species.", [["additional viral species", "PROBLEM", 138, 162], ["viral species", "OBSERVATION", 149, 162]]], ["However, the vast majority of viruses do not have strong experimental evidence for protein coding regions, making it difficult to build a Virus Variation module including an annotation pipeline.", [["protein coding regions", "DNA", 83, 105], ["protein coding regions", "PROBLEM", 83, 105], ["a Virus Variation module", "PROBLEM", 136, 160], ["viruses", "OBSERVATION", 30, 37]]], ["In these cases annotation will need to be inferred from related, experimentally studied viruses, requiring new approaches and better ways of standardizing gene and protein information across multiple groups of viruses.", [["experimentally studied viruses", "PROBLEM", 65, 95], ["new approaches", "TREATMENT", 107, 121], ["standardizing gene and protein information", "TREATMENT", 141, 183], ["viruses", "OBSERVATION", 210, 217]]], ["Our current annotation pipeline development is directed toward these goals, and we intend to extend public access to these pipelines beyond our current influenza virus module.", [["influenza virus", "ORGANISM", 152, 167], ["our current influenza virus module", "PROBLEM", 140, 174], ["influenza virus", "OBSERVATION", 152, 167]]], ["We also intend to reveal resource-derived annotation as tracks on multiple sequence alignments, making annotated sequences available for download and improving access to our data sets.", [["multiple sequence alignments", "TEST", 66, 94], ["annotated sequences", "TEST", 103, 122]]], ["This will also enable users to limit downloads and multiple sequence alignments to selected mature peptides for polyprotein sequences, and trees to be built from selected genomic regions.FUTURE DIRECTIONSFinally, there are a variety of enhancements to our tools under development.", [["polyprotein sequences", "DNA", 112, 133], ["genomic regions", "DNA", 171, 186], ["multiple sequence alignments", "TEST", 51, 79], ["polyprotein sequences", "TEST", 112, 133]]], ["We are developing improved tree visualizations that support better search and markup functions, similar to those currently used in the influenza virus module.", [["influenza virus", "ORGANISM", 135, 150], ["influenza virus", "SPECIES", 135, 150], ["the influenza virus module", "PROBLEM", 131, 157], ["improved", "OBSERVATION_MODIFIER", 18, 26], ["tree visualizations", "OBSERVATION", 27, 46], ["influenza virus", "OBSERVATION", 135, 150]]], ["Some limitations of the tree function will be addressed at a later time by giving the user the option of viewing the quick tree which is currently offered, or a more sophisticated combination of MUSCLE-multiple sequence alignment and phylogenetic tree.", [["MUSCLE", "ANATOMY", 195, 201], ["phylogenetic tree", "OBSERVATION", 234, 251]]], ["Ultimately, the presumed very large sequencing datasets of the future will ultimately require better ways to evaluate data retrieved from searches which, in turn, will require better integration of search functions with data visualizations such as trees.FUTURE DIRECTIONSMembers of the scientific community are encouraged to contact the NCBI Help Desk (ncbi-help@ncbi.nlm.nih.gov) to make suggestions to improve the Virus Variation Resource, or to assist with establishing annotation or metadata standards.", [["data visualizations", "TEST", 220, 239], ["very", "OBSERVATION_MODIFIER", 25, 29], ["large", "OBSERVATION_MODIFIER", 30, 35]]]], "PMC7219410": [["Main TextThe emergence of novel respiratory viruses such as SARS-CoV-2 results in rapid dissemination through virus-naive populations and an accumulation of critically ill patients in hospitals across the globe.", [["respiratory viruses", "DISEASE", 32, 51], ["SARS", "DISEASE", 60, 64], ["critically ill", "DISEASE", 157, 171], ["SARS-CoV-2", "ORGANISM", 60, 70], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180], ["SARS-CoV", "SPECIES", 60, 68], ["novel respiratory viruses", "PROBLEM", 26, 51], ["SARS-CoV", "TEST", 60, 68], ["rapid dissemination through virus", "PROBLEM", 82, 115], ["naive populations", "PROBLEM", 116, 133], ["respiratory viruses", "OBSERVATION", 32, 51], ["rapid", "OBSERVATION_MODIFIER", 82, 87], ["dissemination", "OBSERVATION", 88, 101], ["accumulation", "OBSERVATION_MODIFIER", 141, 153], ["critically", "OBSERVATION_MODIFIER", 157, 167], ["ill", "OBSERVATION_MODIFIER", 168, 171], ["globe", "ANATOMY", 205, 210]]], ["In the absence of an effective vaccine or proven treatment, this accelerating threat to human health must be met with swift deployment of experimental therapeutics.", [["human", "ORGANISM", 88, 93], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["an effective vaccine", "TREATMENT", 18, 38], ["treatment", "TREATMENT", 49, 58], ["experimental therapeutics", "TREATMENT", 138, 163]]], ["Dozens of prospective drugs and other therapies are being tested in clinical trials or applied via off-label or compassionate use protocols for patients with life-threatening complications of infection with SARS-CoV-2.", [["infection", "DISEASE", 192, 201], ["SARS", "DISEASE", 207, 211], ["patients", "ORGANISM", 144, 152], ["CoV-2", "ORGANISM", 212, 217], ["patients", "SPECIES", 144, 152], ["SARS-CoV", "SPECIES", 207, 215], ["prospective drugs", "TREATMENT", 10, 27], ["other therapies", "TREATMENT", 32, 47], ["compassionate use protocols", "TREATMENT", 112, 139], ["infection", "PROBLEM", 192, 201], ["infection", "OBSERVATION", 192, 201]]], ["To date, the potential promise for viral control and disease amelioration with each new approach has been balanced by problematic data concerning possible elevated risk for serious adverse events.", [["viral control", "TREATMENT", 35, 48], ["disease amelioration", "PROBLEM", 53, 73], ["each new approach", "TREATMENT", 79, 96], ["elevated risk", "PROBLEM", 155, 168], ["serious adverse events", "PROBLEM", 173, 195]]], ["This is particularly true for natural killer (NK) cells, whose celebrated antiviral capacity and strong safety profile in the oncology clinic may encourage hasty application of these cells against SARS-CoV-2.", [["natural killer (NK) cells", "ANATOMY", 30, 55], ["cells", "ANATOMY", 183, 188], ["SARS", "DISEASE", 197, 201], ["natural killer (NK) cells", "CELL", 30, 55], ["cells", "CELL", 183, 188], ["SARS-CoV-2", "ORGANISM", 197, 207], ["natural killer (NK) cells", "CELL_TYPE", 30, 55], ["SARS-CoV", "SPECIES", 197, 205], ["these cells", "TREATMENT", 177, 188], ["SARS", "PROBLEM", 197, 201]]], ["Critically, a wealth of data in a variety of respiratory infections reveals a frightening proclivity for NK cells to exacerbate lung damage during viral injury.", [["respiratory", "ANATOMY", 45, 56], ["NK cells", "ANATOMY", 105, 113], ["lung", "ANATOMY", 128, 132], ["respiratory infections", "DISEASE", 45, 67], ["lung damage", "DISEASE", 128, 139], ["viral injury", "DISEASE", 147, 159], ["NK cells", "CELL", 105, 113], ["lung", "ORGAN", 128, 132], ["NK cells", "CELL_TYPE", 105, 113], ["respiratory infections", "PROBLEM", 45, 67], ["a frightening proclivity", "PROBLEM", 76, 100], ["NK cells", "PROBLEM", 105, 113], ["lung damage", "PROBLEM", 128, 139], ["viral injury", "PROBLEM", 147, 159], ["respiratory", "ANATOMY", 45, 56], ["infections", "OBSERVATION", 57, 67], ["lung", "ANATOMY", 128, 132], ["damage", "OBSERVATION", 133, 139], ["viral injury", "OBSERVATION", 147, 159]]], ["Here, we weigh evidence supporting and discouraging clinical use of NK cells in the present pandemic, as well as in future outbreaks of respiratory pathogens.", [["NK cells", "ANATOMY", 68, 76], ["respiratory", "ANATOMY", 136, 147], ["respiratory pathogens", "DISEASE", 136, 157], ["NK cells", "CELL", 68, 76], ["NK cells", "CELL_TYPE", 68, 76], ["NK cells", "TREATMENT", 68, 76], ["respiratory pathogens", "PROBLEM", 136, 157], ["respiratory pathogens", "OBSERVATION", 136, 157]]], ["This assessment aims to provide insights for clinicians considering application of NK cells in the care of SARS-CoV-2 infected patients.Main TextNumerous cellular and biologic therapies harnessing the antitumor capabilities of NK cells have proven both beneficial and safe in treatment of cancer.", [["NK cells", "ANATOMY", 83, 91], ["cellular", "ANATOMY", 154, 162], ["antitumor", "ANATOMY", 201, 210], ["NK cells", "ANATOMY", 227, 235], ["cancer", "ANATOMY", 289, 295], ["SARS-CoV-2 infected", "DISEASE", 107, 126], ["cancer", "DISEASE", 289, 295], ["NK cells", "CELL", 83, 91], ["SARS-CoV-2", "ORGANISM", 107, 117], ["patients", "ORGANISM", 127, 135], ["TextNumerous cellular", "CELL", 141, 162], ["antitumor", "CANCER", 201, 210], ["NK cells", "CELL", 227, 235], ["cancer", "CANCER", 289, 295], ["NK cells", "CELL_TYPE", 83, 91], ["NK cells", "CELL_TYPE", 227, 235], ["patients", "SPECIES", 127, 135], ["SARS-CoV", "SPECIES", 107, 115], ["This assessment", "TEST", 0, 15], ["application of NK cells", "TREATMENT", 68, 91], ["SARS", "PROBLEM", 107, 111], ["biologic therapies", "TREATMENT", 167, 185], ["NK cells", "PROBLEM", 227, 235], ["cancer", "PROBLEM", 289, 295], ["NK cells", "OBSERVATION", 227, 235], ["cancer", "OBSERVATION", 289, 295]]], ["These approaches include infusion of allogeneic NK-cell products derived from umbilical cord blood, unrelated blood donors, induced pluripotent stem cells, and established cell lines (e.g., NK-92).", [["NK-cell", "ANATOMY", 48, 55], ["umbilical cord blood", "ANATOMY", 78, 98], ["blood", "ANATOMY", 110, 115], ["pluripotent stem cells", "ANATOMY", 132, 154], ["cell lines", "ANATOMY", 172, 182], ["NK", "ANATOMY", 190, 192], ["NK-cell products", "CELL", 48, 64], ["cord blood", "ORGANISM_SUBSTANCE", 88, 98], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["donors", "ORGANISM_SUBSTANCE", 116, 122], ["pluripotent stem cells", "CELL", 132, 154], ["cell lines", "CELL", 172, 182], ["NK-92", "CELL", 190, 195], ["allogeneic NK-cell products", "PROTEIN", 37, 64], ["induced pluripotent stem cells", "CELL_LINE", 124, 154], ["established cell lines", "CELL_LINE", 160, 182], ["NK-92", "CELL_LINE", 190, 195], ["allogeneic NK-cell products", "TREATMENT", 37, 64], ["umbilical cord blood", "TEST", 78, 98], ["unrelated blood donors", "PROBLEM", 100, 122], ["induced pluripotent stem cells", "PROBLEM", 124, 154], ["established cell lines", "TREATMENT", 160, 182], ["NK", "TEST", 190, 192], ["umbilical cord", "ANATOMY", 78, 92], ["pluripotent stem cells", "OBSERVATION", 132, 154], ["cell lines", "OBSERVATION", 172, 182]]], ["Adaptive subsets of NK cells, including cytokine-induced memory-like NK cells, exhibit enhanced responsiveness and function in patients (Romee et al., 2016).", [["NK cells", "ANATOMY", 20, 28], ["memory-like NK cells", "ANATOMY", 57, 77], ["NK cells", "CELL", 20, 28], ["memory-like NK cells", "CELL", 57, 77], ["patients", "ORGANISM", 127, 135], ["NK cells", "CELL_TYPE", 20, 28], ["cytokine", "PROTEIN", 40, 48], ["memory-like NK cells", "CELL_TYPE", 57, 77], ["patients", "SPECIES", 127, 135], ["NK cells", "TREATMENT", 20, 28], ["cytokine", "TEST", 40, 48], ["enhanced responsiveness", "PROBLEM", 87, 110], ["NK cells", "OBSERVATION", 20, 28], ["NK cells", "OBSERVATION", 69, 77]]], ["The antitumor capacity of these therapeutic NK cells can be further enhanced via incorporation of chimeric antigen receptors (CARs) or other engineered components.", [["antitumor", "ANATOMY", 4, 13], ["NK cells", "ANATOMY", 44, 52], ["antitumor", "CANCER", 4, 13], ["NK cells", "CELL", 44, 52], ["chimeric antigen receptors", "GENE_OR_GENE_PRODUCT", 98, 124], ["CARs", "GENE_OR_GENE_PRODUCT", 126, 130], ["therapeutic NK cells", "CELL_TYPE", 32, 52], ["chimeric antigen receptors", "PROTEIN", 98, 124], ["CARs", "PROTEIN", 126, 130], ["The antitumor capacity", "PROBLEM", 0, 22], ["these therapeutic NK cells", "TREATMENT", 26, 52], ["chimeric antigen receptors", "TREATMENT", 98, 124], ["antitumor", "OBSERVATION_MODIFIER", 4, 13], ["capacity", "OBSERVATION_MODIFIER", 14, 22], ["therapeutic NK cells", "OBSERVATION", 32, 52]]], ["In the context of numerous hematologic cancers and a handful of solid tumors, NK-cell-based regimens combined with preconditioning (i.e., radiation or chemotherapy) appear highly efficacious with an improved safety profile over parallel approaches using T cells (Liu et al., 2020).", [["hematologic cancers", "ANATOMY", 27, 46], ["solid tumors", "ANATOMY", 64, 76], ["NK-cell", "ANATOMY", 78, 85], ["T cells", "ANATOMY", 254, 261], ["hematologic cancers", "DISEASE", 27, 46], ["tumors", "DISEASE", 70, 76], ["hematologic cancers", "CANCER", 27, 46], ["solid tumors", "CANCER", 64, 76], ["NK-cell", "CELL", 78, 85], ["T cells", "CELL", 254, 261], ["T cells", "CELL_TYPE", 254, 261], ["numerous hematologic cancers", "PROBLEM", 18, 46], ["solid tumors", "PROBLEM", 64, 76], ["NK-cell-based regimens", "TREATMENT", 78, 100], ["preconditioning", "TREATMENT", 115, 130], ["radiation or chemotherapy", "TREATMENT", 138, 163], ["numerous", "OBSERVATION_MODIFIER", 18, 26], ["hematologic cancers", "OBSERVATION", 27, 46], ["solid", "OBSERVATION_MODIFIER", 64, 69], ["tumors", "OBSERVATION", 70, 76]]], ["The latter feature putatively relates to a reduced capacity of NK cells to trigger cytokine release syndrome (Romee et al., 2016, Liu et al., 2020), a feared complication of CAR T cell approaches.", [["NK cells", "ANATOMY", 63, 71], ["T cell", "ANATOMY", 178, 184], ["NK cells", "CELL", 63, 71], ["CAR T cell", "CELL", 174, 184], ["NK cells", "CELL_TYPE", 63, 71], ["cytokine", "PROTEIN", 83, 91], ["a reduced capacity of NK cells", "PROBLEM", 41, 71], ["cytokine release syndrome", "PROBLEM", 83, 108], ["CAR T cell approaches", "TREATMENT", 174, 195], ["reduced", "OBSERVATION_MODIFIER", 43, 50], ["capacity", "OBSERVATION_MODIFIER", 51, 59], ["NK cells", "OBSERVATION", 63, 71]]], ["Elevated interleukin-6 (IL-6) production is an important component of both cytokine release syndrome and the harmful cytokine storm elicited during pathogenic SARS-CoV-2 infection (Chen et al., 2020), so the reduced capacity of NK-cell infusions to trigger or amplify these responses is viewed as an advantage over T cell-based therapies to combat severe disease in the present pandemic.Main TextFurthermore, extensive studies provide evidence that early innate functions of NK cells are essential and beneficial in immune defense against respiratory viral infections.", [["NK-cell", "ANATOMY", 228, 235], ["T cell", "ANATOMY", 315, 321], ["NK cells", "ANATOMY", 475, 483], ["SARS-CoV-2 infection", "DISEASE", 159, 179], ["respiratory viral infections", "DISEASE", 539, 567], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 9, 22], ["IL-6", "GENE_OR_GENE_PRODUCT", 24, 28], ["SARS-CoV-2", "ORGANISM", 159, 169], ["NK-cell", "CELL", 228, 235], ["T cell", "CELL", 315, 321], ["NK cells", "CELL", 475, 483], ["interleukin-6", "PROTEIN", 9, 22], ["cytokine", "PROTEIN", 75, 83], ["cytokine", "PROTEIN", 117, 125], ["NK cells", "CELL_TYPE", 475, 483], ["SARS-CoV-2", "SPECIES", 159, 169], ["Elevated interleukin", "PROBLEM", 0, 20], ["IL", "TEST", 24, 26], ["both cytokine release syndrome", "PROBLEM", 70, 100], ["the harmful cytokine storm", "PROBLEM", 105, 131], ["pathogenic SARS", "PROBLEM", 148, 163], ["CoV-2 infection", "PROBLEM", 164, 179], ["the reduced capacity", "PROBLEM", 204, 224], ["NK-cell infusions", "TREATMENT", 228, 245], ["T cell-based therapies", "TREATMENT", 315, 337], ["severe disease", "PROBLEM", 348, 362], ["extensive studies", "TEST", 409, 426], ["NK cells", "PROBLEM", 475, 483], ["respiratory viral infections", "PROBLEM", 539, 567], ["interleukin-6", "OBSERVATION", 9, 22], ["both cytokine release syndrome", "OBSERVATION", 70, 100], ["severe", "OBSERVATION_MODIFIER", 348, 354], ["disease", "OBSERVATION", 355, 362], ["viral infections", "OBSERVATION", 551, 567]]], ["These activities include antiviral cytokine production (e.g., interferon [IFN]-\u03b3) and cytolysis of virus-infected cells.", [["cells", "ANATOMY", 114, 119], ["interferon [IFN]-\u03b3", "GENE_OR_GENE_PRODUCT", 62, 80], ["cells", "CELL", 114, 119], ["cytokine", "PROTEIN", 35, 43], ["interferon [IFN]-\u03b3", "PROTEIN", 62, 80], ["virus-infected cells", "CELL_TYPE", 99, 119], ["antiviral cytokine production", "TREATMENT", 25, 54], ["interferon [IFN", "TREATMENT", 62, 77], ["cytolysis of virus", "PROBLEM", 86, 104], ["infected cells", "PROBLEM", 105, 119], ["infected cells", "OBSERVATION", 105, 119]]], ["At low to intermediate inoculum doses of respiratory syncytial virus (RSV), Sendai virus (parainfluenza virus), and influenza A virus (IAV) infections in mice and hamsters, the activities of NK cells can reduce viral burden and protect from fatal disease (Cong and Wei, 2019).", [["NK cells", "ANATOMY", 191, 199], ["respiratory syncytial virus", "DISEASE", 41, 68], ["parainfluenza virus", "DISEASE", 90, 109], ["influenza A virus (IAV) infections", "DISEASE", 116, 150], ["respiratory syncytial virus", "ORGANISM", 41, 68], ["RSV", "ORGANISM", 70, 73], ["Sendai virus", "ORGANISM", 76, 88], ["parainfluenza virus", "ORGANISM", 90, 109], ["influenza A virus", "ORGANISM", 116, 133], ["IAV", "ORGANISM", 135, 138], ["mice", "ORGANISM", 154, 158], ["hamsters", "ORGANISM", 163, 171], ["NK cells", "CELL", 191, 199], ["NK cells", "CELL_TYPE", 191, 199], ["respiratory syncytial virus", "SPECIES", 41, 68], ["Sendai virus", "SPECIES", 76, 88], ["parainfluenza virus", "SPECIES", 90, 109], ["influenza A virus", "SPECIES", 116, 133], ["mice", "SPECIES", 154, 158], ["hamsters", "SPECIES", 163, 171], ["respiratory syncytial virus", "SPECIES", 41, 68], ["RSV", "SPECIES", 70, 73], ["Sendai virus", "SPECIES", 76, 88], ["parainfluenza virus", "SPECIES", 90, 109], ["influenza A virus", "SPECIES", 116, 133], ["IAV", "SPECIES", 135, 138], ["mice", "SPECIES", 154, 158], ["hamsters", "SPECIES", 163, 171], ["respiratory syncytial virus (RSV)", "PROBLEM", 41, 74], ["Sendai virus (parainfluenza virus)", "PROBLEM", 76, 110], ["influenza A virus (IAV) infections", "PROBLEM", 116, 150], ["NK cells", "TREATMENT", 191, 199], ["viral burden", "PROBLEM", 211, 223], ["fatal disease", "PROBLEM", 241, 254], ["respiratory", "ANATOMY", 41, 52], ["syncytial virus", "OBSERVATION", 53, 68], ["fatal", "OBSERVATION_MODIFIER", 241, 246]]], ["The relative contributions of conventional NK cells recruited into the lung from the circulation during infection versus the phenotypically unique resident NK cells in human lungs remain undefined.", [["NK cells", "ANATOMY", 43, 51], ["lung", "ANATOMY", 71, 75], ["NK cells", "ANATOMY", 156, 164], ["lungs", "ANATOMY", 174, 179], ["infection", "DISEASE", 104, 113], ["NK cells", "CELL", 43, 51], ["lung", "ORGAN", 71, 75], ["NK cells", "CELL", 156, 164], ["human", "ORGANISM", 168, 173], ["lungs", "ORGAN", 174, 179], ["NK cells", "CELL_TYPE", 43, 51], ["phenotypically unique resident NK cells", "CELL_TYPE", 125, 164], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 168, 173], ["conventional NK cells", "TREATMENT", 30, 51], ["infection", "PROBLEM", 104, 113], ["conventional NK cells", "OBSERVATION", 30, 51], ["lung", "ANATOMY", 71, 75], ["circulation", "ANATOMY", 85, 96], ["infection", "OBSERVATION", 104, 113], ["NK cells", "OBSERVATION", 156, 164], ["human", "ANATOMY_MODIFIER", 168, 173], ["lungs", "ANATOMY", 174, 179]]], ["Yet, the hypofunctional status of human-lung-resident NK cells during homeostasis (Marquardt et al., 2017) suggests that persistence of highly active NK cells in the lung may be more harmful than beneficial, potentially worsening lung injury.Main TextIndeed, NK cells can exacerbate lung injury and reduce survival of mice during respiratory infections that are characterized by higher titers of virus and exaggerated inflammatory responses.", [["lung", "ANATOMY", 40, 44], ["NK cells", "ANATOMY", 54, 62], ["NK cells", "ANATOMY", 150, 158], ["lung", "ANATOMY", 166, 170], ["lung", "ANATOMY", 230, 234], ["NK cells", "ANATOMY", 259, 267], ["lung", "ANATOMY", 283, 287], ["respiratory", "ANATOMY", 330, 341], ["lung injury", "DISEASE", 230, 241], ["lung injury", "DISEASE", 283, 294], ["respiratory infections", "DISEASE", 330, 352], ["human", "ORGANISM", 34, 39], ["lung-resident NK cells", "CELL", 40, 62], ["NK cells", "CELL", 150, 158], ["lung", "ORGAN", 166, 170], ["lung", "ORGAN", 230, 234], ["NK cells", "CELL", 259, 267], ["lung", "ORGAN", 283, 287], ["mice", "ORGANISM", 318, 322], ["human-lung-resident NK cells", "CELL_TYPE", 34, 62], ["NK cells", "CELL_TYPE", 150, 158], ["NK cells", "CELL_TYPE", 259, 267], ["human", "SPECIES", 34, 39], ["mice", "SPECIES", 318, 322], ["human", "SPECIES", 34, 39], ["mice", "SPECIES", 318, 322], ["highly active NK cells in the lung", "PROBLEM", 136, 170], ["worsening lung injury", "PROBLEM", 220, 241], ["NK cells", "PROBLEM", 259, 267], ["lung injury", "PROBLEM", 283, 294], ["respiratory infections", "PROBLEM", 330, 352], ["higher titers of virus", "PROBLEM", 379, 401], ["exaggerated inflammatory responses", "PROBLEM", 406, 440], ["lung", "ANATOMY", 40, 44], ["highly", "OBSERVATION_MODIFIER", 136, 142], ["active NK cells", "OBSERVATION", 143, 158], ["lung", "ANATOMY", 166, 170], ["worsening", "OBSERVATION_MODIFIER", 220, 229], ["lung", "ANATOMY", 230, 234], ["injury", "OBSERVATION", 235, 241], ["NK cells", "OBSERVATION", 259, 267], ["lung", "ANATOMY", 283, 287], ["injury", "OBSERVATION", 288, 294], ["infections", "OBSERVATION", 342, 352], ["higher", "OBSERVATION_MODIFIER", 379, 385], ["titers", "OBSERVATION_MODIFIER", 386, 392], ["exaggerated", "OBSERVATION_MODIFIER", 406, 417], ["inflammatory", "OBSERVATION_MODIFIER", 418, 430]]], ["Exuberant NK-cell activity, including IFN-\u03b3 production, contributes to this aggravated lung inflammation during both IAV and RSV infections (Cong and Wei, 2019, Li et al., 2012, Abdul-Careem et al., 2012).", [["NK-cell", "ANATOMY", 10, 17], ["lung", "ANATOMY", 87, 91], ["lung inflammation", "DISEASE", 87, 104], ["IAV and RSV infections", "DISEASE", 117, 139], ["NK-cell", "CELL", 10, 17], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 38, 43], ["lung", "ORGAN", 87, 91], ["IAV", "ORGANISM", 117, 120], ["RSV", "ORGANISM", 125, 128], ["IFN", "PROTEIN", 38, 41], ["IAV", "SPECIES", 117, 120], ["RSV", "SPECIES", 125, 128], ["IFN-\u03b3 production", "PROBLEM", 38, 54], ["this aggravated lung inflammation", "PROBLEM", 71, 104], ["RSV infections", "PROBLEM", 125, 139], ["cell activity", "OBSERVATION", 13, 26], ["lung", "ANATOMY", 87, 91], ["inflammation", "OBSERVATION", 92, 104], ["RSV infections", "OBSERVATION", 125, 139]]], ["Moreover, elevated IL-2 and IL-18 amplify these pathological activities of NK cells during these infections and promote interstitial pneumonia (Okamoto et al., 2002, Harker et al., 2010, McKinstry et al., 2019).", [["NK cells", "ANATOMY", 75, 83], ["interstitial", "ANATOMY", 120, 132], ["infections", "DISEASE", 97, 107], ["interstitial pneumonia", "DISEASE", 120, 142], ["IL-2", "GENE_OR_GENE_PRODUCT", 19, 23], ["IL-18", "GENE_OR_GENE_PRODUCT", 28, 33], ["NK cells", "CELL", 75, 83], ["IL-2 and IL-18", "PROTEIN", 19, 33], ["NK cells", "CELL_TYPE", 75, 83], ["elevated IL", "PROBLEM", 10, 21], ["IL", "TEST", 28, 30], ["NK cells", "PROBLEM", 75, 83], ["these infections", "PROBLEM", 91, 107], ["interstitial pneumonia", "PROBLEM", 120, 142], ["NK cells", "OBSERVATION", 75, 83], ["interstitial", "ANATOMY_MODIFIER", 120, 132], ["pneumonia", "OBSERVATION", 133, 142]]], ["Irreversible damage of the lungs by NK cells may be more than just an unfortunate side effect of IFN-\u03b3 production, as the robust cytolytic elimination of virus-infected airway epithelial cells by NK cells is a critical antiviral function that may exceed the functional and regenerative capacity of the lung.", [["lungs", "ANATOMY", 27, 32], ["NK cells", "ANATOMY", 36, 44], ["airway epithelial cells", "ANATOMY", 169, 192], ["NK cells", "ANATOMY", 196, 204], ["lung", "ANATOMY", 302, 306], ["IFN-\u03b3", "CHEMICAL", 97, 102], ["lungs", "ORGAN", 27, 32], ["NK cells", "CELL", 36, 44], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 97, 102], ["airway epithelial cells", "CELL", 169, 192], ["NK cells", "CELL", 196, 204], ["lung", "ORGAN", 302, 306], ["NK cells", "CELL_TYPE", 36, 44], ["IFN", "PROTEIN", 97, 100], ["virus-infected airway epithelial cells", "CELL_TYPE", 154, 192], ["NK cells", "CELL_TYPE", 196, 204], ["Irreversible damage of the lungs", "PROBLEM", 0, 32], ["NK cells", "PROBLEM", 36, 44], ["IFN-\u03b3 production", "PROBLEM", 97, 113], ["virus", "PROBLEM", 154, 159], ["infected airway epithelial cells", "PROBLEM", 160, 192], ["NK cells", "PROBLEM", 196, 204], ["damage", "OBSERVATION", 13, 19], ["lungs", "ANATOMY", 27, 32], ["NK cells", "OBSERVATION", 36, 44], ["infected", "OBSERVATION_MODIFIER", 160, 168], ["airway epithelial cells", "OBSERVATION", 169, 192], ["NK cells", "OBSERVATION", 196, 204], ["antiviral function", "OBSERVATION", 219, 237], ["regenerative capacity", "OBSERVATION", 273, 294], ["lung", "ANATOMY", 302, 306]]], ["Of note, the low numbers of NK cells detected in peripheral blood of patients with severe SARS-CoV-2 infections (Wang et al., 2020) may reflect recruitment of pathogenic NK cells to the lungs rather than a true decrease in total NK cell numbers.", [["NK cells", "ANATOMY", 28, 36], ["peripheral blood", "ANATOMY", 49, 65], ["NK cells", "ANATOMY", 170, 178], ["lungs", "ANATOMY", 186, 191], ["NK cell", "ANATOMY", 229, 236], ["SARS-CoV-2 infections", "DISEASE", 90, 111], ["NK cells", "CELL", 28, 36], ["peripheral blood", "ORGANISM_SUBSTANCE", 49, 65], ["patients", "ORGANISM", 69, 77], ["SARS-CoV-2", "ORGANISM", 90, 100], ["NK cells", "CELL", 170, 178], ["lungs", "ORGAN", 186, 191], ["NK cell", "CELL", 229, 236], ["NK cells", "CELL_TYPE", 28, 36], ["pathogenic NK cells", "CELL_TYPE", 159, 178], ["patients", "SPECIES", 69, 77], ["NK cells", "PROBLEM", 28, 36], ["severe SARS", "PROBLEM", 83, 94], ["CoV-2 infections", "PROBLEM", 95, 111], ["pathogenic NK cells", "PROBLEM", 159, 178], ["a true decrease in total NK cell numbers", "PROBLEM", 204, 244], ["NK cells", "OBSERVATION", 28, 36], ["peripheral", "ANATOMY_MODIFIER", 49, 59], ["blood", "ANATOMY", 60, 65], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["SARS", "OBSERVATION", 90, 94], ["may reflect", "UNCERTAINTY", 132, 143], ["recruitment", "OBSERVATION_MODIFIER", 144, 155], ["pathogenic NK cells", "OBSERVATION", 159, 178], ["lungs", "ANATOMY", 186, 191], ["decrease", "OBSERVATION_MODIFIER", 211, 219], ["total NK cell numbers", "OBSERVATION", 223, 244]]], ["Indeed, single-cell RNA sequencing of lung bronchoalveolar lavage fluid (BAL) demonstrated higher frequencies of NK cells in the lungs of patients with severe SARS-CoV-2 infections (Liao et al., 2020).", [["lung bronchoalveolar lavage fluid", "ANATOMY", 38, 71], ["BAL", "ANATOMY", 73, 76], ["NK cells", "ANATOMY", 113, 121], ["lungs", "ANATOMY", 129, 134], ["SARS-CoV-2 infections", "DISEASE", 159, 180], ["lung bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 38, 71], ["NK cells", "CELL", 113, 121], ["lungs", "ORGAN", 129, 134], ["patients", "ORGANISM", 138, 146], ["CoV-2", "ORGANISM", 164, 169], ["NK cells", "CELL_TYPE", 113, 121], ["patients", "SPECIES", 138, 146], ["lung bronchoalveolar lavage fluid (BAL)", "TEST", 38, 77], ["higher frequencies of NK cells", "PROBLEM", 91, 121], ["severe SARS", "PROBLEM", 152, 163], ["CoV-2 infections", "PROBLEM", 164, 180], ["lung", "ANATOMY", 38, 42], ["bronchoalveolar lavage fluid", "OBSERVATION", 43, 71], ["higher", "OBSERVATION_MODIFIER", 91, 97], ["NK cells", "OBSERVATION", 113, 121], ["lungs", "ANATOMY", 129, 134], ["severe", "OBSERVATION_MODIFIER", 152, 158], ["SARS", "OBSERVATION", 159, 163], ["CoV", "OBSERVATION_MODIFIER", 164, 167]]], ["In total, the potential for NK-cell based therapies to cause substantial harm to the lungs may outweigh the potential benefits of the possible antiviral activities of these cells.Main TextAt the time of this writing, three global trials incorporating NK-cell based cellular therapies have been initiated.", [["NK-cell", "ANATOMY", 28, 35], ["lungs", "ANATOMY", 85, 90], ["cells", "ANATOMY", 173, 178], ["NK-cell", "ANATOMY", 251, 258], ["cellular", "ANATOMY", 265, 273], ["NK-cell", "CELL", 28, 35], ["lungs", "ORGAN", 85, 90], ["cells", "CELL", 173, 178], ["NK-cell", "CELL", 251, 258], ["cellular", "CELL", 265, 273], ["NK-cell based therapies", "TREATMENT", 28, 51], ["substantial harm to the lungs", "PROBLEM", 61, 90], ["antiviral activities of these cells", "TREATMENT", 143, 178], ["NK-cell based cellular therapies", "TREATMENT", 251, 283], ["substantial", "OBSERVATION_MODIFIER", 61, 72], ["harm", "OBSERVATION", 73, 77], ["lungs", "ANATOMY", 85, 90]]], ["These include infusion of allogeneic NK cells (https://clinicaltrials.gov/ct2/show/NCT04344548), placenta-derived (Kang et al., 2013) cord blood NK cells (https://clinicaltrials.gov/ct2/show/NCT04280224), and NK cells bearing an innovative CAR designed to engage the SARS-CoV-2 via its putative cellular receptor (ACE2) (https://clinicaltrials.gov/ct2/show/NCT04324996).", [["NK cells", "ANATOMY", 37, 45], ["placenta", "ANATOMY", 97, 105], ["cord blood NK cells", "ANATOMY", 134, 153], ["NK cells", "ANATOMY", 209, 217], ["cellular", "ANATOMY", 295, 303], ["SARS", "DISEASE", 267, 271], ["NK cells", "CELL", 37, 45], ["placenta", "TISSUE", 97, 105], ["cord blood NK cells", "CELL", 134, 153], ["NK cells", "CELL", 209, 217], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 267, 277], ["cellular receptor", "GENE_OR_GENE_PRODUCT", 295, 312], ["ACE2", "GENE_OR_GENE_PRODUCT", 314, 318], ["allogeneic NK cells", "CELL_TYPE", 26, 45], ["cord blood NK cells", "CELL_TYPE", 134, 153], ["NK cells", "CELL_TYPE", 209, 217], ["CAR", "PROTEIN", 240, 243], ["putative cellular receptor", "PROTEIN", 286, 312], ["ACE2", "PROTEIN", 314, 318], ["SARS-CoV", "SPECIES", 267, 275], ["infusion of allogeneic NK cells", "TREATMENT", 14, 45], ["cord blood NK cells", "TEST", 134, 153], ["the SARS", "TEST", 263, 271], ["CoV", "TEST", 272, 275], ["allogeneic NK cells", "OBSERVATION", 26, 45], ["placenta", "ANATOMY", 97, 105], ["cord", "ANATOMY", 134, 138], ["NK cells", "OBSERVATION", 145, 153]]], ["The reasonable desire to treat patients with severe SARS-CoV-2 infections using these experimental therapies will conflict with the need to learn as much as possible about their safety.", [["SARS", "DISEASE", 52, 56], ["infections", "DISEASE", 63, 73], ["patients", "ORGANISM", 31, 39], ["CoV-2", "ORGANISM", 57, 62], ["patients", "SPECIES", 31, 39], ["severe SARS", "PROBLEM", 45, 56], ["CoV-2 infections", "PROBLEM", 57, 73], ["these experimental therapies", "TREATMENT", 80, 108], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["SARS", "OBSERVATION", 52, 56]]], ["The timelines of these experimental studies are compressed (<2 months) and will be carried out on only a few severely ill patients.", [["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["these experimental studies", "TEST", 17, 43]]], ["This may make it challenging to distinguish harmful treatment outcomes from a general lack of efficacy if trial participants succumb to disease.", [["participants", "SPECIES", 112, 124], ["disease", "PROBLEM", 136, 143]]], ["Thus, while hopes remain high that the potent antiviral functionality of these NK cells will provide clinical benefit, the potential for damage to the lungs, liver, and kidneys should be serious concerns and monitored very carefully in these trials.Main TextImportantly, the timing of therapeutic administration of NK cells will also dictate the balance between their beneficial antiviral and detrimental pathologic effects.", [["NK cells", "ANATOMY", 79, 87], ["lungs", "ANATOMY", 151, 156], ["liver", "ANATOMY", 158, 163], ["kidneys", "ANATOMY", 169, 176], ["NK cells", "ANATOMY", 315, 323], ["NK cells", "CELL", 79, 87], ["lungs", "ORGAN", 151, 156], ["liver", "ORGAN", 158, 163], ["kidneys", "ORGAN", 169, 176], ["NK cells", "CELL", 315, 323], ["NK cells", "CELL_TYPE", 79, 87], ["NK cells", "CELL_TYPE", 315, 323], ["damage to the lungs, liver, and kidneys", "PROBLEM", 137, 176], ["therapeutic administration of NK cells", "TREATMENT", 285, 323], ["their beneficial antiviral", "TREATMENT", 362, 388], ["detrimental pathologic effects", "PROBLEM", 393, 423], ["lungs", "ANATOMY", 151, 156], ["liver", "ANATOMY", 158, 163], ["kidneys", "ANATOMY", 169, 176]]], ["During Sendai parainfluenza virus infection of mice, early infusion of NK cells partially controlled low-dose infection, whereas therapy initiation at a later stage of infection increased viral replication and associated morbidity (Mostafa et al., 2018).", [["NK cells", "ANATOMY", 71, 79], ["Sendai parainfluenza virus infection", "DISEASE", 7, 43], ["infection", "DISEASE", 110, 119], ["infection", "DISEASE", 168, 177], ["Sendai parainfluenza virus", "ORGANISM", 7, 33], ["mice", "ORGANISM", 47, 51], ["NK cells", "CELL", 71, 79], ["NK cells", "CELL_TYPE", 71, 79], ["Sendai parainfluenza virus", "SPECIES", 7, 33], ["mice", "SPECIES", 47, 51], ["Sendai parainfluenza virus", "SPECIES", 7, 33], ["mice", "SPECIES", 47, 51], ["Sendai parainfluenza virus infection of mice", "PROBLEM", 7, 51], ["early infusion of NK cells", "TREATMENT", 53, 79], ["low-dose infection", "PROBLEM", 101, 119], ["therapy", "TREATMENT", 129, 136], ["infection increased viral replication", "PROBLEM", 168, 205], ["Sendai parainfluenza virus", "OBSERVATION", 7, 33], ["infection", "OBSERVATION", 168, 177], ["viral replication", "OBSERVATION", 188, 205]]], ["Similarly, patient-specific factors are likely to impact the efficacy of NK-cell based therapeutics, as severe SARS-CoV-2 infection is associated with hypoxia and elevated IL-6 (Chen et al., 2020), which can significantly impair the function of NK cells (Cifaldi et al., 2015).", [["NK-cell", "ANATOMY", 73, 80], ["NK cells", "ANATOMY", 245, 253], ["SARS", "DISEASE", 111, 115], ["infection", "DISEASE", 122, 131], ["hypoxia", "DISEASE", 151, 158], ["patient", "ORGANISM", 11, 18], ["NK-cell", "CELL", 73, 80], ["SARS-CoV-2", "ORGANISM", 111, 121], ["IL-6", "GENE_OR_GENE_PRODUCT", 172, 176], ["NK cells", "CELL", 245, 253], ["NK cells", "CELL_TYPE", 245, 253], ["patient", "SPECIES", 11, 18], ["NK-cell based therapeutics", "TREATMENT", 73, 99], ["severe SARS", "PROBLEM", 104, 115], ["CoV-2 infection", "PROBLEM", 116, 131], ["hypoxia", "PROBLEM", 151, 158], ["elevated IL", "PROBLEM", 163, 174], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["NK cells", "OBSERVATION", 245, 253]]], ["The potential role of elevated IL-6 in poor outcome of SARS-CoV-2 infections has even led to clinical trials investigating the utility of drugs that inhibit IL-6 (e.g., tocilizumab; https://clinicaltrials.gov/ct2/show/NCT04335071) or JAK signaling (e.g., tofacitinib; https://clinicaltrials.gov/ct2/show/NCT04332042) in the treatment of critical illness in SARS-CoV-2 patients.", [["SARS", "DISEASE", 55, 59], ["infections", "DISEASE", 66, 76], ["tofacitinib", "CHEMICAL", 255, 266], ["critical illness", "DISEASE", 337, 353], ["SARS", "DISEASE", 357, 361], ["tofacitinib", "CHEMICAL", 255, 266], ["IL-6", "GENE_OR_GENE_PRODUCT", 31, 35], ["SARS-CoV-2", "ORGANISM", 55, 65], ["IL-6", "GENE_OR_GENE_PRODUCT", 157, 161], ["tocilizumab", "SIMPLE_CHEMICAL", 169, 180], ["JAK", "GENE_OR_GENE_PRODUCT", 234, 237], ["tofacitinib", "SIMPLE_CHEMICAL", 255, 266], ["SARS-CoV-2", "ORGANISM", 357, 367], ["patients", "ORGANISM", 368, 376], ["IL-6", "PROTEIN", 31, 35], ["IL-6", "PROTEIN", 157, 161], ["JAK", "PROTEIN", 234, 237], ["patients", "SPECIES", 368, 376], ["SARS-CoV", "SPECIES", 55, 63], ["SARS-CoV", "SPECIES", 357, 365], ["elevated IL", "PROBLEM", 22, 33], ["SARS", "PROBLEM", 55, 59], ["CoV-2 infections", "PROBLEM", 60, 76], ["drugs", "TREATMENT", 138, 143], ["IL", "TEST", 157, 159], ["tocilizumab", "TREATMENT", 169, 180], ["JAK signaling", "PROBLEM", 234, 247], ["tofacitinib", "TREATMENT", 255, 266], ["elevated", "OBSERVATION_MODIFIER", 22, 30]]], ["Of note, tofacitinib and related JAK inhibitors can reduce the number and function of NK cells, highlighting how clinical benefit of such drugs could stem, in part, from depletion of potentially pathogenic NK cells.", [["NK cells", "ANATOMY", 86, 94], ["NK cells", "ANATOMY", 206, 214], ["tofacitinib", "CHEMICAL", 9, 20], ["tofacitinib", "CHEMICAL", 9, 20], ["tofacitinib", "SIMPLE_CHEMICAL", 9, 20], ["JAK", "GENE_OR_GENE_PRODUCT", 33, 36], ["NK cells", "CELL", 86, 94], ["NK cells", "CELL", 206, 214], ["JAK", "PROTEIN", 33, 36], ["NK cells", "CELL_TYPE", 86, 94], ["pathogenic NK cells", "CELL_TYPE", 195, 214], ["tofacitinib", "TREATMENT", 9, 20], ["related JAK inhibitors", "TREATMENT", 25, 47], ["NK cells", "PROBLEM", 86, 94], ["such drugs", "TREATMENT", 133, 143], ["potentially pathogenic NK cells", "PROBLEM", 183, 214], ["NK cells", "OBSERVATION", 86, 94], ["potentially", "UNCERTAINTY", 183, 194], ["pathogenic NK cells", "OBSERVATION", 195, 214]]], ["A final consideration in translation of the clinical success of NK cells in oncology to treatment of severe SARS-CoV-2 infections lies in the paucity of information regarding both efficacy and safety of such NK-cell infusions performed in the absence of the lymphodepleting preconditioning regimens commonly coupled to this approach in cancer therapy.Main TextThese data and observations highlight the complexities of using NK-cell-based therapies in the treatment of current and future pandemic respiratory viral infections.", [["NK cells", "ANATOMY", 64, 72], ["NK", "ANATOMY", 208, 210], ["cell", "ANATOMY", 211, 215], ["cancer", "ANATOMY", 336, 342], ["NK-cell", "ANATOMY", 424, 431], ["SARS", "DISEASE", 108, 112], ["infections", "DISEASE", 119, 129], ["cancer", "DISEASE", 336, 342], ["respiratory viral infections", "DISEASE", 496, 524], ["NK cells", "CELL", 64, 72], ["SARS-CoV-2", "ORGANISM", 108, 118], ["NK-cell", "CELL", 208, 215], ["cancer", "CANCER", 336, 342], ["NK-cell", "CELL", 424, 431], ["NK cells", "CELL_TYPE", 64, 72], ["NK cells", "TREATMENT", 64, 72], ["severe SARS", "PROBLEM", 101, 112], ["CoV-2 infections", "PROBLEM", 113, 129], ["such NK-cell infusions", "TREATMENT", 203, 225], ["the lymphodepleting preconditioning regimens", "TREATMENT", 254, 298], ["cancer therapy", "TREATMENT", 336, 350], ["Main TextThese data", "TEST", 351, 370], ["NK-cell-based therapies", "TREATMENT", 424, 447], ["the treatment", "TREATMENT", 451, 464], ["future pandemic respiratory viral infections", "PROBLEM", 480, 524], ["NK cells", "OBSERVATION", 64, 72], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["SARS", "OBSERVATION", 108, 112], ["cancer", "OBSERVATION", 336, 342], ["viral infections", "OBSERVATION", 508, 524]]], ["Data from each case, including lung-specific viral burden and cytokine measurements before and after therapy, will be critical for the interpretation and future implementation of NK-cell therapeutics.", [["lung", "ANATOMY", 31, 35], ["NK-cell", "ANATOMY", 179, 186], ["lung", "ORGAN", 31, 35], ["NK-cell", "CELL", 179, 186], ["cytokine", "PROTEIN", 62, 70], ["specific viral burden", "PROBLEM", 36, 57], ["cytokine measurements", "TEST", 62, 83], ["therapy", "TREATMENT", 101, 108], ["NK-cell therapeutics", "TREATMENT", 179, 199], ["lung", "ANATOMY", 31, 35]]], ["Trial design and candidate selection for NK-cell infusion in SARS-CoV-2 patients should be carefully considered and should weigh potential canonical antiviral benefits against the elevated risk for pathogenic consequences of NK cells in the context of severe respiratory viral infection.", [["NK-cell", "ANATOMY", 41, 48], ["NK cells", "ANATOMY", 225, 233], ["SARS", "DISEASE", 61, 65], ["respiratory viral infection", "DISEASE", 259, 286], ["NK-cell", "CELL", 41, 48], ["SARS-CoV-2", "ORGANISM", 61, 71], ["patients", "ORGANISM", 72, 80], ["NK cells", "CELL", 225, 233], ["NK cells", "CELL_TYPE", 225, 233], ["patients", "SPECIES", 72, 80], ["SARS-CoV", "SPECIES", 61, 69], ["Trial design and candidate selection", "TREATMENT", 0, 36], ["NK-cell infusion", "TREATMENT", 41, 57], ["SARS", "PROBLEM", 61, 65], ["canonical antiviral benefits", "TREATMENT", 139, 167], ["NK cells", "PROBLEM", 225, 233], ["severe respiratory viral infection", "PROBLEM", 252, 286], ["NK cells", "OBSERVATION", 225, 233], ["severe", "OBSERVATION_MODIFIER", 252, 258], ["respiratory", "ANATOMY", 259, 270], ["viral infection", "OBSERVATION", 271, 286]]], ["In a time of true uncertainty, with vulnerable and desperate patients who are willing to accept almost any experimental therapy, it is critical for the scientific and medical communities to ensure that the scientific support for novel interventions is strong, the risks and benefits of novel therapies are well balanced, and trial protocols are robust and well monitored.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["any experimental therapy", "TREATMENT", 103, 127], ["the scientific support", "TREATMENT", 202, 224], ["novel interventions", "TREATMENT", 229, 248], ["novel therapies", "TREATMENT", 286, 301], ["trial protocols", "TREATMENT", 325, 340]]], ["Patients are not currently able to live by the ancient saying caveat emptor (let the buyer beware), so the scientific community must do so for them.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]]], "PMC7348575": [["IntroductionCoronaviruses are enveloped, positive-sense single-stranded RNA viruses belonging to the family Coronaviridae [1].", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["IntroductionCoronaviruses", "PROBLEM", 0, 25]]], ["Their genomes are approximately 30 kb in length, are polycistronic, and have a peculiar transcription mechanism that results in the production of a nested set of subgenomic mRNAs [1].", [["subgenomic mRNAs", "RNA", 162, 178], ["approximately", "OBSERVATION_MODIFIER", 18, 31], ["30 kb", "OBSERVATION_MODIFIER", 32, 37]]], ["Their virions are mainly composed of four structural proteins: nucleocapsid (N), membrane (M), envelope (E), and spike (S) proteins, all of which are essential building blocks for virion formation [1].", [["virions", "ANATOMY", 6, 13], ["membrane", "ANATOMY", 81, 89], ["virion", "ANATOMY", 180, 186], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 63, 79], ["membrane", "CELLULAR_COMPONENT", 81, 89], ["virion", "CELLULAR_COMPONENT", 180, 186], ["structural proteins", "PROTEIN", 42, 61], ["nucleocapsid (N), membrane (M), envelope (E), and spike (S) proteins", "PROTEIN", 63, 131], ["membrane (M), envelope (E)", "PROBLEM", 81, 107], ["spike (S) proteins", "PROBLEM", 113, 131], ["virion formation", "PROBLEM", 180, 196]]], ["The spike proteins are the most external structures of coronavirus particles, and they are responsible for attachment of the virus to target cells (via specific ligand-receptor interactions) and, consequently, for the initiation of infection [1].IntroductionCoronaviruses are recognized animal and human pathogens [2].", [["cells", "ANATOMY", 141, 146], ["infection", "DISEASE", 232, 241], ["coronavirus", "ORGANISM", 55, 66], ["cells", "CELL", 141, 146], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 258, 271], ["human", "ORGANISM", 298, 303], ["spike proteins", "PROTEIN", 4, 18], ["target cells", "CELL_TYPE", 134, 146], ["human", "SPECIES", 298, 303], ["human", "SPECIES", 298, 303], ["The spike proteins", "PROBLEM", 0, 18], ["coronavirus particles", "PROBLEM", 55, 76], ["the virus", "PROBLEM", 121, 130], ["infection", "PROBLEM", 232, 241], ["coronavirus particles", "OBSERVATION", 55, 76], ["infection", "OBSERVATION", 232, 241]]], ["Up to the end of 2019, there were six coronaviruses known to cause respiratory disease in humans, with varying degrees of severity: human coronavirus (HCoV)-OC43, HCoV-229E, HCoV-NL63, HCoV-HKU1, severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV) [1, 3].", [["respiratory", "ANATOMY", 67, 78], ["respiratory disease", "DISEASE", 67, 86], ["acute respiratory syndrome coronavirus", "DISEASE", 203, 241], ["SARS-CoV)", "DISEASE", 243, 252], ["Middle East respiratory syndrome coronavirus", "DISEASE", 258, 302], ["humans", "ORGANISM", 90, 96], ["human coronavirus", "ORGANISM", 132, 149], ["HCoV)-OC43", "ORGANISM", 151, 161], ["HCoV-229E", "ORGANISM", 163, 172], ["HCoV-NL63", "ORGANISM", 174, 183], ["HCoV-HKU1", "ORGANISM", 185, 194], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 196, 241], ["SARS-CoV", "ORGANISM", 243, 251], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 258, 302], ["MERS-CoV", "ORGANISM", 304, 312], ["humans", "SPECIES", 90, 96], ["human", "SPECIES", 132, 137], ["coronavirus", "SPECIES", 138, 149], ["humans", "SPECIES", 90, 96], ["human coronavirus", "SPECIES", 132, 149], ["HCoV", "SPECIES", 151, 155], ["HCoV-229E", "SPECIES", 163, 172], ["HCoV", "SPECIES", 174, 178], ["HCoV", "SPECIES", 185, 189], ["severe acute respiratory syndrome coronavirus", "SPECIES", 196, 241], ["SARS-CoV", "SPECIES", 243, 251], ["Middle East respiratory syndrome coronavirus", "SPECIES", 258, 302], ["MERS-CoV", "SPECIES", 304, 312], ["six coronaviruses", "PROBLEM", 34, 51], ["respiratory disease in humans", "PROBLEM", 67, 96], ["varying degrees of severity", "PROBLEM", 103, 130], ["human coronavirus", "TEST", 132, 149], ["HCoV", "TEST", 151, 155], ["OC43", "TEST", 157, 161], ["HCoV", "TEST", 163, 167], ["HCoV", "TEST", 174, 178], ["HCoV", "TEST", 185, 189], ["HKU1", "PROBLEM", 190, 194], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 196, 241], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 258, 302], ["respiratory disease", "OBSERVATION", 67, 86], ["severe", "OBSERVATION_MODIFIER", 196, 202], ["acute", "OBSERVATION_MODIFIER", 203, 208], ["respiratory syndrome coronavirus", "OBSERVATION", 209, 241], ["Middle", "ANATOMY_MODIFIER", 258, 264], ["respiratory syndrome", "OBSERVATION", 270, 290]]], ["MERS-CoV emerged in the Saudi Arabia in 2012 and has since spread to 26 other countries [4].", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["MERS-CoV", "SPECIES", 0, 8]]], ["Infection is known to cause a wide range of manifestations, varying from asymptomatic to acute respiratory distress syndrome, which can evolve to circulatory collapse, multiorgan failure, and death [5].", [["respiratory", "ANATOMY", 95, 106], ["circulatory", "ANATOMY", 146, 157], ["multiorgan", "ANATOMY", 168, 178], ["Infection", "DISEASE", 0, 9], ["respiratory distress syndrome", "DISEASE", 95, 124], ["circulatory collapse", "DISEASE", 146, 166], ["multiorgan failure", "DISEASE", 168, 186], ["death", "DISEASE", 192, 197], ["Infection", "PROBLEM", 0, 9], ["a wide range of manifestations", "PROBLEM", 28, 58], ["acute respiratory distress syndrome", "PROBLEM", 89, 124], ["circulatory collapse", "PROBLEM", 146, 166], ["multiorgan failure", "PROBLEM", 168, 186], ["death", "PROBLEM", 192, 197], ["wide range", "OBSERVATION_MODIFIER", 30, 40], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["respiratory distress syndrome", "OBSERVATION", 95, 124], ["circulatory", "OBSERVATION_MODIFIER", 146, 157], ["collapse", "OBSERVATION", 158, 166], ["multiorgan failure", "OBSERVATION", 168, 186]]], ["According to the World Health Organizations (WHO), as of the end of November 2019, 2494 laboratory-confirmed human cases have been reported, 858 of which were fatal (34.4% case-fatality rate).IntroductionIn December 2019, a cluster of cases of atypical pneumonia of unknown etiology in Wuhan, China, attracted global attention [6\u20138].", [["pneumonia", "DISEASE", 253, 262], ["human", "ORGANISM", 109, 114], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["fatality rate", "TEST", 177, 190], ["atypical pneumonia", "PROBLEM", 244, 262], ["atypical", "OBSERVATION_MODIFIER", 244, 252], ["pneumonia", "OBSERVATION", 253, 262]]], ["A novel coronavirus was isolated from these patients, and named SARS-CoV-2.", [["coronavirus", "ORGANISM", 8, 19], ["patients", "ORGANISM", 44, 52], ["SARS-CoV-2", "ORGANISM", 64, 74], ["patients", "SPECIES", 44, 52], ["SARS-CoV", "SPECIES", 64, 72], ["A novel coronavirus", "PROBLEM", 0, 19], ["coronavirus", "OBSERVATION", 8, 19]]], ["Infection with this new virus also has a wide range of clinical manifestations, from asymptomatic, to mild fever with dry cough, to severe pneumonia [9].IntroductionIn this study, we analyzed the global gene expression of human pulmonary epithelial cells infected with MERS-CoV or SARS-CoV-2 by microarray to understand the pulmonary pathological consequences of infection by these two coronaviruses.Viruses and cells ::: Materials and methodsThe SARS-CoV-2 strain hCoV-19/Korea/CNUHV03/2020 was isolated in our laboratory from human clinical samples collected at the Chungnam National University Hospital (Daejeon, South Korea).", [["pulmonary epithelial cells", "ANATOMY", 228, 254], ["pulmonary", "ANATOMY", 324, 333], ["cells", "ANATOMY", 412, 417], ["samples", "ANATOMY", 543, 550], ["fever", "DISEASE", 107, 112], ["dry cough", "DISEASE", 118, 127], ["pneumonia", "DISEASE", 139, 148], ["infection", "DISEASE", 363, 372], ["human", "ORGANISM", 222, 227], ["pulmonary epithelial cells", "CELL", 228, 254], ["MERS-CoV", "ORGANISM", 269, 277], ["SARS-CoV-2", "ORGANISM", 281, 291], ["pulmonary", "ORGAN", 324, 333], ["coronaviruses", "ORGANISM", 386, 399], ["Viruses", "CELL", 400, 407], ["cells", "CELL", 412, 417], ["SARS-CoV-2 strain", "ORGANISM", 447, 464], ["hCoV-19", "ORGANISM", 465, 472], ["Korea", "ORGANISM", 473, 478], ["CNUHV03/2020", "GENE_OR_GENE_PRODUCT", 479, 491], ["human", "ORGANISM", 528, 533], ["human pulmonary epithelial cells", "CELL_TYPE", 222, 254], ["human", "SPECIES", 222, 227], ["human", "SPECIES", 528, 533], ["human", "SPECIES", 222, 227], ["MERS-CoV", "SPECIES", 269, 277], ["SARS-CoV", "SPECIES", 281, 289], ["SARS-CoV-2 strain hCoV-19/Korea/CNUHV03/2020", "SPECIES", 447, 491], ["human", "SPECIES", 528, 533], ["Infection", "PROBLEM", 0, 9], ["this new virus", "PROBLEM", 15, 29], ["clinical manifestations", "PROBLEM", 55, 78], ["mild fever", "PROBLEM", 102, 112], ["dry cough", "PROBLEM", 118, 127], ["severe pneumonia", "PROBLEM", 132, 148], ["this study", "TEST", 168, 178], ["human pulmonary epithelial cells", "PROBLEM", 222, 254], ["SARS", "PROBLEM", 281, 285], ["the pulmonary pathological consequences of infection", "PROBLEM", 320, 372], ["these two coronaviruses", "PROBLEM", 376, 399], ["methods", "TEST", 436, 443], ["The SARS", "TEST", 443, 451], ["CoV", "TEST", 452, 455], ["strain hCoV", "TEST", 458, 469], ["Korea/CNUHV03/2020", "TEST", 473, 491], ["wide range", "OBSERVATION_MODIFIER", 41, 51], ["mild", "OBSERVATION_MODIFIER", 102, 106], ["fever", "OBSERVATION", 107, 112], ["dry", "OBSERVATION_MODIFIER", 118, 121], ["cough", "OBSERVATION", 122, 127], ["severe", "OBSERVATION_MODIFIER", 132, 138], ["pneumonia", "OBSERVATION", 139, 148], ["pulmonary", "ANATOMY", 228, 237], ["epithelial cells", "OBSERVATION", 238, 254], ["pulmonary", "ANATOMY", 324, 333], ["pathological", "OBSERVATION", 334, 346], ["infection", "OBSERVATION", 363, 372]]], ["Vero cells, cultured in minimal essential medium (MEM) supplemented with 2% fetal bovine serum (FBS), were used in the isolation protocol.", [["Vero cells", "ANATOMY", 0, 10], ["fetal bovine serum", "ANATOMY", 76, 94], ["FBS", "ANATOMY", 96, 99], ["Vero cells", "CELL", 0, 10], ["bovine", "ORGANISM", 82, 88], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["FBS", "ORGANISM_SUBSTANCE", 96, 99], ["Vero cells", "CELL_LINE", 0, 10], ["bovine", "SPECIES", 82, 88], ["Vero cells", "PROBLEM", 0, 10], ["2% fetal bovine serum (FBS", "TREATMENT", 73, 99], ["the isolation protocol", "TREATMENT", 115, 137], ["minimal", "OBSERVATION_MODIFIER", 24, 31], ["essential", "OBSERVATION_MODIFIER", 32, 41], ["medium", "OBSERVATION_MODIFIER", 42, 48]]], ["The MERS-CoV strain EMC2012 was kindly provided by Dr. Bart Haagmans and Dr. Ron Fouchier (Erasmus Medical Center).", [["MERS-CoV", "ORGANISM", 4, 12], ["MERS-CoV", "SPECIES", 4, 12]]], ["All experimental procedures involving potential contact with MERS-CoV or SARS-CoV-2 were conducted in a biosafety level 3 (BSL3) laboratory, certified by the Korean government.Viruses and cells ::: Materials and methodsPrimary human pulmonary epithelial cells were purchased from ScienCell research laboratories (Carlsbad, CA, USA) and maintained in alveolar epithelial cell medium (AEpicM) supplemented with 10% FBS.Determination of viral titers by plaque assay ::: Materials and methodsPrimary human pulmonary epithelial cells, grown in 6-well plates, were infected with MERS-CoV or SARS-CoV-2 at an MOI of 0.01, and their culture supernatants were collected on days 2, 4 and 6 postinfection.", [["cells", "ANATOMY", 188, 193], ["pulmonary epithelial cells", "ANATOMY", 233, 259], ["alveolar epithelial cell", "ANATOMY", 350, 374], ["FBS", "ANATOMY", 413, 416], ["plaque", "ANATOMY", 450, 456], ["pulmonary epithelial cells", "ANATOMY", 502, 528], ["supernatants", "ANATOMY", 633, 645], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 61, 69], ["Viruses", "CELL", 176, 183], ["cells", "CELL", 188, 193], ["human", "ORGANISM", 227, 232], ["pulmonary epithelial cells", "CELL", 233, 259], ["alveolar epithelial cell", "CELL", 350, 374], ["FBS", "ORGANISM_SUBSTANCE", 413, 416], ["human", "ORGANISM", 496, 501], ["pulmonary epithelial cells", "CELL", 502, 528], ["MERS-CoV", "ORGANISM", 573, 581], ["SARS-CoV-2", "ORGANISM", 585, 595], ["human pulmonary epithelial cells", "CELL_TYPE", 227, 259], ["human pulmonary epithelial cells", "CELL_TYPE", 496, 528], ["human", "SPECIES", 227, 232], ["human", "SPECIES", 496, 501], ["MERS-CoV", "SPECIES", 61, 69], ["human", "SPECIES", 227, 232], ["human", "SPECIES", 496, 501], ["MERS-CoV", "SPECIES", 573, 581], ["SARS-CoV", "SPECIES", 585, 593], ["All experimental procedures", "TREATMENT", 0, 27], ["Primary human pulmonary epithelial cells", "PROBLEM", 219, 259], ["Carlsbad", "TEST", 313, 321], ["alveolar epithelial cell medium (AEpicM)", "TREATMENT", 350, 390], ["10% FBS", "TREATMENT", 409, 416], ["viral titers", "PROBLEM", 434, 446], ["Primary human pulmonary epithelial cells", "PROBLEM", 488, 528], ["MERS", "TEST", 573, 577], ["SARS", "PROBLEM", 585, 589], ["CoV", "TEST", 590, 593], ["an MOI", "TEST", 599, 605], ["their culture supernatants", "TEST", 619, 645], ["pulmonary", "ANATOMY", 233, 242], ["epithelial cells", "OBSERVATION", 243, 259], ["alveolar epithelial", "ANATOMY", 350, 369], ["cell medium", "OBSERVATION", 370, 381], ["viral titers", "OBSERVATION", 434, 446], ["plaque", "OBSERVATION", 450, 456], ["pulmonary", "ANATOMY", 502, 511], ["epithelial cells", "OBSERVATION", 512, 528], ["grown", "OBSERVATION_MODIFIER", 530, 535], ["infected", "OBSERVATION", 559, 567]]], ["Viral titers were measured by plaque assay.", [["plaque", "ANATOMY", 30, 36], ["Viral", "ORGANISM", 0, 5], ["Viral titers", "TEST", 0, 12], ["plaque assay", "TEST", 30, 42], ["titers", "OBSERVATION", 6, 12], ["plaque", "OBSERVATION", 30, 36]]], ["Briefly, serial tenfold dilutions of the collected culture supernatants were added to confluent Vero cell cultures and incubated for 4 h.", [["supernatants", "ANATOMY", 59, 71], ["Vero cell cultures", "ANATOMY", 96, 114], ["Vero cell cultures", "CELL", 96, 114], ["confluent Vero cell cultures", "CELL_LINE", 86, 114], ["serial tenfold dilutions", "TREATMENT", 9, 33], ["the collected culture supernatants", "TEST", 37, 71], ["confluent Vero cell cultures", "TEST", 86, 114], ["Vero cell", "OBSERVATION", 96, 105]]], ["Afterwards, cultures were overlaid with 1% electrophoretic agar (LPS Solution, Korea) and incubated for 4 days.", [["cultures", "ANATOMY", 12, 20], ["cultures", "TEST", 12, 20], ["1% electrophoretic agar (LPS Solution", "TREATMENT", 40, 77]]], ["Cells were then stained with 0.1% crystal violet (Sigma-Aldrich, St. Louis, MO, USA) in a 37% formaldehyde solution, and plaque-forming units (pfu) were measured.Analysis of gene expression patterns by microarray ::: Materials and methodsPrimary human pulmonary epithelial cells, grown in 6-well plates, were infected with MERS-CoV or SARS-CoV-2 at an MOI of 2 for 12 hours when viral particles were produced in the infected cells.", [["Cells", "ANATOMY", 0, 5], ["plaque", "ANATOMY", 121, 127], ["pulmonary epithelial cells", "ANATOMY", 252, 278], ["cells", "ANATOMY", 425, 430], ["formaldehyde", "CHEMICAL", 94, 106], ["formaldehyde", "CHEMICAL", 94, 106], ["Cells", "CELL", 0, 5], ["crystal violet", "SIMPLE_CHEMICAL", 34, 48], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 50, 63], ["St. Louis", "ORGANISM", 65, 74], ["formaldehyde", "SIMPLE_CHEMICAL", 94, 106], ["human", "ORGANISM", 246, 251], ["pulmonary epithelial cells", "CELL", 252, 278], ["MERS-CoV", "ORGANISM", 323, 331], ["SARS-CoV-2", "ORGANISM", 335, 345], ["cells", "CELL", 425, 430], ["human pulmonary epithelial cells", "CELL_TYPE", 246, 278], ["infected cells", "CELL_TYPE", 416, 430], ["human", "SPECIES", 246, 251], ["human", "SPECIES", 246, 251], ["MERS-CoV", "SPECIES", 323, 331], ["SARS-CoV", "SPECIES", 335, 343], ["Cells", "TEST", 0, 5], ["a 37% formaldehyde solution", "TREATMENT", 88, 115], ["plaque", "TEST", 121, 127], ["Primary human pulmonary epithelial cells", "PROBLEM", 238, 278], ["SARS", "PROBLEM", 335, 339], ["CoV", "TEST", 340, 343], ["viral particles", "PROBLEM", 379, 394], ["the infected cells", "PROBLEM", 412, 430], ["plaque", "OBSERVATION", 121, 127], ["pulmonary", "ANATOMY", 252, 261], ["epithelial cells", "OBSERVATION", 262, 278], ["grown", "OBSERVATION_MODIFIER", 280, 285], ["infected", "OBSERVATION", 309, 317], ["infected cells", "OBSERVATION", 416, 430]]], ["Uninfected cells were maintained under the same conditions as negative controls.", [["cells", "ANATOMY", 11, 16], ["cells", "CELL", 11, 16], ["Uninfected cells", "PROBLEM", 0, 16]]], ["Total RNA was then isolated using an RNeasy Mini Kit (QIAGEN, Hilden, Germany).", [["Total RNA", "TEST", 0, 9]]], ["The purified RNAs from infected and uninfected cells were analyzed using microarray (Affymetrix Human 2.0 ST array).", [["cells", "ANATOMY", 47, 52], ["cells", "CELL", 47, 52], ["Human", "ORGANISM", 96, 101], ["purified RNAs", "RNA", 4, 17], ["uninfected cells", "CELL_TYPE", 36, 52], ["Human", "SPECIES", 96, 101], ["The purified RNAs", "PROBLEM", 0, 17], ["infected and uninfected cells", "PROBLEM", 23, 52], ["microarray (Affymetrix Human 2.0 ST array)", "TREATMENT", 73, 115], ["RNAs", "OBSERVATION_MODIFIER", 13, 17], ["infected", "OBSERVATION_MODIFIER", 23, 31], ["uninfected cells", "OBSERVATION", 36, 52]]], ["This analysis was performed commercially (ebiogen, Seoul, South Korea).Analysis of gene expression patterns by microarray ::: Materials and methodsRNA quality was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, USA), and the quantity was determined by ND-1000 spectrophotometer (NanoDrop Technologies, USA).Analysis of gene expression patterns by microarray ::: Materials and methodsRNA samples were used as input in the Affymetrix procedure as recommended by the manufacturer (http://www.affymetrix.com).", [["This analysis", "TEST", 0, 13], ["methodsRNA samples", "TEST", 394, 412], ["the Affymetrix procedure", "TREATMENT", 435, 459]]], ["Briefly, total RNA from each sample was converted to double-stranded cDNA using a random hexamer incorporating a T7 promoter.", [["sample", "ANATOMY", 29, 35], ["double-stranded cDNA", "DNA", 53, 73], ["T7 promoter", "DNA", 113, 124], ["double-stranded cDNA", "TREATMENT", 53, 73], ["a random hexamer incorporating a T7 promoter", "TREATMENT", 80, 124]]], ["Amplified RNA (cRNA) was then generated from the double-stranded cDNA template in an in vitro transcription (IVT) reaction and purified using an Affymetrix sample cleanup module. cDNA was regenerated in a random-primed reverse transcription reaction using a dNTP mix containing dUTP.", [["dNTP", "CHEMICAL", 258, 262], ["dUTP", "CHEMICAL", 278, 282], ["dNTP", "CHEMICAL", 258, 262], ["dUTP", "CHEMICAL", 278, 282], ["dNTP", "SIMPLE_CHEMICAL", 258, 262], ["dUTP", "SIMPLE_CHEMICAL", 278, 282], ["double-stranded cDNA template", "DNA", 49, 78], ["cDNA", "DNA", 179, 183], ["the double-stranded cDNA template", "TREATMENT", 45, 78], ["an in vitro transcription", "TREATMENT", 82, 107], ["an Affymetrix sample cleanup module", "TREATMENT", 142, 177], ["a dNTP mix", "TREATMENT", 256, 266], ["cleanup module", "OBSERVATION", 163, 177]]], ["The cDNA was then fragmented by UDG and APE 1 restriction endonucleases and end-labeled in a terminal transferase reaction incorporating a biotinylated dideoxynucleotide.", [["UDG", "SIMPLE_CHEMICAL", 32, 35], ["dideoxynucleotide", "SIMPLE_CHEMICAL", 152, 169], ["cDNA", "DNA", 4, 8], ["UDG and APE 1 restriction endonucleases", "DNA", 32, 71], ["terminal transferase", "PROTEIN", 93, 113], ["biotinylated dideoxynucleotide", "PROTEIN", 139, 169], ["UDG", "TEST", 32, 35], ["APE 1 restriction endonucleases", "TREATMENT", 40, 71], ["a terminal transferase reaction", "PROBLEM", 91, 122], ["a biotinylated dideoxynucleotide", "TREATMENT", 137, 169], ["fragmented", "OBSERVATION_MODIFIER", 18, 28], ["terminal", "OBSERVATION_MODIFIER", 93, 101], ["transferase reaction", "OBSERVATION", 102, 122]]], ["Fragmented end-labeled cDNA was hybridized to the Affymetrix arrays for 16 h at 45 \u00b0C and 60 rpm as described in the Gene Chip Whole Transcript (WT) Sense Target Labeling Assay Manual (Affymetrix).", [["Fragmented end-labeled cDNA", "DNA", 0, 27], ["Affymetrix arrays", "DNA", 50, 67], ["Fragmented end-labeled cDNA", "TREATMENT", 0, 27], ["the Affymetrix arrays", "TREATMENT", 46, 67], ["the Gene Chip Whole Transcript (WT)", "TREATMENT", 113, 148], ["Manual (Affymetrix)", "TREATMENT", 177, 196]]], ["After hybridization, the chips were stained using streptavidin phycoerythrin (SAPE), washed in a GeneChip Fluidics Station 450 (Affymetrix), and scanned by using a GeneChip Array Scanner 3000 7G (Affymetrix).Analysis of gene expression patterns by microarray ::: Materials and methodsAfter the final wash and staining step, the Affymetrix array was scanned using an Affymetrix Model 3000 G7 scanner, and the image data were extracted using Affymetrix Command Console software 1.1.", [["streptavidin phycoerythrin", "CHEMICAL", 50, 76], ["streptavidin phycoerythrin", "SIMPLE_CHEMICAL", 50, 76], ["SAPE", "SIMPLE_CHEMICAL", 78, 82], ["streptavidin phycoerythrin", "PROTEIN", 50, 76], ["SAPE", "PROTEIN", 78, 82], ["the chips", "TREATMENT", 21, 30], ["streptavidin phycoerythrin", "TREATMENT", 50, 76], ["a GeneChip Array Scanner", "TREATMENT", 162, 186], ["the Affymetrix array", "TEST", 324, 344], ["the image data", "TEST", 404, 418]]], ["The raw.cel file generated by the above procedure contained expression intensity data and was used for the next step.", [["the above procedure", "TREATMENT", 30, 49], ["expression intensity data", "TEST", 60, 85]]], ["Expression data were generated by Transcriptome Analysis Console 4.0.1.", [["Expression data", "TEST", 0, 15]]], ["For normalization, the RMA (robust multi-average) algorithm implemented in the Transcriptome Analysis Console software was used.Ethics statement ::: Materials and methodsClinical sample collection from patients was approved by the CNU hospital ethics committee.", [["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 202, 210], ["Clinical sample collection", "TEST", 170, 196]]], ["The samples were collected with the consent of the patients.Viral infectivity in primary human pulmonary epithelial cells ::: ResultsTo evaluate if there were differences in the infectivity of MERS-CoV or SARS-CoV-2, we infected primary human pulmonary epithelial cells at an MOI of 0.01 and subsequently measured viral titers by plaque assay.", [["samples", "ANATOMY", 4, 11], ["pulmonary epithelial cells", "ANATOMY", 95, 121], ["pulmonary epithelial cells", "ANATOMY", 243, 269], ["plaque", "ANATOMY", 330, 336], ["patients", "ORGANISM", 51, 59], ["Viral", "ORGANISM", 60, 65], ["human", "ORGANISM", 89, 94], ["pulmonary epithelial cells", "CELL", 95, 121], ["MERS-CoV", "ORGANISM", 193, 201], ["SARS-CoV-2", "ORGANISM", 205, 215], ["human", "ORGANISM", 237, 242], ["pulmonary epithelial cells", "CELL", 243, 269], ["primary human pulmonary epithelial cells", "CELL_TYPE", 81, 121], ["primary human pulmonary epithelial cells", "CELL_TYPE", 229, 269], ["patients", "SPECIES", 51, 59], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 237, 242], ["human", "SPECIES", 89, 94], ["MERS-CoV", "SPECIES", 193, 201], ["SARS-CoV", "SPECIES", 205, 213], ["human", "SPECIES", 237, 242], ["The samples", "TEST", 0, 11], ["Viral infectivity in primary human pulmonary epithelial cells", "PROBLEM", 60, 121], ["the infectivity of MERS", "PROBLEM", 174, 197], ["CoV", "PROBLEM", 198, 201], ["SARS", "PROBLEM", 205, 209], ["CoV", "TEST", 210, 213], ["infected primary human pulmonary epithelial cells", "PROBLEM", 220, 269], ["an MOI", "TEST", 273, 279], ["viral titers", "TEST", 314, 326], ["plaque assay", "TEST", 330, 342], ["infectivity", "OBSERVATION", 66, 77], ["pulmonary", "ANATOMY", 95, 104], ["epithelial cells", "OBSERVATION", 105, 121], ["infected", "OBSERVATION_MODIFIER", 220, 228], ["pulmonary epithelial", "ANATOMY", 243, 263], ["cells", "OBSERVATION", 264, 269], ["viral titers", "OBSERVATION", 314, 326], ["plaque", "OBSERVATION", 330, 336]]], ["Viral growth was similar.", [["Viral growth", "TEST", 0, 12], ["growth", "OBSERVATION_MODIFIER", 6, 12], ["similar", "OBSERVATION_MODIFIER", 17, 24]]], ["The mean viral titers of lung cells infected with MERS-CoV were 2 \u00d7 105, 9 \u00d7 105, and 9.8 \u00d7 105 pfu after 2, 4, and 6 days of infection, respectively.", [["lung cells", "ANATOMY", 25, 35], ["infection", "DISEASE", 126, 135], ["lung cells", "CELL", 25, 35], ["MERS-CoV", "ORGANISM", 50, 58], ["lung cells", "CELL_TYPE", 25, 35], ["MERS-CoV", "SPECIES", 50, 58], ["The mean viral titers", "TEST", 0, 21], ["lung cells", "PROBLEM", 25, 35], ["CoV", "TEST", 55, 58], ["infection", "PROBLEM", 126, 135], ["lung", "ANATOMY", 25, 29], ["cells", "OBSERVATION", 30, 35], ["infected", "OBSERVATION_MODIFIER", 36, 44], ["infection", "OBSERVATION", 126, 135]]], ["The mean viral titers determined for SARS-CoV-2 were 2.2 \u00d7 105, 8.5 \u00d7 105, and 9.5 \u00d7 105 at the same time points (Fig. 1).Global gene expression in primary human pulmonary epithelial cells ::: ResultsTo investigate the impact of MERS-CoV and SARS-CoV-2 infection on global gene expression patterns in primary human lung cells, we infected them with each of these viruses at an MOI of 2, extracted total RNA, and performed a microarray analysis.", [["pulmonary epithelial cells", "ANATOMY", 162, 188], ["lung cells", "ANATOMY", 315, 325], ["infection", "DISEASE", 253, 262], ["human", "ORGANISM", 156, 161], ["pulmonary epithelial cells", "CELL", 162, 188], ["MERS-CoV", "ORGANISM", 229, 237], ["SARS-CoV-2", "ORGANISM", 242, 252], ["human", "ORGANISM", 309, 314], ["lung cells", "CELL", 315, 325], ["primary human pulmonary epithelial cells", "CELL_TYPE", 148, 188], ["primary human lung cells", "CELL_TYPE", 301, 325], ["human", "SPECIES", 156, 161], ["human", "SPECIES", 309, 314], ["SARS-CoV", "SPECIES", 37, 45], ["human", "SPECIES", 156, 161], ["MERS-CoV", "SPECIES", 229, 237], ["SARS-CoV", "SPECIES", 242, 250], ["human", "SPECIES", 309, 314], ["The mean viral titers", "TEST", 0, 21], ["SARS", "TEST", 37, 41], ["CoV", "TEST", 42, 45], ["Global gene expression", "PROBLEM", 122, 144], ["MERS", "PROBLEM", 229, 233], ["CoV", "PROBLEM", 234, 237], ["SARS", "PROBLEM", 242, 246], ["CoV", "PROBLEM", 247, 250], ["2 infection", "PROBLEM", 251, 262], ["global gene expression patterns", "PROBLEM", 266, 297], ["primary human lung cells", "PROBLEM", 301, 325], ["these viruses", "PROBLEM", 357, 370], ["a microarray analysis", "TEST", 422, 443], ["gene expression", "OBSERVATION", 129, 144], ["pulmonary", "ANATOMY", 162, 171], ["epithelial cells", "OBSERVATION", 172, 188], ["lung cells", "ANATOMY", 315, 325], ["viruses", "OBSERVATION", 363, 370]]], ["Uninfected cells processed under the same conditions were used to define the baseline.", [["cells", "ANATOMY", 11, 16], ["cells", "CELL", 11, 16], ["Uninfected cells", "TREATMENT", 0, 16]]], ["Overall, the number of differentially expressed genes was higher in MERS-CoV-infected cells than in SARS-CoV-2-infected cells.", [["cells", "ANATOMY", 86, 91], ["cells", "ANATOMY", 120, 125], ["MERS-CoV", "ORGANISM", 68, 76], ["cells", "CELL", 86, 91], ["SARS-CoV-2", "ORGANISM", 100, 110], ["cells", "CELL", 120, 125], ["MERS-CoV-infected cells", "CELL_LINE", 68, 91], ["infected cells", "CELL_TYPE", 111, 125], ["MERS-CoV", "SPECIES", 68, 76], ["SARS-CoV", "SPECIES", 100, 108], ["infected cells", "PROBLEM", 77, 91], ["SARS", "PROBLEM", 100, 104], ["CoV", "TEST", 105, 108], ["infected cells", "PROBLEM", 111, 125], ["higher", "OBSERVATION_MODIFIER", 58, 64], ["infected cells", "OBSERVATION", 77, 91], ["infected cells", "OBSERVATION", 111, 125]]], ["Out of a total of 44,556 genes analyzed, 127 were differentially expressed in human lung cells infected with MERS-CoV, whereas 50 were differentially expressed in SARS-CoV-2-infected cells (Fig. 2A, C, and D).", [["lung cells", "ANATOMY", 84, 94], ["cells", "ANATOMY", 183, 188], ["human", "ORGANISM", 78, 83], ["lung cells", "CELL", 84, 94], ["MERS-CoV", "ORGANISM", 109, 117], ["SARS-CoV-2", "ORGANISM", 163, 173], ["cells", "CELL", 183, 188], ["Fig. 2A", "CELL", 190, 197], ["C", "CELL", 199, 200], ["human lung cells", "CELL_TYPE", 78, 94], ["infected cells", "CELL_TYPE", 174, 188], ["human", "SPECIES", 78, 83], ["CoV-", "SPECIES", 168, 172], ["human", "SPECIES", 78, 83], ["MERS-CoV", "SPECIES", 109, 117], ["SARS-CoV", "SPECIES", 163, 171], ["human lung cells", "PROBLEM", 78, 94], ["SARS", "TEST", 163, 167], ["CoV", "TEST", 168, 171], ["infected cells", "PROBLEM", 174, 188], ["lung", "ANATOMY", 84, 88], ["infected cells", "OBSERVATION", 174, 188]]], ["Interestingly, our convergent analysis showed that the expression of only eight genes was modulated by both coronaviruses: matrix metallopeptidase 3 (MMP3), oligodendrocyte myelin glycoprotein (OMG), CC chemokine ligand 20 (CCL20), follicular dendritic cell secreted protein (FDCSP), C-X-C ligand 5 (CXCL5), CXCL6, CXCL8 and interleukin-33 (IL-33).", [["matrix metallopeptidase 3", "GENE_OR_GENE_PRODUCT", 123, 148], ["MMP3", "GENE_OR_GENE_PRODUCT", 150, 154], ["oligodendrocyte myelin glycoprotein", "GENE_OR_GENE_PRODUCT", 157, 192], ["OMG", "GENE_OR_GENE_PRODUCT", 194, 197], ["CC chemokine ligand 20", "GENE_OR_GENE_PRODUCT", 200, 222], ["CCL20", "GENE_OR_GENE_PRODUCT", 224, 229], ["follicular dendritic cell secreted protein", "GENE_OR_GENE_PRODUCT", 232, 274], ["FDCSP", "GENE_OR_GENE_PRODUCT", 276, 281], ["C-X-C ligand 5", "GENE_OR_GENE_PRODUCT", 284, 298], ["CXCL5", "GENE_OR_GENE_PRODUCT", 300, 305], ["CXCL6", "GENE_OR_GENE_PRODUCT", 308, 313], ["CXCL8", "GENE_OR_GENE_PRODUCT", 315, 320], ["interleukin-33", "GENE_OR_GENE_PRODUCT", 325, 339], ["IL-33", "GENE_OR_GENE_PRODUCT", 341, 346], ["matrix metallopeptidase 3", "PROTEIN", 123, 148], ["MMP3", "PROTEIN", 150, 154], ["oligodendrocyte myelin glycoprotein", "PROTEIN", 157, 192], ["OMG", "PROTEIN", 194, 197], ["CC chemokine ligand 20", "PROTEIN", 200, 222], ["CCL20", "PROTEIN", 224, 229], ["follicular dendritic cell secreted protein", "PROTEIN", 232, 274], ["FDCSP", "PROTEIN", 276, 281], ["C-X-C ligand 5", "PROTEIN", 284, 298], ["CXCL5", "PROTEIN", 300, 305], ["CXCL6", "PROTEIN", 308, 313], ["CXCL8", "PROTEIN", 315, 320], ["interleukin-33", "PROTEIN", 325, 339], ["IL", "PROTEIN", 341, 343], ["our convergent analysis", "TEST", 15, 38], ["matrix metallopeptidase", "TEST", 123, 146], ["MMP3", "TEST", 150, 154], ["oligodendrocyte myelin glycoprotein", "TEST", 157, 192], ["CC chemokine ligand", "TEST", 200, 219], ["CCL20", "TEST", 224, 229], ["follicular dendritic cell secreted protein", "TEST", 232, 274], ["FDCSP", "TEST", 276, 281], ["C", "TEST", 284, 285], ["CXCL5", "TEST", 300, 305], ["CXCL6", "TEST", 308, 313], ["CXCL8", "TEST", 315, 320], ["interleukin", "TEST", 325, 336], ["IL", "TEST", 341, 343], ["follicular", "ANATOMY", 232, 242], ["dendritic cell", "OBSERVATION", 243, 257]]], ["The differential gene expression patterns showed similar profiles in human lung cells infected by either MERS-CoV or SARS-CoV-2 (Fig. 2B).", [["lung cells", "ANATOMY", 75, 85], ["human", "ORGANISM", 69, 74], ["lung cells", "CELL", 75, 85], ["MERS-CoV", "ORGANISM", 105, 113], ["SARS-CoV-2", "ORGANISM", 117, 127], ["Fig. 2B", "ORGANISM", 129, 136], ["human lung cells", "CELL_TYPE", 69, 85], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 69, 74], ["MERS-CoV", "SPECIES", 105, 113], ["SARS-CoV", "SPECIES", 117, 125], ["The differential gene expression patterns", "TEST", 0, 41], ["similar profiles in human lung cells", "PROBLEM", 49, 85], ["SARS", "PROBLEM", 117, 121], ["CoV", "TEST", 122, 125], ["lung", "ANATOMY", 75, 79]]], ["Most of the proteins encoded by these genes belong to distinct families and consequently have distinct functions, such as the proteolytic breakdown of extracellular matrix proteins (MMP3) [10], the maintenance of the structural integrity of the myelin sheath (OMG) [11], the direction of protein transport (FDCSP) [13], the chemoattraction of lymphocytes and neutrophils (CCL20, CXCL5, CXCL6 and CXCL8) [12, 14\u201316], or regulation of immune responses (IL-33) [17].Global gene expression in primary human pulmonary epithelial cells ::: ResultsTo better understand the gene expression differences in primary human pulmonary epithelial cells infected by MERS-CoV or SARS-CoV-2, we further limited our analysis and looked at genes related to cell damage, antiviral defense, immunity (senso lato), and inflammation (Table 1, Fig. 2 and Supplementary Figs.", [["extracellular matrix", "ANATOMY", 151, 171], ["myelin sheath", "ANATOMY", 245, 258], ["lymphocytes", "ANATOMY", 343, 354], ["neutrophils", "ANATOMY", 359, 370], ["pulmonary epithelial cells", "ANATOMY", 503, 529], ["pulmonary epithelial cells", "ANATOMY", 611, 637], ["cell", "ANATOMY", 737, 741], ["inflammation", "DISEASE", 796, 808], ["extracellular matrix proteins", "GENE_OR_GENE_PRODUCT", 151, 180], ["MMP3", "GENE_OR_GENE_PRODUCT", 182, 186], ["myelin sheath", "CELLULAR_COMPONENT", 245, 258], ["lymphocytes", "CELL", 343, 354], ["neutrophils", "CELL", 359, 370], ["CCL20", "GENE_OR_GENE_PRODUCT", 372, 377], ["CXCL5", "GENE_OR_GENE_PRODUCT", 379, 384], ["CXCL6", "GENE_OR_GENE_PRODUCT", 386, 391], ["CXCL8", "GENE_OR_GENE_PRODUCT", 396, 401], ["14\u201316", "GENE_OR_GENE_PRODUCT", 408, 413], ["IL-33", "GENE_OR_GENE_PRODUCT", 451, 456], ["human", "ORGANISM", 497, 502], ["pulmonary epithelial cells", "CELL", 503, 529], ["human", "ORGANISM", 605, 610], ["pulmonary epithelial cells", "CELL", 611, 637], ["MERS-CoV", "ORGANISM", 650, 658], ["SARS-CoV-2", "ORGANISM", 662, 672], ["cell", "CELL", 737, 741], ["extracellular matrix proteins", "PROTEIN", 151, 180], ["MMP3", "PROTEIN", 182, 186], ["lymphocytes", "CELL_TYPE", 343, 354], ["neutrophils", "CELL_TYPE", 359, 370], ["CCL20", "PROTEIN", 372, 377], ["CXCL5", "PROTEIN", 379, 384], ["CXCL6", "PROTEIN", 386, 391], ["CXCL8", "PROTEIN", 396, 401], ["primary human pulmonary epithelial cells", "CELL_TYPE", 489, 529], ["primary human pulmonary epithelial cells", "CELL_TYPE", 597, 637], ["human", "SPECIES", 497, 502], ["human", "SPECIES", 605, 610], ["human", "SPECIES", 497, 502], ["human", "SPECIES", 605, 610], ["MERS-CoV", "SPECIES", 650, 658], ["SARS-CoV", "SPECIES", 662, 670], ["the proteolytic breakdown of extracellular matrix proteins", "PROBLEM", 122, 180], ["protein transport", "TEST", 288, 305], ["lymphocytes", "TEST", 343, 354], ["neutrophils", "TEST", 359, 370], ["CCL20", "TEST", 372, 377], ["CXCL5", "TEST", 379, 384], ["CXCL6", "TEST", 386, 391], ["CXCL8", "TEST", 396, 401], ["immune responses", "TEST", 433, 449], ["IL", "TEST", 451, 453], ["Global gene expression", "PROBLEM", 463, 485], ["primary human pulmonary epithelial cells", "PROBLEM", 597, 637], ["SARS", "PROBLEM", 662, 666], ["CoV", "TEST", 667, 670], ["our analysis", "TEST", 693, 705], ["cell damage", "PROBLEM", 737, 748], ["antiviral defense", "TREATMENT", 750, 767], ["immunity (senso lato", "TREATMENT", 769, 789], ["inflammation", "PROBLEM", 796, 808], ["myelin", "ANATOMY", 245, 251], ["sheath", "ANATOMY_MODIFIER", 252, 258], ["lymphocytes", "ANATOMY", 343, 354], ["neutrophils", "ANATOMY", 359, 370], ["gene expression", "OBSERVATION", 470, 485], ["pulmonary", "ANATOMY", 503, 512], ["epithelial cells", "OBSERVATION", 513, 529], ["pulmonary", "ANATOMY", 611, 620], ["epithelial cells", "OBSERVATION", 621, 637], ["cell damage", "OBSERVATION", 737, 748]]], ["S1-S4).", [["S1-S4", "GENE_OR_GENE_PRODUCT", 0, 5], ["S1", "PROTEIN", 0, 2], ["S4", "ANATOMY", 3, 5]]], ["Out of 4443 genes, 24 and 16 were differentially expressed in cells infected with MERS-CoV and SARS-CoV-2, respectively (\u02c3 2-fold increase compared to uninfected cells) (Fig. 3).Global gene expression in primary human pulmonary epithelial cells ::: ResultsConcerning antiviral-defense-related genes, only six were identified as differentially expressed, out of a total of 596.", [["cells", "ANATOMY", 62, 67], ["cells", "ANATOMY", 162, 167], ["pulmonary epithelial cells", "ANATOMY", 218, 244], ["cells", "CELL", 62, 67], ["MERS-CoV", "ORGANISM", 82, 90], ["SARS-CoV-2", "ORGANISM", 95, 105], ["cells", "CELL", 162, 167], ["human", "ORGANISM", 212, 217], ["pulmonary epithelial cells", "CELL", 218, 244], ["uninfected cells", "CELL_TYPE", 151, 167], ["primary human pulmonary epithelial cells", "CELL_TYPE", 204, 244], ["human", "SPECIES", 212, 217], ["MERS-CoV", "SPECIES", 82, 90], ["SARS-CoV", "SPECIES", 95, 103], ["human", "SPECIES", 212, 217], ["MERS", "TEST", 82, 86], ["CoV", "TEST", 87, 90], ["SARS", "TEST", 95, 99], ["CoV", "TEST", 100, 103], ["fold increase", "PROBLEM", 125, 138], ["Global gene expression", "PROBLEM", 178, 200], ["gene expression", "OBSERVATION", 185, 200], ["pulmonary", "ANATOMY", 218, 227], ["epithelial cells", "OBSERVATION", 228, 244]]], ["Of these, TNFAIP3 and guanylate-binding protein 4 (GBP4) showed the highest variation in their expression level, in cells infected with MERS-CoV (4.50-fold) and SARS-CoV-2 (4.14-fold) (Supplementary Fig. S1).", [["cells", "ANATOMY", 116, 121], ["guanylate", "CHEMICAL", 22, 31], ["TNFAIP3", "GENE_OR_GENE_PRODUCT", 10, 17], ["guanylate-binding protein 4", "GENE_OR_GENE_PRODUCT", 22, 49], ["GBP4", "GENE_OR_GENE_PRODUCT", 51, 55], ["cells", "CELL", 116, 121], ["MERS-CoV", "ORGANISM", 136, 144], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 161, 171], ["S1", "GENE_OR_GENE_PRODUCT", 204, 206], ["TNFAIP3", "PROTEIN", 10, 17], ["guanylate-binding protein 4", "PROTEIN", 22, 49], ["GBP4", "PROTEIN", 51, 55], ["S1", "PROTEIN", 204, 206], ["MERS-CoV", "SPECIES", 136, 144], ["SARS-CoV", "SPECIES", 161, 169], ["TNFAIP3", "TEST", 10, 17], ["guanylate-binding protein", "TEST", 22, 47], ["GBP4", "TEST", 51, 55], ["the highest variation in their expression level", "PROBLEM", 64, 111], ["MERS", "TEST", 136, 140], ["CoV", "TEST", 141, 144], ["SARS", "TEST", 161, 165], ["CoV", "TEST", 166, 169], ["highest variation", "OBSERVATION", 68, 85]]], ["Importantly, GBP4 is known to be directly involved in protective immunity against viruses [18, 19].Global gene expression in primary human pulmonary epithelial cells ::: ResultsWith respect to cell-damage-related genes, out of a total of 1115, nine and five were found to be differentially expressed in human lung cells infected with MERS-CoV and SARS-CoV-2, respectively compared to uninfected cells.", [["pulmonary epithelial cells", "ANATOMY", 139, 165], ["cell", "ANATOMY", 193, 197], ["lung cells", "ANATOMY", 309, 319], ["cells", "ANATOMY", 395, 400], ["GBP4", "GENE_OR_GENE_PRODUCT", 13, 17], ["human", "ORGANISM", 133, 138], ["pulmonary epithelial cells", "CELL", 139, 165], ["cell", "CELL", 193, 197], ["human", "ORGANISM", 303, 308], ["lung cells", "CELL", 309, 319], ["MERS-CoV", "ORGANISM", 334, 342], ["SARS-CoV-2", "ORGANISM", 347, 357], ["cells", "CELL", 395, 400], ["GBP4", "PROTEIN", 13, 17], ["primary human pulmonary epithelial cells", "CELL_TYPE", 125, 165], ["human lung cells", "CELL_TYPE", 303, 319], ["uninfected cells", "CELL_TYPE", 384, 400], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 303, 308], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 303, 308], ["MERS-CoV", "SPECIES", 334, 342], ["SARS-CoV", "SPECIES", 347, 355], ["Global gene expression", "PROBLEM", 99, 121], ["human lung cells", "PROBLEM", 303, 319], ["MERS", "TEST", 334, 338], ["SARS", "TEST", 347, 351], ["CoV", "TEST", 352, 355], ["gene expression", "OBSERVATION", 106, 121], ["pulmonary", "ANATOMY", 139, 148], ["epithelial cells", "OBSERVATION", 149, 165], ["lung", "ANATOMY", 309, 313], ["uninfected cells", "OBSERVATION", 384, 400]]], ["Of these, tumor necrosis factor \u03b1-induced protein 3 (TNFAIP3) and prostaglandin-endoperoxide synthase 2 (PTGS2) were the ones with the highest variation in their expression level, in cells infected with MERS-CoV (4.50-fold) and SARS-CoV-2 (3.23-fold) (Supplementary Fig. S2).", [["cells", "ANATOMY", 183, 188], ["tumor", "DISEASE", 10, 15], ["necrosis", "DISEASE", 16, 24], ["prostaglandin-endoperoxide", "CHEMICAL", 66, 92], ["prostaglandin-endoperoxide", "CHEMICAL", 66, 92], ["tumor necrosis factor \u03b1-induced protein 3", "GENE_OR_GENE_PRODUCT", 10, 51], ["TNFAIP3", "GENE_OR_GENE_PRODUCT", 53, 60], ["prostaglandin-endoperoxide synthase 2", "GENE_OR_GENE_PRODUCT", 66, 103], ["PTGS2", "GENE_OR_GENE_PRODUCT", 105, 110], ["cells", "CELL", 183, 188], ["MERS-CoV", "ORGANISM", 203, 211], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 228, 238], ["tumor necrosis factor \u03b1-induced protein 3", "PROTEIN", 10, 51], ["TNFAIP3", "PROTEIN", 53, 60], ["prostaglandin-endoperoxide synthase 2", "PROTEIN", 66, 103], ["PTGS2", "PROTEIN", 105, 110], ["S2", "PROTEIN", 271, 273], ["MERS-CoV", "SPECIES", 203, 211], ["SARS-CoV", "SPECIES", 228, 236], ["tumor necrosis factor \u03b1-induced protein", "TEST", 10, 49], ["TNFAIP3", "TEST", 53, 60], ["prostaglandin-endoperoxide synthase", "TEST", 66, 101], ["PTGS2", "TEST", 105, 110], ["MERS", "TEST", 203, 207], ["CoV", "TEST", 208, 211], ["SARS", "TEST", 228, 232], ["CoV", "TEST", 233, 236], ["tumor", "OBSERVATION_MODIFIER", 10, 15], ["necrosis", "OBSERVATION", 16, 24]]], ["While TNFAIP3 is known to inhibit NF-\u03baB activation and TNF-mediated apoptosis, PTGS2 is involved in the conversion of arachidonic acid to prostaglandin H2 [20].Global gene expression in primary human pulmonary epithelial cells ::: ResultsAdditionally, looking at immune responses as a whole (Supplementary Fig. S3), out of a total of 2044 genes involved in immunity, 20 and 10 genes were found to be differentially expressed in human lung cells infected with MERS-CoV and SARS-CoV-2, respectively compared to uninfected cells.", [["pulmonary epithelial cells", "ANATOMY", 200, 226], ["lung cells", "ANATOMY", 434, 444], ["cells", "ANATOMY", 520, 525], ["arachidonic acid", "CHEMICAL", 118, 134], ["prostaglandin H2", "CHEMICAL", 138, 154], ["arachidonic acid", "CHEMICAL", 118, 134], ["prostaglandin H2 [20]", "CHEMICAL", 138, 159], ["TNFAIP3", "GENE_OR_GENE_PRODUCT", 6, 13], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 34, 39], ["TNF", "GENE_OR_GENE_PRODUCT", 55, 58], ["PTGS2", "GENE_OR_GENE_PRODUCT", 79, 84], ["arachidonic acid", "SIMPLE_CHEMICAL", 118, 134], ["prostaglandin H2", "SIMPLE_CHEMICAL", 138, 154], ["human", "ORGANISM", 194, 199], ["pulmonary epithelial cells", "CELL", 200, 226], ["human", "ORGANISM", 428, 433], ["lung cells", "CELL", 434, 444], ["MERS-CoV", "ORGANISM", 459, 467], ["SARS-CoV-2", "ORGANISM", 472, 482], ["cells", "CELL", 520, 525], ["TNFAIP3", "PROTEIN", 6, 13], ["NF-\u03baB", "PROTEIN", 34, 39], ["TNF", "PROTEIN", 55, 58], ["PTGS2", "PROTEIN", 79, 84], ["primary human pulmonary epithelial cells", "CELL_TYPE", 186, 226], ["human lung cells", "CELL_TYPE", 428, 444], ["uninfected cells", "CELL_TYPE", 509, 525], ["human", "SPECIES", 194, 199], ["human", "SPECIES", 428, 433], ["human", "SPECIES", 194, 199], ["human", "SPECIES", 428, 433], ["MERS-CoV", "SPECIES", 459, 467], ["SARS-CoV", "SPECIES", 472, 480], ["NF", "PROBLEM", 34, 36], ["TNF", "PROBLEM", 55, 58], ["apoptosis", "PROBLEM", 68, 77], ["arachidonic acid to prostaglandin H2", "TREATMENT", 118, 154], ["Global gene expression", "PROBLEM", 160, 182], ["human lung cells", "PROBLEM", 428, 444], ["SARS", "TEST", 472, 476], ["CoV", "TEST", 477, 480], ["gene expression", "OBSERVATION", 167, 182], ["pulmonary", "ANATOMY", 200, 209], ["epithelial cells", "OBSERVATION", 210, 226], ["lung", "ANATOMY", 434, 438], ["uninfected cells", "OBSERVATION", 509, 525]]], ["CXCL1 and CXCL6 showed the highest variation in their expression level, in each of these contexts (4.69-fold and 8.63-fold, respectively).", [["CXCL1", "GENE_OR_GENE_PRODUCT", 0, 5], ["CXCL6", "GENE_OR_GENE_PRODUCT", 10, 15], ["CXCL1", "PROTEIN", 0, 5], ["CXCL6", "PROTEIN", 10, 15], ["CXCL1", "TEST", 0, 5], ["CXCL6", "TEST", 10, 15], ["the highest variation", "PROBLEM", 23, 44], ["highest", "OBSERVATION_MODIFIER", 27, 34], ["variation", "OBSERVATION_MODIFIER", 35, 44], ["expression level", "OBSERVATION", 54, 70]]], ["Both CXCL1 and CXCL6 are known to be important chemotactic factors affecting the migration of neutrophils and granulocytes [21, 22].Global gene expression in primary human pulmonary epithelial cells ::: ResultsOut of 688 genes involved in inflammatory responses (Supplementary Fig. S4), 12 and 11 genes were differentially expressed in human lung cells infected with MERS-CoV and SARS-CoV-2, respectively, compared to the basal conditions.", [["neutrophils", "ANATOMY", 94, 105], ["granulocytes", "ANATOMY", 110, 122], ["pulmonary epithelial cells", "ANATOMY", 172, 198], ["lung cells", "ANATOMY", 342, 352], ["CXCL1", "GENE_OR_GENE_PRODUCT", 5, 10], ["CXCL6", "GENE_OR_GENE_PRODUCT", 15, 20], ["neutrophils", "CELL", 94, 105], ["granulocytes", "CELL", 110, 122], ["human", "ORGANISM", 166, 171], ["pulmonary epithelial cells", "CELL", 172, 198], ["S4", "GENE_OR_GENE_PRODUCT", 282, 284], ["human", "ORGANISM", 336, 341], ["lung cells", "CELL", 342, 352], ["MERS-CoV", "ORGANISM", 367, 375], ["SARS-CoV-2", "ORGANISM", 380, 390], ["CXCL1", "PROTEIN", 5, 10], ["CXCL6", "PROTEIN", 15, 20], ["chemotactic factors", "PROTEIN", 47, 66], ["neutrophils", "CELL_TYPE", 94, 105], ["granulocytes", "CELL_TYPE", 110, 122], ["primary human pulmonary epithelial cells", "CELL_TYPE", 158, 198], ["human lung cells", "CELL_TYPE", 336, 352], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 336, 341], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 336, 341], ["MERS-CoV", "SPECIES", 367, 375], ["SARS-CoV", "SPECIES", 380, 388], ["Both CXCL1 and CXCL6", "TEST", 0, 20], ["chemotactic factors", "PROBLEM", 47, 66], ["neutrophils", "TEST", 94, 105], ["granulocytes", "TEST", 110, 122], ["Global gene expression", "PROBLEM", 132, 154], ["inflammatory responses", "PROBLEM", 239, 261], ["human lung cells", "PROBLEM", 336, 352], ["MERS", "PROBLEM", 367, 371], ["SARS", "PROBLEM", 380, 384], ["CoV", "TEST", 385, 388], ["CXCL1", "OBSERVATION", 5, 10], ["known to be", "UNCERTAINTY", 25, 36], ["migration", "OBSERVATION_MODIFIER", 81, 90], ["gene expression", "OBSERVATION", 139, 154], ["pulmonary", "ANATOMY", 172, 181], ["epithelial cells", "OBSERVATION", 182, 198], ["inflammatory", "OBSERVATION_MODIFIER", 239, 251], ["lung", "ANATOMY", 342, 346]]], ["Because inflammation and immunity are known to overlap, CXCL6 appeared again as the gene with the highest variation in its expression level, in both MERS-CoV- and SARS-CoV-2-infected cells (8.63-fold and 6.50 fold, respectively).DiscussionHighly pathogenic coronaviruses such as MERS-CoV, SARS-CoV, and the newly identified SARS-CoV-2 have the potential to cause severe pneumonia in humans.", [["cells", "ANATOMY", 183, 188], ["inflammation", "DISEASE", 8, 20], ["pneumonia", "DISEASE", 370, 379], ["CXCL6", "GENE_OR_GENE_PRODUCT", 56, 61], ["MERS-CoV", "ORGANISM", 149, 157], ["SARS-CoV-2", "ORGANISM", 163, 173], ["cells", "CELL", 183, 188], ["coronaviruses", "ORGANISM", 257, 270], ["MERS-CoV", "ORGANISM", 279, 287], ["SARS-CoV", "ORGANISM", 289, 297], ["SARS-CoV-2", "ORGANISM", 324, 334], ["humans", "ORGANISM", 383, 389], ["CXCL6", "PROTEIN", 56, 61], ["infected cells", "CELL_TYPE", 174, 188], ["humans", "SPECIES", 383, 389], ["MERS-CoV", "SPECIES", 149, 157], ["SARS-CoV", "SPECIES", 163, 171], ["MERS-CoV", "SPECIES", 279, 287], ["SARS-CoV", "SPECIES", 289, 297], ["SARS-CoV", "SPECIES", 324, 332], ["humans", "SPECIES", 383, 389], ["inflammation", "PROBLEM", 8, 20], ["CXCL6", "TEST", 56, 61], ["CoV", "TEST", 154, 157], ["SARS", "TEST", 163, 167], ["CoV", "TEST", 168, 171], ["infected cells", "PROBLEM", 174, 188], ["pathogenic coronaviruses", "PROBLEM", 246, 270], ["CoV", "PROBLEM", 284, 287], ["SARS", "PROBLEM", 289, 293], ["CoV", "PROBLEM", 294, 297], ["severe pneumonia in humans", "PROBLEM", 363, 389], ["inflammation", "OBSERVATION", 8, 20], ["highest variation", "OBSERVATION", 98, 115], ["coronaviruses", "OBSERVATION", 257, 270], ["severe", "OBSERVATION_MODIFIER", 363, 369], ["pneumonia", "OBSERVATION", 370, 379]]], ["In this study, we used a microarray assay to analyze the global gene expression of human pulmonary epithelial cells infected with MERS-CoV or SARS-CoV-2 to investigate the impact of coronavirus infection on lung cells and, consequently, on the respiratory system as a whole.DiscussionInterestingly, we found that, out of the 44,566 human genes analyzed, more were differentially expressed in cells infected with MERS-CoV than in cells infected with SARS-CoV-2 (127 vs. 50 genes).", [["pulmonary epithelial cells", "ANATOMY", 89, 115], ["lung cells", "ANATOMY", 207, 217], ["respiratory system", "ANATOMY", 244, 262], ["cells", "ANATOMY", 392, 397], ["cells", "ANATOMY", 429, 434], ["coronavirus infection", "DISEASE", 182, 203], ["human", "ORGANISM", 83, 88], ["pulmonary epithelial cells", "CELL", 89, 115], ["MERS-CoV", "ORGANISM", 130, 138], ["SARS-CoV-2", "ORGANISM", 142, 152], ["coronavirus", "ORGANISM", 182, 193], ["lung cells", "CELL", 207, 217], ["human", "ORGANISM", 332, 337], ["cells", "CELL", 392, 397], ["MERS-CoV", "ORGANISM", 412, 420], ["cells", "CELL", 429, 434], ["SARS-CoV-2", "ORGANISM", 449, 459], ["human pulmonary epithelial cells", "CELL_TYPE", 83, 115], ["lung cells", "CELL_TYPE", 207, 217], ["44,566 human genes", "DNA", 325, 343], ["SARS-CoV-2", "DNA", 449, 459], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 332, 337], ["human", "SPECIES", 83, 88], ["MERS-CoV", "SPECIES", 130, 138], ["SARS-CoV", "SPECIES", 142, 150], ["coronavirus", "SPECIES", 182, 193], ["human", "SPECIES", 332, 337], ["MERS-CoV", "SPECIES", 412, 420], ["SARS-CoV-2", "SPECIES", 449, 459], ["this study", "TEST", 3, 13], ["a microarray assay", "TEST", 23, 41], ["human pulmonary epithelial cells", "PROBLEM", 83, 115], ["SARS", "PROBLEM", 142, 146], ["CoV", "TEST", 147, 150], ["coronavirus infection on lung cells", "PROBLEM", 182, 217], ["SARS", "PROBLEM", 449, 453], ["CoV", "TEST", 454, 457], ["pulmonary", "ANATOMY", 89, 98], ["epithelial cells", "OBSERVATION", 99, 115], ["coronavirus", "OBSERVATION_MODIFIER", 182, 193], ["infection", "OBSERVATION", 194, 203], ["lung", "ANATOMY", 207, 211]]], ["These results may be related to the observation that MERS-CoV infections tend to be more severe than those caused by the new SARS-CoV-2.", [["infections", "DISEASE", 62, 72], ["MERS-CoV", "ORGANISM", 53, 61], ["SARS-CoV-2", "ORGANISM", 125, 135], ["MERS-CoV", "SPECIES", 53, 61], ["SARS-CoV", "SPECIES", 125, 133], ["CoV infections", "PROBLEM", 58, 72], ["the new SARS", "PROBLEM", 117, 129], ["may be related to", "UNCERTAINTY", 14, 31], ["new", "OBSERVATION_MODIFIER", 121, 124], ["SARS", "OBSERVATION", 125, 129]]], ["Based on the currently available data, the mortality rates for MERS-CoV and SARS-CoV-2 infections are approximately 36%, and less than 10%, respectively.DiscussionHowever, when we limited the analysis to inflammatory-response-related genes, the number of differentially expressed genes was similar in in vitro MERS-CoV and SARS-CoV-2 infections (12 and 11 genes, respectively).", [["SARS", "DISEASE", 76, 80], ["infections", "DISEASE", 87, 97], ["infections", "DISEASE", 334, 344], ["MERS-CoV", "ORGANISM", 63, 71], ["SARS-CoV-2", "ORGANISM", 76, 86], ["MERS-CoV", "ORGANISM", 310, 318], ["SARS-CoV-2", "ORGANISM", 323, 333], ["CoV-", "SPECIES", 81, 85], ["MERS-CoV", "SPECIES", 63, 71], ["SARS-CoV", "SPECIES", 76, 84], ["MERS-CoV", "SPECIES", 310, 318], ["SARS-CoV", "SPECIES", 323, 331], ["the mortality rates", "TEST", 39, 58], ["MERS", "TEST", 63, 67], ["CoV", "TEST", 68, 71], ["SARS", "TEST", 76, 80], ["CoV", "TEST", 81, 84], ["2 infections", "PROBLEM", 85, 97], ["inflammatory-response", "PROBLEM", 204, 225], ["CoV", "PROBLEM", 315, 318], ["SARS", "PROBLEM", 323, 327], ["CoV", "PROBLEM", 328, 331], ["2 infections", "PROBLEM", 332, 344]]], ["This may suggest that both infections lead to similar local inflammatory responses, which is not unexpected, considering that the two viruses are closely related and that inflammation is dependent on innate (nonspecific) immunity.", [["infections", "DISEASE", 27, 37], ["inflammation", "DISEASE", 171, 183], ["both infections", "PROBLEM", 22, 37], ["similar local inflammatory responses", "PROBLEM", 46, 82], ["the two viruses", "PROBLEM", 126, 141], ["inflammation", "PROBLEM", 171, 183], ["innate (nonspecific) immunity", "TREATMENT", 200, 229], ["may suggest", "UNCERTAINTY", 5, 16], ["both", "OBSERVATION_MODIFIER", 22, 26], ["infections", "OBSERVATION", 27, 37], ["similar", "OBSERVATION_MODIFIER", 46, 53], ["local", "OBSERVATION_MODIFIER", 54, 59], ["inflammatory", "OBSERVATION", 60, 72], ["not unexpected", "UNCERTAINTY", 93, 107], ["viruses", "OBSERVATION", 134, 141], ["inflammation", "OBSERVATION", 171, 183]]], ["On the other hand, when we looked at immune-response-related genes, the cells infected with MERS-CoV had twice as many differentially expressed genes as the cells infected with SARS-CoV-2 (20 vs. 10).", [["cells", "ANATOMY", 72, 77], ["cells", "ANATOMY", 157, 162], ["SARS", "DISEASE", 177, 181], ["cells", "CELL", 72, 77], ["MERS-CoV", "ORGANISM", 92, 100], ["cells", "CELL", 157, 162], ["SARS-CoV-2", "ORGANISM", 177, 187], ["MERS-CoV", "DNA", 92, 100], ["MERS-CoV", "SPECIES", 92, 100], ["SARS-CoV-2", "SPECIES", 177, 187], ["the cells", "PROBLEM", 68, 77], ["SARS", "TEST", 177, 181], ["CoV", "TEST", 182, 185]]], ["These results suggest that the two infections lead to different immune responses, which are in line with previously published data.", [["infections", "DISEASE", 35, 45], ["the two infections", "PROBLEM", 27, 45], ["infections", "OBSERVATION", 35, 45]]], ["A recent study revealed that immunity-related gene expression patterns in a human lung cancer cell line (Calu-3) infected with MERS-CoV or SARS-CoV were different [23].", [["lung cancer cell line", "ANATOMY", 82, 103], ["Calu-3", "ANATOMY", 105, 111], ["lung cancer", "DISEASE", 82, 93], ["human", "ORGANISM", 76, 81], ["lung cancer cell line", "CELL", 82, 103], ["Calu-3", "CELL", 105, 111], ["MERS-CoV", "ORGANISM", 127, 135], ["SARS-CoV", "ORGANISM", 139, 147], ["human lung cancer cell line", "CELL_LINE", 76, 103], ["Calu-3", "CELL_LINE", 105, 111], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["MERS-CoV", "SPECIES", 127, 135], ["SARS-CoV", "SPECIES", 139, 147], ["A recent study", "TEST", 0, 14], ["gene expression patterns", "PROBLEM", 46, 70], ["a human lung cancer", "PROBLEM", 74, 93], ["Calu", "TEST", 105, 109], ["MERS", "PROBLEM", 127, 131], ["SARS", "PROBLEM", 139, 143], ["lung", "ANATOMY", 82, 86], ["cancer cell line", "OBSERVATION", 87, 103]]], ["While the expression of genes coding for IL-1\u03b2, IL-6 and IL-8 was shown to be significantly upregulated in cells infected with MERS-CoV compared to cells infected with SARS-CoV, the reverse was observed for the expression of genes coding for TNF-\u03b1, IFN-\u03b2 and IP-10 (up to 30 h postinfection) [23].", [["cells", "ANATOMY", 107, 112], ["cells", "ANATOMY", 148, 153], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 41, 46], ["IL-6", "GENE_OR_GENE_PRODUCT", 48, 52], ["IL-8", "GENE_OR_GENE_PRODUCT", 57, 61], ["cells", "CELL", 107, 112], ["MERS-CoV", "ORGANISM", 127, 135], ["cells", "CELL", 148, 153], ["SARS-CoV", "ORGANISM", 168, 176], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 242, 247], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 249, 254], ["IP-10", "GENE_OR_GENE_PRODUCT", 259, 264], ["IL", "PROTEIN", 41, 43], ["IL-6", "PROTEIN", 48, 52], ["IL-8", "PROTEIN", 57, 61], ["TNF", "PROTEIN", 242, 245], ["IFN", "PROTEIN", 249, 252], ["\u03b2", "PROTEIN", 253, 254], ["MERS-CoV", "SPECIES", 127, 135], ["SARS-CoV", "SPECIES", 168, 176], ["IL", "TEST", 41, 43], ["IL", "TEST", 48, 50], ["IL", "TEST", 57, 59], ["MERS", "PROBLEM", 127, 131], ["CoV", "PROBLEM", 132, 135], ["SARS", "PROBLEM", 168, 172], ["TNF", "TEST", 242, 245], ["IFN", "TEST", 249, 252], ["IP", "TEST", 259, 261]]], ["In fact, even in the context of SARS-CoV-2 infection alone, cytokine and chemokine plasma profiles have been shown to differ between patients with different levels of disease severity [24].", [["plasma", "ANATOMY", 83, 89], ["SARS", "DISEASE", 32, 36], ["infection", "DISEASE", 43, 52], ["SARS-CoV-2", "ORGANISM", 32, 42], ["plasma", "ORGANISM_SUBSTANCE", 83, 89], ["patients", "ORGANISM", 133, 141], ["cytokine", "PROTEIN", 60, 68], ["chemokine", "PROTEIN", 73, 82], ["patients", "SPECIES", 133, 141], ["SARS-CoV", "SPECIES", 32, 40], ["SARS", "PROBLEM", 32, 36], ["CoV-2 infection", "PROBLEM", 37, 52], ["cytokine and chemokine plasma profiles", "TEST", 60, 98], ["disease severity", "PROBLEM", 167, 183], ["SARS", "OBSERVATION", 32, 36], ["infection", "OBSERVATION", 43, 52]]], ["While IL-1\u03b2, IL-1RA, IL-8, IL-9, basic FGF, GMCSF, IFN-\u03b3, IP-10, MIP-1\u03b2, PDGF, and VEGF concentrations were comparable between ICU- (intensive care unit) and non-ICU-admitted COVID-19 patients, the concentrations of IL-1, IL-7, IL-10, GCSF, IP-10, MCP1, MIP-1\u03b1, and TNF-\u03b1 levels were higher in ICU-admitted patients than in non-ICU-admitted patients [24].DiscussionWe found that CXCL6, which is a chemoattractant for neutrophilic granulocytes [15, 22], was the most strongly upregulated inflammatory gene in human pulmonary epithelial cells infected with SARS-CoV-2.", [["neutrophilic granulocytes", "ANATOMY", 417, 442], ["pulmonary epithelial cells", "ANATOMY", 514, 540], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 6, 11], ["IL-1RA", "GENE_OR_GENE_PRODUCT", 13, 19], ["IL-8", "GENE_OR_GENE_PRODUCT", 21, 25], ["IL-9", "GENE_OR_GENE_PRODUCT", 27, 31], ["basic", "GENE_OR_GENE_PRODUCT", 33, 38], ["FGF", "GENE_OR_GENE_PRODUCT", 39, 42], ["GMCSF", "GENE_OR_GENE_PRODUCT", 44, 49], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 51, 56], ["IP-10", "GENE_OR_GENE_PRODUCT", 58, 63], ["MIP-1\u03b2", "GENE_OR_GENE_PRODUCT", 65, 71], ["PDGF", "GENE_OR_GENE_PRODUCT", 73, 77], ["VEGF", "GENE_OR_GENE_PRODUCT", 83, 87], ["patients", "ORGANISM", 184, 192], ["IL-1", "GENE_OR_GENE_PRODUCT", 216, 220], ["IL-7", "GENE_OR_GENE_PRODUCT", 222, 226], ["IL-10", "GENE_OR_GENE_PRODUCT", 228, 233], ["GCSF", "GENE_OR_GENE_PRODUCT", 235, 239], ["IP-10", "GENE_OR_GENE_PRODUCT", 241, 246], ["MCP1", "GENE_OR_GENE_PRODUCT", 248, 252], ["MIP-1\u03b1", "GENE_OR_GENE_PRODUCT", 254, 260], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 266, 271], ["patients", "ORGANISM", 307, 315], ["patients", "ORGANISM", 341, 349], ["CXCL6", "GENE_OR_GENE_PRODUCT", 379, 384], ["neutrophilic granulocytes", "CELL", 417, 442], ["human", "ORGANISM", 508, 513], ["pulmonary epithelial cells", "CELL", 514, 540], ["SARS-CoV-2", "ORGANISM", 555, 565], ["IL", "PROTEIN", 6, 8], ["IL-9", "PROTEIN", 27, 31], ["basic FGF", "PROTEIN", 33, 42], ["GMCSF", "PROTEIN", 44, 49], ["IFN", "PROTEIN", 51, 54], ["MIP", "PROTEIN", 65, 68], ["PDGF", "PROTEIN", 73, 77], ["VEGF", "PROTEIN", 83, 87], ["GCSF", "PROTEIN", 235, 239], ["MCP1", "PROTEIN", 248, 252], ["TNF", "PROTEIN", 266, 269], ["CXCL6", "PROTEIN", 379, 384], ["neutrophilic granulocytes", "CELL_TYPE", 417, 442], ["inflammatory gene", "DNA", 487, 504], ["human pulmonary epithelial cells", "CELL_TYPE", 508, 540], ["patients", "SPECIES", 184, 192], ["patients", "SPECIES", 307, 315], ["patients", "SPECIES", 341, 349], ["human", "SPECIES", 508, 513], ["human", "SPECIES", 508, 513], ["SARS-CoV", "SPECIES", 555, 563], ["IL", "TEST", 6, 8], ["IL", "TEST", 13, 15], ["IL", "TEST", 21, 23], ["IL", "TEST", 27, 29], ["basic FGF", "TEST", 33, 42], ["GMCSF", "TEST", 44, 49], ["IFN", "TEST", 51, 54], ["IP", "TEST", 58, 60], ["MIP", "TEST", 65, 68], ["PDGF", "TEST", 73, 77], ["VEGF concentrations", "TEST", 83, 102], ["COVID", "TEST", 175, 180], ["IL", "TEST", 216, 218], ["IL", "TEST", 222, 224], ["IL", "TEST", 228, 230], ["GCSF", "TEST", 235, 239], ["IP", "TEST", 241, 243], ["MCP1", "TEST", 248, 252], ["MIP", "TEST", 254, 257], ["TNF", "TEST", 266, 269], ["neutrophilic granulocytes", "PROBLEM", 417, 442], ["upregulated inflammatory gene in human pulmonary epithelial cells", "PROBLEM", 475, 540], ["most strongly", "OBSERVATION_MODIFIER", 461, 474], ["upregulated", "OBSERVATION_MODIFIER", 475, 486], ["inflammatory gene", "OBSERVATION", 487, 504], ["human", "ANATOMY_MODIFIER", 508, 513], ["pulmonary", "ANATOMY", 514, 523], ["epithelial cells", "OBSERVATION", 524, 540]]], ["CXCL6 may be involved in the development of severe pneumonia in humans infected with SARS-CoV-2 by recruiting inflammatory leukocytes into human lungs.DiscussionWe used the primary human pulmonary epithelial cells to investigate changes in gene expression when SARS-CoV-2 infects lung cells.", [["inflammatory leukocytes", "ANATOMY", 110, 133], ["lungs", "ANATOMY", 145, 150], ["pulmonary epithelial cells", "ANATOMY", 187, 213], ["lung cells", "ANATOMY", 280, 290], ["pneumonia", "DISEASE", 51, 60], ["SARS", "DISEASE", 85, 89], ["CXCL6", "GENE_OR_GENE_PRODUCT", 0, 5], ["humans", "ORGANISM", 64, 70], ["SARS-CoV-2", "ORGANISM", 85, 95], ["inflammatory leukocytes", "CELL", 110, 133], ["human", "ORGANISM", 139, 144], ["lungs", "ORGAN", 145, 150], ["human", "ORGANISM", 181, 186], ["pulmonary epithelial cells", "CELL", 187, 213], ["SARS-CoV-2", "ORGANISM", 261, 271], ["lung cells", "CELL", 280, 290], ["CXCL6", "PROTEIN", 0, 5], ["inflammatory leukocytes", "CELL_TYPE", 110, 133], ["primary human pulmonary epithelial cells", "CELL_TYPE", 173, 213], ["lung cells", "CELL_TYPE", 280, 290], ["humans", "SPECIES", 64, 70], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 181, 186], ["humans", "SPECIES", 64, 70], ["SARS-CoV", "SPECIES", 85, 93], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 181, 186], ["SARS-CoV", "SPECIES", 261, 269], ["severe pneumonia in humans", "PROBLEM", 44, 70], ["SARS", "PROBLEM", 85, 89], ["CoV", "TEST", 90, 93], ["recruiting inflammatory leukocytes into human lungs", "PROBLEM", 99, 150], ["the primary human pulmonary epithelial cells", "TREATMENT", 169, 213], ["SARS", "PROBLEM", 261, 265], ["CoV-2 infects lung cells", "PROBLEM", 266, 290], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["pneumonia", "OBSERVATION", 51, 60], ["infected", "OBSERVATION_MODIFIER", 71, 79], ["inflammatory leukocytes", "OBSERVATION", 110, 133], ["human", "ANATOMY_MODIFIER", 139, 144], ["lungs", "ANATOMY", 145, 150], ["pulmonary", "ANATOMY", 187, 196], ["epithelial cells", "OBSERVATION", 197, 213], ["lung", "ANATOMY", 280, 284], ["cells", "OBSERVATION", 285, 290]]], ["Considering that SARS-CoV-2 infects human lungs, our model might reflect some of the changes that occur in lung cells of humans infected with SARS-CoV-2.", [["lungs", "ANATOMY", 42, 47], ["lung cells", "ANATOMY", 107, 117], ["SARS", "DISEASE", 17, 21], ["SARS", "DISEASE", 142, 146], ["SARS-CoV-2", "ORGANISM", 17, 27], ["human", "ORGANISM", 36, 41], ["lungs", "ORGAN", 42, 47], ["lung cells", "CELL", 107, 117], ["humans", "ORGANISM", 121, 127], ["SARS-CoV-2", "ORGANISM", 142, 152], ["lung cells", "CELL_TYPE", 107, 117], ["human", "SPECIES", 36, 41], ["humans", "SPECIES", 121, 127], ["SARS-CoV", "SPECIES", 17, 25], ["human", "SPECIES", 36, 41], ["humans", "SPECIES", 121, 127], ["SARS-CoV", "SPECIES", 142, 150], ["SARS", "PROBLEM", 17, 21], ["CoV-2 infects human lungs", "PROBLEM", 22, 47], ["SARS", "OBSERVATION", 17, 21], ["lungs", "ANATOMY", 42, 47], ["lung", "ANATOMY", 107, 111], ["infected", "OBSERVATION_MODIFIER", 128, 136]]], ["However, further in vivo study is needed to confirm our data, using human ACE (angiotensin converting enzyme)-2 transgenic mice infected with SARS-CoV-2.DiscussionIn this study, we used the laboratory MERS-CoV strain EMC2012 because we did not have a recent MERS-CoV isolate.", [["angiotensin", "CHEMICAL", 79, 90], ["human", "ORGANISM", 68, 73], ["ACE (angiotensin converting enzyme)-2", "GENE_OR_GENE_PRODUCT", 74, 111], ["mice", "ORGANISM", 123, 127], ["SARS-CoV-2", "ORGANISM", 142, 152], ["MERS-CoV", "ORGANISM", 201, 209], ["MERS-CoV", "ORGANISM", 258, 266], ["angiotensin converting enzyme", "PROTEIN", 79, 108], ["human", "SPECIES", 68, 73], ["mice", "SPECIES", 123, 127], ["human", "SPECIES", 68, 73], ["mice", "SPECIES", 123, 127], ["SARS-CoV", "SPECIES", 142, 150], ["MERS-CoV", "SPECIES", 201, 209], ["MERS-CoV", "SPECIES", 258, 266], ["vivo study", "TEST", 20, 30], ["human ACE (angiotensin converting enzyme)", "TREATMENT", 68, 109], ["this study", "TEST", 166, 176], ["CoV isolate", "TREATMENT", 263, 274]]], ["Further study may be needed to investigate gene modulation in lung cells using a more recent MERS-CoV strain.DiscussionIn conclusion, the greater number of differentially expressed genes in primary pulmonary epithelial cells infected with MERS-CoV than in those infected with SARS-CoV-2 may explain the why MERS-CoV infections more frequently lead to worse outcomes than SARS-CoV-2 infections.", [["lung cells", "ANATOMY", 62, 72], ["primary pulmonary epithelial cells", "ANATOMY", 190, 224], ["SARS", "DISEASE", 276, 280], ["infections", "DISEASE", 316, 326], ["SARS-CoV-2 infections", "DISEASE", 371, 392], ["lung cells", "CELL", 62, 72], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 93, 101], ["pulmonary epithelial cells", "CELL", 198, 224], ["MERS-CoV", "ORGANISM", 239, 247], ["SARS-CoV-2", "ORGANISM", 276, 286], ["MERS-CoV", "ORGANISM", 307, 315], ["SARS-CoV-2", "ORGANISM", 371, 381], ["lung cells", "CELL_TYPE", 62, 72], ["primary pulmonary epithelial cells", "CELL_TYPE", 190, 224], ["MERS-CoV", "SPECIES", 93, 101], ["MERS-CoV", "SPECIES", 239, 247], ["SARS-CoV", "SPECIES", 276, 284], ["MERS-CoV", "SPECIES", 307, 315], ["SARS-CoV-2", "SPECIES", 371, 381], ["Further study", "TEST", 0, 13], ["gene modulation in lung cells", "PROBLEM", 43, 72], ["CoV strain", "PROBLEM", 98, 108], ["primary pulmonary epithelial cells", "PROBLEM", 190, 224], ["SARS", "PROBLEM", 276, 280], ["CoV infections", "PROBLEM", 312, 326], ["SARS", "PROBLEM", 371, 375], ["CoV-2 infections", "PROBLEM", 376, 392], ["lung", "ANATOMY", 62, 66], ["pulmonary", "ANATOMY", 198, 207], ["epithelial cells", "OBSERVATION", 208, 224], ["infections", "OBSERVATION", 382, 392]]]]}